<SEC-DOCUMENT>0001628280-20-016446.txt : 20201113
<SEC-HEADER>0001628280-20-016446.hdr.sgml : 20201113
<ACCEPTANCE-DATETIME>20201113171611
ACCESSION NUMBER:		0001628280-20-016446
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201113
DATE AS OF CHANGE:		20201113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		201312565

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:2bbc8fb5-37a0-49a2-88e4-922c4b8dea28,g:76b63af8-607f-4b3f-a750-f8a8dfc06213,d:79bdbd3b4fc54ce0b1f7e776238df573--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:cpix="http://www.cumberlandpharma.com/20200930" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180L2ZyYWc6Y2Q4ZmY1N2JlYTliNGU1MGFiZjlmOWViYmI0YTg5NjYvdGFibGU6ODViMmI4ZDY2MDk2NDZiZThhZDM2MmY5Yzk1Y2NkMGEvdGFibGVyYW5nZTo4NWIyYjhkNjYwOTY0NmJlOGFkMzYyZjljOTVjY2QwYV81LTEtMS0xLTA_63cfb404-9746-46f9-bfc9-c0b5457d836f">2020</ix:nonNumeric><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180L2ZyYWc6Y2Q4ZmY1N2JlYTliNGU1MGFiZjlmOWViYmI0YTg5NjYvdGFibGU6ODViMmI4ZDY2MDk2NDZiZThhZDM2MmY5Yzk1Y2NkMGEvdGFibGVyYW5nZTo4NWIyYjhkNjYwOTY0NmJlOGFkMzYyZjljOTVjY2QwYV82LTEtMS0xLTA_8b014f49-cedc-48a0-82eb-9edbc5da1d5e">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180L2ZyYWc6Y2Q4ZmY1N2JlYTliNGU1MGFiZjlmOWViYmI0YTg5NjYvdGFibGU6ODViMmI4ZDY2MDk2NDZiZThhZDM2MmY5Yzk1Y2NkMGEvdGFibGVyYW5nZTo4NWIyYjhkNjYwOTY0NmJlOGFkMzYyZjljOTVjY2QwYV83LTEtMS0xLTA_355e9036-85fd-4971-9bf2-ef3e7fc7bcb5">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180L2ZyYWc6Y2Q4ZmY1N2JlYTliNGU1MGFiZjlmOWViYmI0YTg5NjYvdGV4dHJlZ2lvbjpjZDhmZjU3YmVhOWI0ZTUwYWJmOWY5ZWJiYjRhODk2Nl83OQ_94febea4-a4dd-48a9-aa72-510b5a26c71e">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180L2ZyYWc6Y2Q4ZmY1N2JlYTliNGU1MGFiZjlmOWViYmI0YTg5NjYvdGV4dHJlZ2lvbjpjZDhmZjU3YmVhOWI0ZTUwYWJmOWY5ZWJiYjRhODk2Nl84MA_a4af4f15-d21d-4142-93b6-c19d0e87e6c8">0001087294</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i806f0e664f9d4316a3583b5943ad619c_I20201110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2aae3ade58f14629babea615840c16d4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib48367eed5394c5ea20e7dc76326dace_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i51d553293659413f87554dc788d4bcce_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b79c2df727e4b81b6070f5e05dfd76a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbfd45792901404db84b4c62a7d2ab4b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98c007d4ad524e538f8276538642ea78_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b9bb42baaef4c5094e0ab9146fbecb9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d3c6c171eb84faea1a073a15ee27d73_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b2670bfac16431b81e1d0ae43216d38_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief40d394930e4ad8aa55d1f1875a0473_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id532a92619594716b8d454accfec3e8c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2aa2b7754394bca86b16a6b683ae214_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dfbc6c701c545729ec01b3e104fd1fa_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id931366f1dd048809e78a414f3cc4061_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe4dbdb42df24afb92bd43a4728b5831_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7330257a2be7418096532eb1e582d5d5_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i466e638f1cf944169e790ce328cd7e79_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8f9b7046ef944bf8bc512a3664d2b5c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1766bc56f0844f99bf09b7d344eb14ed_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8e552015b714eeb8c0eba2c8da97ef4_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i183ac2b291524d89a1a470882b24289e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i437f92c999684ffb86a16fe5adde240b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i728e3047fc24462aab7d9ddd4d5160fd_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99444b1a69614eebaa428eeb94e3bb1d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e8253dce984097b996ea192173d741_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4af8aa9fc5194cd4a1b4cda6e6eed41b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f5deb38ccd648d2b3ae820c2917f209_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3789f076fc20455ba5086e4654a7b173_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3e79a34ef554fed993caa85ec4ed80b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ce06f07f5994164ae6cf178e40174fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if07b4fb1f80e4674a4387c2c2fb38f86_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8216f15d99a94a2a86c19d3b1bad2bf5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89152ce5d22b489f9ea811b4bb61d18d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a06f5b04844061940fdd3b9480439c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26772e0071d34883b195a26267505a52_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbc1fd769f9740e989a4d2fd47f1ced4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icae833f7b3f44f0f9e58b7193716452c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ca469517291478aa2e4c1fa421bd3d3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife9646ecd78c471da7ec0b9ae8d48366_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6edc159368b349ed8d34e1d4bd240e22_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40b1cdafe584ea8a9f3cf4307d96744_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if52f80cf1d0e45cb97aae49b8c8230f2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic21315fbf39347a28cfc557393bc9c1f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0c42cdc6a024ef985b79c61a90bbe9e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32fea5db2d3c47e9a21a5f1f1ab0b6e4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d382f4a1c3c4e77bba4a6e17311df80_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13e05db5bc634c8395dc7ba20fd01c1f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a6b0baa09b04dc8ad7327ed08a971d4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa532992c0504e0ba3d7d267f54270d4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe1c68d19eec4a38a757dd2e42c81bf6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37fd46b1fc0d4e5c9cf794637e21ef86_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d9d3ac014b4702a58b9bc1204a2cb5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f9e4efabd72491282314ba3c4151d14_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:Segment</xbrli:measure></xbrli:unit><xbrli:context id="id07d176dae7e493b8fd0de707a8f73b1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab8d543293c243d483f364b765f13a5a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a4e269bc9b4de18ca89b7b6757b95e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b1300825a343c492f6cec5fac50c3f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b6aa7e3eea8489992e4ccb91292c2ba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f317e5f67db4275a57f6749f14461f1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971765b8c0cf44faa48dc5064fcf9605_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eb93e31604f48009bc491bfe2432446_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i595eb369427c497fac23d3e8c5820214_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd5b9e6ccc0d4886acc721fa7dbb63c7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie302cf43817549578a8f9ef152a447b1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25de277b0b0646cb9281cd16f837c44a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90fb467e2733434596b17207333e3bfe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ce5aa81441845e89b5271f86420011f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc6245a0edd04497ac8b9d6d6e9f57ab_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf4e408c7b1844ffb641ff92ed986d13_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie79fe091e6954839a3d9614623decb4f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia33026525efb4a2fba6cc177559e712b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideedcf83bae049bdaf355ac459d10cf8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9da2d5ab42648409a9408e0b935a37d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52c8721688534cb184cbf86471fe0d57_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f094a21244147fb9ce5e1bb5b80e965_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1481a754bb38453f812b6c54c7a6c98b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd27b429249456c90fc071b0ff8b3bd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5902cac206e44f0da81556294b8309f5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d88d58c35bc420b81d5571b5f859389_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b0440b8c0a141a6bd9f692f2deeb4ba_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9483466598e4f23ae7a5abdf7100ada_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fb1ae19da3f45d18b49aaf25f1dbd88_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie18912dcb3d24ad7a55576713413c72c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3299d8817d7541f3bdc4c7f01ae7bd80_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5447d4c0f5a349c1a9861329416d6e25_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if90916a859244a87afe32a6420d18ffa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c798a624494da4a9a833b2d4b416cd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a8c2296b3941e0a307a7590c71f19b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95daedfded3c472b9eb62ad072b1551e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i810fe6fe3d5d4acc95a6434905ad9bbd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11f33391c5194ed3a2eab2153394a830_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc85fa1f23c400f98a38cd8f0ac2143_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e3533c9ef434f2296767af0d6fa95cd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6666cecacb694b16a57f4cfa2cedd55d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b09030d4c8746e39c72272a8087f528_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43031ec5d6b146e396b7ed311aeda9fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e39f507697344bf966ae5d85dc07c38_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ibb00b2069e194ae3b41a6bbd3811b9ef_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cea20af1c7a4bf8892167b3a57bb8b3_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5651034dcdff44f08080de6ea37be942_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f1cc7c6f3f64637b1ca6aea46ce29a1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a446f495cd042eca3da6e7c97bb5b5d_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eed37f174f24049b2b6ad3653f05bbe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41de7f64b76f4893a406e9afd4a76a14_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6006916e3bab4f718de88600cfdcb08d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i930ad17f078c46d582cdf90475e66e78_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2affeac992f45c1807ad24d6642935c_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02dfaa25707a4e09b76974e10fd34245_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26301daa05cd47268f1bd0644a7e18a1_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia98b89ba857e4a2cb67df1f1038088f9_I20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FourthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19338c6b30fd4b21b231c47865291087_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2620c3a3fad4da8b66e2277201834e8_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i407f51866f02409cb9fad138500d14d1_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaadf65c3ea20463da1472b122fe42d41_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19e5831ccde74dbba7c187512febfbb2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d96acd949234acfb136a690bec1d7ce_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04eb73a534cd4abf9da31ee653c6edde_D20200420-20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-20</xbrli:startDate><xbrli:endDate>2020-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6ec3802e7f5429586813fbc92cd89e5_I20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i593c0deb73804b658d160e2556b47e42_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0afbb1a866c34e2b917ab586687f4135_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75f6e5e1e35347acb9908a1fc5e7a4d9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i657f7cc3031d4101af068d47a7501bd3_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i582dbdc998d44cdbab1a7981ad14c27c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5495d94083d24a5989730f4a6f7ba7da_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a6bfe43ca624e09b88b884aa61ffce5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89aa0df8ed9e4d689422daf8e8aeff91_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da1b98b323a4b7fb67fd0ac6aa17246_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af93abad7204f41a2937bac9ef79281_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c32aec9cced429d9682d29a48e13689_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bdfcc93ab6345078a0b921b7524f21f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eee9c230ea246608d8ad3a6a84a3a71_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc4d6bac512842b1af4d4a5a540f3881_D20191001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb62c40adac4ab6b3e98357baff55af_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6687a95bae3143d5b4bd7100bc41042c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i955fd3b444074d18a8861d6a9e06f6e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDI0_26ccb216-1d53-4043-8477-6e8d3e008991">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6MjBjZWFlYmQzNGIwNGQyOGJmZDQ0NDljYzdkZGNkM2EvdGFibGVyYW5nZToyMGNlYWViZDM0YjA0ZDI4YmZkNDQ0OWNjN2RkY2QzYV8wLTAtMS0xLTA_51fca158-3c23-426d-83e2-9da4880f5e68">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8xMDk5NTExNjI5ODE5_00beaa23-8cb5-4565-a950-e839b3da2d55">September 30, 2020</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YjAzNzk3NTFkZDc0NDQxNzgzN2JlNDY2OGVkNGI1MzAvdGFibGVyYW5nZTpiMDM3OTc1MWRkNzQ0NDE3ODM3YmU0NjY4ZWQ0YjUzMF8wLTAtMS0xLTA_c5aa0bc4-47df-4ed7-92de-5e3cba934c98">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDE4_9cb07708-5efb-4a76-aa61-e439b70f1fd9">001-33637</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDI3_0a3aa515-c8c7-4c6c-ae59-4b363cb811b6">Cumberland Pharmaceuticals Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified In Its Charter)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8wLTAtMS0xLTA_dcf0d76d-8ab2-41e1-8aae-ff64cced49a4">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8wLTItMS0xLTA_b1e4abd9-acf9-4a5f-95ce-71d195f9a64c">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMTI5N2M5ZWY3YjU0MjAxODFhMTVhNzQ5MmFjYzMzMV81_9839231c-1eac-4b25-aad9-15138fc10242">2525 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMTI5N2M5ZWY3YjU0MjAxODFhMTVhNzQ5MmFjYzMzMV85_a7937d36-e0df-4e47-bb49-e11c095ce8c0">Suite 950</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMTI5N2M5ZWY3YjU0MjAxODFhMTVhNzQ5MmFjYzMzMV8xMw_94fea98f-0b82-44ed-8127-bb3e9f371073">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMTI5N2M5ZWY3YjU0MjAxODFhMTVhNzQ5MmFjYzMzMV8xNw_9bf4a540-f320-46c6-af7e-2fa9c3229870">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8zLTItMS0xLTA_b85de85a-deda-47e3-9dca-65282a3a9439">37203</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDIw_12a65283-7f76-4914-a5df-0108578c1ce8">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDIx_c080729c-6c06-4c23-818d-5047b13fa11a">255-0068</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDIy_eedc4313-7811-48a6-ab11-aa69c29e6c2d">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDE5_4663b5ae-21ca-451d-937a-05f2f8024265">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWRmZGE4NDBiNzZlNDNiMTgzM2M0Y2Y4OTk4NWEzMTYvdGFibGVyYW5nZTphZGZkYTg0MGI3NmU0M2IxODMzYzRjZjg5OTg1YTMxNl8xLTAtMS0xLTA_35c21b91-e5fd-4ea5-88ac-951b773b5b29">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWRmZGE4NDBiNzZlNDNiMTgzM2M0Y2Y4OTk4NWEzMTYvdGFibGVyYW5nZTphZGZkYTg0MGI3NmU0M2IxODMzYzRjZjg5OTg1YTMxNl8xLTUtMS0xLTA_479ac604-c5bd-46ac-b860-4c3633262ae4">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWRmZGE4NDBiNzZlNDNiMTgzM2M0Y2Y4OTk4NWEzMTYvdGFibGVyYW5nZTphZGZkYTg0MGI3NmU0M2IxODMzYzRjZjg5OTg1YTMxNl8yLTItMS0xLTA_84db1b0f-6776-4763-bf11-e0550349db3e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDIz_b125b40e-37aa-4878-a0c6-ed8ed997be9d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:23.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of exchange on which registered</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding&#160;at November 9, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWFlNWU4MjhiYzlmNDQ1ZGExMjAxNjU4YWRhZTZlZTgvdGFibGVyYW5nZTphYWU1ZTgyOGJjOWY0NDVkYTEyMDE2NThhZGFlNmVlOF8xLTAtMS0xLTA_c3de2ece-c0b9-439d-aa11-fbc17aa07982">Common stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWFlNWU4MjhiYzlmNDQ1ZGExMjAxNjU4YWRhZTZlZTgvdGFibGVyYW5nZTphYWU1ZTgyOGJjOWY0NDVkYTEyMDE2NThhZGFlNmVlOF8xLTItMS0xLTA_7860f767-3fb3-4056-9e38-877e73b258ab">CPIX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWFlNWU4MjhiYzlmNDQ1ZGExMjAxNjU4YWRhZTZlZTgvdGFibGVyYW5nZTphYWU1ZTgyOGJjOWY0NDVkYTEyMDE2NThhZGFlNmVlOF8xLTQtMS0xLTA_d89b56a9-ca8d-40c2-b951-bb3a690b006c">NASDAQ Global Select Market</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i806f0e664f9d4316a3583b5943ad619c_I20201110" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWFlNWU4MjhiYzlmNDQ1ZGExMjAxNjU4YWRhZTZlZTgvdGFibGVyYW5nZTphYWU1ZTgyOGJjOWY0NDVkYTEyMDE2NThhZGFlNmVlOF8xLTYtMS0xLTA_f82a5bf1-126a-4fd9-a73f-a4848622be99">15,036,923</ix:nonFraction></span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_10">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;padding-right:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_13">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_13">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_16">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_19">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_22">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_25">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_25">4</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_28">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_28">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_61">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_61">16</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_82">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_82">27</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_85">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_85">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_88">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_88">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_91">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_91">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_94">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_94">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_97">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_97">30</a></span></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_103">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_103">31</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_106">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i79bdbd3b4fc54ce0b1f7e776238df573_106">32</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_13"></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_16"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMy0xLTEtMS0w_81710ca7-e226-4191-9abf-182aea7cbae9">26,646,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMy0zLTEtMS0w_884c2edd-f01e-4d0b-8354-e5d6d6b22438">28,212,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNS0xLTEtMS0w_bd5b2591-70c6-4fb6-8cce-3948cf839157">9,661,407</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNS0zLTEtMS0w_ae609960-c006-4e38-9f40-9e5ca113009e">7,843,917</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNi0xLTEtMS0w_a6e0b769-21ef-4003-ac51-3690ac507a95">10,080,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNi0zLTEtMS0w_44b4b590-b6f9-43ae-965f-40d941cbf650">8,871,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNy0xLTEtMS0w_003d395e-fba8-4a9a-ba46-97d0edffa630">727,670</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNy0zLTEtMS0w_ecb384a5-f5d1-4cb7-bee2-b4bc2db9eb8f">2,477,813</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfOC0xLTEtMS0w_7c1899ad-442d-4162-85db-6dd9d95503b2">1,778,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfOC0zLTEtMS0w_367b0241-15a7-4abe-a7b6-533ed188bab5">2,757,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfOS0xLTEtMS0w_1d72f3eb-b62f-466e-b88d-ce5098197bd7">48,894,079</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfOS0zLTEtMS0w_838f0679-068a-4a8c-8bb8-41d27668a16f">50,163,075</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTAtMS0xLTEtMA_aff30a22-4550-4f01-80c0-3d17254c1ada">12,649,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTAtMy0xLTEtMA_4c697fa0-cbf4-4065-9a24-ea8245b58db9">15,554,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTEtMS0xLTEtMA_e23ec190-280c-4b77-9175-83f428e2a25e">602,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTEtMy0xLTEtMA_92f85e39-0ad9-4d0a-8075-268d93119399">747,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTItMS0xLTEtMA_1304b6ba-07a4-4e6f-bfec-52194028b890">28,180,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTItMy0xLTEtMA_10738e56-7641-4f8d-ab04-aa01b3391afc">30,920,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTMtMS0xLTEtMA_13ccd029-c7e7-4c4a-ab50-81e03ed3fb96">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTMtMy0xLTEtMA_48366bea-1217-4271-ae1b-10c494a708f2">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTQtMS0xLTEtMA_bb66e516-81d1-4892-9fcb-6bd4f8511f0c">21,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTQtMy0xLTEtMA_97c5ebf7-0ed7-4431-9e08-9c861ae669e2">21,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTUtMS0xLTEtMA_da2f3247-a2fa-48bc-9733-06fb4cfc3cc7">2,267,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTUtMy0xLTEtMA_73853f4e-b175-415c-b69c-ed56e7a68bb4">2,960,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTYtMS0xLTEtMA_44bf0e20-f920-4435-b6a4-c241605d3644">2,511,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTYtMy0xLTEtMA_9014b2d6-1727-4d44-8236-112e943b2fb5">3,298,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTctMS0xLTEtMA_7a49e0aa-310e-49a1-a28c-e74bdfb2caf8">96,009,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTctMy0xLTEtMA_f042da5d-d7b4-42e8-b539-cde043edb25d">104,549,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjAtMS0xLTEtMA_8f14246a-f2b9-4a8d-94dc-fd22e2a5fb63">10,833,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjAtMy0xLTEtMA_607f9965-8723-4669-b09a-57e61a43dff7">9,993,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjEtMS0xLTEtMA_48398525-3e2b-4c6a-85e3-d5e26a16048c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjEtMy0xLTEtMA_69d7698d-d5c5-4921-8226-3feb5a9ae0dd">1,918,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjItMS0xLTEtMA_5810fa0f-9be6-43be-b43f-8f832ef5d5ed">991,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjItMy0xLTEtMA_6c0c18cb-5849-4209-923c-fa2ce43439af">920,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LinesOfCreditCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjMtMS0xLTEtMTk_62b0d0f6-cf70-49af-bed6-9c5edd3c58cb">2,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:LinesOfCreditCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjMtMy0xLTEtMTk_9f81cbec-c9de-497b-b9a2-218bf8eba8b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjMtMS0xLTEtMA_d4f8ac6b-4850-4bdb-8748-ffa0e902e3eb">10,112,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjMtMy0xLTEtMA_e109bc9d-5bbf-4351-bcc3-1090cafc244d">11,317,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjQtMS0xLTEtMA_3234b9fa-59a7-4e37-8908-1848b9281437">23,938,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjQtMy0xLTEtMA_8af1849c-9a12-451a-9935-8837d20957fa">24,150,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjUtMS0xLTEtMA_7c28da46-5dba-477c-8c8c-c03ceea7879b">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjUtMy0xLTEtMA_b052841f-c504-44c7-80e0-1b495a88ff41">18,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjYtMS0xLTEtMA_bfeb40bd-82a3-474f-8ccf-179474b50435">1,323,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjYtMy0xLTEtMA_8af13e3f-82dd-4edb-a075-ad62fbdbcfcb">2,076,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjctMS0xLTEtMA_9741ebdd-1b5e-41ec-8738-5162c2383f9d">7,904,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjctMy0xLTEtMA_45c992c8-9a2a-4073-8226-ac3f613444bd">8,737,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjgtMS0xLTEtMA_9335dd40-5040-4086-bbbe-aa2ddc846aa1">48,166,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjgtMy0xLTEtMA_cbaa3750-62dc-4c32-ab29-24c752efac94">53,464,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjktMS0xLTEtMA_51ad0cab-fefc-45b9-8e87-215eae9f9d4f"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjktMy0xLTEtMA_c1168de5-ea51-4ead-9ebf-5ce3209658d7"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;<ix:nonFraction unitRef="usdPerShare" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzE3_92a3a022-9af4-4127-aa0f-34d83b2b7b98"><ix:nonFraction unitRef="usdPerShare" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzE3_faa0ebb9-fc82-4631-8d67-a9ed403f90b0">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzMx_608602a1-7401-4be3-97ea-78df5e0c3055"><ix:nonFraction unitRef="shares" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzMx_de708b29-cb7e-4783-bb3b-59cdcaa9d44a">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzUz_32aa97f5-16f4-4eed-a7fd-6e9cf53ca502"><ix:nonFraction unitRef="shares" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzUz_89c66577-61e4-4f0c-8219-9be7693109d4">15,084,372</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzYw_c789e6b3-1366-4a7d-915d-90b13fabf118"><ix:nonFraction unitRef="shares" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzYw_ce51757b-0cab-4572-8625-dcde6c270773">15,263,355</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMS0xLTEtMA_29ccc6db-e49a-42c8-936a-2224965018a1">49,176,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMy0xLTEtMA_b4abf02d-d137-42f2-8456-b73861df82f3">49,914,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzMtMS0xLTEtMA_b3cdd169-71da-4a41-98df-44d30f723372">1,247,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzMtMy0xLTEtMA_63c20bf1-250e-413a-9f2d-ed9796527970">1,208,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzQtMS0xLTEtMA_f3b1468d-0645-45a1-bd17-cd97bd586366">47,928,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzQtMy0xLTEtMA_3d9312ab-2f7b-472f-a6f6-5e347fbb140b">51,122,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzUtMS0xLTEtMA_7a0015a3-e4f7-4394-9759-89faaa6cf2f8">85,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzUtMy0xLTEtMA_7c3d01c6-9746-4349-bd08-f315c59fcd82">37,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzYtMS0xLTEtMA_0bc63762-9134-4dee-945e-ef140d20aca0">47,843,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzYtMy0xLTEtMA_361b03d5-e705-47fc-b5d3-7f36a7243606">51,085,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzctMS0xLTEtMA_7ba572cf-94f3-42eb-af2d-a32dc821f185">96,009,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzctMy0xLTEtMA_1abe1294-d5a6-4d98-b766-1d295bce5690">104,549,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMi0xLTEtMS0w_3c845a34-6641-4042-93f1-3db372f2c06a">9,250,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMi0zLTEtMS0w_af363671-b2e5-47c8-bf2d-122b961c9aee">6,935,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMi01LTEtMS0w_8c4993ce-380f-4ffe-a1d9-47902e66cce8">27,179,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMi03LTEtMS0w_03fd59ab-280f-4e15-b1a9-42a831c72b05">25,082,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNC0xLTEtMS0w_8c206724-66b7-44c3-9e88-667cf9315776">2,142,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNC0zLTEtMS0w_28e1d379-5216-466c-bb68-febbea7c7e43">1,580,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNC01LTEtMS0w_fc85daea-7be9-46a5-8d9c-d2346ba2b075">6,387,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNC03LTEtMS0w_18ae2c75-65ab-4876-b3ba-25c8c365f58e">5,031,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNS0xLTEtMS0w_7e0742ad-d8f8-4554-9b1a-8959d05f1b7d">3,587,842</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNS0zLTEtMS0w_a2158190-70f0-407a-a57b-a9e237a670bb">3,812,467</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNS01LTEtMS0w_8aa205b3-4654-45e6-8cd6-76bf0965939e">11,160,924</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNS03LTEtMS0w_4e53fae5-1894-45c3-bc16-848052021115">11,231,778</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNi0xLTEtMS0w_1de61b97-869d-4165-854d-07eb135c7bd7">1,230,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNi0zLTEtMS0w_3b99813d-82d8-466d-b9ce-d9984acc3524">1,672,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNi01LTEtMS0w_c870718f-a770-4b69-8de9-e44b9a74d1c4">4,374,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNi03LTEtMS0w_91d96dd0-c296-443e-ae6e-bfe5b8e12aaa">4,788,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNy0xLTEtMS0w_8226ad5e-ae9b-45ac-880c-b43b4cd0a57d">2,381,273</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNy0zLTEtMS0w_efb8e402-c1e5-4fc5-af9a-09bcecdb7ace">2,032,129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNy01LTEtMS0w_9d32f83b-935d-4c32-89e4-6bf9648608cc">6,608,322</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNy03LTEtMS0w_5426541c-ce3f-44a8-97ca-b3563532dd13">6,839,187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOC0xLTEtMS0w_38de8255-52ab-44bb-b2c6-d30f5c21a719">1,117,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOC0zLTEtMS0w_8b55a071-a067-4bf9-9467-a72e1aba90f2">1,033,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOC01LTEtMS0w_2101e84d-152c-4777-b307-2facc1389715">3,284,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOC03LTEtMS0w_99911cb3-1aee-4993-afdb-1ab72d68fae7">3,085,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOS0xLTEtMS0w_b6f8301b-c810-413c-adfe-ff1e0d579487">10,459,375</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOS0zLTEtMS0w_d72c17b3-c076-4637-af3c-5ac096026385">10,131,875</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOS01LTEtMS0w_57031076-2068-4a22-98ef-14b46c887aea">31,815,250</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOS03LTEtMS0w_ccd6e876-8db4-4e2a-9b03-10e9a0198031">30,976,534</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTAtMS0xLTEtMA_9ef15477-480d-4872-a47e-1e1cd9bc1b67">1,208,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTAtMy0xLTEtMA_db6d0d04-37f2-4a0e-9305-c0172c60f831">3,196,436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTAtNS0xLTEtMA_e31d8a65-a507-4fe9-a254-c6d5b2654b14">4,635,650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTAtNy0xLTEtMA_de3b2c81-a1de-46e7-aad7-2dc02f01b80c">5,893,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTEtMS0xLTEtMA_427ca1bd-13b9-468a-a2b2-645828539245">12,004</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTEtMy0xLTEtMA_9f5a231e-a834-455a-94b8-4ba28e343d1e">50,511</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTEtNS0xLTEtMA_46e17015-b128-431e-880f-50229018cbfa">70,553</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTEtNy0xLTEtMA_5a06ddde-c632-474c-8a9c-0816988f8304">195,915</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTItMS0xLTEtMA_0cec5268-97e3-4fe2-b129-e0fa2d95df43">75,210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTItMy0xLTEtMA_40d40758-4304-4bfd-9f80-349886e6b792">64,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTItNS0xLTEtMA_777361f6-354a-4252-940a-2f360bedacea">227,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTItNy0xLTEtMA_28fc7fa4-900b-4c64-b04a-9b835d08ac58">216,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTMtMS0xLTEtMA_19a5ff8f-d961-4dec-956e-196e33fa174a">1,271,892</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTMtMy0xLTEtMA_4c74256b-4c7f-4020-b8ec-a6a024bee5b0">3,311,824</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTMtNS0xLTEtMA_c92a2a5f-01a4-41b4-9176-9f13c2b85c72">4,792,827</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTMtNy0xLTEtMA_6edc627d-6ee1-48a0-ae13-d895e89decec">5,914,865</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTQtMS0xLTEtMA_96492f75-3df0-4698-b09b-00cf4e3b97b0">3,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTQtMy0xLTEtMA_e4b9f0db-9295-4aa8-86c9-e815a4d3a1f3">4,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTQtNS0xLTEtMA_fe789b9a-c2b7-404d-bfcb-6c64a7dc10ce">45,423</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTQtNy0xLTEtMA_3d488bf9-0a90-4702-8826-1d416a3303cd">72,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTUtMS0xLTEtMA_dc933537-d6c3-48ff-a0cd-f6960200066e">1,275,620</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTUtMy0xLTEtMA_381be7ac-a55e-4cbb-8b4e-b27c2ab55f63">3,316,286</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTUtNS0xLTEtMA_ba6c153c-d20c-4201-9194-d99af8da848f">4,838,250</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTUtNy0xLTEtMA_279857ff-511d-4ae7-99f6-6e2ae17c9f5f">5,842,361</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTYtMS0xLTEtMA_810e6874-b3f8-4a92-ab84-d9901715c353">777,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTYtMy0xLTEtMA_9bd44394-86b7-4da6-9f91-dd9bcfe0d2bd">1,349,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTYtNS0xLTEtMA_31a5f830-9e36-446a-bdb9-0b6b6c6c847b">2,334,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTYtNy0xLTEtMA_bf1f3af9-faff-4042-b46b-2684d5e47fd2">3,268,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTctMS0xLTEtMA_7c120e3b-7a84-4df6-b4b4-ef3fee1a3dd7">497,704</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTctMy0xLTEtMA_6eac5a43-e67b-435f-aa7d-89e6f7749169">1,966,935</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTctNS0xLTEtMA_f7a3f5c7-7346-4b3c-a706-5377b195e2b9">2,503,439</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTctNy0xLTEtMA_854a8d3f-5411-4706-9a32-a439a2787e25">2,574,165</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTgtMS0xLTEtMA_df562953-c9f0-4226-91a7-24dc38981cd8">15,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTgtMy0xLTEtMA_bab9f3ca-afdc-4cc1-8633-81bba402b9bb">13,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTgtNS0xLTEtMA_058de113-d6f7-46c0-8dfd-d000d9e95ebf">47,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTgtNy0xLTEtMA_53700455-ad83-4e97-aee6-ffb515c89a96">2,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTktMS0xLTEtMA_180a2986-e02b-4467-bf4c-ca6cb1d6a282">481,737</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTktMy0xLTEtMA_51079ceb-063b-4736-a081-28fb404a8fb9">1,953,668</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTktNS0xLTEtMA_ccc4dc60-fb64-412b-be54-1d316c350883">2,455,633</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTktNy0xLTEtMA_b6bf7a28-b262-4a5b-bbcf-7220da734f82">2,577,053</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjEtMS0xLTEtMA_c63a89a7-6447-44f6-a43c-f9cde23e26ff">0.08</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjEtMy0xLTEtMA_6a5323b0-3367-4c6f-8de5-addead3f9ad8">0.22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjEtNS0xLTEtMA_ce4d0a9f-2997-4907-8137-613a952671a2">0.31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjEtNy0xLTEtMA_f3647442-6292-4754-8268-82f45a74db63">0.38</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjItMS0xLTEtMA_34775022-dac9-4c8b-9f27-397ecbda50b3">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjItMy0xLTEtMA_21d57ce8-704b-4372-ad50-36da31e9b6f7">0.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjItNS0xLTEtMA_8c1b6d37-3748-48c0-9063-818dfccbb05d">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjItNy0xLTEtMA_b46f96d1-5d2f-473c-80eb-12e626b6dc51">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjMtMS0xLTEtMA_98d083fb-0298-4932-ab2b-4134fd1daac0">0.03</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjMtMy0xLTEtMA_007189ea-6c3d-4637-8fef-c6fcdde9c883">0.13</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjMtNS0xLTEtMA_ab7c0717-a335-40fc-8d60-7dac4c3bca9d">0.16</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjMtNy0xLTEtMA_e1b15612-93f7-45b7-bedf-2901cbcc04fe">0.17</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjUtMS0xLTEtMA_836a4f7d-d33c-41cd-b050-21433715d822">0.08</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjUtMy0xLTEtMA_59710a8e-6743-4459-a6d6-597a179486b5">0.22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjUtNS0xLTEtMA_c202a72e-e404-4587-95c9-370455bc9b2f">0.31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjUtNy0xLTEtMA_a1cb6b89-d699-4732-8780-08cbd7b64384">0.38</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjYtMS0xLTEtMA_8592f224-8283-4775-9a9a-39e861ed2d4d">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjYtMy0xLTEtMA_d0eb876a-56df-44e0-823d-7ec9f1d0a432">0.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjYtNS0xLTEtMA_80b7f76d-4206-4d3f-8fc2-6f25af60da83">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjYtNy0xLTEtMA_f1a1b805-fec1-4901-82c6-bf4a2435cd00">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjctMS0xLTEtMA_79b9d96f-c0bb-4169-800e-992e0f0b4062">0.03</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjctMy0xLTEtMA_0938a04d-9f8f-4680-8452-bd70a64fdc61">0.13</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjctNS0xLTEtMA_d8c7e2c1-ff03-4708-9b11-dfdda828b859">0.16</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjctNy0xLTEtMA_539562b7-7921-442f-96ed-0ed6bb8b0935">0.17</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjktMS0xLTEtMA_8dfcac58-c245-479b-90ea-d8198b82823c">15,134,583</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjktMy0xLTEtMA_3b6e15d2-7246-4765-9742-c48e22fe21b2">15,368,027</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjktNS0xLTEtMA_0e159637-02d4-496a-b203-4931667f0908">15,206,179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjktNy0xLTEtMA_41976643-df91-4c1d-abea-2c78c614ea27">15,454,159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMzAtMS0xLTEtMA_680661da-9c2e-4bc7-bb8a-ef68aff517cb">15,134,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMzAtMy0xLTEtMA_bef24f96-7f94-4b28-aa5e-e7f87d8c4a77">15,368,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMzAtNS0xLTEtMA_b68d2d90-e060-4487-afbb-a6507fa3130a">15,206,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMzAtNy0xLTEtMA_7dad67b7-bb9e-40b1-9a84-98a6333c5d90">15,454,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,503,438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMy0zLTEtMS0w_1d774375-c870-4c25-af54-d9bb5f23477e">2,574,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNC0xLTEtMS0w_f9c0b223-3110-468b-9fa2-48b87d31ed7d">2,334,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNC0zLTEtMS0w_b3684d21-b220-42c1-82a1-bf505d73369c">3,268,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,838,249)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNS0zLTEtMS0w_34102501-45d9-4a28-a8a7-8c1e145015c6">5,842,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNy0xLTEtMS0w_613c388c-e8c0-428e-a699-620fa69919db">3,524,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNy0zLTEtMS0w_9000a2fd-c601-455a-85d1-110c27427975">3,278,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfOC0xLTEtMS0w_a2eaff2d-e420-4c88-b5f2-cb6ca258aa75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfOC0zLTEtMS0w_2e688db1-b0f2-46fc-a84a-d3d1361a5419">43,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfOS0xLTEtMS0w_895ee644-0818-4133-8a9d-d14aebd45f07">805,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfOS0zLTEtMS0w_8a84ac57-19c4-4834-b767-d7fcbb3c97dc">1,107,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTAtMS0xLTEtMA_1705c9e6-8a5b-4bc1-bd04-501d044d26f2">806,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTAtMy0xLTEtMA_6ce8c804-fe0f-4c01-8af7-15570631bd57">681,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTEtMS0xLTEtMA_3af19422-44ae-45ef-b3d4-1949e4096923">36,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTEtMy0xLTEtMA_327db869-f067-40e4-b668-9ff7a915c021">36,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash investment gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTItMS0xLTEtMA_213aad4a-0706-4044-9467-481065c56eb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTItMy0xLTEtMA_6d817466-e60f-4f16-8bf0-5bd7a52b7038">34,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTQtMS0xLTEtMA_c0d19c97-3cb0-4757-b316-92e67e5a4762">1,817,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTQtMy0xLTEtMA_2de24f82-2242-42b1-a6c6-6edac16a6475">1,026,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTUtMS0xLTEtMA_0d1adcad-1e05-4b65-9be0-85a5bfc2ef45">1,696,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTUtMy0xLTEtMA_d7d88852-abca-4151-86f2-0a60f6c8231b">1,332,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTYtMS0xLTEtMA_908d3ed6-f93b-4ad6-aa7e-3f362e62d703">1,962,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTYtMy0xLTEtMA_97f40e3f-ab14-4818-b790-9c837a6b0c5b">195,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTctMS0xLTEtMA_269d6b7c-c9e1-4e48-b0ca-00ed476e190d">3,417,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTctMy0xLTEtMA_3bdeb0a1-499d-4c3b-b740-087dae7afca4">539,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTgtMS0xLTEtMA_e1b3b9cb-d4af-408e-b8ad-b16af58e9c1c">1,585,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTgtMy0xLTEtMA_6888685c-aaad-4b0b-a8c7-d2e51d20ee75">207,648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTktMS0xLTEtMA_678782f8-ddc0-44ca-b16b-2fda57cabefb">2,395,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTktMy0xLTEtMA_4a003989-4e4d-4613-80c2-3563686908df">284,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjAtMS0xLTEtMA_505b36f7-35a0-42aa-99df-7db9ec811eb2">2,166,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjAtMy0xLTEtMA_a508e50a-4761-4bc4-aba7-3ad4e28d5745">2,483,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjEtMS0xLTEtMA_1e750025-bf9a-4ecf-a758-6618e7a411c0">4,561,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjEtMy0xLTEtMA_da8a51a3-dde9-4822-8b96-303f73679e3b">2,199,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjMtMS0xLTEtMA_d1a811c2-4480-41d3-84e2-50074228abef">95,189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjMtMy0xLTEtMA_89a9cec0-c99f-4cc3-b39b-a4e4bb2fc859">166,407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjQtMS0xLTEtMA_c28ed2a9-b181-4953-8d67-bd508dc04df3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjQtMy0xLTEtMA_7ce78207-9200-45b1-b548-20ecd2e5967d">9,627,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjUtMS0xLTEtMA_5f22bb2a-4f69-4aa7-8910-7d2dbbd28a85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjUtMy0xLTEtMA_93480273-b087-4c84-bf49-7994f1d44214">15,686,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from surrender of life insurance policies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLifeInsurancePolicies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjYtMS0xLTEtMTExOQ_bf1684e9-894e-4956-a43b-2b83522c00ae">460,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromLifeInsurancePolicies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjYtMy0xLTEtMTExOQ_6c5b0f67-3e0b-40ce-8126-8d9a58ab09d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjYtMS0xLTEtMA_ec88a97e-c215-4ecc-a7be-481462e963b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjYtMy0xLTEtMA_ec180742-d1cc-43a9-ba80-d8c951783bd9">5,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjctMS0xLTEtMA_ab18ec10-d2d0-445b-b8a0-65e2b366eb70">1,807,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjctMy0xLTEtMA_cbd83afd-a941-4def-9832-d91f69f6eeb1">498,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjgtMS0xLTEtMA_d1d92e7e-381e-4902-8d25-d56a8ed0ca27">1,441,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjgtMy0xLTEtMA_1a759470-0609-4b03-8107-9949c4821f78">394,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzEtMS0xLTEtMA_e2a303ce-d078-4f46-aaf8-0b0f36458531">44,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzEtMy0xLTEtMA_6d0075c0-1a40-48f0-b6cf-7b7c5c5dc65d">56,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzItMS0xLTEtMA_7670dc12-6126-4262-bfb1-feba334fa9f9">45,500,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzItMy0xLTEtMA_a40ca680-119f-41db-8995-94ec2354c745">56,000,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of deferred loan costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzQtMS0xLTEtMA_0af70ba8-9a5a-429f-a0f3-88553a4dbadb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzQtMy0xLTEtMA_d9fb5d61-c91f-4ba5-9752-fba6ca12d9c2">52,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzUtMS0xLTEtMA_b14b2dd3-2b07-430c-95fb-462f4e41f4c9">834,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzUtMy0xLTEtMA_a947abd3-1d3d-4ab5-b158-6c100effddd8">908,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares from noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzgtMS0xLTEtMA_dda69f64-6e09-441e-97e6-6d0f8599c7a0">800,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzgtMy0xLTEtMA_945cd36a-e3c2-4fae-b631-5fd6989d632b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzktMS0xLTEtMA_2c0aeef9-be8b-404b-b995-2f9b23ce9d40">1,551,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzktMy0xLTEtMA_b486326f-2aa2-4534-80dd-185231950ae1">2,593,778</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDAtMS0xLTEtMA_643e74ba-a671-4d28-92f5-007aa3ce7661">4,685,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDAtMy0xLTEtMA_17c21507-cd35-4617-a6aa-5ee5e2e89687">3,554,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDEtMS0xLTEtMA_923ad82a-3dfb-4c9a-93fe-dc15a9d7a4af">1,566,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDEtMy0xLTEtMA_2a2bdc4c-a863-45bb-a828-93668c8a6e70">960,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDItMS0xLTEtMA_c288ab12-5793-46d1-b35f-256ac30934bf">28,212,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b79c2df727e4b81b6070f5e05dfd76a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDItMy0xLTEtMA_c928998c-4107-4c5a-86e0-355dd1b1767a">27,938,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDMtMS0xLTEtMA_c93d919c-cc77-43bb-99cd-854a86ace542">26,646,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd45792901404db84b4c62a7d2ab4b_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDMtMy0xLTEtMA_8362a4da-0df0-447b-993b-970b79fb89b0">26,978,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_25"></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98c007d4ad524e538f8276538642ea78_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMi0xLTEtMS0w_fc66179c-a415-4418-b870-5dc9c4238e75">15,481,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c007d4ad524e538f8276538642ea78_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMi0zLTEtMS0w_582154fd-edc5-43a5-9068-816f52b031db">51,098,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b9bb42baaef4c5094e0ab9146fbecb9_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMi01LTEtMS0w_99e11dd6-866e-409a-85f0-034abb14d3d3">4,746,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d3c6c171eb84faea1a073a15ee27d73_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMi03LTEtMS0w_5d14919e-b02b-4b94-8d53-266f97d81ab3">274,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b79c2df727e4b81b6070f5e05dfd76a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMi05LTEtMS0w_6f4bc998-937e-4d2d-a844-d3f3700d3838">55,570,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b2670bfac16431b81e1d0ae43216d38_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMy0xLTEtMS0w_d2f0e1f1-042a-4282-af29-522d03ab172e">187,486</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2670bfac16431b81e1d0ae43216d38_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMy0zLTEtMS0w_92aedca2-19f4-4aad-a874-a6e504e7c9b2">364,434</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief40d394930e4ad8aa55d1f1875a0473_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMy05LTEtMS0w_63514e18-15bb-4f01-8a81-fed482762b35">364,434</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6b2670bfac16431b81e1d0ae43216d38_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNC0xLTEtMS0w_c7989a56-8c8f-49f4-99ce-820bd47bfc25">121,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b2670bfac16431b81e1d0ae43216d38_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNC0zLTEtMS0w_e5998124-ce28-41fa-a8bf-04e7f6dd4e58">703,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief40d394930e4ad8aa55d1f1875a0473_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNC05LTEtMS0w_65b79c10-6606-481a-8cb7-623207a9f128">703,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id532a92619594716b8d454accfec3e8c_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNS01LTEtMS0w_c875d3f2-a9be-4c1d-8490-905245bfee35">73,878</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2aa2b7754394bca86b16a6b683ae214_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNS03LTEtMS0w_02fb60c6-425c-4f68-a4ae-6d8da497e596">33,460</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief40d394930e4ad8aa55d1f1875a0473_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNS05LTEtMS0w_4c1de8b2-11f5-498e-8040-e85761682c61">40,418</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1dfbc6c701c545729ec01b3e104fd1fa_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNi0xLTEtMS0w_4e50f862-b28c-4cb8-be86-d1830c0cfbff">15,547,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dfbc6c701c545729ec01b3e104fd1fa_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNi0zLTEtMS0w_01d47994-0d51-4f45-950d-156019d6d654">50,759,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id931366f1dd048809e78a414f3cc4061_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNi01LTEtMS0w_26cb8182-bb98-4c57-86ac-4b56044cfb70">4,672,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe4dbdb42df24afb92bd43a4728b5831_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNi03LTEtMS0w_68fd22c3-1265-47dd-be52-624bb33e78cb">240,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7330257a2be7418096532eb1e582d5d5_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNi05LTEtMS0w_3d769cb0-b52f-4705-b893-161a1894be4a">55,190,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1dfbc6c701c545729ec01b3e104fd1fa_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMC0xLTEtMS0w_775d67c9-bf35-45f9-becb-289aa6baae6e">15,547,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dfbc6c701c545729ec01b3e104fd1fa_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMC0zLTEtMS0w_5b8c40a7-2fbf-4b79-8ddb-39e0ac9f0910">50,759,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id931366f1dd048809e78a414f3cc4061_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMC01LTEtMS0w_7ce042d7-a40b-4db6-bbab-631187477617">4,672,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe4dbdb42df24afb92bd43a4728b5831_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMC03LTEtMS0w_d90a3f91-1482-4c65-b464-6caf24303d3a">240,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7330257a2be7418096532eb1e582d5d5_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMC05LTEtMS0w_ad0838d1-5274-499c-9906-c0953e52ba6c">55,190,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMS0xLTEtMS0w_156098d8-eebd-4c22-8d27-3b898bb27479">8,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMS0zLTEtMS0w_6162a88b-fcec-4cef-b97c-7118ed42cb81">396,548</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466e638f1cf944169e790ce328cd7e79_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMS05LTEtMS0w_a1c23935-79e3-47b5-a17e-f0b3dda535ac">396,548</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares from noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMi0zLTEtMS0w_654293bb-6180-42af-a49f-fa281a80551c">685,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8f9b7046ef944bf8bc512a3664d2b5c_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMi03LTEtMS0w_e21f18ac-0c8b-4849-a30d-93914032c4e6">114,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i466e638f1cf944169e790ce328cd7e79_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMi05LTEtMS0w_9841635e-ef60-4ac5-a3cd-550293c1e880">800,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMy0xLTEtMS0w_15e2d7f0-79d5-41ed-aff8-23b322b0b994">84,447</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMy0zLTEtMS0w_791ed917-afd3-4bc8-954d-a544ee3f45d4">531,746</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i466e638f1cf944169e790ce328cd7e79_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMy05LTEtMS0w_26383195-4c29-49be-8f11-69d0a68afd66">531,746</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1766bc56f0844f99bf09b7d344eb14ed_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNC01LTEtMS0w_50525926-d062-4518-99a9-a1b57d205eea">549,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8f9b7046ef944bf8bc512a3664d2b5c_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNC03LTEtMS0w_a049e9fc-0f90-4bd2-8c41-4d4acc04aef5">17,305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i466e638f1cf944169e790ce328cd7e79_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNC05LTEtMS0w_1dc6d3b6-b37d-4aee-8c72-b28a83749290">566,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2019</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8e552015b714eeb8c0eba2c8da97ef4_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNS0xLTEtMS0w_7bbbad36-4cad-464a-8b59-9106d7e9032a">15,471,070</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e552015b714eeb8c0eba2c8da97ef4_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNS0zLTEtMS0w_9280b23a-4bee-41d9-9d2e-a8892d6e7d99">49,938,254</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i183ac2b291524d89a1a470882b24289e_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNS01LTEtMS0w_18c3791a-511b-48a6-8509-5779fed7e337">4,122,769</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i437f92c999684ffb86a16fe5adde240b_I20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNS03LTEtMS0w_480dc414-be88-4a0b-bab9-8e29ca26b850">372,306</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728e3047fc24462aab7d9ddd4d5160fd_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNS05LTEtMS0w_c18c09d5-3c52-424c-8c75-91c547b38554">53,688,717</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8e552015b714eeb8c0eba2c8da97ef4_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMC0xLTEtMS0xMTQ_46ca856b-639f-4fb3-8f84-1a6c1b7391c6">15,471,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e552015b714eeb8c0eba2c8da97ef4_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMC0zLTEtMS0xMTQ_135bfcbc-ee90-4307-90ce-08b2a3be4ca6">49,938,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i183ac2b291524d89a1a470882b24289e_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMC01LTEtMS0xMTQ_b6df9602-b4f5-4a85-bb22-b5fcc3c57c34">4,122,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i437f92c999684ffb86a16fe5adde240b_I20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMC03LTEtMS0xMTQ_00cd3ce7-63f7-4a23-a872-d3d525dc7e7f">372,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728e3047fc24462aab7d9ddd4d5160fd_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMC05LTEtMS0xMTQ_492ca9fb-0c12-473a-8805-69337c0f8f85">53,688,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMS0xLTEtMS0xMTQ_b324e321-f799-4fda-8841-82d9ec79ec14">6,450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMS0zLTEtMS0xMTQ_ae260e33-41d6-45d6-8d99-7d2b7b9b8195">346,835</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMS05LTEtMS0xMTQ_5cda4ba2-eab8-44c6-988b-bf31f8c41ac3">346,835</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares from noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMi0zLTEtMS0xMTQ_2c29c5de-ae8b-4242-89f8-02de85ab205d">640,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99444b1a69614eebaa428eeb94e3bb1d_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMi03LTEtMS0xMTQ_99e7334f-7721-4a90-a951-ef3d963bd2a7">359,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMi05LTEtMS0xMTQ_4c158356-58e9-423c-8077-a7a0f9c5b369">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMy0xLTEtMS0xMTQ_51c1f55a-3fdf-486d-b988-d8e9a8f3b589">246,242</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMy0zLTEtMS0xMTQ_e99730f1-f617-482a-b05e-c815f928f7c2">1,361,689</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMy05LTEtMS0xMTQ_0ec98fbd-bfd7-490b-87fe-61d2e4e303d3">1,361,689</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3e8253dce984097b996ea192173d741_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNC01LTEtMS0xMTQ_534c7638-1332-4b27-b21f-57919b2e6fc4">1,953,668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99444b1a69614eebaa428eeb94e3bb1d_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNC03LTEtMS0xMTQ_5fe36477-5408-46d3-84b5-7ff11ec2483f">13,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNC05LTEtMS0xMTQ_fc0da82c-9539-4c54-b1d7-755701b33d70">1,966,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2019</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4af8aa9fc5194cd4a1b4cda6e6eed41b_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNS0xLTEtMS0xMjY4_5344213a-13a2-4c28-8bf7-abb9bbae41e2">15,231,278</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af8aa9fc5194cd4a1b4cda6e6eed41b_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNS0zLTEtMS0xMjY1_21a574b7-57ba-43ea-b6ff-d36ca7ce1905">49,563,807</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f5deb38ccd648d2b3ae820c2917f209_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNS01LTEtMS0xMjcy_610c65fb-64a2-428b-a2b8-12483c8db612">2,169,101</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3789f076fc20455ba5086e4654a7b173_I20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNS03LTEtMS0xMjc0_c60414d3-8755-4c24-a725-e1acd8742d8f">25,980</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd45792901404db84b4c62a7d2ab4b_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNS05LTEtMS0xMjYz_d7fb8f99-8329-4822-91b6-c65a89e634e8">51,706,928</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3e79a34ef554fed993caa85ec4ed80b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMi0xLTEtMS0w_a5182f35-5ef3-4455-ac6b-e942e408ef89">15,263,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e79a34ef554fed993caa85ec4ed80b_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMi0zLTEtMS0w_de15750b-8dfd-4cd3-8bb1-78965264933a">49,914,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce06f07f5994164ae6cf178e40174fe_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMi01LTEtMS0w_1ca1c6f9-c12a-47b8-b52f-9243eace4c1d">1,208,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b4fb1f80e4674a4387c2c2fb38f86_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMi03LTEtMS0w_635f5c77-b16e-4245-9865-a26bc753ae64">37,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMi05LTEtMS0w_c97ea4ec-3810-4081-9ac0-0313fc33f2c3">51,085,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8216f15d99a94a2a86c19d3b1bad2bf5_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMy0xLTEtMS0w_19e9b389-7c55-4888-bd75-fa1d7ed0bfe8">219,850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8216f15d99a94a2a86c19d3b1bad2bf5_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMy0zLTEtMS0w_c6f13dd1-ecfe-4ba2-9291-2139b5fa661d">264,574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89152ce5d22b489f9ea811b4bb61d18d_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMy05LTEtMS0w_aa9b806b-10b3-4e95-a98a-26fe96965ced">264,574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8216f15d99a94a2a86c19d3b1bad2bf5_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNC0xLTEtMS0w_b0cb0d93-e12b-4d99-9b42-2cc9da8ff25f">164,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8216f15d99a94a2a86c19d3b1bad2bf5_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNC0zLTEtMS0w_47ea7093-a363-4053-9686-fd21c5e414d0">441,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89152ce5d22b489f9ea811b4bb61d18d_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNC05LTEtMS0w_d57a2523-d34c-4e65-9a52-5c1615c3cc32">441,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62a06f5b04844061940fdd3b9480439c_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNS01LTEtMS0w_db246fe9-b9a5-41a8-b313-ec3ed2320cef">1,055,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26772e0071d34883b195a26267505a52_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNS03LTEtMS0w_a6b1b920-b945-4abc-918f-8c3090274738">9,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89152ce5d22b489f9ea811b4bb61d18d_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNS05LTEtMS0w_759e5c4f-91df-4fbe-98b9-1ab862f81f6c">1,065,145</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbc1fd769f9740e989a4d2fd47f1ced4_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNi0xLTEtMS0w_2c2f4054-f9b1-4492-b45c-c1c815058206">15,318,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc1fd769f9740e989a4d2fd47f1ced4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNi0zLTEtMS0w_f637fe5b-0052-4a1f-80d6-8c0adda30924">49,737,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae833f7b3f44f0f9e58b7193716452c_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNi01LTEtMS0w_49285752-3f23-47f0-a304-483178d03354">152,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca469517291478aa2e4c1fa421bd3d3_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNi03LTEtMS0w_d5f4bd11-714a-43ca-8120-b12a75e19b0c">47,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9646ecd78c471da7ec0b9ae8d48366_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNi05LTEtMS0w_2f75a559-f0f3-4413-995f-815dedb08ed8">49,843,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbc1fd769f9740e989a4d2fd47f1ced4_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMC0xLTEtMS0w_76866803-3690-4fb6-8a45-768ec2e21efc">15,318,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc1fd769f9740e989a4d2fd47f1ced4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMC0zLTEtMS0w_2d0331d1-7742-4ea8-9881-198d6606932d">49,737,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae833f7b3f44f0f9e58b7193716452c_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMC01LTEtMS0w_7efa1561-9f39-4f10-adf4-abcbc314f485">152,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca469517291478aa2e4c1fa421bd3d3_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMC03LTEtMS0w_95306963-d090-4072-ad06-9b67697134db">47,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9646ecd78c471da7ec0b9ae8d48366_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMC05LTEtMS0w_59f4426a-e91e-4e1f-84f0-95b327d4f442">49,843,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6edc159368b349ed8d34e1d4bd240e22_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMS0xLTEtMS0w_2aa7fb39-dbb3-4847-a24d-30d1eeed9307">4,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edc159368b349ed8d34e1d4bd240e22_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMS0zLTEtMS0w_2754b3f7-2822-4ca0-82a5-3e7277535282">278,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40b1cdafe584ea8a9f3cf4307d96744_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMS05LTEtMS0w_d2455288-20d4-4807-b1a1-8ee333c2f712">278,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6edc159368b349ed8d34e1d4bd240e22_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMi0xLTEtMS0w_2c5c05d7-268f-4f4e-b12f-b39bb5b7fdb8">141,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6edc159368b349ed8d34e1d4bd240e22_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMi0zLTEtMS0w_4b77dcb4-6e50-4cfa-a1dc-904db546f58e">769,648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic40b1cdafe584ea8a9f3cf4307d96744_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMi05LTEtMS0w_b4634a3c-c6a7-4c74-ad6d-5a011dfd5362">769,648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if52f80cf1d0e45cb97aae49b8c8230f2_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMy01LTEtMS0w_54cf1945-c06f-42c9-9eb6-cc5b6faf86a4">918,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21315fbf39347a28cfc557393bc9c1f_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMy03LTEtMS0w_4ce8fa1f-3785-493f-b147-0a67c7be2026">22,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic40b1cdafe584ea8a9f3cf4307d96744_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMy05LTEtMS0w_eb732db7-9517-4f06-97fe-bd635e0c2b89">940,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0c42cdc6a024ef985b79c61a90bbe9e_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfNC0xLTEtMS0w_fdd0f1a3-dee1-4f62-aaa9-1392b62a58e7">15,181,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c42cdc6a024ef985b79c61a90bbe9e_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfNC0zLTEtMS0w_2e99f8e7-1f24-4bdb-8292-7acb6d373c36">49,246,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32fea5db2d3c47e9a21a5f1f1ab0b6e4_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfNC01LTEtMS0w_9df56f40-e6b8-4388-9a9d-887e536cd74c">765,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d382f4a1c3c4e77bba4a6e17311df80_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfNC03LTEtMS0w_7b6409c1-24b8-4275-b949-5228e5dc7e02">69,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e05db5bc634c8395dc7ba20fd01c1f_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfNC05LTEtMS0w_99de2034-1ecf-438a-84b5-de659935ed3a">48,411,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0c42cdc6a024ef985b79c61a90bbe9e_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMC0xLTEtMS03Mzk_2892bdcc-c572-4e5e-af43-1f79a0c2baf8">15,181,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c42cdc6a024ef985b79c61a90bbe9e_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMC0zLTEtMS03Mzk_33f7a98c-44ae-4757-821e-d3507b934581">49,246,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32fea5db2d3c47e9a21a5f1f1ab0b6e4_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMC01LTEtMS03Mzk_56a68f51-01c9-4522-a272-e6945538e6aa">765,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d382f4a1c3c4e77bba4a6e17311df80_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMC03LTEtMS03Mzk_6d1ca28c-98d0-48a7-b193-4de99d207e49">69,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e05db5bc634c8395dc7ba20fd01c1f_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMC05LTEtMS03Mzk_f4b7ee11-30cb-414d-af06-a04ac91d3591">48,411,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a6b0baa09b04dc8ad7327ed08a971d4_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMS0xLTEtMS03Mzk_6d1764fc-a0a0-44af-89fa-0f311f1d0763">4,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6b0baa09b04dc8ad7327ed08a971d4_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMS0zLTEtMS03Mzk_02d9425d-0d8f-44a1-85fd-d5e6a1f6d237">262,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMS05LTEtMS03Mzk_145b0588-f5a0-4ed9-839e-a567225db742">262,415</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5a6b0baa09b04dc8ad7327ed08a971d4_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMi0xLTEtMS03Mzk_9c85f5c5-c742-4eb1-bd0c-164a039cfce1">101,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a6b0baa09b04dc8ad7327ed08a971d4_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMi0zLTEtMS03Mzk_8679c202-8f15-4b2c-a5be-b5c84311e82a">332,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMi05LTEtMS03Mzk_d6416b7e-b18b-488f-bd48-73587bace1b4">332,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa532992c0504e0ba3d7d267f54270d4_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMy01LTEtMS03Mzk_d43a429a-c3eb-4844-8c07-bff555be369e">481,737</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe1c68d19eec4a38a757dd2e42c81bf6_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMy03LTEtMS03Mzk_1adccc1d-d111-4e5a-97fd-25edaf7b6f71">15,967</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMy05LTEtMS03Mzk_6146402c-5848-4427-8dfa-9df7875cf413">497,704</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37fd46b1fc0d4e5c9cf794637e21ef86_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfNC0xLTEtMS0xMjc2_5b622dc5-ab72-4538-9f92-76f9df995d8c">15,084,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37fd46b1fc0d4e5c9cf794637e21ef86_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfNC0zLTEtMS0xMjgw_227eb86c-d0f0-4898-81bd-e99f76ac77d7">49,176,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1d9d3ac014b4702a58b9bc1204a2cb5_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfNC01LTEtMS0xMjgy_490e3cbc-6ce0-4d80-9220-7e47f62bd910">1,247,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f9e4efabd72491282314ba3c4151d14_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfNC03LTEtMS0xMjg0_ce2fab72-eb7b-418b-b179-3379af0e3019">85,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfNC05LTEtMS0xMjc4_f8c8a085-8e6a-4ff7-9a34-2566c20e98ca">47,843,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_31"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zMS9mcmFnOmNiNjgwNjYzOTdjMjQ4MjJiZDYwOGM0OTAzYzA4MWU1L3RleHRyZWdpb246Y2I2ODA2NjM5N2MyNDgyMmJkNjA4YzQ5MDNjMDgxZTVfMTExMTk_63245673-46b4-4de3-8853-c5bc0c43b538" continuedAt="i099ae46e343240d6ba508fbd784d9f03" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i099ae46e343240d6ba508fbd784d9f03" continuedAt="i74a54faf07b546b5a7bcae16f4547fd5"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2019 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the &#8220;2019 Annual Report on Form 10-K&#8221;). The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 10, for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification of prior period amounts</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made certain reclassifications to prior period amounts to conform to the current-year presentation of the reporting of research and development expense and general and administrative expense on the condensed consolidated statements of operations. Certain costs and expenses related to research and development were previously reported as general and administrative expenses on the condensed consolidated statements of operations. These reclassifications have no effect on the reported operating loss or equity for the 2019 periods presented. </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect the employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland's sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, much of their contact has shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.  Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  During this </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i74a54faf07b546b5a7bcae16f4547fd5" continuedAt="ia0540cc9f00744e185883afcf4963924"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pandemic, less patients sought care, some patients postponed elective surgeries and Cumberland's access to medical facilities was substantially limited.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain the employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zMS9mcmFnOmNiNjgwNjYzOTdjMjQ4MjJiZDYwOGM0OTAzYzA4MWU1L3RleHRyZWdpb246Y2I2ODA2NjM5N2MyNDgyMmJkNjA4YzQ5MDNjMDgxZTVfMTExMjI_d9f8f627-4802-45e2-8c78-73ae2c8c5156" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Adopted Accounting Pronouncement</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zMS9mcmFnOmNiNjgwNjYzOTdjMjQ4MjJiZDYwOGM0OTAzYzA4MWU1L3RleHRyZWdpb246Y2I2ODA2NjM5N2MyNDgyMmJkNjA4YzQ5MDNjMDgxZTVfMTExMjM_2bf63bcc-0d1f-43a9-8a0d-6c71bd2f2ee8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:continuation id="ia0540cc9f00744e185883afcf4963924" continuedAt="ibd7814a0259843c692a4f38907eecfbe"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zMS9mcmFnOmNiNjgwNjYzOTdjMjQ4MjJiZDYwOGM0OTAzYzA4MWU1L3RleHRyZWdpb246Y2I2ODA2NjM5N2MyNDgyMmJkNjA4YzQ5MDNjMDgxZTVfMTExMjU_be9575a1-96d9-40a5-9737-43c3552c6351" continuedAt="i1df52386cad9456db85f3219c4e971b1" escape="true">Operating Segments</ix:nonNumeric></ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibd7814a0259843c692a4f38907eecfbe"><ix:continuation id="i1df52386cad9456db85f3219c4e971b1">The Company has <ix:nonFraction unitRef="segment" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zMS9mcmFnOmNiNjgwNjYzOTdjMjQ4MjJiZDYwOGM0OTAzYzA4MWU1L3RleHRyZWdpb246Y2I2ODA2NjM5N2MyNDgyMmJkNjA4YzQ5MDNjMDgxZTVfMTAzMTU_8ac70437-3212-43d2-bf80-651e51e24bc3">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation></ix:continuation> </span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_34"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RleHRyZWdpb246ZjQ1MzBiZjFkNWE0NGYyNmE3MzIxZDE1NGUzN2JiZThfMzQzNA_ce47c01a-0880-4e96-a936-fe72c6338f81" continuedAt="i8ad5898f2d824783a50e5db8c1535629" escape="true">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i8ad5898f2d824783a50e5db8c1535629"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in marketable securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of September 30, 2020 and December 31, 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of September 30, 2020 and December 31, 2019, all trading securities were investments with original maturities of less than ninety days and as a result, were classified as cash equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:81pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -   Significant inputs to the valuation model are unobservable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RleHRyZWdpb246ZjQ1MzBiZjFkNWE0NGYyNmE3MzIxZDE1NGUzN2JiZThfMzQzMg_2a571bbd-d916-4ef9-849f-0596e45ab8b3" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:28.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07d176dae7e493b8fd0de707a8f73b1_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC0xLTEtMS0w_150bbc96-ead1-42e2-a418-71527160e604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab8d543293c243d483f364b765f13a5a_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC0zLTEtMS0w_dc3f60c0-6888-45cf-bf1c-e781f086c267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a4e269bc9b4de18ca89b7b6757b95e_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC01LTEtMS0w_223a8653-4d6e-4da2-a196-ce0d1164b2a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b1300825a343c492f6cec5fac50c3f_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC03LTEtMS0w_78df5f80-0a78-4a8a-87bb-dbbc5102a7b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b6aa7e3eea8489992e4ccb91292c2ba_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC05LTEtMS0w_b46125fa-fa4b-4fcc-aa1e-7537ef1f0a97">2,119,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f317e5f67db4275a57f6749f14461f1_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC0xMS0xLTEtMA_bf8191ed-8bf5-435c-b20c-a7af9fb76489">2,119,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of marketable  securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971765b8c0cf44faa48dc5064fcf9605_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi0xLTEtMS0w_bbf0b269-6984-4f0c-913a-b1a685bc4ace">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb93e31604f48009bc491bfe2432446_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi0zLTEtMS0w_62b62e4d-581f-4422-bafd-e63e8beccfae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi01LTEtMS0w_5de2a2cf-4f55-4cb0-bf96-08c69a547120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595eb369427c497fac23d3e8c5820214_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi03LTEtMS0w_544b26d4-84e8-445b-b4a5-bdfc284ad746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd5b9e6ccc0d4886acc721fa7dbb63c7_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi05LTEtMS0w_3af029a0-5dbb-4f1d-abdd-0309b4c51010">2,119,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi0xMS0xLTEtMA_5f1848dc-ba56-45be-95a2-6b4e64a2fd08">2,119,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_37"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RleHRyZWdpb246M2VlOGNhNzhiNzkwNDA2OWI2OTM3OWIzZTRjY2Q2MjZfNDMy_fdc2f7e5-4bd6-4676-87e2-54d1ffa9bfd2" continuedAt="i705fd36de02545a2bb5287f9848b8027" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i705fd36de02545a2bb5287f9848b8027"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RleHRyZWdpb246M2VlOGNhNzhiNzkwNDA2OWI2OTM3OWIzZTRjY2Q2MjZfNDMz_bd5ef630-2a14-45bf-870b-ca0301207356" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2020 and 2019:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfMy0xLTEtMS0w_dc933537-d6c3-48ff-a0cd-f6960200066e">1,275,620</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfMy0zLTEtMS0w_381be7ac-a55e-4cbb-8b4e-b27c2ab55f63">3,316,286</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNC0xLTEtMS0w_810e6874-b3f8-4a92-ab84-d9901715c353">777,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNC0zLTEtMS0w_9bd44394-86b7-4da6-9f91-dd9bcfe0d2bd">1,349,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNS0xLTEtMS0w_df562953-c9f0-4226-91a7-24dc38981cd8">15,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNS0zLTEtMS0w_bab9f3ca-afdc-4cc1-8633-81bba402b9bb">13,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNi0xLTEtMS0w_180a2986-e02b-4467-bf4c-ca6cb1d6a282">481,737</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNi0zLTEtMS0w_51079ceb-063b-4736-a081-28fb404a8fb9">1,953,668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfOC0xLTEtMS0w_8dfcac58-c245-479b-90ea-d8198b82823c">15,134,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfOC0zLTEtMS0w_3b6e15d2-7246-4765-9742-c48e22fe21b2">15,368,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfMTAtMS0xLTEtMA_680661da-9c2e-4bc7-bb8a-ef68aff517cb">15,134,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfMTAtMy0xLTEtMA_bef24f96-7f94-4b28-aa5e-e7f87d8c4a77">15,368,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfMy0xLTEtMS0w_ba6c153c-d20c-4201-9194-d99af8da848f">4,838,250</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfMy0zLTEtMS0w_279857ff-511d-4ae7-99f6-6e2ae17c9f5f">5,842,361</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNC0xLTEtMS0w_31a5f830-9e36-446a-bdb9-0b6b6c6c847b">2,334,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNC0zLTEtMS0w_bf1f3af9-faff-4042-b46b-2684d5e47fd2">3,268,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNS0xLTEtMS0w_058de113-d6f7-46c0-8dfd-d000d9e95ebf">47,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNS0zLTEtMS0w_53700455-ad83-4e97-aee6-ffb515c89a96">2,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNi0xLTEtMS0w_ccc4dc60-fb64-412b-be54-1d316c350883">2,455,633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNi0zLTEtMS0w_b6bf7a28-b262-4a5b-bbcf-7220da734f82">2,577,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfOC0xLTEtMS0w_0e159637-02d4-496a-b203-4931667f0908">15,206,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfOC0zLTEtMS0w_41976643-df91-4c1d-abea-2c78c614ea27">15,454,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfOS0xLTEtMS0w_dd6c223f-195b-4901-996a-00ab599e630a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfOS0zLTEtMS0w_92e0f461-7307-44a3-8c35-43ce9526c42e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfMTAtMS0xLTEtMA_b68d2d90-e060-4487-afbb-a6507fa3130a">15,206,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfMTAtMy0xLTEtMA_7dad67b7-bb9e-40b1-9a84-98a6333c5d90">15,454,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and 2019, restricted stock awards and options to purchase <ix:nonFraction unitRef="shares" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RleHRyZWdpb246M2VlOGNhNzhiNzkwNDA2OWI2OTM3OWIzZTRjY2Q2MjZfMjUz_ad96c4ab-32e1-4e5e-89f9-8674cced46f7">197,210</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RleHRyZWdpb246M2VlOGNhNzhiNzkwNDA2OWI2OTM3OWIzZTRjY2Q2MjZfMjYw_203fc88b-6c91-4433-93e1-c61d46344b5f">3,600</ix:nonFraction> shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div id="i79bdbd3b4fc54ce0b1f7e776238df573_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjMzMw_26069a21-d2f9-4817-a2bf-8420f6952bc0" continuedAt="i8ba22c9028e94ebf88f97a555797ee40" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i8ba22c9028e94ebf88f97a555797ee40"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. </span></div><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjMyOQ_9dee81b1-6076-4bc5-96f2-56c0097ee7fe" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie302cf43817549578a8f9ef152a447b1_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMy0xLTEtMS0w_6296417f-b8f4-4b44-81ea-20daf71e9b07">218,462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25de277b0b0646cb9281cd16f837c44a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMy0zLTEtMS0w_0336afbc-5e5e-4c30-bb9d-cc79bc1621e4">777,185</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90fb467e2733434596b17207333e3bfe_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMy01LTEtMS0w_81806951-8afb-40c9-bd47-cfb8097589ac">1,527,173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce5aa81441845e89b5271f86420011f_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMy03LTEtMS0w_1feb4b46-5505-40c0-87e1-8e3164c41b48">2,608,160</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6245a0edd04497ac8b9d6d6e9f57ab_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNC0xLTEtMS0w_be859111-a609-4c66-abb3-ea10e53cae65">516,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf4e408c7b1844ffb641ff92ed986d13_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNC0zLTEtMS0w_063defb0-aa0c-46f6-b630-42ae4cf38d95">116,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79fe091e6954839a3d9614623decb4f_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNC01LTEtMS0w_eec74c39-a860-4a57-883c-3d71c7976c1f">640,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33026525efb4a2fba6cc177559e712b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNC03LTEtMS0w_d7cb62d3-2571-4d50-b4c0-e921246d02d8">794,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideedcf83bae049bdaf355ac459d10cf8_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNS0xLTEtMS0w_0e6a3f10-e4d7-4e84-8c8f-d6cac7a3ca5f">3,615,557</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9da2d5ab42648409a9408e0b935a37d_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNS0zLTEtMS0w_7f2400c6-267d-4c66-bbfd-6a11e683d22d">2,924,237</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52c8721688534cb184cbf86471fe0d57_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNS01LTEtMS0w_cbceb907-4795-48ad-ab14-e80a82580a40">10,387,046</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f094a21244147fb9ce5e1bb5b80e965_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNS03LTEtMS0w_13dd0c5f-fa24-4c4d-86ff-de02b39881b4">9,720,434</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1481a754bb38453f812b6c54c7a6c98b_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNi0xLTEtMS0w_92af7254-df90-48ec-a173-21c4e3d2f387">406,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd27b429249456c90fc071b0ff8b3bd_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNi0zLTEtMS0w_5e71d9a6-2863-4b19-9231-cd69f50613bd">224,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5902cac206e44f0da81556294b8309f5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNi01LTEtMS0w_53f5def0-08c4-42df-ac2a-6508918ab64b">790,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d88d58c35bc420b81d5571b5f859389_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNi03LTEtMS0w_5f1649ff-cc8d-4c3d-a8c2-66a401f18c30">724,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0440b8c0a141a6bd9f692f2deeb4ba_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNy0xLTEtMS0w_0504c5ec-a9d9-4217-b271-62e0c900f0c3">1,416,146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9483466598e4f23ae7a5abdf7100ada_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNy0zLTEtMS0w_a486a786-bd97-4414-8e77-950543f8a1a1">1,170,567</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fb1ae19da3f45d18b49aaf25f1dbd88_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNy01LTEtMS0w_14a44f5d-f060-4cd0-8f13-96cc9e0312e9">3,677,434</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie18912dcb3d24ad7a55576713413c72c_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNy03LTEtMS0w_368e51b9-bed2-4c8c-976c-bea7670e5ef9">3,543,166</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3299d8817d7541f3bdc4c7f01ae7bd80_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOC0xLTEtMS0w_899fe3a0-b7b9-45b1-a552-ee8d0f1c22fb">2,813,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5447d4c0f5a349c1a9861329416d6e25_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOC0zLTEtMS0w_1a7bd2d2-c5ff-4ac5-aa0b-61da4d21ec8c">1,451,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if90916a859244a87afe32a6420d18ffa_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOC01LTEtMS0w_b0c66910-5bd4-4222-9757-4d4eecbdb9f5">8,551,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c798a624494da4a9a833b2d4b416cd_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOC03LTEtMS0w_b4bebd2a-0825-42d8-b5da-cf8417abfbc2">6,156,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a8c2296b3941e0a307a7590c71f19b_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOS0xLTEtMS0w_53921d87-993f-4e02-b811-f20b818e0209">265,047</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95daedfded3c472b9eb62ad072b1551e_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOS0zLTEtMS0w_9c7b6414-c52a-42ce-a789-7c5ab42cb354">270,852</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i810fe6fe3d5d4acc95a6434905ad9bbd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOS01LTEtMS0w_3801a808-0142-4889-95a3-01516b806561">1,605,570</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f33391c5194ed3a2eab2153394a830_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOS03LTEtMS0w_a34d696f-f02c-4558-9a99-7590d172e637">1,535,981</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMTAtMS0xLTEtMA_5d7a0aae-3a2a-45a3-acd3-0ec4ed885fbd">9,250,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMTAtMy0xLTEtMA_5f9b71e3-6322-47af-8588-79837b499e52">6,935,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMTAtNS0xLTEtMA_1aaf4ae4-8220-45d7-872f-362ba8033d08">27,179,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMTAtNy0xLTEtMA_9fc75bae-dffb-4ed8-99d7-7b83ae60461f">25,082,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i6cc85fa1f23c400f98a38cd8f0ac2143_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjIxNw_b3b48ba1-de99-4b50-b50a-4bf3459275e3">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6e3533c9ef434f2296767af0d6fa95cd_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjIyNA_7478b020-6ee0-4ad0-8fcf-546838c56356">0.2</ix:nonFraction> million for the three months ended September 30, 2020 and 2019, and $<ix:nonFraction unitRef="usd" contextRef="i6666cecacb694b16a57f4cfa2cedd55d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjI3MQ_011e3e04-ad9e-4501-8a39-07bee5fa650e">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7b09030d4c8746e39c72272a8087f528_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjI3OA_515ff6ad-44fd-4a79-9ca5-c518b63fbec6">0.9</ix:nonFraction> million for the nine months ended September 30, 2020 and 2019, respectively.</span></div></ix:continuation><div id="i79bdbd3b4fc54ce0b1f7e776238df573_43"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMTk4Ng_1a4510ba-e2c7-4226-a0bb-3f621c392cb4" continuedAt="ieec4d3b05687496cba311e116e099a15" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="ieec4d3b05687496cba311e116e099a15" continuedAt="i50d61c2f5e5445b4adb54bfdbfd7dfed"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At September 30, 2020 and December 31, 2019, there were no cumulative obsolescence and discontinuance losses necessary.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at multiple locations. As that API is consumed in production, the value of the API is transferred from raw materials to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i50d61c2f5e5445b4adb54bfdbfd7dfed"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">finished goods inventory. Cumberland also maintains API for its Vaprisol brand which is classified as raw materials inventory.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consigned inventory represents Authorized Generic product which is shipped to the Company&#8217;s distribution partner and stored until sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories that are classified as non-current inventories.  The Company also has obtained $<ix:nonFraction unitRef="usd" contextRef="i43031ec5d6b146e396b7ed311aeda9fd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMTY0NQ_0e0619fc-b38e-4638-b00c-1ce60add6342">0.4</ix:nonFraction>&#160;million in non-current inventory for API related to its ifetroban clinical initiatives. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020 and December 31, 2019, total non-current inventory, including Vibativ and ifetroban, was $<ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMTA5OTUxMTYzMDEwMQ_64b2b7cd-5036-4948-a4e1-7eb14726a36f">12.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMTgwOQ_05002ff1-3bcd-419e-bb77-1e01a175852f">15.6</ix:nonFraction>&#160;million, respectively. The Company had $<ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMjE5OTAyMzI1NzU4MQ_461a51fe-15ca-4a70-a81d-bead90aab7c2">2.7</ix:nonFraction> million of Vibativ finished goods included in non-current inventory at September 30, 2020 and did not have any finished goods included in the non-current inventories at December 31, 2019. </span></div><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMTk4NQ_d67fb9c1-cedf-44db-96d1-b52e3fdce570" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following:</span></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:57.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMi0yLTEtMS0w_b3a4dabf-3645-4603-9ebc-caac20721ff2">17,064,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMi00LTEtMS0w_08e30314-1177-47bf-be5a-9c9ec9df601c"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMi00LTEtMS0w_9af82daa-eb8d-4137-b904-ed7a5a6acac5">19,345,723</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMy0yLTEtMS0w_c5da7325-fb74-49e5-838d-908e842e6f66">250,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMy00LTEtMS0w_6279b88e-7c12-4636-99c3-10bcfe7d35d4"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMy00LTEtMS0w_dfa92176-2af6-4f10-ae58-ec5ee3c4519c">416,468</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNC0yLTEtMS0w_c5d1f9ed-da6c-4244-be0d-6da6e862dcdb">5,414,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNC00LTEtMS0w_21a7572e-7145-46e4-8fe9-53c057ecbb82"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNC00LTEtMS0w_ba585f71-43ae-4f47-86ba-62422cb3e054">4,664,055</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNS0yLTEtMS0w_356eca39-3d56-45f0-ba61-2c1f2fe48fd0">22,729,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNS00LTEtMS0w_0c31476f-665a-46cc-82ef-f6355c6689f6">24,426,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNi0yLTEtMS0w_11f5bf7e-3110-420c-9494-9ae7751bc07d">12,649,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNi00LTEtMS0w_678dbe7c-ac42-427e-9278-a9e043c632a6">15,554,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNy0yLTEtMS0w_b2eece9d-5e68-42ad-a8f9-b971d217d3e8">10,080,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNy00LTEtMS0w_a484a681-e37d-478b-94f3-f73b53588d14">8,871,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_46"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RleHRyZWdpb246YWIwYWM3ODZkZjE4NGVkNWEyYjA4ZDQ3OTc0MGQ3MGRfMTc5NA_933c34a8-ca4e-4e55-8dfe-2fab149edcf6" continuedAt="icbe3767d7d2e47ec87ebcd596936bc3d" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="icbe3767d7d2e47ec87ebcd596936bc3d" continuedAt="ifa297dadcc3c48ca829ee4e42b9784da"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases classified as operating leases. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RleHRyZWdpb246YWIwYWM3ODZkZjE4NGVkNWEyYjA4ZDQ3OTc0MGQ3MGRfMTYzNw_f2123260-174e-4e4d-acfe-9e4399c14d7f">7.42</ix:nonFraction>%. The weighted-average remaining lease term at September 30, 2020 is <ix:nonNumeric contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RleHRyZWdpb246YWIwYWM3ODZkZjE4NGVkNWEyYjA4ZDQ3OTc0MGQ3MGRfMTY5Mg_a6ac60c9-90c9-4ea7-ae14-5ad12a192099">2.2</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RleHRyZWdpb246YWIwYWM3ODZkZjE4NGVkNWEyYjA4ZDQ3OTc0MGQ3MGRfMTc5NQ_485e9c6c-8cfb-44f3-b2c2-cae1b6ce3a11" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOmEwZjUyNGRkZjYxNzRhNGFiZTU4MzlkZDhiZDRmNzFkL3RhYmxlcmFuZ2U6YTBmNTI0ZGRmNjE3NGE0YWJlNTgzOWRkOGJkNGY3MWRfMS0yLTEtMS0w_da2f3247-a2fa-48bc-9733-06fb4cfc3cc7">2,267,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOmEwZjUyNGRkZjYxNzRhNGFiZTU4MzlkZDhiZDRmNzFkL3RhYmxlcmFuZ2U6YTBmNTI0ZGRmNjE3NGE0YWJlNTgzOWRkOGJkNGY3MWRfMS00LTEtMS0w_adaaae97-ca49-4eff-81cb-e5fee7146e03">2,960,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfMS0yLTEtMS0w_5810fa0f-9be6-43be-b43f-8f832ef5d5ed">991,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfMS00LTEtMS0w_0b833995-fb48-4fd2-8ab3-45c97ffe67a3">920,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfMy0yLTEtMS0w_bfeb40bd-82a3-474f-8ccf-179474b50435">1,323,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfMy00LTEtMS0w_b1ad6ff1-500c-49fd-ab91-6d9bbd8fe9ab">2,076,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfNC0yLTEtMS0w_dd2989c6-971a-43f2-a484-8bcb1b38410f">2,315,761</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfNC00LTEtMS0w_e431d227-3a35-48e9-9786-ba5fe7a9fe87">2,996,903</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RleHRyZWdpb246YWIwYWM3ODZkZjE4NGVkNWEyYjA4ZDQ3OTc0MGQ3MGRfMTc5Ng_4466b21a-6095-4685-8d63-be1d0081d2d9" continuedAt="iab976e73f88747ad967fb48aaf546cab" escape="true"></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><ix:continuation id="ifa297dadcc3c48ca829ee4e42b9784da"><ix:continuation id="iab976e73f88747ad967fb48aaf546cab"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:76.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at September 30, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfMS0yLTEtMS0w_e4a47a4d-c047-4aaf-a124-1955ccae9ceb">288,781</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfMi0yLTEtMS0w_e5dd9595-3265-44ed-84bd-25ed8c596502">1,144,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfMy0yLTEtMS0w_b1793d1f-dc20-4efb-a54e-e127fce513be">1,019,313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfNC0yLTEtMS0w_8bc30cff-66af-4cd0-a08a-d185c84122e7">92,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:zerodash" name="cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfNS0yLTEtMS0w_8a824dff-815a-4e53-b7dd-997e10f3d1bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfNi0yLTEtMS0w_df7b55d9-367c-4bc8-b5a5-e6425459c9a7">2,545,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfNy0yLTEtMS0w_365cec16-f7c4-4309-8a3b-6b8ff8efe151">229,700</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfOC0yLTEtMS0w_e15ad447-69d9-4f38-a56a-c9d977e88882">2,315,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_49"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNzMxNA_7a4bd390-4d0a-42e6-ba9f-aecd047e6b69" continuedAt="ie0f423b49a7e4a03b8e32c94804f3925" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="ie0f423b49a7e4a03b8e32c94804f3925" continuedAt="icea2ae371930408992135b59cbf313bf"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="ibb00b2069e194ae3b41a6bbd3811b9ef_I20100513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTI5_098ae41a-550e-4b1e-ae0c-8963972e3622">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="i8cea20af1c7a4bf8892167b3a57bb8b3_I20160131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjkw_73671c84-3c72-4508-b974-d352b9eeab34">10</ix:nonFraction> million repurchase program to replace the prior authorizations.  During the nine months ended September 30, 2020 and September 30, 2019, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i5651034dcdff44f08080de6ea37be942_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMzk2_3b52f490-e43b-4385-93b7-87f0b7f3bb22">407,683</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i1f1cc7c6f3f64637b1ca6aea46ce29a1_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNDEw_b4f8f426-91a5-4f81-99a9-c5d9302b5748">452,155</ix:nonFraction>, respectively, of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i5651034dcdff44f08080de6ea37be942_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNDYy_3fadca04-77b5-45b4-ab37-ef8b9b80212d">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f1cc7c6f3f64637b1ca6aea46ce29a1_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjE5OTAyMzI2MjkwNA_5ba39d6d-87bf-4d56-b91a-a6019d674399">2.6</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2020 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  During the nine months ended September 30, 2020, a total of <ix:nonFraction unitRef="shares" contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjE2NQ_9f46ea93-7399-4645-bc5e-301550321cdf">10,080</ix:nonFraction> shares have been purchased.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sale</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i0a446f495cd042eca3da6e7c97bb5b5d_D20171101-20171130" decimals="-6" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfOTc2_3cf8c2aa-329b-4ec3-9664-0226616cf1ce">100</ix:nonFraction> million in corporate securities. The Shelf Registration was declared effective in January 2018 including an At-The-Market ("ATM") feature enabling the Company to sell shares at market prices.  The Company did not issue any shares under the ATM during the nine months ended September 30, 2020 or September 30, 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, and September 30, 2019, the Company issued <ix:nonFraction unitRef="shares" contextRef="i5eed37f174f24049b2b6ad3653f05bbe_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTMwMw_ff5bb096-2f54-4ab7-84b1-7805934458a5">230,491</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i41de7f64b76f4893a406e9afd4a76a14_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTMxNw_ea7cd7a9-ce54-4966-bfcd-0dec331a9c4e">225,869</ix:nonFraction> shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <ix:nonNumeric contextRef="i6006916e3bab4f718de88600cfdcb08d_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNzMxOA_27df579d-b552-45c1-b485-50837ba7104e">one-year</ix:nonNumeric> anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumberland Emerging Technologies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an agreement whereby Hongkong WinHealth Pharma Group Ltd. ("WinHealth") made a $<ix:nonFraction unitRef="usd" contextRef="i930ad17f078c46d582cdf90475e66e78_I20190430" decimals="-6" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTkyNQ_1e622c72-9f89-440e-a1bc-28ec8521c8a3">1</ix:nonFraction>&#160;million investment in CET through the purchase of shares of its common stock. As part of the agreement, WinHealth obtained the rights to name an individual for appointment to the CET Board of Directors  as well as the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, during 2019, Cumberland also made an additional $<ix:nonFraction unitRef="usd" contextRef="i930ad17f078c46d582cdf90475e66e78_I20190430" decimals="-6" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjMwMg_d1445918-55da-4c73-8ec6-d4e0382aa911">1</ix:nonFraction>&#160;million investment in CET.  Cumberland purchased additional CET common shares through contribution of $<ix:nonFraction unitRef="usd" contextRef="ib2affeac992f45c1807ad24d6642935c_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentCashContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjM5OQ_d573f6ac-ac8b-4b3b-976a-d0ccb9860679">0.3</ix:nonFraction>&#160;million in cash and a conversion of $<ix:nonFraction unitRef="usd" contextRef="i02dfaa25707a4e09b76974e10fd34245_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjQzMA_8ec0960a-80f9-4a32-9f08-c1ac8efc1730">0.7</ix:nonFraction>&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for $<ix:nonFraction unitRef="usd" contextRef="i26301daa05cd47268f1bd0644a7e18a1_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjYwNQ_46ed80d1-4539-4a85-9b9f-5788fb8db769">0.8</ix:nonFraction>&#160;million that was funded during 2020.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $<ix:nonFraction unitRef="usd" contextRef="ia98b89ba857e4a2cb67df1f1038088f9_I20201007" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjE3Mw_2d6f83e0-8db3-46c0-9aa4-e8e1c3e9c812">15</ix:nonFraction>&#160;million and Cumberland has the ability to request an increase of up to an additional $<ix:nonFraction unitRef="usd" contextRef="ia98b89ba857e4a2cb67df1f1038088f9_I20201007" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjE0MA_2872198a-1368-4ae7-ab75-002fb4a5a685">5</ix:nonFraction>&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $<ix:nonFraction unitRef="usd" contextRef="ia98b89ba857e4a2cb67df1f1038088f9_I20201007" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjE1Mg_ec434b0e-2f7c-47f4-b0fa-29e77b07f8ff">20</ix:nonFraction>&#160;million, which was also the maximum aggregate principal available for </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="icea2ae371930408992135b59cbf313bf" continuedAt="ie33ad743aeef4b108eda5e9d7d977043"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrowing under the previously amended Pinnacle Agreement. The Fourth Amendment extends the maturity date of the Pinnacle Agreement through October 1, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement. The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of September 30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="i19338c6b30fd4b21b231c47865291087_D20200814-20200814" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjExMg_3d475739-554e-46b7-b40a-d5ea0487dbb5">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie2620c3a3fad4da8b66e2277201834e8_D20200814-20200814" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjExOQ_d65274ab-a3a5-4e50-9645-3449c724220f">2.75</ix:nonFraction>% above LIBOR with a minimum LIBOR of <ix:nonFraction unitRef="number" contextRef="i407f51866f02409cb9fad138500d14d1_D20200814-20200814" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjEyNg_1137001a-b271-48a5-b940-8f4782c491b6">0.90</ix:nonFraction>%. The applicable interest rate under the Pinnacle Agreement was <ix:nonFraction unitRef="number" contextRef="iaadf65c3ea20463da1472b122fe42d41_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNDQ0Mw_aba27eac-1617-4366-bced-f8dd6818ffe8">2.90</ix:nonFraction>% at September 30, 2020, prior to entering into the Fourth Amendment.  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="i19e5831ccde74dbba7c187512febfbb2_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjEzMw_661d18a5-3673-4be7-9a98-ab4761d4d4ef">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. As of September 30, 2020 and December 31, 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="i9d96acd949234acfb136a690bec1d7ce_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjE5OTAyMzI2MzI4Mg_32696a96-4f09-4293-b89f-7f67f59db63a">17.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNDcyMg_b052841f-c504-44c7-80e0-1b495a88ff41">18.5</ix:nonFraction> million in borrowings outstanding under our revolving credit facility, respectively.  Of the $<ix:nonFraction unitRef="usd" contextRef="i9d96acd949234acfb136a690bec1d7ce_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjE5OTAyMzI2OTA0Ng_32696a96-4f09-4293-b89f-7f67f59db63a">17.0</ix:nonFraction> million in borrowings outstanding at September 30, 2020, $<ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LinesOfCreditCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjE5OTAyMzI2OTA4OQ_ae1b133d-90bc-4977-a982-fbd1db6cba7f">2.0</ix:nonFraction> million is classified as current based on the terms of the Fourth Amendment.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i04eb73a534cd4abf9da31ee653c6edde_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNDk0Mw_8fe63e02-31d6-43c6-8091-1c7fce450603">2,187,140</ix:nonFraction> pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP is administered by the U.S. Small Business Administration ("SBA").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan matures April 14, 2022, and bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="id6ec3802e7f5429586813fbc92cd89e5_I20200420" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNTI1NA_b9fe871c-f42e-4adb-b089-589ddbdb37d5">1.0</ix:nonFraction>% per year, payable monthly commencing during November 2020. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the date of funding the Company has used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As result, the Company has recorded the $<ix:nonFraction unitRef="usd" contextRef="i04eb73a534cd4abf9da31ee653c6edde_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNjIyOA_8fe63e02-31d6-43c6-8091-1c7fce450603">2,187,140</ix:nonFraction> as a deferred income liability, which is included as a component of other current liabilities on the condensed consolidated balance sheet. The Company intends to apply IAS 20 to the PPP loan forgiveness and has presented the amounts expected to be forgiven as deferred income. The Company will account for the anticipated forgiveness of the PPP loan under IAS 20 when the Company believes that the forgiveness is reasonably assured.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. In October 2020, the Company submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to SBA for the SBA's review and approval. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $<ix:nonFraction unitRef="usd" contextRef="i593c0deb73804b658d160e2556b47e42_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjE4Ng_4f6dcdae-50ab-4b0b-9a71-994b55044016">0.2</ix:nonFraction>&#160;million equity contribution and an initial investment from Cumberland in the form of $<ix:nonFraction unitRef="usd" contextRef="i0afbb1a866c34e2b917ab586687f4135_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjIwMA_abc5af37-02bf-4707-8d07-5cb663b8942e">0.2</ix:nonFraction>&#160;million convertible note. The joint venture will seek additional future </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie33ad743aeef4b108eda5e9d7d977043">capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.</ix:continuation>   </span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_52"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181Mi9mcmFnOmZkZGVkNjllMDg1MDQzNmY5ODA4MjVlYzM1MjJiZmQ1L3RleHRyZWdpb246ZmRkZWQ2OWUwODUwNDM2Zjk4MDgyNWVjMzUyMmJmZDVfNjM2_071f9184-afb6-418c-9b36-ab3576305608" continuedAt="i82b0f8564add45649e79afdd52034d8e" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i82b0f8564add45649e79afdd52034d8e" continuedAt="i4e0e6331c5db411898a0f2bc21efd92c">As of September 30, 2020, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="i75f6e5e1e35347acb9908a1fc5e7a4d9_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181Mi9mcmFnOmZkZGVkNjllMDg1MDQzNmY5ODA4MjVlYzM1MjJiZmQ1L3RleHRyZWdpb246ZmRkZWQ2OWUwODUwNDM2Zjk4MDgyNWVjMzUyMmJmZDVfNjM_79796c30-8646-4082-8a2e-7ce5ac7d2360">56.3</ix:nonFraction> million in federal net operating loss carryforwards including approximately $<ix:nonFraction unitRef="usd" contextRef="i2aae3ade58f14629babea615840c16d4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181Mi9mcmFnOmZkZGVkNjllMDg1MDQzNmY5ODA4MjVlYzM1MjJiZmQ1L3RleHRyZWdpb246ZmRkZWQ2OWUwODUwNDM2Zjk4MDgyNWVjMzUyMmJmZDVfMTM0_2c65ea3f-151d-4fc8-b775-7c6ec1dd3c37">44.1</ix:nonFraction> million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4e0e6331c5db411898a0f2bc21efd92c">The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</ix:continuation> </span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_55"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181NS9mcmFnOmZkNmZhMzU1YzJjNDQ3YmU5NzI4MTgzOWRhY2I0ODBmL3RleHRyZWdpb246ZmQ2ZmEzNTVjMmM0NDdiZTk3MjgxODM5ZGFjYjQ4MGZfMTAyMg_5f01a0f2-0b81-4dd3-afeb-fd97eac5d57c" continuedAt="i2b8ac02426c54a7ca3a8bc35ff85918b" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="i2b8ac02426c54a7ca3a8bc35ff85918b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 10 do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span></ix:continuation></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_58"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10) <ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNjUxOA_ab53e377-af01-4870-a90d-ec5c377538bf" continuedAt="i27635d5d4e2847c3be729abbf11e57ae" escape="true">ADDITIONS AND RETURN OF PRODUCT RIGHTS</ix:nonNumeric></span></div><ix:continuation id="i27635d5d4e2847c3be729abbf11e57ae" continuedAt="i5bca2e76da2d4cb1a2995c99087bad45"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  The Company expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i657f7cc3031d4101af068d47a7501bd3_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDcwOA_b5b151c0-426e-440a-b651-2a0649be8c7a">20.0</ix:nonFraction>&#160;million at the closing of the transaction and a $<ix:nonFraction unitRef="usd" contextRef="i657f7cc3031d4101af068d47a7501bd3_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDY4OQ_011733d9-4bfa-41f2-9662-ac11e79d5bae">5.0</ix:nonFraction>&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i657f7cc3031d4101af068d47a7501bd3_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDcwMw_6dccc6f0-6b52-4921-b750-2c308d3d4cf2">20</ix:nonFraction>% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNjUxOQ_9fdae32c-10cc-4629-a858-94ae9f5b2388" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the initial payments and consideration for the business combination:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.269%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE3ODA5ZWY3YWMxMzQzOTJhYTJjZDhkZDcwNTFhNzM4L3RhYmxlcmFuZ2U6MTc4MDllZjdhYzEzNDM5MmFhMmNkOGRkNzA1MWE3MzhfMi0xLTEtMS0w_c35d8e79-d613-47a3-8e57-b40ac86b792b">20,000,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment during 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE3ODA5ZWY3YWMxMzQzOTJhYTJjZDhkZDcwNTFhNzM4L3RhYmxlcmFuZ2U6MTc4MDllZjdhYzEzNDM5MmFhMmNkOGRkNzA1MWE3MzhfMy0xLTEtMS0w_b8789c93-2ac2-4543-a7b9-09b95de158bf">5,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="cpix:PaymentsForContingentConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE3ODA5ZWY3YWMxMzQzOTJhYTJjZDhkZDcwNTFhNzM4L3RhYmxlcmFuZ2U6MTc4MDllZjdhYzEzNDM5MmFhMmNkOGRkNzA1MWE3MzhfNC0xLTEtMS0w_e36f2bd1-9932-4d17-a273-03b85a482c1d">9,182,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE3ODA5ZWY3YWMxMzQzOTJhYTJjZDhkZDcwNTFhNzM4L3RhYmxlcmFuZ2U6MTc4MDllZjdhYzEzNDM5MmFhMmNkOGRkNzA1MWE3MzhfNS0xLTEtMS0w_a167fc2e-4f3a-481f-9e1a-ff723a0fbb0a">34,182,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNjUyMA_a3da4942-3d7b-4382-b8b1-2b6b7767cf69" continuedAt="ic48a314321d6434dac9f8eb1708fc675" escape="true">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i5bca2e76da2d4cb1a2995c99087bad45" continuedAt="i51c195d40edf4f539c873e7e20ed342b"><div style="margin-top:6pt;text-align:justify"><ix:continuation id="ic48a314321d6434dac9f8eb1708fc675"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfMC0xLTEtMS0w_33fd5b9b-c9a8-4d77-9c53-c15ed99e2ec0">6,624,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - unlabeled vials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfMS0xLTEtMS0w_a7b7cbc8-fad0-4b97-8b8c-b473e6643d7d">3,970,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - validation vials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfMi0xLTEtMS0w_fe00f875-0df6-4259-9a50-5e4af774cce2">1,827,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfMy0xLTEtMS0w_be8abfd4-1912-4a67-afc9-e8e7650f0aa9">9,129,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfNC0xLTEtMS0w_1c2f497e-4fcc-4239-91fe-c27fa176e168">21,550,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property amortizable intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfNi0xLTEtMS0w_ffe75796-d949-490b-8086-ab74bab9e206">11,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfNy0xLTEtMS0w_989d5753-e5cb-49d2-9296-1c2e91dd5946">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles and goodwill</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfOC0xLTEtMS0w_9f686fd1-414a-465f-ae0e-cbf2355a3e82">12,632,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfOS0xLTEtMS0w_f2d57291-6d47-4de3-81c2-8484a8aef180">34,182,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. </span></div><ix:nonNumeric contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNjUyMQ_b352dd2b-f5a1-4f1c-9a01-b1051f189088" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.977%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582dbdc998d44cdbab1a7981ad14c27c_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE0ZDA4NGRhNTEwYTQxMjk4MTg5MmQwYTc0YmVlZjZjL3RhYmxlcmFuZ2U6MTRkMDg0ZGE1MTBhNDEyOTgxODkyZDBhNzRiZWVmNmNfOS0xLTEtMS0w_41f5d1b6-a8e3-4da2-8ce5-47a1c791693a">8,633,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE0ZDA4NGRhNTEwYTQxMjk4MTg5MmQwYTc0YmVlZjZjL3RhYmxlcmFuZ2U6MTRkMDg0ZGE1MTBhNDEyOTgxODkyZDBhNzRiZWVmNmNfMTAtMS0xLTEtMA_dff4ff65-8926-4cc3-9419-526ecda2482d">834,014</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE0ZDA4NGRhNTEwYTQxMjk4MTg5MmQwYTc0YmVlZjZjL3RhYmxlcmFuZ2U6MTRkMDg0ZGE1MTBhNDEyOTgxODkyZDBhNzRiZWVmNmNfMTEtMS0xLTEtMA_784bfdec-f121-4723-8970-109230201288">806,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE0ZDA4NGRhNTEwYTQxMjk4MTg5MmQwYTc0YmVlZjZjL3RhYmxlcmFuZ2U6MTRkMDg0ZGE1MTBhNDEyOTgxODkyZDBhNzRiZWVmNmNfMTItMS0xLTEtMA_4aa7f1ca-9290-415c-8035-5dd71b5f9d13">1,112,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE0ZDA4NGRhNTEwYTQxMjk4MTg5MmQwYTc0YmVlZjZjL3RhYmxlcmFuZ2U6MTRkMDg0ZGE1MTBhNDEyOTgxODkyZDBhNzRiZWVmNmNfMTMtMS0xLTEtMA_30285658-2720-458a-94f2-2688c759aa94">8,105,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMjQ2NA_a754508e-050c-437f-a666-ab7ebea4bd24">8.1</ix:nonFraction>&#160;million was classified as other current liabilities of $<ix:nonFraction unitRef="usd" contextRef="i5495d94083d24a5989730f4a6f7ba7da_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMjUxNA_ef696233-eada-4f13-b457-4b235fe80ab9">2.8</ix:nonFraction>&#160;million and other long-term liabilities of $<ix:nonFraction unitRef="usd" contextRef="i5a6bfe43ca624e09b88b884aa61ffce5_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMjU1Mg_0950b3b5-bf17-46b4-8c82-b35f0a3a5adf">5.3</ix:nonFraction>&#160;million on the condensed consolidated balance sheet as of September 30, 2020.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V.&#8217; ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="i89aa0df8ed9e4d689422daf8e8aeff91_D20161101-20161130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDcyMw_b891d0c1-7edd-4e00-b15c-8accb029f5ed">100,000</ix:nonFraction> at closing.  The Company provided $<ix:nonFraction unitRef="usd" contextRef="i89aa0df8ed9e4d689422daf8e8aeff91_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDc5NQ_e0178915-fc1e-48b9-b901-07cba57c6679">0.9</ix:nonFraction>&#160;million in consideration through a grant of <ix:nonFraction unitRef="shares" contextRef="i0da1b98b323a4b7fb67fd0ac6aa17246_D20161101-20161130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDczMw_3714fc34-98c6-4ab5-a179-12c8982e8016">180,000</ix:nonFraction> restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectible product and authorization to market them under the RediTrex brand name.  The <ix:nonFraction unitRef="shares" contextRef="i0da1b98b323a4b7fb67fd0ac6aa17246_D20161101-20161130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDc0Mg_9cc46208-3770-42d3-b314-40082670956a">180,000</ix:nonFraction> shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $<ix:nonFraction unitRef="usd" contextRef="i8af93abad7204f41a2937bac9ef79281_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDc1MQ_f725da2f-2e71-49ef-bddf-a7315938e71c">0.9</ix:nonFraction>&#160;million on the vesting date. The FDA approval also resulted in a $<ix:nonFraction unitRef="usd" contextRef="i2c32aec9cced429d9682d29a48e13689_I20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDc2NQ_468671b2-2729-475f-acf5-7456b34ebd04">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020 and was recorded as an other current liability at December 31, 2019.  Cumberland has approximately $<ix:nonFraction unitRef="usd" contextRef="i1bdfcc93ab6345078a0b921b7524f21f_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDc3OQ_96d03c30-0979-41c0-a7cb-08807e283d12">1.9</ix:nonFraction>&#160;million in net intangible assets related to RediTrex at September 30, 2020.  During the three months ended June 30, 2020, Cumberland recognized $<ix:nonFraction unitRef="usd" contextRef="i6eee9c230ea246608d8ad3a6a84a3a71_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNDE2MA_d10c8348-531f-40a3-8a9f-bb73a225eda3">0.5</ix:nonFraction>&#160;million of other revenue in its condensed consolidated statement of operations for a collaborative payment due from Nordic. The payment was received during July 2020.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#8220;the Products&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i51c195d40edf4f539c873e7e20ed342b" continuedAt="i1bb7a3af903e4216bce6117e1c13c6b6"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Dissolution Agreement, Cumberland is receiving $<ix:nonFraction unitRef="usd" contextRef="ibc4d6bac512842b1af4d4a5a540f3881_D20191001-20210930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTEyMQ_067c56a7-d152-4334-9f80-0cbe2bfc234d">5</ix:nonFraction>&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first three quarterly installments totaling $<ix:nonFraction unitRef="usd" contextRef="i9cb62c40adac4ab6b3e98357baff55af_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTI5OA_e49bd2f4-f5ff-43d0-9bf7-c5ad2bcf50c3">2.3</ix:nonFraction> million during the nine months ended September 30, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations and will record each future quarterly installment over the two year period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As there are no expenses associated with these payments, approximately $<ix:nonFraction unitRef="usd" contextRef="i9cb62c40adac4ab6b3e98357baff55af_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTQ5MA_e49bd2f4-f5ff-43d0-9bf7-c5ad2bcf50c3">2.3</ix:nonFraction> million in discontinued operations income was recorded during the period ended September 30, 2020. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Products provided $<ix:nonFraction unitRef="usd" contextRef="i6687a95bae3143d5b4bd7100bc41042c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTU5MQ_d26f7272-d379-42b3-aacd-27b3d720ba27">8.8</ix:nonFraction>&#160;million in revenue, with $<ix:nonFraction unitRef="usd" contextRef="i6687a95bae3143d5b4bd7100bc41042c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTYxMQ_0eda52a7-c43e-4100-a975-b3fa40eeff76">5.5</ix:nonFraction>&#160;million in direct expenses resulting in $<ix:nonFraction unitRef="usd" contextRef="i6687a95bae3143d5b4bd7100bc41042c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTY0Ng_583f5069-d88a-4c76-9de7-fbb007609051">3.3</ix:nonFraction>&#160;million in discontinued operations income during the nine months ended September 30, 2019. These direct expenses do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those sales and marketing individuals who supported the Products have subsequently shifted their efforts to support other Cumberland brands.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="i1bb7a3af903e4216bce6117e1c13c6b6" continuedAt="i90e057fe27b8448da71ed8457e830b68"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019 current assets of discontinued operations included $<ix:nonFraction unitRef="usd" contextRef="i955fd3b444074d18a8861d6a9e06f6e9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNjA2Mw_2cf4184c-d09c-4180-bd88-c2b94e6d23c3">0.5</ix:nonFraction>&#160;million in remaining </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventory for the Products sold and returned to Clinigen as part of the transaction. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, </span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i90e057fe27b8448da71ed8457e830b68">the remaining balance of the current assets of discontinued operations were accounts receivable and the current liabilities of discontinued operations were accounts payable associated with Ethyol and Totect.  As of September 30, 2020, the remaining balance of the current assets of discontinued operations was accounts receivable.   The accounts receivable and accounts payable balances were not sold or disposed of as part of the Dissolution Agreement.</ix:continuation>  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure regarding forward-looking statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ significantly from the results discussed in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; management of our growth and integration of our acquisitions and impacts on our business as well as national and international markets and economies resulting from the 2020 COVID-19 pandemic. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and September 30, 2020, respectively, and other filings with the SEC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div><span><br/></span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_64"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Our primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve the quality of care for patients and address unmet or poorly met medical needs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to bring our medicines to patients in their countries.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of FDA approved brands includes:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of pain and fever;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, and amoxicillin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of Helicobacter pylori (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections, and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">RediTrex</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">methotrexate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have Phase II clinical programs underway evaluating our ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis, and Aspirin-Exacerbated Respiratory Disease. We have also completed initial Phase II clinical studies with ifetroban in patients with Hepatorenal Syndrome and patients with Portal Hypertension.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has both product development and commercial capabilities, and we believe we can leverage our existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing, and finance. Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary formulations, manages our clinical studies, prepares all regulatory submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacture, release and shipment of our products. Our marketing and sales team is responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth Strategy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland's growth strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products. We currently market six FDA-approved products in the United States and expect to introduce our seventh product, RediTrex, before the end of 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our international partners, we are working to bring our medicines to patients in their countries. Our clinical team is developing a pipeline of new product candidates largely to address unmet medical needs. We also look for opportunities to expand the approved use of our products for additional patient populations through clinical trials, through new presentations, and through our support for select, investigator-initiated studies. Through our active business development initiative, we are pursuing the acquisition of additional marketed brands and late-stage development product candidates in our target medical specialties. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we are supplementing these activities with the earlier stage drug development at Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary. CET partners with academic research institutions to identify and progress promising, new product candidates, which Cumberland has the opportunity to further develop and commercialize.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we are seeking long term sustainable growth by executing on the following:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Support and expand the use of our marketed products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to explore opportunities for label expansion to bring our products to new patient populations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As examples, we have secured pediatric approvals, expanding the labeling for both our Acetadote and Caldolor brands. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selectively add complementary brands.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to our product development activities, we are also seeking to acquire products and late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA approved drugs, as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisition of Vibativ represents the largest product acquisition we have completed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Progress clinical pipeline and incubate future product opportunities at CET.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe it is important to build a pipeline of innovative new product opportunities. Our ifetroban Phase II development programs represent the implementation of this strategy. At CET, we are supplementing our acquisition and late-stage development activities with the early-stage drug development activities. CET partners with universities and other research organizations to develop promising, early-stage product candidates, which Cumberland has the opportunity to further develop and commercialize. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leverage our infrastructure through co-promotion partnerships.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that our commercial infrastructure can help drive prescription volume and product sales. We also look for strategic co-promotion partners that can complement our capabilities and enhance the opportunity for our brands. Our co-promotion arrangements with Poly Pharmaceuticals, Inc. and Foxland Pharmaceuticals, Inc allow us to expand current promotional support for Kristalose across the U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">     </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Build an international contribution to our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established our own commercial capabilities, including two sales divisions to promote our approved brands in the U.S. We have also entered into agreements with a group of international partners to register our products and make them available to patients in their countries. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Vibativ resulted in several new international partners and market opportunities.  We will continue to support and selectively expand our network of international partners, while assisting with the registration and commercialization efforts in their respective territories.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manage our operations with financial discipline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We work to manage our expenses in line with our revenues in order to deliver positive cash flow from operations. Our goal is to maintain a healthy financial position, with favorable gross margins, and a strong balance sheet. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. Our website address is www.cumberlandpharma.com. We make available through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all material press releases and other reports as soon as reasonably practicable after their filing with the U.S. Securities and Exchange Commission, (&#8220;SEC&#8221;). These filings are also available to the public at </span><span style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In April 2020, we issued our inaugural Environmental, Social and Governance (&#8220;ESG&#8221;) report which is also available on our website.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2) strain of coronavirus that causes COVID-19, a respiratory illness. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s facilities have remained open, as our business is considered to be essential by the United States Department of Homeland Security. We have implemented measures to address the impact of the novel coronavirus on our operations and taken appropriate action to protect our employees, secure our supply chain, and support the patients who can benefit from our medicines. All our employees have been provided the opportunity to work remotely, and those who wish to work at our offices are asked to follow the health guidelines outlined by the Centers for Disease Control. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, their contact has shifted from in person to telephonic and electronic communications. Travel across the organization and attendance at medical meetings have largely been discontinued. Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  During this pandemic, less patients sought care, some patients postponed elective surgeries and Cumberland's access to medical facilities was substantially limited.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party organizations around the world to supply components, manufacture and distribute our products. We are aware that we may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. We continue to monitor the coronavirus situation both in the U.S. and internationally in order to maintain our employees&#8217; safety and well-being, while also keeping our business operating.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the uncertainty of such changes, we are unable to quantify the impact on our future results as of the date of this filing. For additional discussion of the risks associated with COVID-19, please review the section entitled &#8220;Risk Factors&#8221; of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Omeclamox-Pak Supply Update</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has partnered with a select group of FDA-approved facilities to manufacture its line of branded pharmaceutical products. The Company has been carefully monitoring its supply chain during the pandemic and preparing for its economic impact. The packager for Cumberland&#8217;s Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19, and their operations are currently suspended. Cumberland is awaiting resumption of those operations while also exploring other alternatives to restart the product&#8217;s packaging. Meanwhile, we informed the FDA of a shortage of the Omeclamox-Pak effective October 14, 2020, and have not provided a date for the availability of new inventory. Cumberland noted that there is currently some remaining inventory of the product in the distribution channels.  For additional discussion of the risks discussed above, see Part II, Item 1A "Risk Factors" in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Caldolor Clinical Manuscripts</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-steroidal anti-inflammatory drug (&#8220;NSAID&#8221;), Caldolor may be used as the sole method of treatment for mild to moderate pain or as part of a multimodal treatment for severe pain. In January 2020, we commenced the national launch of our next generation Caldolor (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection product. This formulation of Caldolor comes in a ready-to-use bag that may be administered without dilution for pain relief. This launch follows FDA approval in 2019 of the product's new delivery method. The new, premixed presentation provides healthcare professionals a formulation that is easy to administer, helping manage the treatment of patient pain and fever, while reducing opioid consumption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Cumberland announced a study published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Orthopedic Trauma</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, evaluating the efficacy of Caldolor administration in the management of acute pain in orthopedic trauma patients. The study also measured Caldolor&#8217;s ability in minimizing opioid use. This single-center, randomized, double-blind, placebo-controlled study found that Caldolor (ibuprofen) Injection reduced the quantity of opioids required to manage pain after a traumatic injury with fracture. In addition, the time to first narcotic medication was longer in the Caldolor group than with hospital standard of care. Pain was also managed better in the Caldolor group compared to standard of care narcotics. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in August 2020, Cumberland announced the results of a review of nine clinical studies evaluating Caldolor. The comprehensive review was published in the journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Therapeutics</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and involved 1,062 adult patients, with 757 receiving Caldolor and 305 receiving placebo or a comparator medication. The data noted that the use of Caldolor improved post-surgery recovery, decreased surgical stress, and reduced the use of opioids and over-the-counter medication. The study determined that patients given Caldolor experienced less postoperative pain and decreased opioid use. Study authors also concluded that the rapid administration and preemptive use of Caldolor should be considered in Enhanced Recovery After Surgery protocols for the management of postoperative pain including that of traumatic origin. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The joint venture will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP is administered by the U.S. Small Business Administration ("SBA").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly commencing during November 2020. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the date of funding we have used the loan amount for such qualifying expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from our PPP loan, we currently do not foresee doing so.  In October 2020, we submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to the SBA for the SBA's review and approval. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ifetroban Phase II Clinical Programs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating our ifetroban product candidate in a series of clinical studies. We have completed three pilot Phase II studies involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure, 2) patients with Portal Hypertension associated with chronic liver disease and 3) patients suffering from Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. A follow-up Phase II study is currently underway for this asthma indication. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are currently evaluating ifetroban in two pilot Phase II studies of 1) patients with Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 2) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy. This rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional pilot studies of ifetroban are underway, including several investigator-initiated trials. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment in our clinical studies was interrupted during 2020 due to the COVID-19 pandemic. While enrollment of new patients is currently limited, we are working to ensure that patients already entered into a trial continue to receive their study drug. Many of our clinical study sites have reopened and resumed screening of patients for potential enrollment into our studies. We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban, our first new chemical entity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Hospital Product Candidate</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed the preclinical studies for a cholesterol-reducing agent for use in the hospital setting. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2017, we completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA. A Phase II study has been initiated and patient enrollment completed. We have completed the study report, filed it with the FDA and are now determining the next steps for this product development program.</span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_67"></div><div style="margin-bottom:6pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2019 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Judgments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, fair value of marketable securities, inventories, provision for income taxes, fair value of contingent consideration liability, share-based compensation, research and development expenses and intangible assets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended September 30, 2020 compared to the three months ended September 30, 2019 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited interim statements of operations for continuing operations for the three months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,587,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812,467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,625)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,459,375&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,875&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,500&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,208,686)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,196,436)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,004&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,511)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,515&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,271,892)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,311,824)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039,932&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,728)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,462)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275,620)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,316,286)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040,666&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues by product for the periods presented: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(558,723)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,813,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,047&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,852&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,805)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the three months ended September 30, 2020, were $9.3 million compared to $6.9 million for the three months ended September 30, 2019.  As detailed in the table above, net revenue increased for five of our marketed products: Vibativ, Kristalose, Omeclamox-Pak, Caldolor and Vaprisol during the quarter.  We returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen effective January 1, 2020.  As a result, the 2019 revenues and expenses associated with the products are combined and reclassified into discontinued operations in our financial statements. In exchange for the return of these product license rights and associated non-compete provisions, Cumberland is receiving $5 million in financial consideration paid over the two-years following the return date. The third installment of $0.8 million due from Clinigen was recorded during the three months ended September 30, 2020, as discontinued operations.  We do not incur expenses associated with these payments from Clinigen.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $2.8 million for the three months ended September 30, 2020, an increase of $1.4 million over the same period last year.  The increase was a result of improved sales volumes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue increased by $0.7 million during the third quarter of 2020, when compared to the prior year period.  The increase was primarily the result of increased sales volumes for the product.  </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $1.4 million for the third quarter of 2020, an increase of $0.2 million compared to the same period last year. The improvement in net revenue was the result of an increase in international shipments of Caldolor when compared to the prior year period, which were partially offset by lower domestic shipments of the product.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue was $0.4 million for the third quarter of 2020, an increase of $0.2 million. This increase of net sales compared to the third quarter of 2019 is primarily due to increased sales volumes for the product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak revenue increased $0.4 million for the third quarter of 2020, compared to the third quarter of 2019, primarily due to an increase in sales volumes and improved net pricing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was a decrease of $0.6 million in the product's revenue when compared to the prior year period as a result of lower sales volumes during the period. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st of products sold for the third quarter of 2020 and 2019 were $2.1 million and $1.6 million, respectively. Cost of products sold, as a percentage of net revenues, were 23.2% during the three months ended September 30, 2020, compared to 22.8% during the three months ended September 30, 2019.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, particularly the increase in sales of Vibativ.   The increase in Vibativ costs of product sold in the current period was $0.4 million due to increased product sales.  The Vibativ inventory sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.  The increase in costs of product sold expense included $0.2 million that was the result of a step up in the fair value of the inventory over the cost to Theravance, as required under purchase accounting rules.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the third quarter of 2020 decreased $0.2 million compared to the prior year period.  This decrease is primarily attributable to decreases in direct promotional spending, meeting costs and travel expenses.  There were partially offsetting increases in royalty costs associated with growth in Vibativ sales during the current quarter. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs were $1.2 million for the third quarter of 2020 and $1.7 million for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, cost of the per patient study protocol and patients involved in the development of our new product candidates. We continue to fund our ongoing clinical initiatives associated with our pipeline products.  The decrease in costs were primarily the result of decreased study activity as well as decreases in the costs of our medical science liaison activities partially offset by increases in our annual FDA user fees.     </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the third quarter of 2020 increased to $2.4 million from  $2.0 million during the third quarter of 2019 as a result of increases in business development, professional, legal and insurance costs.  These increases were partially offset by decreases in non-cash stock based compensation during the period.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,813,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524,664&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246,939&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765,963&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended September 30, 2020, and three months ended September 30, 2019, totaled approximately $1.1 million and $1.0 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense for the three months ended September 30, 2020, was comparable to the income tax expense for the three months ended September 30, 2019.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we had approximately $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations.  We expect to continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine months ended September 30, 2020 compared to the nine months ended September 30, 2019 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited interim statements of operations for continuing operations for the nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,179,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,082,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,387,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,031,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,160,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,231,778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,854)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,788,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,608,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,839,187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230,865)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,284,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,085,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,815,250&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,976,534&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838,716&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,635,650)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,893,792)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,553&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,915&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125,362)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216,988)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,792,827)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,914,865)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122,038&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,423)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,838,250)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,842,361)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004,111&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues by product for the periods presented: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,080,987)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,720,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,612&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,677,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543,166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,156,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605,570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535,981&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,589&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,179,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,082,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096,858&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the nine months ended September 30, 2020, were $27.2 million compared to $25.1 million for the nine months ended September 30, 2019.  As detailed in the table above, net revenue increased during the first nine months of 2020 for four of our marketed products: Vibativ, Kristalose, Caldolor and Vaprisol.  This resulted in an overall 8.4% revenue increase partially offset by decreases in our other two products. We returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen effective January 1, 2020.  As a result, the 2019 revenues and expenses associated with the products are combined and reclassified into discontinued operations in our financial statements. In exchange for the return of these product license rights and associated non-compete provision, Cumberland is receiving $5 million in financial consideration paid over the two-years following the return date. The first three installments totaling $2.3 million due from Clinigen was recorded during the nine months ended September 30, 2020, as discontinued operations.  We do not incur expenses associated with these payments from Clinigen.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $8.6 million for the nine months ended September 30, 2020, an increase of $2.4 million over the same period last year.  The 38.9% increase in net revenue was a result of improved sales volume for the product.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue was $10.4 million during the first nine months of 2020, an increase of $0.7 million  for the same period last year.  The 7% increase in net revenue was a result of improved sales volume for the product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue was $0.8 million for the first nine months of 2020, which is an increase of net sales of $0.1 million compared to the first nine months of 2019 primarily due to increased sales volumes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak revenue decreased $0.2 million for the nine months ended September 30, 2020, compared to the nine months ended September 30, 2019, primarily due to a decrease in sales volumes.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. There was a decrease of $1.1 million in the product's year to date revenue for the nine months ended September 30, 2020, when compared to the prior year period as a result of lower sales volumes, partially offset by improved net pricing. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $3.7 million for the first three quarters of 2020, an increase of $0.1&#160;million compared to the same period last year.  The 4% improvement in net revenue was the result of an increase in international shipments of Caldolor when compared to the prior year period, which were partially offset by lower domestic shipments of the product, significantly impacted by COVID - 19 and a reduction in elective surgeries.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st of products sold for the first nine months of 2020 and 2019 were $6.4 million and $5.0 million, respectively. Cost of products sold, as a percentage of net revenues, were 23.5% during the nine months ended September 30, 2020, compared to 20.1% during the nine months ended September 30, 2019.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, particularly the increase in sales of Vibativ.    The increase in Vibativ costs of product sold in the current period was $1.0 million due to increased product sales.  The Vibativ inventory sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.  The increase in costs of product sold expense included $0.5 million that was the result of a step up in the fair value of the inventory over the cost to Theravance, as required under purchase accounting rules. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the nine months ended September 30, 2020 and 2019 were both $11.2 million.  Overall, there was a small decrease in selling and marketing expenses, with decreases in direct promotional spending, meeting costs and travel expenses.  These decreases were partially offset by increases in salaries as well as increases in royalty costs associated with growth in Vibativ sales during the period.    </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs were $4.4 million for the first nine months of  2020 and $4.8 million for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, cost of the per patient study protocol and patients involved in the development of our new product candidates. We continue to fund our ongoing clinical initiatives associated with our pipeline products.  We experienced a decrease in study activity offset by increases in our annual FDA user fees.      </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the nine months ended September 30, 2020, decreased to $6.6 million from $6.8 million during the nine months ended September 30, 2019 as a result of decreases in advisory, legal and professional fees.  We also experienced a reduction in non-cash stock based compensation during the period.  A portion of these decreased costs were for 2019 expenses related to our acquisition of Vibativ. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,156,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,765,810&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760,759&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,116&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361,994&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the nine months ended September 30, 2020, and nine months ended September 30, 2019, totaled approximately $3.3 million and $3.1 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense (benefit) for the nine months ended September 30, 2020, as a percentage of loss from continuing operations before income taxes, was 0.9%, compared to (1.2)% for the nine months ended September 30, 2019.  </span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_76"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash flows provided by our operations, the proceeds from the Paycheck Protection Program loan, the amounts borrowed and available under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest a portion of our cash reserves in marketable securities including short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper.  At September 30, 2020 and December 31, 2019, all our investments had original maturities of less than ninety days and as a result were classified as cash equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our liquidity and working capital as of September 30, 2020 and December 31, 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,646,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,212,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,646,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,212,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (current assets less current liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,956,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit availability</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net changes in cash and cash equivalents for the nine months ended September 30, 2020 and September 30, 2019:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,561,140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199,356&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,441,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,685,477)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,554,625)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,566,105)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(960,536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $1.6 million decrease in cash and cash equivalents for the nine months ended September 30, 2020, was primarily attributable to cash used in investing and financing activities.  Cash provided by operating activities of $4.6 million was positively impacted by decreases in  inventory of $1.7 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $4.3 million.  Cash used by investing activities was the result of additions to intangibles of $1.8 million, equipment of $0.1 million and the payment of $1.0 million to Nordic.  Our financing activities included the net repayment of $1.5 million on our revolving line of credit, the $1.6 million in cash used to repurchase shares of our common stock as well as the $0.8 million used for the repurchase of a portion of CET's shares. </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $1.0 million decrease in cash and cash equivalents for the nine months ended September 30, 2019 was attributable to cash used in financing activities, partially offset by the $2.2&#160;million and the $0.4 million in cash provided by operating and investing activities, respectively.  Cash provided by operating activities of $2.2 million was positively impacted by the decrease in inventory as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $4.4 million.  Cash provided by investing activities was increased by net sales of marketable securities of $6.1 million, partially offset by the $5.0&#160;million payment to Theravance as part of the acquisition of Vibativ and the additions to intangibles of $0.5 million.  Our financing activities reflected the $2.6 million in cash used to repurchase shares of our common stock. </span></div><div style="margin-top:11pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, we entered into a Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The Fourth Amendment extends the maturity date of the Pinnacle Agreement through October 1, 2022 and provides for a principal available for borrowing of up to $15 million.  We also have the ability to request an increase of up to an additional $5 million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20 million. On May 10, 2019, we entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021, as well as modified certain definitions and terms of the existing financial covenants.  On October 17, 2018, we entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  For a summary of the material terms of the Pinnacle Agreement, as amended, see Note 7 to the accompanying unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pinnacle Agreement, we were initially subject to one financial covenant, the maintenance of a Funded Debt Ratio. On August 14, 2018, we amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  We were in compliance with the Tangible Capital Ratio financial covenant as of September 30, 2020. We expect to maintain compliance with the Tangible Capital Ratio financial covenant in future periods. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. For a summary of the material terms of the Paycheck Protection Program loan, see Note 7 to the accompanying unaudited condensed consolidated financial statements.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the date of funding we have used the loan amount for such qualifying expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from our PPP loan, we currently do not foresee doing so.  In October 2020, we submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to the U.S. Small Business Administration ("SBA") for the SBA's review and approval. </span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_79"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020 and 2019, we did not engage in any off-balance sheet arrangements.</span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_82"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts. The Company did not have any investments classified as marketable securities at September 30, 2020. Based on current interest rates, we do not believe we are exposed to significant downside risk related to change in interest on our investment accounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  The pricing under the Fourth Amendment of the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 2.90% at September 30, 2020, prior to entering into the Fourth Amendment.   As of September 30, 2020, we had $17.0 million in borrowings outstanding under our revolving credit facility. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Rate Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the nine months ended September 30, 2020 and 2019.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_85"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company&#8217;s management has concluded that, as of the end of such period, the Company&#8217;s disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, there has not been any change in our internal control over financial reporting that has materially affected, or is likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_91"></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_94"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are updating the following risk factor that appears in the 2019 Annual Report on Form 10-K under the section titled "Risk Factors."</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RISKS RELATED TO OUR BUSINESS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">If any manufacturer or partner we rely upon fails to supply our products in the amounts we require on a timely basis, or fails to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may be unable to meet demand for our products and may lose potential revenues.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not manufacture any of our products, and we do not currently plan to develop any capacity to do so. Our dependence upon third parties for the manufacture of our products could adversely affect our profit margins or our ability to develop and deliver products on a timely and competitive basis. If for any reason we are unable to obtain or retain third-party manufacturers on commercially acceptable terms, we may not be able to sell our products as planned. Furthermore, if we encounter delays or difficulties with contract manufacturers in producing our products, the distribution, marketing and subsequent sales of these products could be adversely affected. A long-term inability to meet demand for our products could result in impairment of our brands overall future and the carrying value of the assets associated with our brands. The recent COVID-19 pandemic may create local issues for our third party-manufacturers and introduce delays in our manufacturing process.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: We have agreements with two manufacturers, and one manufacturer provided commercial supplies of the product during 2019. If the manufacturer of Acetadote is unable to produce marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for our product.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: We have agreements with multiple manufacturers for the supply of Caldolor and during 2019 we obtained commercial supplies from three of these manufacturers for our international and domestic Caldolor requirements. If the manufacturers of Caldolor are unable to produce marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for our product.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: The active pharmaceutical ingredient for Kristalose is manufactured at a single facility by an international supplier. We also have manufacturing relationships with two packagers who provided finished supplies of the product for commercial and sampling purposes during 2019. If these facilities are damaged or destroyed, or if local conditions result in a work stoppage, we could suffer an inability to meet demand for our product. Kristalose is manufactured through a complex process. It would be particularly difficult to find a new manufacturer of Kristalose active pharmaceutical ingredient on an expedited basis. As a result of these factors, our ability to manufacture Kristalose may be substantially impaired if the manufacturer is unable or unwilling to supply sufficient quantities of the product.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Omeclamox-Pak</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Prior to our asset purchase agreement with GEL that closed in December 2018, GEL managed the packaging and supply of Omeclamox-Pak commercial and sample units. Following our acquisition of the remaining rights to the brand in late 2018, we assumed responsibility for the packaging and supply of the product. During 2019 we entered into a new packaging arrangement for this product. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has been carefully monitoring its supply chain during the pandemic and preparing for its economic impact. The packager for Cumberland&#8217;s Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19, and their operations are currently suspended. Cumberland is awaiting resumption of those operations while also exploring other alternatives to restart the product&#8217;s packaging. Meanwhile, we informed the FDA of a shortage of the Omeclamox-Pak effective October 14, 2020, and have not provided a date for the availability of new inventory. Cumberland noted that there is currently some remaining inventory of the product in the distribution channels.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to obtain marketable inventory in the future, we could suffer an inability to meet demand for our product. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: As part of the acquisition of Vaprisol, we purchased an existing supply of raw material inventory. In addition, as part of this transaction, we were assigned a commercial supply agreement with the historical Vaprisol manufacturer. In 2018, the manufacturer informed us that they would no longer be able to provide the product following the manufacturing of one final batch which is expected to provide us with a multi-year supply. Therefore, we are evaluating alternatives for a new manufacturer to provide us with long term supplies of the product. If we are unable to produce additional marketable inventory in sufficient quantities of Vaprisol, we could suffer an inability to meet demand for our product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Through our acquisition of Vibativ, we acquired a multi-year supply of raw material, work in process and finished goods inventory. As a result of the agreement, we are now responsible for the future manufacture of the product and completed the transfer of the product&#8217;s manufacturing activities to a new supplier in 2019. If we are unable to obtain marketable inventory in the future, we could suffer an inability to meet demand for our product.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Under our agreement with Nordic, they will be responsible for providing us the packaged and labeled commercial supply of the RediTrex product. If we are unable to obtain marketable inventory in the future, we could suffer an inability to meet demand for our product.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, all manufacturers of our products and product candidates must comply with current good manufacturing practices, ("GMPs"), enforced by the FDA through its facilities inspection program. These requirements include quality control, quality assurance and the maintenance of records and documentation. Manufacturers of our products may be unable to comply with GMP requirements and with other FDA, state and foreign regulatory requirements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have no control over our manufacturers&#8217; compliance with these regulations and standards. If our third-party manufacturers do not comply with these requirements, we could be subject to:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:12.53pt">Fines and civil penalties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:12.53pt">Suspension of production or distribution;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:12.53pt">Suspension or delay in product approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:12.53pt">Product seizure or recall; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:12.53pt">Withdrawal of product approval.</span></div><div><span><br/></span></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_97"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity, by month, during the three months ended September 30, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares (or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Unit)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares (or Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased&#160;as&#160;Part</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Publicly</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Announced Plans</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">or Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Value) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;(or&#160;Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">that May Yet Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased&#160;Under</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">the Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,887</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,887</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,711,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,196</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,196</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,606,469&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,271</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,271</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,485,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,354</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,354</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Of this amount, 1,324 shares were repurchased directly through private purchases at the then-current fair market value of common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020q3-exhibit101.htm">Third Amendment to Revolving Credit Note and Fourth Amendment to Revolving Credit Loan Agreement, dated as of October 7, 2020 by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020q3-exhibit101.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020q3-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020q3-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020q3-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i79bdbd3b4fc54ce0b1f7e776238df573_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.416%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 13, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Bonner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bonner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a2020q3-exhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i0b5abd2ba99a45b28c0444444a2dff37_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">THIRD AMENDMENT TO REVOLVING CREDIT NOTE AND </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">FOURTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">THIS THIRD AMENDMENT TO REVOLVING CREDIT NOTE AND FOURTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) is entered into as of October 7, 2020, by and between CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), and PINNACLE BANK, a Tennessee banking corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">RECITALS&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:7.62pt">Borrower issued to the order of Lender that certain $12,000,000.00 Revolving Credit Note dated July 31, 2017, as amended by that certain First Amendment to Revolving Credit Note and Second Amendment to Revolving Credit Loan Agreement dated October 17, 2018 whereby among other changes the principal amount thereof was increased to up to $20,000,000.00, and as amended by that certain Second Amendment to Revolving Credit Note and Third Amendment to Revolving Credit Loan Agreement dated May 10, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:7.62pt">Borrower and the Lender entered into that certain Revolving Credit Loan Agreement dated as of July 31, 2017, as amended by that certain First Amendment to Revolving Credit Loan Agreement dated August 14, 2018, as amended by that certain First Amendment to Revolving Credit Note and Second Amendment to Revolving Credit Loan Agreement dated October 17, 2018 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Second Amendment to Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), and as amended by that certain Second Amendment to Revolving Credit Note and Third Amendment to Revolving Credit Loan Agreement dated May 10, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Capitalized terms not otherwise defined therein have the same meaning as set forth in the Loan Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:7.01pt">Borrower and the Lender desire to amend the Note and Loan Agreement as provided herein.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8.84pt">The maximum principal amount of the Note, as set forth in the upper right hand corner of the first page and within the first paragraph thereof, is hereby decreased by $5,000,000.00 to $15,000,000.00.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8.84pt">The fifth paragraph of the Note, regarding repayment, is hereby amended and restated as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This Note shall be payable as follows&#58; (a) commencing on October 1, 2020 and continuing on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> day of each consecutive month thereafter through and including September 1, 2022, the Borrower shall pay to the Lender and amount equal to all accrued and unpaid interest&#59; and (b) this Note shall mature on October 1, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), at which time Borrower shall pay to the Lender an amount equal to all outstanding principal, plus all accrued and unpaid interest and any other outstanding fees and expenses due and payable under the Loan Documents. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8.84pt">Borrower acknowledges that as of the date of this Amendment, the current &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Applicable Margin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">,&#8221; as defined within the Note, is 275 basis points per annum.  This Amendment does not contain any revisions to the current definition of Applicable Margin.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8.84pt">All references to the principal amount of the Note, and the Loan amount, set forth within the Loan Agreement are hereby amended and restated to mean $15,000,000.00, including without limitation the following&#58; (i) the description of the Loan in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Loan Agreement&#59; and (ii) the definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; set forth within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Loan Agreement. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8.84pt;text-decoration:underline">Section 1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Loan Agreement is hereby amended and restated as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Increase of Availability Under Note.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that no Default or Event of Default under the Note exists or is threatened, the Borrower, commencing October 1, 2020, may from time to time request in writing that the Lender increase the principal amount available under the Note by an aggregate principal amount of up to an additional $5,000,000.00&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that the Lender in the exercise of its sole discretion shall determine whether it will or will not fund any requested increase. In connection with any request by the Borrower for an increase, the following shall apply&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8pt">each approved increase must be in a minimum amount of no less than $1,000,000.00&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8pt">no request for an increase shall be delivered to Lender less than ninety (90) days prior to the Maturity Date&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8.67pt">the Borrower&#8217;s request to the Lender for an increase shall be made in writing at least thirty (30) Business Days prior to the date the Borrower desires the requested increase to be funded and in connection with any such written request the Borrower shall submit&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-23.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18pt">the purpose for the increase,</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-26.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18pt">Borrower&#8217;s calculations, including pro-forma calculations, establishing to Lender&#8217;s satisfaction that none of the financial covenants set forth in the Loan Documents have been violated, nor will such be violated immediately after any approved funding, and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-29.31pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18pt">Borrower&#8217;s certification that all representations and warranties contained in the Loan Documents are true and correct as of the date of the request, and that no Default or Events of Default under the Loan Documents exist or are threatened.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Lender shall review the request by Borrower for an increase in funding, and the Lender, in the exercise of its sole discretion, shall determine whether to approve any request. In the event the Lender elects to fund any requested increase, Borrower shall&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(w)&#160;&#160;&#160;&#160;cause the Lender to receive, at Borrower&#8217;s expense, satisfactory evidence that the lien and security interest against the Collateral remains a first perfected security interest in favor of Lender, subject to no encumbrance objectionable to Lender&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(x)&#160;&#160;&#160;&#160;cause the Lender to receive all loan documentation required by Lender to evidence the increase, including without limitation, such loan documentation as required to insure that all guaranties and security agreements include the increase&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(y)&#160;&#160;&#160;&#160;pay to Lender all costs and expenses incurred by Lender in connection with the increase, including, without limitation, indebtedness tax, UCC filing costs, and attorney fees&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(z)&#160;&#160;&#160;&#160;pay to Lender a loan fee equal to ten (10) basis points of the amount by which the Note is increased.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8.84pt;text-decoration:underline">Section 6.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Loan Agreement is hereby amended and restated as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.11 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Dividends and Repurchase or Redemption of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Borrower shall not be permitted to pay dividends or to repurchase or redeem shares of its stock or that of any Subsidiary except as follows&#58; (i) Borrower may pay dividends and&#47;or repurchase or redeem such stock in an aggregate amount not to exceed $4,000,000 from October 1, 2020 to the Maturity Date&#59; and (ii) shares net settled for restricted share vesting up to $300,000 annually shall not count towards the limitation set forth in item (i).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8.84pt;text-decoration:underline">Section 7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Loan Agreement is hereby amended and restated as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.6       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Liquidity Cure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. For a fifteen (15) day period after the occurrence of an Event of Default under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> hereof (such Event of Default being deemed to have occurred on the date on which the Compliance Certificate for such period is required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> hereof), Borrower may cure such Event of Default by depositing and maintaining on account with Lender a cash amount equal to all outstanding Indebtedness hereunder. Borrower may only exercise the liquidity cure described herein twice during the period from October 1, 2020 to the Maturity Date. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8.84pt">The definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">EBITDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; set forth within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Loan Agreement is hereby amended to add the following sentence to the end of such definition&#58; For purposes of calculating EBITDA, EBITDA shall only include EBITDA arising from a permitted Acquisition if Lender is provided with a quality of earnings report related to any such Acquisition reasonably acceptable to Lender.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8.84pt">The definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">LIBOR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; set forth within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Loan Agreement is hereby amended to add the following sentence to the end of such definition&#58; Notwithstanding anything herein to the contrary, in no event shall LIBOR be less than 0.90% per annum.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:2.73pt">The definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; set forth within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Loan Agreement is hereby amended and restated to mean October 1, 2022. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:2.73pt">As a condition to the effectiveness of this Amendment, Borrower agrees to pay all fees and expenses set forth in the Closing Statement executed in connection with this Amendment. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:2.73pt">The Note and Loan Agreement are not amended in any other respect.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:2.73pt">Borrower reaffirms the terms and provisions of the Loan Documents and agrees that such terms and provisions are valid and binding, enforceable in accordance with its terms and provisions, subject to no defense, counterclaim, or objection.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;signatures commence on following page&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><div id="i0b5abd2ba99a45b28c0444444a2dff37_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ENTERED INTO as of the date first written above.</font></div><div style="margin-bottom:6pt;padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:53.846%"><tr><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">BORROWER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CUMBERLAND PHARMACEUTICALS INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.J. Kazimi, Chief Executive Officer</font></div><div><font><br></font></div></td></tr></table></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:53.846%"><tr><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">LENDER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PINNACLE BANK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tim Bewley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tim Bewley, Senior Vice Presiden</font></td></tr></table></div><div style="padding-left:252pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Signature Page to Second Amendment to Revolving Credit Loan Note and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Third Amendment to Revolving Credit Loan Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a2020q3-exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if56b3811667347bb90c89f8a96b050ee_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, A.J. Kazimi, certify that&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;padding-left:30pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 13, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a2020q3-exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i44f20b2e6cd64191bec6da1af51f3bb1_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Bonner, certify that&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;padding-left:30pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 13, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bonner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a2020q3-exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ifd75853724bd4d9db33891dd098da9b0_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended September 30, 2020 of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and Michael Bonner, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:38.888%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 13, 2020</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bonner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 13, 2020</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cpix-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2bbc8fb5-37a0-49a2-88e4-922c4b8dea28,g:76b63af8-607f-4b3f-a750-f8a8dfc06213-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquity" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinCashEquivalentsandMarketableSecurities" roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities">
        <link:definition>2104102 - Disclosure - Investments in Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinCashEquivalentsandMarketableSecuritiesTables" roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>2406402 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2107103 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2308302 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>2409403 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2111104 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2312303 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails">
        <link:definition>2413405 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2114105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2315304 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>2416406 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>2118106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>2319305 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>2420408 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>2421409 - Disclosure - Leases (Lease Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>2123107 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtDebtDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails">
        <link:definition>2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2126108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2427413 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>2128109 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRights" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights">
        <link:definition>2129110 - Disclosure - Additions and Returns of Product Rights</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsTables" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables">
        <link:definition>2330306 - Disclosure - Additions and Returns of Product Rights (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails">
        <link:definition>2431414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails">
        <link:definition>2432415 - Disclosure - Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails">
        <link:definition>2433416 - Disclosure - Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsChangeinConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
        <link:definition>2434417 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_ShareholdersEquityTextualAbstract" abstract="true" name="ShareholdersEquityTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_WinHealthInvestmentSingaporeLtdDomain" abstract="true" name="WinHealthInvestmentSingaporeLtdDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPurchaseOfShares" abstract="false" name="SubsidiaryInvestmentPurchaseOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_PaymentsForContingentConsideration" abstract="false" name="PaymentsForContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" abstract="false" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NordicGroupBVMember" abstract="true" name="NordicGroupBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_FourthAmendmentMember" abstract="true" name="FourthAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_GloriaPharmaceuticalsMember" abstract="true" name="GloriaPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ClinigenHealthcareLimitedMember" abstract="true" name="ClinigenHealthcareLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_HongKongWinHealthPharmaGroupCoLimitedMember" abstract="true" name="HongKongWinHealthPharmaGroupCoLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" abstract="false" name="TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentCashContribution" abstract="false" name="SubsidiaryInvestmentCashContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" abstract="false" name="SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" abstract="false" name="SubsidiaryInvestmentPaymentsForReturnOfCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cpix-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2bbc8fb5-37a0-49a2-88e4-922c4b8dea28,g:76b63af8-607f-4b3f-a750-f8a8dfc06213-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2b8d9abe-3a4c-4b40-b19e-f9db5ff51ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_485b870c-2318-4476-b242-d169fb8f5938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2b8d9abe-3a4c-4b40-b19e-f9db5ff51ceb" xlink:to="loc_us-gaap_Liabilities_485b870c-2318-4476-b242-d169fb8f5938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_88b26685-5214-4243-88f2-eec7e71421ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2b8d9abe-3a4c-4b40-b19e-f9db5ff51ceb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_88b26685-5214-4243-88f2-eec7e71421ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_06ae0cb8-bdb0-41a0-b819-013bcac2e4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2b8d9abe-3a4c-4b40-b19e-f9db5ff51ceb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_06ae0cb8-bdb0-41a0-b819-013bcac2e4fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c6803c6-9406-4b17-a6ed-0e7ef4e64804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a25f5ae6-e3ca-4d98-b1d1-6dcf880040cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6c6803c6-9406-4b17-a6ed-0e7ef4e64804" xlink:to="loc_us-gaap_CommonStockValue_a25f5ae6-e3ca-4d98-b1d1-6dcf880040cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175d0f45-c23a-403a-9a57-673e05e0d5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6c6803c6-9406-4b17-a6ed-0e7ef4e64804" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175d0f45-c23a-403a-9a57-673e05e0d5e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7b064640-eca8-4f78-a9e6-181215ff73c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7b064640-eca8-4f78-a9e6-181215ff73c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_050413b6-5677-42ad-ab81-9d1fbb5b297a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_050413b6-5677-42ad-ab81-9d1fbb5b297a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dc69530b-e236-4620-a378-572eede0aedb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_Goodwill_dc69530b-e236-4620-a378-572eede0aedb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_a9e98c66-a0b6-4b42-95c5-0d324f75dfdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_InventoryNoncurrent_a9e98c66-a0b6-4b42-95c5-0d324f75dfdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cb705738-19e9-4cf4-9e7d-8e48cae72f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_AssetsCurrent_cb705738-19e9-4cf4-9e7d-8e48cae72f0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0280d698-61ce-43d8-92d9-6b2eff95a69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0280d698-61ce-43d8-92d9-6b2eff95a69e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0b4ae891-12d9-48e7-bb20-9901d571f181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0b4ae891-12d9-48e7-bb20-9901d571f181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c1fb2807-2385-4d91-a59e-fb9f45479c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c1fb2807-2385-4d91-a59e-fb9f45479c7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b406b25c-66a2-4326-a384-59ba5a626837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b406b25c-66a2-4326-a384-59ba5a626837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bb75b1e6-4d15-4305-9a0c-081e4c06c81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:to="loc_us-gaap_AccountsPayableCurrent_bb75b1e6-4d15-4305-9a0c-081e4c06c81e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6b298f44-5af8-4367-9d1e-1a3cc64b98f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6b298f44-5af8-4367-9d1e-1a3cc64b98f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_62681849-d93c-4af7-a5ae-a33035210aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_62681849-d93c-4af7-a5ae-a33035210aab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_13cd71a2-5672-404c-8d4f-b9dccf4da83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:to="loc_us-gaap_LinesOfCreditCurrent_13cd71a2-5672-404c-8d4f-b9dccf4da83a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1fc9fb5e-0588-4e98-af01-fe4fd3834c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_a28131a7-542c-4ae9-a2dc-ac19e52c4f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1fc9fb5e-0588-4e98-af01-fe4fd3834c67" xlink:to="loc_us-gaap_LongTermLineOfCredit_a28131a7-542c-4ae9-a2dc-ac19e52c4f30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a719d0a9-6971-4b4e-a74e-5657c32e89de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1fc9fb5e-0588-4e98-af01-fe4fd3834c67" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a719d0a9-6971-4b4e-a74e-5657c32e89de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_782c5c91-73ab-4df1-8737-bf0fe85025a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1fc9fb5e-0588-4e98-af01-fe4fd3834c67" xlink:to="loc_us-gaap_LiabilitiesCurrent_782c5c91-73ab-4df1-8737-bf0fe85025a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_489ffd8f-71e0-4f89-9dff-43d6a8443482" xlink:href="cpix-20200930.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1fc9fb5e-0588-4e98-af01-fe4fd3834c67" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_489ffd8f-71e0-4f89-9dff-43d6a8443482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_03a9a98c-14f3-43e8-a5a6-ba88c1ba87e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff39336f-ad19-43c1-ae98-7bf8b07ce912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_03a9a98c-14f3-43e8-a5a6-ba88c1ba87e6" xlink:to="loc_us-gaap_StockholdersEquity_ff39336f-ad19-43c1-ae98-7bf8b07ce912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f39760df-0799-4c74-bb2c-306fd2d2defa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_03a9a98c-14f3-43e8-a5a6-ba88c1ba87e6" xlink:to="loc_us-gaap_MinorityInterest_f39760df-0799-4c74-bb2c-306fd2d2defa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e978d4d2-ef92-402d-838c-221904bbcc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e978d4d2-ef92-402d-838c-221904bbcc3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_49129f5e-246a-4473-9934-8c976ff6deb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_49129f5e-246a-4473-9934-8c976ff6deb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ce7b05bd-f352-4345-aa4d-38f59fc849c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ce7b05bd-f352-4345-aa4d-38f59fc849c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7cbebfe0-9418-4acd-9407-a58bfae148aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:to="loc_us-gaap_OtherAssetsCurrent_7cbebfe0-9418-4acd-9407-a58bfae148aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4d945b01-ff1b-4dd6-9a57-1352ccd16e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:to="loc_us-gaap_InventoryNet_4d945b01-ff1b-4dd6-9a57-1352ccd16e25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d93c2f7c-cf8b-415e-a61c-d4d20046e3af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d93c2f7c-cf8b-415e-a61c-d4d20046e3af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_3161f181-911a-4dd9-8ee0-20fd12542c48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:to="loc_us-gaap_SellingAndMarketingExpense_3161f181-911a-4dd9-8ee0-20fd12542c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3247ebfa-a98f-4a03-8d1b-c1d6d83022b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3247ebfa-a98f-4a03-8d1b-c1d6d83022b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9ecde327-ddc7-4fc2-b212-8f2797c9273a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9ecde327-ddc7-4fc2-b212-8f2797c9273a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3b67ea13-2dda-4340-86c7-db9c4cf5ea59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3b67ea13-2dda-4340-86c7-db9c4cf5ea59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c387623c-cfb2-4f58-9a32-c47b0a0e6e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b0866bd5-5ca8-4cad-a7f5-35df7f44e1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c387623c-cfb2-4f58-9a32-c47b0a0e6e2b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b0866bd5-5ca8-4cad-a7f5-35df7f44e1ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_08284c47-b8a2-44ab-a56f-83efb3098a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c387623c-cfb2-4f58-9a32-c47b0a0e6e2b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_08284c47-b8a2-44ab-a56f-83efb3098a29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8b2d57ba-4b6e-4f2e-92a8-7420d1c0d206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5145480b-408b-4742-b9a0-5f41a2ca9d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8b2d57ba-4b6e-4f2e-92a8-7420d1c0d206" xlink:to="loc_us-gaap_ProfitLoss_5145480b-408b-4742-b9a0-5f41a2ca9d30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a9c791ff-ff4c-4f1b-971a-a98771ab3394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8b2d57ba-4b6e-4f2e-92a8-7420d1c0d206" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a9c791ff-ff4c-4f1b-971a-a98771ab3394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7c62d53a-ee01-41e0-bb28-80a55b585bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b69e3a6a-c3cf-40a2-baac-a219da4857e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7c62d53a-ee01-41e0-bb28-80a55b585bf8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b69e3a6a-c3cf-40a2-baac-a219da4857e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1e3e94fe-01a5-4642-bf28-a13c37b62a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7c62d53a-ee01-41e0-bb28-80a55b585bf8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1e3e94fe-01a5-4642-bf28-a13c37b62a57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f2ceb798-412f-416e-8cdf-9d37c06011cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d0b7617-5e45-44c8-ace1-2182fb546783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f2ceb798-412f-416e-8cdf-9d37c06011cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d0b7617-5e45-44c8-ace1-2182fb546783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_632fb421-51eb-4214-b294-17b155872317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f2ceb798-412f-416e-8cdf-9d37c06011cf" xlink:to="loc_us-gaap_CostsAndExpenses_632fb421-51eb-4214-b294-17b155872317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_16795fc2-4894-43de-8813-d3749f424d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_deea9a26-2e48-4b2d-8c44-0f1f96d68384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_16795fc2-4894-43de-8813-d3749f424d8c" xlink:to="loc_us-gaap_OperatingIncomeLoss_deea9a26-2e48-4b2d-8c44-0f1f96d68384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_780507a4-cb3f-4515-a90a-a7d3c72ef984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_16795fc2-4894-43de-8813-d3749f424d8c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_780507a4-cb3f-4515-a90a-a7d3c72ef984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_64cdef20-91b8-445c-90eb-b2b5cfa3ecf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_16795fc2-4894-43de-8813-d3749f424d8c" xlink:to="loc_us-gaap_InterestExpense_64cdef20-91b8-445c-90eb-b2b5cfa3ecf9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2f94991-7861-4e8d-8144-5597dec19837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c12bb0c-8875-4240-980d-b18d280330a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2f94991-7861-4e8d-8144-5597dec19837" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c12bb0c-8875-4240-980d-b18d280330a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_508690cf-a6e8-4035-aa4b-a5c2cd7cff20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2f94991-7861-4e8d-8144-5597dec19837" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_508690cf-a6e8-4035-aa4b-a5c2cd7cff20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f0b29bba-9506-45b9-98a3-d669dae1c2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2f94991-7861-4e8d-8144-5597dec19837" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f0b29bba-9506-45b9-98a3-d669dae1c2a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_184fd780-2fca-49a3-8e7e-0bc90dc34763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_184fd780-2fca-49a3-8e7e-0bc90dc34763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7ea9fdbc-94bf-4a27-be27-f36fce80f438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7ea9fdbc-94bf-4a27-be27-f36fce80f438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_2e1dbc31-bde4-4225-8ed3-5874d2052b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_2e1dbc31-bde4-4225-8ed3-5874d2052b52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e560d115-9c93-46ea-91af-3d3e16091503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e560d115-9c93-46ea-91af-3d3e16091503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_b693eee2-41a9-430e-a8a2-e898c4340b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_b693eee2-41a9-430e-a8a2-e898c4340b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3c9b4b4c-7e0d-441b-b289-4fe4f19a7426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3c9b4b4c-7e0d-441b-b289-4fe4f19a7426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fc077a24-a5a1-41c5-8705-0e75e3be46ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fc077a24-a5a1-41c5-8705-0e75e3be46ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bb8cd681-dc32-4855-a4f2-4b75e1092914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bb8cd681-dc32-4855-a4f2-4b75e1092914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_de654c0a-0156-4e67-9e20-38c38a9f65c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_de654c0a-0156-4e67-9e20-38c38a9f65c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_be02d689-a4d0-4528-a1ba-c325b2f11f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_be02d689-a4d0-4528-a1ba-c325b2f11f66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_bbdbdfe0-a03a-4bf6-a899-00ea67b4f066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_bbdbdfe0-a03a-4bf6-a899-00ea67b4f066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_e8dcfc91-4d75-434d-ab27-e8e42817b0ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_e8dcfc91-4d75-434d-ab27-e8e42817b0ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_0e694137-b295-423a-ba8c-34979891f64f" xlink:href="cpix-20200930.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_0e694137-b295-423a-ba8c-34979891f64f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b7e42d21-b7bc-4f0a-93e9-802e34a3f7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b7e42d21-b7bc-4f0a-93e9-802e34a3f7b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d7d32a61-0b40-46a2-b20b-a7f18ecfed59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d7d32a61-0b40-46a2-b20b-a7f18ecfed59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_67c23e56-51b6-44ae-ada4-54ce46d5e6fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_67c23e56-51b6-44ae-ada4-54ce46d5e6fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c58f5568-17cc-42f0-8f9e-788f69f4700f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c58f5568-17cc-42f0-8f9e-788f69f4700f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c73032ab-6a42-42fd-8a45-8444c9e1127a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c73032ab-6a42-42fd-8a45-8444c9e1127a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0f8459cd-c139-4c27-bba6-d2d4b128250b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0f8459cd-c139-4c27-bba6-d2d4b128250b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_3dc5d52f-bbfe-4cb2-bf7a-3e13c8adcaf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_3dc5d52f-bbfe-4cb2-bf7a-3e13c8adcaf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_896756bb-e45a-436f-b2c0-44b0d97871ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_896756bb-e45a-436f-b2c0-44b0d97871ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_9553d423-5b3d-4247-9f5d-6adbec904e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_9553d423-5b3d-4247-9f5d-6adbec904e58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2396ee6b-813c-404f-83bc-bfe3c514cc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_ShareBasedCompensation_2396ee6b-813c-404f-83bc-bfe3c514cc49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7b219fa4-ecce-4be5-aa9a-d22a9889accc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7b219fa4-ecce-4be5-aa9a-d22a9889accc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9f317550-f423-42d8-a46b-62dac3fed472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8313ed24-ad00-42f7-ba88-179cc8609e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9f317550-f423-42d8-a46b-62dac3fed472" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8313ed24-ad00-42f7-ba88-179cc8609e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_be5ef775-135a-477a-b18a-2caa760af161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9f317550-f423-42d8-a46b-62dac3fed472" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_be5ef775-135a-477a-b18a-2caa760af161" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6972c98-0040-4aed-b922-f3b4c3c5bc05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f17f781-db36-4bb6-b216-4e5b3bbd9634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6972c98-0040-4aed-b922-f3b4c3c5bc05" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f17f781-db36-4bb6-b216-4e5b3bbd9634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c671d9c0-fac2-449b-8778-60d633d7055c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6972c98-0040-4aed-b922-f3b4c3c5bc05" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c671d9c0-fac2-449b-8778-60d633d7055c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20200930.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#RevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20200930.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6044419b-ead2-415a-aac1-eec1e46cd20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_9b3be858-25fe-4f2e-b5f3-e04a3c205f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6044419b-ead2-415a-aac1-eec1e46cd20d" xlink:to="loc_us-gaap_InventoryNoncurrent_9b3be858-25fe-4f2e-b5f3-e04a3c205f0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_a4a35a57-419f-4339-825b-bad8a38e09fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6044419b-ead2-415a-aac1-eec1e46cd20d" xlink:to="loc_us-gaap_InventoryGross_a4a35a57-419f-4339-825b-bad8a38e09fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_df4c44b0-bacc-4d70-8157-fb7cd8b601ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_00c2f830-356a-4079-8d4b-6e7644f7a81b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_df4c44b0-bacc-4d70-8157-fb7cd8b601ed" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_00c2f830-356a-4079-8d4b-6e7644f7a81b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_a801d7c8-4a77-481e-818c-d97c4bbf81fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_df4c44b0-bacc-4d70-8157-fb7cd8b601ed" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_a801d7c8-4a77-481e-818c-d97c4bbf81fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4e109878-e1de-4cef-97ab-6d8b0a8e5900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_df4c44b0-bacc-4d70-8157-fb7cd8b601ed" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4e109878-e1de-4cef-97ab-6d8b0a8e5900" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20200930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a132fc40-74a2-4849-9b6e-a218a4fa53c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a132fc40-74a2-4849-9b6e-a218a4fa53c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6bf73495-6b2e-4413-b2df-77e622dd0d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6bf73495-6b2e-4413-b2df-77e622dd0d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_38325fc1-efc8-4e5e-b3c9-9872736282b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_38325fc1-efc8-4e5e-b3c9-9872736282b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_272bf16a-c31a-4939-97af-c034a99cb7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_272bf16a-c31a-4939-97af-c034a99cb7e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_a7d23506-ab03-495d-a91d-ed7131f83dae" xlink:href="cpix-20200930.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:to="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_a7d23506-ab03-495d-a91d-ed7131f83dae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7fb7e9d-af8d-432e-89ee-441031ab7c75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3beeec06-5885-4c34-8486-8e00283e57fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7fb7e9d-af8d-432e-89ee-441031ab7c75" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3beeec06-5885-4c34-8486-8e00283e57fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5afcb629-4e96-4d9d-ad8b-7ad22afa1965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7fb7e9d-af8d-432e-89ee-441031ab7c75" xlink:to="loc_us-gaap_OperatingLeaseLiability_5afcb629-4e96-4d9d-ad8b-7ad22afa1965" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebt"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20200930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20200930.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20200930.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRights"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6453ed2e-b58c-407f-bd92-7781527e7e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5eca78e2-f972-4f28-a886-d9ffe83b9085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6453ed2e-b58c-407f-bd92-7781527e7e81" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5eca78e2-f972-4f28-a886-d9ffe83b9085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_781f4c7e-bd27-4260-a2e9-8efa0baa038a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6453ed2e-b58c-407f-bd92-7781527e7e81" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_781f4c7e-bd27-4260-a2e9-8efa0baa038a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_188ac666-d687-443f-89e2-da216f620c29" xlink:href="cpix-20200930.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6453ed2e-b58c-407f-bd92-7781527e7e81" xlink:to="loc_cpix_PaymentsForContingentConsideration_188ac666-d687-443f-89e2-da216f620c29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_d7623ffa-7f88-4700-b244-f0e70a8596ce" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c6cbfd59-2650-47c2-a9d4-9e8918e0d1fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_d7623ffa-7f88-4700-b244-f0e70a8596ce" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c6cbfd59-2650-47c2-a9d4-9e8918e0d1fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ab7b9271-1f55-4871-b54d-2b3c2647b07f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_d7623ffa-7f88-4700-b244-f0e70a8596ce" xlink:to="loc_us-gaap_Goodwill_ab7b9271-1f55-4871-b54d-2b3c2647b07f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_45e07567-1bf1-4f21-8cb6-e456552a1fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_adb53a37-e8f0-403f-a56a-fce8c7c0c3ae" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_45e07567-1bf1-4f21-8cb6-e456552a1fa3" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_adb53a37-e8f0-403f-a56a-fce8c7c0c3ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_379a8823-66a0-4c23-865e-472922303fad" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_45e07567-1bf1-4f21-8cb6-e456552a1fa3" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_379a8823-66a0-4c23-865e-472922303fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_62b1a920-8dc3-4dee-a1b0-9254dfd3e1fa" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_45e07567-1bf1-4f21-8cb6-e456552a1fa3" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_62b1a920-8dc3-4dee-a1b0-9254dfd3e1fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_e474c5e2-311f-4c7b-bd4c-872dafe95d03" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_45e07567-1bf1-4f21-8cb6-e456552a1fa3" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_e474c5e2-311f-4c7b-bd4c-872dafe95d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1cb52246-4a2e-4a50-b1cd-6d43cdb6960c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_cbfe96e8-a3e3-40f8-a875-9af5cd460ce4" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1cb52246-4a2e-4a50-b1cd-6d43cdb6960c" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_cbfe96e8-a3e3-40f8-a875-9af5cd460ce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_a5291336-07f0-4f87-895a-bf76b9956d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1cb52246-4a2e-4a50-b1cd-6d43cdb6960c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_a5291336-07f0-4f87-895a-bf76b9956d64" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cpix-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2bbc8fb5-37a0-49a2-88e4-922c4b8dea28,g:76b63af8-607f-4b3f-a750-f8a8dfc06213-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended" id="id2a8013f50574eb5ac121fca7d803c89_CoverPage"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i16a0c549a8694044b0ae7e239febada8_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ie64a9a53fe6b482283a8beb6b4a3f9d4_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i86e58a50b918445cb117e138c8fb21af_CondensedConsolidatedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i69bd90d62afe4f7682c5e5575928913e_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended" id="ie73f65a0ec894aff86393e2d4a91df14_CondensedConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4bf6f615-39e0-4d0d-9c08-609df639d153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4bf6f615-39e0-4d0d-9c08-609df639d153" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_774a2cd4-39e0-4bb4-a852-fbf8bb36999f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_774a2cd4-39e0-4bb4-a852-fbf8bb36999f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f13ccd66-0107-436c-bdf0-ed0edaebb43d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f13ccd66-0107-436c-bdf0-ed0edaebb43d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_170a777e-f26f-43e5-932e-4d47e7b43c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_170a777e-f26f-43e5-932e-4d47e7b43c4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6a3d6d3a-d2c8-415e-ba15-521c2bcf6461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6a3d6d3a-d2c8-415e-ba15-521c2bcf6461" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_1064cffc-5f81-4774-a61e-0eca038ab017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_1064cffc-5f81-4774-a61e-0eca038ab017" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f4f463ac-8595-4097-8d97-ce2742a43fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f4f463ac-8595-4097-8d97-ce2742a43fd8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_7e0c3562-14a9-4c06-a259-369b7e5447f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_7e0c3562-14a9-4c06-a259-369b7e5447f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d2b312af-0c0d-4dfa-a4d0-3989e2f27e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_ProfitLoss_d2b312af-0c0d-4dfa-a4d0-3989e2f27e1d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca4a4e2a-b224-4abb-bd7b-9e3002f92a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f1c7f59d-1199-4f10-95fa-4728f6ef818f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0e7cfb2c-20ff-4297-ac5c-37a57c3acee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4bf6f615-39e0-4d0d-9c08-609df639d153" xlink:to="loc_us-gaap_StatementTable_0e7cfb2c-20ff-4297-ac5c-37a57c3acee4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_77889d3f-3c89-4505-86ba-09bcf65cb43c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0e7cfb2c-20ff-4297-ac5c-37a57c3acee4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_77889d3f-3c89-4505-86ba-09bcf65cb43c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_77889d3f-3c89-4505-86ba-09bcf65cb43c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_77889d3f-3c89-4505-86ba-09bcf65cb43c" xlink:to="loc_us-gaap_EquityComponentDomain_77889d3f-3c89-4505-86ba-09bcf65cb43c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b9fc826-be27-4530-8d84-bf5fe235cdb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_77889d3f-3c89-4505-86ba-09bcf65cb43c" xlink:to="loc_us-gaap_EquityComponentDomain_7b9fc826-be27-4530-8d84-bf5fe235cdb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a80461ca-8e89-4f65-adf8-9e9532e5a60e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b9fc826-be27-4530-8d84-bf5fe235cdb5" xlink:to="loc_us-gaap_CommonStockMember_a80461ca-8e89-4f65-adf8-9e9532e5a60e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d8309226-678a-4aff-be9b-1abd56a66262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b9fc826-be27-4530-8d84-bf5fe235cdb5" xlink:to="loc_us-gaap_RetainedEarningsMember_d8309226-678a-4aff-be9b-1abd56a66262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_8997b870-21cb-4aea-ac4b-c307333d816a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b9fc826-be27-4530-8d84-bf5fe235cdb5" xlink:to="loc_us-gaap_NoncontrollingInterestMember_8997b870-21cb-4aea-ac4b-c307333d816a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="i6d6fa1d6892044ecb7793fdfed2f7f54_OrganizationandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended" id="i85602fbecb01486baa1252c2ef0adba6_OrganizationandBasisofPresentationPolicies"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended" id="icced0f38852b494a9bf3ff2079314a7f_OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="extended" id="icfe8fae5e9434d07a9900cf2e947636c_InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended" id="i5ee92bb5c23642e998fb1e41767fa1df_InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="i85beedfcce1a471490ddebf8e70794da_InvestmentsinCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0115ba75-99ed-493f-a216-8571215a35e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_03343937-56fb-44ea-bf5b-fce41251135f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0115ba75-99ed-493f-a216-8571215a35e5" xlink:to="loc_us-gaap_TradingSecurities_03343937-56fb-44ea-bf5b-fce41251135f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e7aa0f18-09fa-4b0c-aaea-81c9f8c8bd43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0115ba75-99ed-493f-a216-8571215a35e5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e7aa0f18-09fa-4b0c-aaea-81c9f8c8bd43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbd91108-30e9-4048-b22e-2b24e39100d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e7aa0f18-09fa-4b0c-aaea-81c9f8c8bd43" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbd91108-30e9-4048-b22e-2b24e39100d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbd91108-30e9-4048-b22e-2b24e39100d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbd91108-30e9-4048-b22e-2b24e39100d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbd91108-30e9-4048-b22e-2b24e39100d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef119d0c-dc47-47d2-b3d6-b17de258a123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbd91108-30e9-4048-b22e-2b24e39100d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef119d0c-dc47-47d2-b3d6-b17de258a123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cf3880e8-a229-443f-a2c9-e495b52a621c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef119d0c-dc47-47d2-b3d6-b17de258a123" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cf3880e8-a229-443f-a2c9-e495b52a621c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3352df52-d2df-4ce5-ae41-5b76f5ada121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef119d0c-dc47-47d2-b3d6-b17de258a123" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3352df52-d2df-4ce5-ae41-5b76f5ada121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_83681818-721b-4ebe-bf82-af6c019fcffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e7aa0f18-09fa-4b0c-aaea-81c9f8c8bd43" xlink:to="loc_us-gaap_FinancialInstrumentAxis_83681818-721b-4ebe-bf82-af6c019fcffe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83681818-721b-4ebe-bf82-af6c019fcffe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_83681818-721b-4ebe-bf82-af6c019fcffe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83681818-721b-4ebe-bf82-af6c019fcffe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_217d95a1-7fd6-4dc0-b322-c16b5a757fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_83681818-721b-4ebe-bf82-af6c019fcffe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_217d95a1-7fd6-4dc0-b322-c16b5a757fa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_76431c9e-97e5-448b-b088-25891f17ece6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_217d95a1-7fd6-4dc0-b322-c16b5a757fa4" xlink:to="loc_us-gaap_CommercialPaperMember_76431c9e-97e5-448b-b088-25891f17ece6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShare"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended" id="ie2cadd5015cb4bb3a39aa9caf5eed01a_EarningsLossPerShare"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended" id="idbadc674aefc4cb6892383ecdbf45f3f_EarningsLossPerShareTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended" id="iec09fae6fcd0481b8ba0a53534c93e1b_EarningsLossPerShareDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended" id="i1d9a4417fd4342948f3d20c6c39eb327_EarningsLossPerShareDetailsTextual"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20200930.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended" id="i403cce75c5a64aa2b6884b62cdb14a1a_Revenues"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended" id="ia7b22f04ebbd409fa429e7eced410cdb_RevenuesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended" id="ie7643e57af844bf8a2dd09545f45936b_RevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_b9a33243-8a0b-42ca-b61b-2d23011065e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_fb719877-a8c9-41a9-ac84-90555b2b707a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_b9a33243-8a0b-42ca-b61b-2d23011065e5" xlink:to="loc_us-gaap_RevenuesAbstract_fb719877-a8c9-41a9-ac84-90555b2b707a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_7ad909f1-5358-459d-b393-597d087e147f" xlink:href="cpix-20200930.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_fb719877-a8c9-41a9-ac84-90555b2b707a" xlink:to="loc_cpix_ProductsAbstract_7ad909f1-5358-459d-b393-597d087e147f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4633e06c-e109-45ad-9172-3b2b83852e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_7ad909f1-5358-459d-b393-597d087e147f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4633e06c-e109-45ad-9172-3b2b83852e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_60db111c-097e-47dc-9c4a-01f40c49857e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_b9a33243-8a0b-42ca-b61b-2d23011065e5" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_60db111c-097e-47dc-9c4a-01f40c49857e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fc3470ac-b84d-42d9-b6ad-98dff2088371" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_60db111c-097e-47dc-9c4a-01f40c49857e" xlink:to="loc_srt_ProductOrServiceAxis_fc3470ac-b84d-42d9-b6ad-98dff2088371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc3470ac-b84d-42d9-b6ad-98dff2088371_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fc3470ac-b84d-42d9-b6ad-98dff2088371" xlink:to="loc_srt_ProductsAndServicesDomain_fc3470ac-b84d-42d9-b6ad-98dff2088371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fc3470ac-b84d-42d9-b6ad-98dff2088371" xlink:to="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_491b7dff-c8e1-4e18-ae0b-e906716bf486" xlink:href="cpix-20200930.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_AcetadoteMember_491b7dff-c8e1-4e18-ae0b-e906716bf486" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_460c66d5-0c41-440f-9bc6-7f2fc9c4fcd4" xlink:href="cpix-20200930.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_OmeclamoxPakMember_460c66d5-0c41-440f-9bc6-7f2fc9c4fcd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_44bfcf88-e123-4132-a0b8-97d97eff84b8" xlink:href="cpix-20200930.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_KristaloseMember_44bfcf88-e123-4132-a0b8-97d97eff84b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_6a0144d4-7a96-4796-9df5-14569fa45519" xlink:href="cpix-20200930.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_VaprisolMember_6a0144d4-7a96-4796-9df5-14569fa45519" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_857dd5b2-f403-444f-a965-112793bab496" xlink:href="cpix-20200930.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_CaldolorMember_857dd5b2-f403-444f-a965-112793bab496" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_bad0f4e7-af2f-46aa-b56f-447a2b252f08" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_VIBATIVMember_bad0f4e7-af2f-46aa-b56f-447a2b252f08" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_7644390e-b41d-4bed-92d7-4eaecac44804" xlink:href="cpix-20200930.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_OtherProductsMember_7644390e-b41d-4bed-92d7-4eaecac44804" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_3ead9275-ad9c-4c42-af8a-e04ed86c42be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_us-gaap_GrantMember_3ead9275-ad9c-4c42-af8a-e04ed86c42be" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20200930.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended" id="i5bf14169f4ae45d3b7d6c1439b7e0571_Inventories"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended" id="i8861e971685a449fbebfb01cf45d0ed0_InventoriesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="ic6527081261f4e54a92831c3c7c7bc41_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_5b5fb6ff-f65b-4cc2-bd98-fd1ffd255d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c0f47c83-fe6b-46ca-9107-9d91c7ed7f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_5b5fb6ff-f65b-4cc2-bd98-fd1ffd255d69" xlink:to="loc_us-gaap_InventoryNoncurrent_c0f47c83-fe6b-46ca-9107-9d91c7ed7f98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_06e625e1-6ad7-4021-be21-383c978cbfbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_5b5fb6ff-f65b-4cc2-bd98-fd1ffd255d69" xlink:to="loc_us-gaap_InventoryFinishedGoods_06e625e1-6ad7-4021-be21-383c978cbfbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_34390169-f105-4a0e-9d04-e82fe727447b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_5b5fb6ff-f65b-4cc2-bd98-fd1ffd255d69" xlink:to="loc_us-gaap_InventoryCurrentTable_34390169-f105-4a0e-9d04-e82fe727447b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e52b459b-de55-4369-b167-18c8f7f5af05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_34390169-f105-4a0e-9d04-e82fe727447b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e52b459b-de55-4369-b167-18c8f7f5af05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e52b459b-de55-4369-b167-18c8f7f5af05_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e52b459b-de55-4369-b167-18c8f7f5af05" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e52b459b-de55-4369-b167-18c8f7f5af05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8e83ac2-ef29-44c3-adee-3c73aadc0c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e52b459b-de55-4369-b167-18c8f7f5af05" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8e83ac2-ef29-44c3-adee-3c73aadc0c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_8f00de63-cacd-46cd-b2dc-7da7e85d963b" xlink:href="cpix-20200930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8e83ac2-ef29-44c3-adee-3c73aadc0c3c" xlink:to="loc_cpix_IfetrobanClinicalMember_8f00de63-cacd-46cd-b2dc-7da7e85d963b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_2ed139f1-ef22-455d-a25f-bd11122e71c3" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8e83ac2-ef29-44c3-adee-3c73aadc0c3c" xlink:to="loc_cpix_VIBATIVMember_2ed139f1-ef22-455d-a25f-bd11122e71c3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended" id="ifd61cc36998d4ae0b707efcb0a52cc45_InventoriesScheduleofInventoriesDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20200930.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended" id="ic0dca2a896f4458b929cdd6540948d10_Leases"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended" id="i0615dfae6d3b423b909803fe3e771f45_LeasesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i8ade6ec8adaa4f8aa7c7856afc32c0cc_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesLeasePositionDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended" id="iff63b6b0eadf49d895f495d4e0e8fa62_LeasesLeasePositionDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended" id="iffee74d51fa24c7589fa5cb0290f9f4d_LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebt"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended" id="icc8886ab1cd64f9a816080d8a33a66f4_ShareholdersEquityandDebt"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="ia0da0bf710d0404b818b6fca927b8fed_ShareholdersEquityandDebtShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ac92d86-764e-42ac-a65a-7c29e53ef189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:href="cpix-20200930.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ac92d86-764e-42ac-a65a-7c29e53ef189" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1ec18ef9-f44a-4d1c-87d7-fe16385e86aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1ec18ef9-f44a-4d1c-87d7-fe16385e86aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_d1045cca-215d-492f-aeb1-c9bb8fd48f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_d1045cca-215d-492f-aeb1-c9bb8fd48f9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_7c64686b-3c9a-4f89-829c-210d4c82189c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_7c64686b-3c9a-4f89-829c-210d4c82189c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_cc6c334c-cc33-4844-9a46-99c778531989" xlink:href="cpix-20200930.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_cc6c334c-cc33-4844-9a46-99c778531989" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b8badbda-6717-4606-8882-bbe71098c52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b8badbda-6717-4606-8882-bbe71098c52d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d294c622-1542-462c-8abb-f269e4e12d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d294c622-1542-462c-8abb-f269e4e12d37" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_455a61f4-3454-4f63-a98c-592d24e96df2" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_455a61f4-3454-4f63-a98c-592d24e96df2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution_1d2fe42e-b515-434d-95d5-060dd37222d0" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_cpix_SubsidiaryInvestmentCashContribution_1d2fe42e-b515-434d-95d5-060dd37222d0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_2dcfe494-d9ad-4e00-a091-c94d16405f50" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_2dcfe494-d9ad-4e00-a091-c94d16405f50" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_71281ce0-ca8c-407d-981d-c547ec66f3bd" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_71281ce0-ca8c-407d-981d-c547ec66f3bd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ac92d86-764e-42ac-a65a-7c29e53ef189" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4defdb70-8e5d-4042-89d4-e5d2d3f8c8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4defdb70-8e5d-4042-89d4-e5d2d3f8c8d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4defdb70-8e5d-4042-89d4-e5d2d3f8c8d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4defdb70-8e5d-4042-89d4-e5d2d3f8c8d1" xlink:to="loc_us-gaap_EquityComponentDomain_4defdb70-8e5d-4042-89d4-e5d2d3f8c8d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_872daac6-351c-477a-9ace-5953f0272d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4defdb70-8e5d-4042-89d4-e5d2d3f8c8d1" xlink:to="loc_us-gaap_EquityComponentDomain_872daac6-351c-477a-9ace-5953f0272d4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_243f9f46-9de7-4bb9-bb67-1d28fd7f508f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_872daac6-351c-477a-9ace-5953f0272d4f" xlink:to="loc_us-gaap_CommonStockMember_243f9f46-9de7-4bb9-bb67-1d28fd7f508f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ee7de312-5f94-44b8-94bf-e6361b6de86c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:to="loc_srt_TitleOfIndividualAxis_ee7de312-5f94-44b8-94bf-e6361b6de86c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ee7de312-5f94-44b8-94bf-e6361b6de86c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_ee7de312-5f94-44b8-94bf-e6361b6de86c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ee7de312-5f94-44b8-94bf-e6361b6de86c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4be02463-733a-461f-8253-8ba75d81482b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_ee7de312-5f94-44b8-94bf-e6361b6de86c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4be02463-733a-461f-8253-8ba75d81482b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_22ae7b5c-2214-4dd6-9925-e991f6506ce1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4be02463-733a-461f-8253-8ba75d81482b" xlink:to="loc_srt_DirectorMember_22ae7b5c-2214-4dd6-9925-e991f6506ce1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1acbf69f-a617-424d-9229-23bedb3fe003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:to="loc_us-gaap_AwardTypeAxis_1acbf69f-a617-424d-9229-23bedb3fe003" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1acbf69f-a617-424d-9229-23bedb3fe003_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1acbf69f-a617-424d-9229-23bedb3fe003" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1acbf69f-a617-424d-9229-23bedb3fe003_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7243946e-1b0e-4c82-ba86-b7ce701e7911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1acbf69f-a617-424d-9229-23bedb3fe003" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7243946e-1b0e-4c82-ba86-b7ce701e7911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ae38abaf-15cd-44b9-a3a0-aa77ff648657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7243946e-1b0e-4c82-ba86-b7ce701e7911" xlink:to="loc_us-gaap_RestrictedStockMember_ae38abaf-15cd-44b9-a3a0-aa77ff648657" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_48e0901c-64f6-44b0-9911-6222b4693aa7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:to="loc_srt_CounterpartyNameAxis_48e0901c-64f6-44b0-9911-6222b4693aa7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48e0901c-64f6-44b0-9911-6222b4693aa7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_48e0901c-64f6-44b0-9911-6222b4693aa7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48e0901c-64f6-44b0-9911-6222b4693aa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0535b8a-6067-499f-8ca3-6f9df0cc8329" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_48e0901c-64f6-44b0-9911-6222b4693aa7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0535b8a-6067-499f-8ca3-6f9df0cc8329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_ba92f722-8322-4c67-a973-453a13b09901" xlink:href="cpix-20200930.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0535b8a-6067-499f-8ca3-6f9df0cc8329" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_ba92f722-8322-4c67-a973-453a13b09901" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_ecc885b2-bb53-4e9c-9873-83607729bb0b" xlink:href="cpix-20200930.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0535b8a-6067-499f-8ca3-6f9df0cc8329" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_ecc885b2-bb53-4e9c-9873-83607729bb0b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended" id="i751d1c5d5edd46adaf89b685ea278a90_ShareholdersEquityandDebtDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_16535cd6-d080-4e66-8985-ac5d2d1b49f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_16535cd6-d080-4e66-8985-ac5d2d1b49f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_dad3f67f-8832-4876-916b-f8d72ca3d1c4" xlink:href="cpix-20200930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_dad3f67f-8832-4876-916b-f8d72ca3d1c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_65c143fc-2b1c-4a94-ad27-fa1cb58d9c04" xlink:href="cpix-20200930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_65c143fc-2b1c-4a94-ad27-fa1cb58d9c04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2981a60a-99cd-4778-9706-8e01cda2e54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2981a60a-99cd-4778-9706-8e01cda2e54f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_80b4d999-1924-4a54-a0ea-23a7c8386149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_80b4d999-1924-4a54-a0ea-23a7c8386149" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_8126b73f-f443-4f50-9881-7d8890af5978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_8126b73f-f443-4f50-9881-7d8890af5978" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_71df5709-d29c-49fa-adcd-37a1ca3461bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_LongTermLineOfCredit_71df5709-d29c-49fa-adcd-37a1ca3461bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_f28000c3-9013-4f32-b2d4-69aa1829b883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_LinesOfCreditCurrent_f28000c3-9013-4f32-b2d4-69aa1829b883" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_40e48ad7-34b0-41be-afc8-713c834f2e5f" xlink:href="cpix-20200930.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_40e48ad7-34b0-41be-afc8-713c834f2e5f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9bd9f03e-50ef-4d38-a333-96a97c74d0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9bd9f03e-50ef-4d38-a333-96a97c74d0e2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ce529215-5387-45b7-b0e9-171728b7ede7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ce529215-5387-45b7-b0e9-171728b7ede7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_2cdddd77-0749-4311-82b7-42f042ae1241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_2cdddd77-0749-4311-82b7-42f042ae1241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_2cdddd77-0749-4311-82b7-42f042ae1241_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_2cdddd77-0749-4311-82b7-42f042ae1241" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_2cdddd77-0749-4311-82b7-42f042ae1241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed0bda6d-0c76-4fbd-9637-20e4cac9a5ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_2cdddd77-0749-4311-82b7-42f042ae1241" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed0bda6d-0c76-4fbd-9637-20e4cac9a5ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_73e4678a-6d7d-40e8-8839-473bea5d7140" xlink:href="cpix-20200930.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed0bda6d-0c76-4fbd-9637-20e4cac9a5ce" xlink:to="loc_cpix_PinnacleBankMember_73e4678a-6d7d-40e8-8839-473bea5d7140" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a21976ee-a101-475a-86e7-adf66de851fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_DebtInstrumentAxis_a21976ee-a101-475a-86e7-adf66de851fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a21976ee-a101-475a-86e7-adf66de851fc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a21976ee-a101-475a-86e7-adf66de851fc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a21976ee-a101-475a-86e7-adf66de851fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_24ca0a51-77c1-421c-993e-0aa2ae26e7d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a21976ee-a101-475a-86e7-adf66de851fc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_24ca0a51-77c1-421c-993e-0aa2ae26e7d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FourthAmendmentMember_7d2e815f-0289-4032-bde2-172eee6b8c2e" xlink:href="cpix-20200930.xsd#cpix_FourthAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_24ca0a51-77c1-421c-993e-0aa2ae26e7d3" xlink:to="loc_cpix_FourthAmendmentMember_7d2e815f-0289-4032-bde2-172eee6b8c2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ef965c46-6aa2-4674-8f62-341839cf6da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_24ca0a51-77c1-421c-993e-0aa2ae26e7d3" xlink:to="loc_us-gaap_LineOfCreditMember_ef965c46-6aa2-4674-8f62-341839cf6da3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2e387ef4-63da-47c8-878e-ff8589750891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_CreditFacilityAxis_2e387ef4-63da-47c8-878e-ff8589750891" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2e387ef4-63da-47c8-878e-ff8589750891_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2e387ef4-63da-47c8-878e-ff8589750891" xlink:to="loc_us-gaap_CreditFacilityDomain_2e387ef4-63da-47c8-878e-ff8589750891_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_88647aa3-75e6-4115-b6e4-a94ef317dced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2e387ef4-63da-47c8-878e-ff8589750891" xlink:to="loc_us-gaap_CreditFacilityDomain_88647aa3-75e6-4115-b6e4-a94ef317dced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f2a74f2b-32b6-47db-a307-9a9a9f922f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_88647aa3-75e6-4115-b6e4-a94ef317dced" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f2a74f2b-32b6-47db-a307-9a9a9f922f51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b0591fc1-66a1-44f7-bd47-aed7b176d791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b0591fc1-66a1-44f7-bd47-aed7b176d791" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b0591fc1-66a1-44f7-bd47-aed7b176d791_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b0591fc1-66a1-44f7-bd47-aed7b176d791" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b0591fc1-66a1-44f7-bd47-aed7b176d791_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0bba7415-e56c-4b2d-879d-9a44d94ede5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b0591fc1-66a1-44f7-bd47-aed7b176d791" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0bba7415-e56c-4b2d-879d-9a44d94ede5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ab16d11b-9efd-4d73-b482-bd14aa4a0af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0bba7415-e56c-4b2d-879d-9a44d94ede5f" xlink:to="loc_us-gaap_SubsequentEventMember_ab16d11b-9efd-4d73-b482-bd14aa4a0af9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8028d925-34aa-4172-8ec0-712e32ca21ed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_srt_RangeAxis_8028d925-34aa-4172-8ec0-712e32ca21ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8028d925-34aa-4172-8ec0-712e32ca21ed_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8028d925-34aa-4172-8ec0-712e32ca21ed" xlink:to="loc_srt_RangeMember_8028d925-34aa-4172-8ec0-712e32ca21ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20fdf9d5-0bb5-4f86-bd11-8d0f0cdcda34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8028d925-34aa-4172-8ec0-712e32ca21ed" xlink:to="loc_srt_RangeMember_20fdf9d5-0bb5-4f86-bd11-8d0f0cdcda34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c09052a-1ac6-4c4e-8d2d-3bacffe362bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20fdf9d5-0bb5-4f86-bd11-8d0f0cdcda34" xlink:to="loc_srt_MinimumMember_5c09052a-1ac6-4c4e-8d2d-3bacffe362bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_20b38c68-7956-48a5-950d-66ba5678615a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20fdf9d5-0bb5-4f86-bd11-8d0f0cdcda34" xlink:to="loc_srt_MaximumMember_20b38c68-7956-48a5-950d-66ba5678615a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d01b5d33-bc83-4d85-89cd-92177a06801c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_VariableRateAxis_d01b5d33-bc83-4d85-89cd-92177a06801c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d01b5d33-bc83-4d85-89cd-92177a06801c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_d01b5d33-bc83-4d85-89cd-92177a06801c" xlink:to="loc_us-gaap_VariableRateDomain_d01b5d33-bc83-4d85-89cd-92177a06801c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_caee02e7-7df9-49ba-924c-e4795e4e7ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_d01b5d33-bc83-4d85-89cd-92177a06801c" xlink:to="loc_us-gaap_VariableRateDomain_caee02e7-7df9-49ba-924c-e4795e4e7ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_44c8f3df-6b1a-438e-b5e1-e57aa3771e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_caee02e7-7df9-49ba-924c-e4795e4e7ddb" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_44c8f3df-6b1a-438e-b5e1-e57aa3771e86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aa156ea3-d342-43f6-86f6-9b367909f0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aa156ea3-d342-43f6-86f6-9b367909f0e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aa156ea3-d342-43f6-86f6-9b367909f0e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa156ea3-d342-43f6-86f6-9b367909f0e5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aa156ea3-d342-43f6-86f6-9b367909f0e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a7469390-a525-4d65-979d-4ebe2ffcf124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa156ea3-d342-43f6-86f6-9b367909f0e5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a7469390-a525-4d65-979d-4ebe2ffcf124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_15d6904c-7198-46ac-9ff5-3066cbd4e085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a7469390-a525-4d65-979d-4ebe2ffcf124" xlink:to="loc_us-gaap_ConvertibleDebtMember_15d6904c-7198-46ac-9ff5-3066cbd4e085" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_96caaa0f-25da-417e-be47-4cb827f2f456" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_srt_CounterpartyNameAxis_96caaa0f-25da-417e-be47-4cb827f2f456" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_96caaa0f-25da-417e-be47-4cb827f2f456_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_96caaa0f-25da-417e-be47-4cb827f2f456" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_96caaa0f-25da-417e-be47-4cb827f2f456_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5d246b06-073b-4374-994d-d00218bf2dc6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_96caaa0f-25da-417e-be47-4cb827f2f456" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5d246b06-073b-4374-994d-d00218bf2dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_979c72eb-c05b-45f1-a033-a6e74e170c27" xlink:href="cpix-20200930.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5d246b06-073b-4374-994d-d00218bf2dc6" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_979c72eb-c05b-45f1-a033-a6e74e170c27" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20200930.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended" id="id4f62ef2520c47b59b8d2c35313995ed_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20200930.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="i122feb915e1a44578072321fa658069b_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_c6d8d015-d345-4023-98ef-b4d100093c20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_e1f392bb-6c7c-4064-9f57-445c13783a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c6d8d015-d345-4023-98ef-b4d100093c20" xlink:to="loc_us-gaap_OperatingLossCarryforwards_e1f392bb-6c7c-4064-9f57-445c13783a62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_51e0a218-7656-4f7d-a8c1-be1bb93a6a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c6d8d015-d345-4023-98ef-b4d100093c20" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_51e0a218-7656-4f7d-a8c1-be1bb93a6a40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4ad5aa8f-9a41-4f91-a2b2-4e48bb6fc77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_51e0a218-7656-4f7d-a8c1-be1bb93a6a40" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4ad5aa8f-9a41-4f91-a2b2-4e48bb6fc77a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4ad5aa8f-9a41-4f91-a2b2-4e48bb6fc77a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4ad5aa8f-9a41-4f91-a2b2-4e48bb6fc77a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4ad5aa8f-9a41-4f91-a2b2-4e48bb6fc77a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6469c657-7d7a-47fe-a875-7fb1ab11f3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4ad5aa8f-9a41-4f91-a2b2-4e48bb6fc77a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6469c657-7d7a-47fe-a875-7fb1ab11f3de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_85f282c2-b94f-4ef0-b450-2279902544ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6469c657-7d7a-47fe-a875-7fb1ab11f3de" xlink:to="loc_us-gaap_DomesticCountryMember_85f282c2-b94f-4ef0-b450-2279902544ec" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20200930.xsd#CollaborativeAgreements"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended" id="ie7c34394fa0b4db7b26e4f3c93d89433_CollaborativeAgreements"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRights"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended" id="i3cf3ebaddd0a4f4fb23e6fe7421af79a_AdditionsandReturnsofProductRights"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended" id="i2f747fe26a7a47c786dfa63580f26a00_AdditionsandReturnsofProductRightsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended" id="ic3cf8243c4a7446f8fda25afdceef871_AdditionsandReturnsofProductRightsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_504f5d46-74a7-457a-88ba-0d7038202084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_504f5d46-74a7-457a-88ba-0d7038202084" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_a9219da7-d7c4-4230-b6eb-5307d887cead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_a9219da7-d7c4-4230-b6eb-5307d887cead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_d6903df8-8e6c-4b82-9120-840f1bfacec9" xlink:href="cpix-20200930.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_d6903df8-8e6c-4b82-9120-840f1bfacec9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_88159907-ddaa-49b0-91e6-0358d1ff10ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_88159907-ddaa-49b0-91e6-0358d1ff10ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_9ea5708f-f23b-4a96-9dfe-37beb1d7cba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_9ea5708f-f23b-4a96-9dfe-37beb1d7cba2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_78452908-a33b-4c59-914a-a3f18d4b8640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_78452908-a33b-4c59-914a-a3f18d4b8640" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_82515526-ed80-4ab4-922b-cd8c332c4856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_82515526-ed80-4ab4-922b-cd8c332c4856" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2c0e54b4-dfee-48ea-a8b3-048d9caf4be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2c0e54b4-dfee-48ea-a8b3-048d9caf4be3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8744332c-e8f8-4424-a30d-b0e5ec2f817d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_Revenues_8744332c-e8f8-4424-a30d-b0e5ec2f817d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_e8dadd71-b506-411c-92ec-49600a8c201a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_e8dadd71-b506-411c-92ec-49600a8c201a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_33d42c2f-1d26-4431-abfd-498a59985918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_OperatingExpenses_33d42c2f-1d26-4431-abfd-498a59985918" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1e66504c-b2bf-4fbd-9ce8-61602336cb84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1e66504c-b2bf-4fbd-9ce8-61602336cb84" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_33f4616c-e4b0-400c-9067-b6ca9c2d3cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_33f4616c-e4b0-400c-9067-b6ca9c2d3cdc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9726ab99-f71b-4438-ad18-4e5b95d91936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9726ab99-f71b-4438-ad18-4e5b95d91936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9726ab99-f71b-4438-ad18-4e5b95d91936_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9726ab99-f71b-4438-ad18-4e5b95d91936" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9726ab99-f71b-4438-ad18-4e5b95d91936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16b07753-75ed-4090-aa8d-e96011682938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9726ab99-f71b-4438-ad18-4e5b95d91936" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16b07753-75ed-4090-aa8d-e96011682938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_96424076-bca3-4f14-9e16-a3c4062b9524" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16b07753-75ed-4090-aa8d-e96011682938" xlink:to="loc_cpix_VIBATIVMember_96424076-bca3-4f14-9e16-a3c4062b9524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_82ea646e-92f0-4d23-9733-ed09c385e88f" xlink:href="cpix-20200930.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16b07753-75ed-4090-aa8d-e96011682938" xlink:to="loc_cpix_MethotrexateMember_82ea646e-92f0-4d23-9733-ed09c385e88f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_20f68235-08ac-4521-b802-654167664dbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:to="loc_srt_CounterpartyNameAxis_20f68235-08ac-4521-b802-654167664dbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20f68235-08ac-4521-b802-654167664dbc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_20f68235-08ac-4521-b802-654167664dbc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20f68235-08ac-4521-b802-654167664dbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e722a267-58e1-44b1-995f-5f22b424dc3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_20f68235-08ac-4521-b802-654167664dbc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e722a267-58e1-44b1-995f-5f22b424dc3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_5a380156-fa5e-41ee-89d6-5f69940c1b29" xlink:href="cpix-20200930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e722a267-58e1-44b1-995f-5f22b424dc3c" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_5a380156-fa5e-41ee-89d6-5f69940c1b29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_82bc3342-d208-4c43-b1ca-f35802565e06" xlink:href="cpix-20200930.xsd#cpix_NordicGroupBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e722a267-58e1-44b1-995f-5f22b424dc3c" xlink:to="loc_cpix_NordicGroupBVMember_82bc3342-d208-4c43-b1ca-f35802565e06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_cbfa032a-5c83-493e-b44d-209aabcb91be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:to="loc_srt_StatementScenarioAxis_cbfa032a-5c83-493e-b44d-209aabcb91be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_cbfa032a-5c83-493e-b44d-209aabcb91be_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_cbfa032a-5c83-493e-b44d-209aabcb91be" xlink:to="loc_srt_ScenarioUnspecifiedDomain_cbfa032a-5c83-493e-b44d-209aabcb91be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1024b11e-00fb-45cf-a124-a2922f33963d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_cbfa032a-5c83-493e-b44d-209aabcb91be" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1024b11e-00fb-45cf-a124-a2922f33963d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_520e0751-1d13-403e-8a18-691c348f7eb0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1024b11e-00fb-45cf-a124-a2922f33963d" xlink:to="loc_srt_ScenarioForecastMember_520e0751-1d13-403e-8a18-691c348f7eb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7298ea1b-4e1b-499b-af2c-478257ce5f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:to="loc_us-gaap_AwardTypeAxis_7298ea1b-4e1b-499b-af2c-478257ce5f23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7298ea1b-4e1b-499b-af2c-478257ce5f23_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7298ea1b-4e1b-499b-af2c-478257ce5f23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7298ea1b-4e1b-499b-af2c-478257ce5f23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2ff1290-a3f5-464f-8c05-5512a8ccdf21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7298ea1b-4e1b-499b-af2c-478257ce5f23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2ff1290-a3f5-464f-8c05-5512a8ccdf21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0c921b1f-3ab3-4921-a95c-a4db339385c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2ff1290-a3f5-464f-8c05-5512a8ccdf21" xlink:to="loc_us-gaap_RestrictedStockMember_0c921b1f-3ab3-4921-a95c-a4db339385c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bf7f5f5c-da8a-4c61-82d5-81ce9ddc5647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bf7f5f5c-da8a-4c61-82d5-81ce9ddc5647" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bf7f5f5c-da8a-4c61-82d5-81ce9ddc5647_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf7f5f5c-da8a-4c61-82d5-81ce9ddc5647" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bf7f5f5c-da8a-4c61-82d5-81ce9ddc5647_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cd0af246-80c3-42fa-87d0-a70044a76fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf7f5f5c-da8a-4c61-82d5-81ce9ddc5647" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cd0af246-80c3-42fa-87d0-a70044a76fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_d1bf07ac-9f0c-4148-94ce-46592e723a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cd0af246-80c3-42fa-87d0-a70044a76fbc" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_d1bf07ac-9f0c-4148-94ce-46592e723a65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8c4b1752-b1cc-4486-bfa2-1f6fd04a9fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cd0af246-80c3-42fa-87d0-a70044a76fbc" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8c4b1752-b1cc-4486-bfa2-1f6fd04a9fbf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended" id="i28f676c52f114539b07512ee3630c200_AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7539c025-ba06-4bad-8e4e-72bfe77b5c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7539c025-ba06-4bad-8e4e-72bfe77b5c3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_62bcae5b-8fce-47bb-a38a-ce56076d24a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_62bcae5b-8fce-47bb-a38a-ce56076d24a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_cf81d6d6-07cc-453b-8547-301f4da18719" xlink:href="cpix-20200930.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:to="loc_cpix_PaymentsForContingentConsideration_cf81d6d6-07cc-453b-8547-301f4da18719" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fbcaa87a-9422-42cf-82a5-b04eadbf8760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fbcaa87a-9422-42cf-82a5-b04eadbf8760" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3ca8ff01-c9d1-478c-aade-a15093c842f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3ca8ff01-c9d1-478c-aade-a15093c842f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4920bdcf-ceb6-4fd0-948c-f4588161f71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3ca8ff01-c9d1-478c-aade-a15093c842f1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4920bdcf-ceb6-4fd0-948c-f4588161f71e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4920bdcf-ceb6-4fd0-948c-f4588161f71e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4920bdcf-ceb6-4fd0-948c-f4588161f71e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4920bdcf-ceb6-4fd0-948c-f4588161f71e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a9bb9a2f-a3a7-4515-ab21-cf4a75e7159c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4920bdcf-ceb6-4fd0-948c-f4588161f71e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a9bb9a2f-a3a7-4515-ab21-cf4a75e7159c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_4e80d3c3-0008-4fad-8fd6-59dfb593d237" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a9bb9a2f-a3a7-4515-ab21-cf4a75e7159c" xlink:to="loc_cpix_VIBATIVMember_4e80d3c3-0008-4fad-8fd6-59dfb593d237" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended" id="ic3df5536d9ca49028f16c01930d2b7b8_AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_44d8cd92-3e69-4102-8a73-40d27f7e022b" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_44d8cd92-3e69-4102-8a73-40d27f7e022b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_8d7036c2-f44a-4d4c-9472-3ed8effc4da2" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_8d7036c2-f44a-4d4c-9472-3ed8effc4da2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_927e8ed1-ee8c-4144-9768-462fae8085a6" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_927e8ed1-ee8c-4144-9768-462fae8085a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_ce261449-13bd-441d-a1a0-4bc0b24af51b" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_ce261449-13bd-441d-a1a0-4bc0b24af51b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2af60168-3cba-45ec-8377-9e3dad08a96c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2af60168-3cba-45ec-8377-9e3dad08a96c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f0718118-ddaf-4e7e-8aa8-dd370e61865b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f0718118-ddaf-4e7e-8aa8-dd370e61865b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b3edc18d-9f55-4980-8ac9-ecf6a9391d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_us-gaap_Goodwill_b3edc18d-9f55-4980-8ac9-ecf6a9391d7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_53fe428b-f0f6-4efc-98c8-48e942991796" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_53fe428b-f0f6-4efc-98c8-48e942991796" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_8d8dfab0-cfed-48bb-aabd-f653a7ea3422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_8d8dfab0-cfed-48bb-aabd-f653a7ea3422" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d6c1764-e58f-4e6f-a0f7-d6207f03e9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d6c1764-e58f-4e6f-a0f7-d6207f03e9da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e1075452-870c-4ee2-bd6f-3a6d909aac56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d6c1764-e58f-4e6f-a0f7-d6207f03e9da" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e1075452-870c-4ee2-bd6f-3a6d909aac56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1075452-870c-4ee2-bd6f-3a6d909aac56_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1075452-870c-4ee2-bd6f-3a6d909aac56" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1075452-870c-4ee2-bd6f-3a6d909aac56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96425c4f-50b2-4e6e-bd39-7a336682d7ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1075452-870c-4ee2-bd6f-3a6d909aac56" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96425c4f-50b2-4e6e-bd39-7a336682d7ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_e21713b5-6003-45dd-8217-a1cf1f2b30ec" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96425c4f-50b2-4e6e-bd39-7a336682d7ec" xlink:to="loc_cpix_VIBATIVMember_e21713b5-6003-45dd-8217-a1cf1f2b30ec" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended" id="i5e00103a09c34f94bd1f997b0e8f27bc_AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bf7b2be6-e2d5-430c-ad5a-d119ac9c363f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bf7b2be6-e2d5-430c-ad5a-d119ac9c363f" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d5431bce-93e3-4b14-8820-fa75090adc89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d5431bce-93e3-4b14-8820-fa75090adc89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_224cd125-c4ad-405c-a01c-0978c4f644af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:to="loc_us-gaap_PaymentsForRoyalties_224cd125-c4ad-405c-a01c-0978c4f644af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fb44afe8-202b-4be2-a882-d37ad3d31c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fb44afe8-202b-4be2-a882-d37ad3d31c2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ba545564-4e84-4da4-a6aa-2f38e41a5f0a" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ba545564-4e84-4da4-a6aa-2f38e41a5f0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a4742cf1-4f53-40da-a932-22aed2f568cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4be39c45-e52d-4094-844f-9f430c18dd32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bf7b2be6-e2d5-430c-ad5a-d119ac9c363f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4be39c45-e52d-4094-844f-9f430c18dd32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c98d7d3a-3b0c-4491-9ce0-d6e4891a8b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4be39c45-e52d-4094-844f-9f430c18dd32" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c98d7d3a-3b0c-4491-9ce0-d6e4891a8b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c98d7d3a-3b0c-4491-9ce0-d6e4891a8b43_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c98d7d3a-3b0c-4491-9ce0-d6e4891a8b43" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c98d7d3a-3b0c-4491-9ce0-d6e4891a8b43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6f10d192-7b14-4146-906f-844013c23c27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c98d7d3a-3b0c-4491-9ce0-d6e4891a8b43" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6f10d192-7b14-4146-906f-844013c23c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_985e9396-de72-451c-8321-93f55023e710" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6f10d192-7b14-4146-906f-844013c23c27" xlink:to="loc_cpix_VIBATIVMember_985e9396-de72-451c-8321-93f55023e710" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cpix-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2bbc8fb5-37a0-49a2-88e4-922c4b8dea28,g:76b63af8-607f-4b3f-a750-f8a8dfc06213-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d5b1251-70b6-4d96-b79a-f1888e7587b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_92c8179f-f615-4dba-a716-0bfdecfed540_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_eb971717-0f11-4e39-9284-cd7413b57a58_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e549a802-87f4-457f-8570-639b9be6aeba_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_7e4f380d-d163-4021-ad5c-ebae905358f8_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20200930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_2d4b2f3f-267c-4666-bd32-5c66295ac76e_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Three</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:href="cpix-20200930.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:to="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_73de7057-cb8d-4689-8d88-9a148a2a044d_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_88cb1207-f89f-4cd6-ab5b-21def9b4cd62_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_0750e703-3c99-4a51-8844-9f0205c4f7fa_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_58f5aac4-0d02-42f1-9ffc-834969d24fef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_8d077c90-431b-49f1-b898-9ac8bb016ca5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2b872479-9ab5-4d84-b51d-76f2ac2a50db_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_941e3d83-5e3b-4845-81a3-982fb8928a38_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - unlabeled vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_09e78d6f-a601-435e-a510-0578d48d69f1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_6ab77424-e859-4916-8514-f54289db959d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c6aeba2c-5dff-4106-9e0d-8b8957977142_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_adecda27-5169-4e15-9fdb-4d39e88369c7_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_35285587-4d55-49dc-b435-7e1e31a23071_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f2effdc4-231c-4d15-b519-88bcdb4f0ff1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_d39ae0f1-3673-44bb-a53c-d4fb7baca5ad_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_f644f19b-6f05-4670-a8d9-ecc2ee046c58_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6888d496-e553-43d5-b5eb-f4ff5ab33504_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_4e9688bf-69ae-4194-9c79-8064ead27a1b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a2e1c4f6-0fd7-4175-ac47-20f98b1c61ce_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_dbaf026b-02ca-4912-94a3-28ede318e030_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20200930.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_811f4a0a-fe1e-4668-844f-c056acaa8ee0_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20200930.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_20da6c33-3c54-48cc-a00f-270e119c1f9b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3ae3f9d5-fbe1-42ed-a2ab-32c64b58998e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_7633ce1a-4ca7-4c25-b0e2-955462cc3076_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_095168b7-d681-4359-89db-e89a8097ac50_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_611f3dd5-975f-4644-ab2c-c2fd1b88cb24_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f884175e-dfb0-456d-901d-1988bd1a59a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ff30f278-6fb5-4ce3-8a8c-d8c5c779a985_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_5e2e066f-d672-4334-83d4-03be6e9e6c05_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of cash</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Cash Contribution</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Cash Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentCashContribution" xlink:to="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4a7bb941-84af-4245-b712-934881ea80cd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_0c526da7-cba8-4d64-a996-720699736ee2_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_887805df-cd63-4d0d-8272-84f0cd39611c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NordicGroupBVMember_d29bc84f-3fbc-488d-b8c4-ce4b8fa87401_terseLabel_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_label_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V. [Member]</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_documentation_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember" xlink:href="cpix-20200930.xsd#cpix_NordicGroupBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NordicGroupBVMember" xlink:to="lab_cpix_NordicGroupBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed4d75c8-74ce-41ce-96ee-66d35cae7e75_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3875b8d3-16ae-46c7-8fc3-589ba648392e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_09eacc38-7bb7-47d3-a8bb-f239dbac02e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from surrender of life insurance policies</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:to="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8e7040c3-9798-42eb-a998-0f10e45f6fce_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_147001e1-df52-45a8-b71d-0a1fbd4f8084_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7f8989ae-3ddc-478c-9e8e-8fc61bbb6987_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_219a9e84-0c19-4a94-bb68-07808d4c5399_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_e266bb7b-3f3e-4395-bd9e-c4915621595e_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0a72ce9b-c479-4a6e-8254-e8359f32b766_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_086a69cf-1106-4eb7-aca9-b949b5edc644_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_8d447300-d392-4514-b6f5-fdcb778132ca_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20200930.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_703a2a6d-21e3-4299-a30e-6d8a81559b94_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_cc8354e8-f5ed-4692-b74c-1ef5e11a0a85_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8b95b6dd-7349-4290-8998-8f0e7c3aff2b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_095848ab-a4dd-42c0-8b58-83f5d9c050ec_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98d479c3-2e6e-442a-b604-f64112f8f382_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_890cecaa-66fb-4447-ad60-d3f242004656_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_6a90ba0e-cea9-4ed6-8f96-b92b7ec0a908_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_f926d844-a875-4a56-9ef3-870771d7b2df_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_dd9a21e5-27a5-4248-8c0e-d8f91fdcb99d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4f9b80e0-146d-4990-88db-f640705ba18b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_04220a0d-1838-42e1-8e7e-4db8d84c0376_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5e18b0a4-fd35-405a-9580-bb8823788e63_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0a7118e9-ccaf-429d-a16d-1beed325eabb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4bfb174d-129e-411c-ab14-e12abf82b827_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_4b7b6007-7125-4e47-9bb1-212aab0bc5d3_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7c4d081b-a9d2-430f-bcb2-38a73987a90a_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_379afe6a-5dfe-493f-b43c-0117c90e9846_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d0503fb1-2ea9-40c3-b98f-2da86f8e6271_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a37aca44-4b10-4a3e-98ec-f89ab5e1277d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_8c621697-cdd1-4de7-b3e3-e51fc3a33807_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b282137-abed-42ce-8d62-8a8a45d144f5_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_1c8376b5-1fd1-4c03-802d-34ca38f2bdb7_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20200930.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_df04f5a5-d0a8-43ac-b91b-9231c7d22db3_terseLabel_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_label_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited [Member]</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_documentation_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember" xlink:href="cpix-20200930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ClinigenHealthcareLimitedMember" xlink:to="lab_cpix_ClinigenHealthcareLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cbb6de9f-2ef0-48a3-85c3-6dfd53768984_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_62a1f265-9a86-4274-aefc-2c0c97dbebae_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_dd1d6780-93be-4580-899a-0e53b7e957c3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6c35cf95-be22-4991-99a4-4d6ba1d2ba82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f7284e1b-7894-4a19-9a90-db797c8c6edb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_daf4017e-48df-41d0-91c6-5b1d75bc9627_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_92c3dc69-21f4-46f0-936a-b4dce2b602f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b403cd2-2429-4925-8448-b5e3addffeb0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f7589b44-f38d-47a5-a315-0cd4ad14620c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4e39ff5b-eabc-4373-a8a7-f5bf2324c760_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0f9c92b1-17d0-4951-bda9-09d3b6f3f978_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_ca56125d-3203-4b9f-801d-a00f826ce401_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_9d1b4209-73da-40b8-a802-db29a276de3c_terseLabel_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_label_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited [Member]</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_documentation_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:href="cpix-20200930.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:to="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_10a481ef-bc7d-48e9-baf7-57d499ef4637_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6088f3c5-8ad4-4a76-8b97-c51e36b10100_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_3369eb21-3b22-4054-9192-92c6f47a52c6_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment through purchase of shares of CET Stock</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:to="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_311c35dd-0cf4-45e1-a418-f4c8d1224ac5_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20200930.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f452444b-4383-428f-bf1f-38c2963f57f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f12c7b63-f9a2-4dd5-9dc5-a11684394d02_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_1826ba71-c08f-410c-bd22-418c39e8c207_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20200930.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_9d5e7adc-4e3c-4495-90de-33c7decb73c4_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_13923807-519c-4f52-be33-956cb5db78bb_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_60ad4a89-f2aa-47a0-9b89-f8c1fd5b4044_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_01c57d4f-1604-45bd-846a-ad01f9145b6f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1f0c955-8579-448b-92db-22e92b3519f4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_aeabfc15-8135-4169-88e1-51a17b8d15ff_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_c4192b83-ab35-4aaa-afbe-65cf24c2b6db_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8d44e069-a101-4aea-a1f9-797520943f78_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_fcc8a088-90ce-49fd-9917-05187d4496cf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_d1ffce93-a297-4eed-994a-f7e6c415b447_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20200930.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_9f3fede3-7e7f-435d-95a6-8820b0cbaf41_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a79be98e-630e-4931-896a-c49bc3d04a6c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_39a9aac2-3e93-4cba-916d-37518f42adea_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract" xlink:href="cpix-20200930.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0b6c6765-4aac-4533-852d-16c6379f3c34_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_988d6411-6d2f-402e-928f-734d107ac53c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_def96ba1-12da-46a0-8fe9-4d959a860283_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca9ee515-86cc-4afd-9b03-e99163fc5fe9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1139599a-0649-45e5-8fca-79f4fb372a38_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_c07c9327-2b06-4380-8ca9-06795ae0a026_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_12d6e0f7-5809-472c-86c4-35eeb1311196_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_70856fd4-0ae6-48b5-a11c-a75e9f7e076e_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investment gains</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_47d8d0a7-aef8-4f89-bc4d-7b007133e6cf_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e07ddb26-24f4-4073-acf6-7338b5731a4e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_a702b1b3-95fa-4ee2-9a34-d0faeef54cae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6b071805-b898-4cff-9dd0-d4882d9f28b0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_f1e768be-e416-429b-bfa3-31c8aff38509_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ddc33656-e577-4cbf-8b83-22bf1b5dc30c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_597378d8-da7d-4e19-aaad-46d9d19f824a_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_cc02880b-fab7-4057-beb5-c6a92b5ed06a_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:href="cpix-20200930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_8f3cff30-6a0d-4cd8-8324-1bdde6100094_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_d81490b8-7691-450f-8b4f-c1263b91d988_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_37600d6c-5dd8-4cbb-8697-b14155eb5479_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_60672add-8a03-41bb-9d87-7fb66c52f4c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0340d2a-37ce-477b-ab55-8bb4cf4cdbba_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_4672133c-1611-4800-9636-3fbc3fdb7c2c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_9242dc45-9a5f-4f47-8eee-b667387f843e_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20200930.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8fd85731-7ee6-40b4-b7ab-51d17fc8eb66_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d8d8b68d-7fd8-4565-b446-2b3fd2e1a1ad_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5a84d2a2-2a17-44db-986e-3b8ac61076c4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a2ecaf1e-a1c6-4985-b591-71e2cb6d1e14_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f88a4831-ead7-40dd-b595-271c238e5dd7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_42273cb9-92e7-49be-8dc4-319a99d76468_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Leases Liabilities at September 30, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_a1452de0-572e-47b8-9701-03b7531aafa7_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_566246e0-1dc4-4398-8e83-9a5c45ce18aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2a9169a8-6fdf-4422-a327-0b1ff68a8edf_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee477217-e139-4acf-a5f9-72e08b81d824_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6745faed-de46-4f9d-8e68-29af321fdd97_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bf72b305-3d8b-4c3b-8259-19d7d45e4612_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_98368244-abf4-40b4-acd1-9e4eaff7503a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e70b92ef-ed49-4420-8092-89ebf5fa145e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a4321af1-61cd-4917-9721-aec7ebb1bd18_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_99045e3e-5321-42fa-9e15-ea0bb5fc9db9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_eb55fbb0-dd3d-4956-8c61-7d7e45ba2268_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_fe519fc8-2210-4b14-ad7a-8b652b0c6273_terseLabel_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_label_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_documentation_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:href="cpix-20200930.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:to="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_b822fac2-b63f-475d-add0-487b6e3b65d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_91bc3e3c-cdbe-41d4-b19f-0f4b48348faa_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ebe3acfc-abe5-4a0a-b7fc-14146ff59b12_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_bcc43014-eba2-4099-ba46-13d30f2ec4e4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4ffbe48-b08f-4cfc-87ce-085f9b8b92f2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f77c5a1b-aafb-4be3-88bf-d7675d917a6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_d0a4725c-c931-4810-ac89-529ac7cdb3f4_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7da52906-9f71-467a-830f-2eba52abb6bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_45ef32aa-9e7b-44d8-ace0-5427f78fc28d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_db0102e0-b5d5-4f37-b057-fd735f933736_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d13c0f26-2a59-408e-acb0-b2771d5e9b7b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ab6d35f-b69e-41c0-a084-3be5e7380daf_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_309f90cf-5c86-4dd9-8428-cc38ab452d52_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_d35b8149-88ca-47be-9994-32f0a8efa027_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of tiered royalty payments (up to)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20200930.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_a097a5ed-9fa7-4b97-b677-08fa23619997_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_e0f0f443-42f3-4f9b-a464-ce8a6bf75c3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of deferred loan costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_3fdd63a0-8efb-40fd-bcd0-877122f57385_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_e91d666c-4818-4037-a2f2-2488dfaa836d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_097c26c3-db02-4354-9d47-fa6a50b79347_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4517d2c7-ce32-4982-a4a3-308c480bb48e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_48018b0f-6f0d-4356-ab48-f8841ebd6c75_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a2d8f54-7810-405e-9dfb-6c1b8ee55f93_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_d53015d7-60ae-47f7-9800-aaa4c6eed5d6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_445414f2-c059-483c-b3d2-958453ae695d_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_26c3b0e7-93c9-4f0f-950f-0b45f4af73da_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_666c1ba8-bb01-4ddc-84b7-f116a3b20674_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_2b92bec2-a641-4054-99fc-0bebdd4b6b10_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_d75d541f-229c-4446-a2db-1fbadc398762_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20200930.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_751d9661-492d-4d34-bb1d-0364dbe6148f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_25644600-e305-4b01-b45b-45627e69fead_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_9d5c7317-ca26-4092-ab7d-d86201ff504a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_b297d100-29ac-4490-9a58-9154089dcac3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested common stock, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1acc8bcd-d6c8-4f9c-827b-b5c103270ad4_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_e370142f-ca57-436c-8605-ee1266800180_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:href="cpix-20200930.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5aace88c-b2b9-48c2-a406-e33a7c2d8006_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_eda661df-a4e5-44fe-a422-a6446e5fa0a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_38da8361-1e7e-4196-a91d-98ac840b1de0_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20200930.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a8f7aa86-2c72-4974-9824-5a80fdf7017b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2777b63f-fce5-4058-8e1a-fa4941780dd0_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_94ab9e32-ddb3-4c06-b11a-67dc2631b854_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_86280e01-2c97-4af4-82a1-a23230a86141_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_edd56e02-fe71-4927-8f66-ca8be8f83ad9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7d6bbc8c-f8b6-4104-94b2-1cd26fe278e8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_36b064b6-08d3-4518-9010-44e94e0133d1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8650ec4e-c910-43a2-8f90-b91b45f78fc6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0f2952bd-647c-4b82-8ac8-ba41a6883ac1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9ef1f90b-066f-43fb-93f5-d7f2880106b1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3f3c7aa6-afba-40fc-8f8f-6718d8f011fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_205248d4-308f-45be-8340-5da1105192e9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_79a9f2ae-e538-4493-8b2e-318548c13302_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_01a063a0-bd40-496a-909a-46cc117c9a9f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_a7f2892a-3b21-453d-9623-a10347fd0aa9_totalLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangibles and goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_c635fe3f-d9e8-46d0-b7bc-d62a0110ea39_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Position</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20200930.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_b5ec7793-2bed-430b-9025-dd38eeb5df13_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_98d0d921-7851-4b76-ad55-dae2b43687e5_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_b0484caf-a06e-4ee1-932e-b6cbdb3657d8_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_9b9f7438-2d2d-45bc-9c9b-6ebed163888b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_e888d96b-13ab-4f79-b66c-ca1d5573c865_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_39b59c03-dd6a-47f9-b486-fcea2b3306c4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_df076562-9fe5-47cc-9858-001be52a70cf_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_271f93b3-324b-4d11-a855-6ebfa04a372f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_8ab8c6ea-0bdf-4163-bd0b-0679bb75eb9b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_32b8c479-f8c1-4b30-858f-0dddc4157c14_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_208d5c96-701a-4871-9553-efd8142a31ce_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_4eac1bec-96ea-49e4-97f1-7f26ed991e60_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_4046c232-9519-4cca-9d89-0736e49bd285_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_50b9c360-df42-41b6-a491-54e2e22f4ecf_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_642f6bdc-3bed-427e-9f72-bf601df14fff_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_12be4a93-1f48-4390-b26c-d7a56178b37f_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_27049dde-eaa0-4738-bbed-a4d992a72b8b_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_827731c2-4457-4616-8960-cf890b7a450f_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_66472d90-f309-43e1-818f-f6fa91026d43_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ef4fe4e3-8852-492e-b7af-7f57fbbae515_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_6f49622d-3ab5-4a43-81da-6bc0fdf73f32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0040703f-c65e-4455-add7-783e12fe12be_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f0f1d61b-ce5c-4a7d-9d01-e8ec45ba5cd5_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_8f926b3b-b48a-4ca2-aef5-081f23c688f2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_21c0eed2-666a-44a9-b662-6d90881d3e1f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_118f97e9-0486-4d16-8b59-52e11026e5d3_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_e960f16a-4d6f-4e57-9928-f58a91e642f9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e9e81665-b3d5-4cc8-a5a8-fa3541881f68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_650ecb99-c19a-438c-a665-066eca6f9c87_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for return of shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:to="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_a8494bd7-e559-4f8c-94f3-7e6dca7e061d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_749f3e8b-2916-458c-8b1a-4fe61f005dc1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_5236c616-de92-43e0-8966-dd8157a52ff7_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_8e6fc73d-17d9-4a5e-b149-848e631ea5dd_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a012ff95-a17e-441d-83a7-6c6f1d1c97d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_230a5353-7175-4bdb-ab5a-fc5746eb2e42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5713b98d-1c30-4b82-900c-911b5d8ff2ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_28c4f948-a819-415d-aa26-9db7b12cc5f2_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross, Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FourthAmendmentMember_7323a28e-da83-4d08-ae98-fe12929123a9_terseLabel_en-US" xlink:label="lab_cpix_FourthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fourth Amendment</link:label>
    <link:label id="lab_cpix_FourthAmendmentMember_label_en-US" xlink:label="lab_cpix_FourthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fourth Amendment [Member]</link:label>
    <link:label id="lab_cpix_FourthAmendmentMember_documentation_en-US" xlink:label="lab_cpix_FourthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fourth Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FourthAmendmentMember" xlink:href="cpix-20200930.xsd#cpix_FourthAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FourthAmendmentMember" xlink:to="lab_cpix_FourthAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_27605eb2-9a36-4732-9664-27b1dbf8af69_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c29b4734-e59a-4989-a331-547b7015c009_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_750a89d5-4ee0-4ad9-8c19-cdfc942c5a8f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_ebe11771-7374-413e-9d67-29aa01bf860e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONS AND RETURN OF PRODUCT RIGHTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_a73ceff0-663b-4a6a-8a18-143a22a9a919_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ef400628-754e-4a5d-9378-4f2313d9ec1a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c7f2baa0-c2fb-4a65-8166-bea1d4e12dc3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7b5a2a3b-7741-4791-9f1a-c23f658be60b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ad244c66-d944-4301-9cae-bf928fb5b23b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_9939614d-c2b6-4889-a51e-31bf6113fa41_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_954d75de-6a87-4712-98b8-919c7ae2689b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d5973df-a79a-41c4-825a-a1697d7bc7b4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5496edce-1b9b-4030-b4c6-61ed1bde573e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_c7e6f27b-69d7-4d7f-b74b-32a0835bb9ea_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_976a3101-de6b-4d74-8a26-ca37751cdaef_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial investment in joint ventures</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_539454f0-e6bb-4c01-9415-d7d2c7b8f023_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_972c0476-8504-48bc-ae2e-70c176adc2d1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_b5c5d74a-3a70-474b-a101-8727ae8fc05b_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a019f3f5-c113-47a4-9d71-a2f2af4ac3e5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ac95cf8d-2d55-421e-843c-cc5df5a08343_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_c638717d-e901-402b-8c8f-9c5de1409ed2_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20200930.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b5332efc-1829-4731-b312-85bdaad9053b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_82cb6edf-b522-43d0-b8c9-f43aaa4a5c88_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f64b7fd8-b79b-4609-a4b7-6a82c8cc3468_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c8bb9e3b-4fc6-41b4-98ba-d58d7a411098_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_3065b0c4-836a-47c2-b9e0-6f375cbff444_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_ade0d02c-6cd8-43b5-92d8-70b946247295_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2bb267c7-4cb4-4571-a62f-ecc2a3e54b21_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93f3a09e-5dc7-45e9-b654-53867d4692b6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b5683186-8ced-43fb-93c0-2b0969e594d2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_5642a1c0-1718-4453-b301-03b93b3ca82d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_98ba75ce-601a-454a-a3b4-c3fc72b27d6f_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4190d865-c340-4a0c-bca6-22bef6964287_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7369e2db-9a7e-400e-92ec-1264b639a8c9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1900d424-ac81-4c9d-bde9-3703d326ab1a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6b69b1f2-04ba-4fb5-bc52-a725965aaec3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3e55b4e0-b27a-4093-b40a-409d239d92fa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_368af370-0a95-45bc-a4bc-6924005be992_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - validation vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_65700c89-1533-4ab3-a054-ec761257e98e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_0d518441-09e7-4bcf-9358-a16e83beca08_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_e465f1fc-4b90-46d2-90b6-c66bd07fa9bc_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_072ea3e8-9b77-4ebf-8841-d55564259471_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_706c4d39-cde0-454d-b1db-5b4c389ebfea_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bf6c9674-dc9d-47e4-b005-21cbc8972aec_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_7d18a0e5-63bb-4267-9f97-c5508b186b34_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_9f41ae74-0d3f-457d-984a-4aaabd02cfff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b9edf4cf-2630-4bb3-95a0-51a6fbba56f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_b61c3a09-b2ab-4bf1-aaf2-bd9bb752753b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8c3c5fff-2352-4eb0-8c9c-81442c07fd6d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e840578c-c1fb-49c7-b95f-789eb2df3a6a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20200930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_4d1ce5fa-59b0-4c86-85da-b98472e2b7ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment during 2019</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6959126d-40e1-40f2-ad25-244e0625e5ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_ad469807-d5ed-409c-bcac-d9e331ac5a89_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_f946fa04-0f7e-4ba1-85d8-35d65b2baafb_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase amount (up to)</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:href="cpix-20200930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_0bb1e19f-e88b-436d-a49a-5cc7277906f7_terseLabel_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration - net sales royalty</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_label_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_documentation_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration" xlink:href="cpix-20200930.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsForContingentConsideration" xlink:to="lab_cpix_PaymentsForContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d8551c1e-2c17-43b4-8abc-16b1baaa738b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_40731d75-2e84-4e33-a7a6-fbcf25d79751_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_6467c421-266e-41f5-81a5-1958aa3e0a52_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d90250e1-3bd3-48a4-8404-1ada51490a68_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d8570ae7-9dbf-4fc5-9bce-1667c979d641_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4eaeee88-f4af-46d6-a99e-099790b2fc1d_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInCurrentOperatingLiabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:href="cpix-20200930.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_cc08bb67-6513-4b79-9185-4cce9652ef98_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_879fc9bc-23c4-4135-872a-01864a3ae791_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_466cedd3-2482-4628-bf0c-9fe8acc60f55_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_d44c6495-74e0-4615-8247-cef207671a00_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_8fe30009-e587-443e-8754-df325a106792_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fd91269f-7db0-4db5-98d8-e231b7d6bd34_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_70cc9430-5be9-4a6f-a534-5f806832ccc0_terseLabel_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_label_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals [Member]</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_documentation_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember" xlink:href="cpix-20200930.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_GloriaPharmaceuticalsMember" xlink:to="lab_cpix_GloriaPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_75b97638-a26e-4ae7-9879-63179dbd9957_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_78e6f148-d081-4508-82dd-43a3a71d3298_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_61c7b91f-368e-4272-995e-d3e976e6db7a_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2f2de854-0b09-4bf8-91f8-4579d6827dec_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_738b47c9-65e9-4aa1-9af7-7853ff4a1d93_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_45d03e9d-a2d5-4fa9-b037-eebf65725427_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_7e22458d-8259-4ce8-916f-9a5cc541410b_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_027426d6-dbca-4f16-9f41-115370f0ffbe_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb970c9b-7909-4e62-bb93-d8ed5630a181_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6f712cf8-2b25-4071-b069-d785be3f591b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_51b07559-52ac-450f-b900-bc1eaae52a4d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_4acc3b40-9ec6-4aa1-ba4f-4e7a893aca8e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0aadc8c-b3c9-4d34-af3c-133b126dedc5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_756caeac-40ae-4dda-a305-7bb2726af1f9_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ea95101b-1bc5-4aa5-80bf-862be8c4cb7b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_74cf94cb-8c8e-45a4-a0fc-6878e82ab9a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of marketable securities, by type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bee5b024-9d42-426a-b3fe-fdb125dabc80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_cb9b1fed-b0a5-4b97-aed1-95ebbce0d798_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6d7eb37c-99f3-4fe8-bb57-8fc374220980_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5d38cbde-664c-4067-aa3d-88b69aea7449_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_7448b256-aec7-48dd-8d59-c726bae37271_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_c9343c51-d01a-47a1-abad-232563ee530b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6ab6cd88-9954-4aed-8b92-d29f8e99ca74_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_ba48c8ba-71f4-4b95-a078-bda57df9b846_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20200930.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_63b78aa2-98c2-4106-aaee-19d806320d75_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_893e63f5-517e-4b22-8d53-a71c3fe50921_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_85120b6d-d6b5-4a33-bf78-213cbd6cd2bd_terseLabel_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_label_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Domain]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_documentation_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:href="cpix-20200930.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:to="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_86a24a4e-7cb4-4089-bcc5-4c6b99399eaf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_f1a34f9d-3d55-4671-a86b-0dfce64a803f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0cc4f39b-0b92-4d9f-8cae-0530e054997c_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f600d4f8-4c60-4797-b774-9ea629f3e396_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_2861277e-0483-4412-988a-1ad13b74c33a_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20200930.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_dbf228e2-183b-4e85-aa77-c95fe2c0c3ef_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_0ed12e80-04c0-4982-a066-4f38d4b50ed2_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of intercompany loans payable</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Conversion Of Intercompany Loans Payable</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Conversion Of Intercompany Loans Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:to="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_79da44c5-db4b-4eec-968a-d68424e4fc3b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e70f107f-2cc9-4410-b33f-c104e7903e33_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cpix-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2bbc8fb5-37a0-49a2-88e4-922c4b8dea28,g:76b63af8-607f-4b3f-a750-f8a8dfc06213-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1b463850-9b94-43e0-a0b6-f8c5dbcc90e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_DocumentType_1b463850-9b94-43e0-a0b6-f8c5dbcc90e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1378150a-4257-4672-9cca-d3e6bcc27c67" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_DocumentQuarterlyReport_1378150a-4257-4672-9cca-d3e6bcc27c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8a299dd9-1308-46d3-8012-e8cd28ecfe34" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_DocumentPeriodEndDate_8a299dd9-1308-46d3-8012-e8cd28ecfe34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0a84bd56-43b3-4dec-9d67-93eadb4b5f52" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_DocumentTransitionReport_0a84bd56-43b3-4dec-9d67-93eadb4b5f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ec9fb896-3a36-47cf-80c4-55bdbc1731d0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityFileNumber_ec9fb896-3a36-47cf-80c4-55bdbc1731d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ce181640-76e8-4f20-8851-e13c2767c754" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityRegistrantName_ce181640-76e8-4f20-8851-e13c2767c754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dd7bc464-92e8-4a55-97e6-d94f69d03b47" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityCentralIndexKey_dd7bc464-92e8-4a55-97e6-d94f69d03b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9f97ec3d-c8f1-4dad-88ca-90b7f41fa21e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_CurrentFiscalYearEndDate_9f97ec3d-c8f1-4dad-88ca-90b7f41fa21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ef7b14d5-15a8-4ad2-8ff2-ea2ed8305730" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_DocumentFiscalYearFocus_ef7b14d5-15a8-4ad2-8ff2-ea2ed8305730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9ed27594-a7a4-4dae-a5de-8b90d85e59d2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9ed27594-a7a4-4dae-a5de-8b90d85e59d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_142ec997-9773-4d60-a3b8-14ac1a76add5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_AmendmentFlag_142ec997-9773-4d60-a3b8-14ac1a76add5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b7c69845-74bb-40a7-9ff3-50389276c370" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b7c69845-74bb-40a7-9ff3-50389276c370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_16532ba0-3a27-4604-9520-aa0587752dce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityTaxIdentificationNumber_16532ba0-3a27-4604-9520-aa0587752dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_78874de3-9e25-47fa-b5c3-83b4725f72ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityAddressAddressLine1_78874de3-9e25-47fa-b5c3-83b4725f72ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_02411741-6e3f-408f-ab54-ff6e13bb3690" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityAddressAddressLine2_02411741-6e3f-408f-ab54-ff6e13bb3690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_53452b01-a31c-40f5-8ea7-17857eea5e16" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityAddressCityOrTown_53452b01-a31c-40f5-8ea7-17857eea5e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_cb80c13d-b675-4b6c-91f0-19347292a1c4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityAddressStateOrProvince_cb80c13d-b675-4b6c-91f0-19347292a1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0197cdec-838e-4084-85ea-00cb7718012b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityAddressPostalZipCode_0197cdec-838e-4084-85ea-00cb7718012b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b82f2c43-26a3-4b89-bf64-03c356da8030" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_CityAreaCode_b82f2c43-26a3-4b89-bf64-03c356da8030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6eb7f3b4-ff54-45c1-91a4-caf3c5ccb038" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_LocalPhoneNumber_6eb7f3b4-ff54-45c1-91a4-caf3c5ccb038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5fb15928-f7da-4b55-b286-c9450cda69b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityCurrentReportingStatus_5fb15928-f7da-4b55-b286-c9450cda69b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_58a8fbc7-1b1c-4b3d-9a00-358290913f93" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityInteractiveDataCurrent_58a8fbc7-1b1c-4b3d-9a00-358290913f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_63f2caa3-f27e-4ae9-ab88-353f9e6311e6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityFilerCategory_63f2caa3-f27e-4ae9-ab88-353f9e6311e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_13a5d0ed-d114-4ae8-af8c-523a3458652f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntitySmallBusiness_13a5d0ed-d114-4ae8-af8c-523a3458652f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4a5fbb81-86b8-4ba1-8005-3baaaa16b121" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityEmergingGrowthCompany_4a5fbb81-86b8-4ba1-8005-3baaaa16b121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2676c387-f592-4853-87d7-846d8302f49e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityShellCompany_2676c387-f592-4853-87d7-846d8302f49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8da7313a-0f51-4142-a0b4-85c44d5d714e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_Security12bTitle_8da7313a-0f51-4142-a0b4-85c44d5d714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f7c8923d-1a42-4183-af00-5b0642ef7b32" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_TradingSymbol_f7c8923d-1a42-4183-af00-5b0642ef7b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b137bcdd-984f-46a3-9d55-5cd1683ac0d9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_SecurityExchangeName_b137bcdd-984f-46a3-9d55-5cd1683ac0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c7c3c83b-db10-4d0b-9907-fed83511f53b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be17a50f-30b7-4ae0-b36a-228ce7340ca9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c7c3c83b-db10-4d0b-9907-fed83511f53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2a391805-7edf-4dcf-b19a-bafb5fa831aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f78c711f-4604-4193-9055-0f0dd3ff4cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a391805-7edf-4dcf-b19a-bafb5fa831aa" xlink:to="loc_us-gaap_AssetsAbstract_f78c711f-4604-4193-9055-0f0dd3ff4cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f2314395-ed4b-4e94-9a93-bdc7f326639b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f78c711f-4604-4193-9055-0f0dd3ff4cd0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f2314395-ed4b-4e94-9a93-bdc7f326639b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a43f37ea-cfe8-43bf-9f0c-ab1dfbfd49b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2314395-ed4b-4e94-9a93-bdc7f326639b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a43f37ea-cfe8-43bf-9f0c-ab1dfbfd49b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_65dbd209-0532-4f43-94f3-545b938ffea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2314395-ed4b-4e94-9a93-bdc7f326639b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_65dbd209-0532-4f43-94f3-545b938ffea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1b1c37d1-59f7-4ac2-b264-5e84a3a5598b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2314395-ed4b-4e94-9a93-bdc7f326639b" xlink:to="loc_us-gaap_InventoryNet_1b1c37d1-59f7-4ac2-b264-5e84a3a5598b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c73b4cd7-0eee-4ce4-b8c5-bb7e7231525e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2314395-ed4b-4e94-9a93-bdc7f326639b" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c73b4cd7-0eee-4ce4-b8c5-bb7e7231525e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_02a1951f-150b-400f-b70a-823d171eb9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2314395-ed4b-4e94-9a93-bdc7f326639b" xlink:to="loc_us-gaap_OtherAssetsCurrent_02a1951f-150b-400f-b70a-823d171eb9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2a87160d-b52f-4d4e-887b-10092989300f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2314395-ed4b-4e94-9a93-bdc7f326639b" xlink:to="loc_us-gaap_AssetsCurrent_2a87160d-b52f-4d4e-887b-10092989300f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_0f8a1e98-c539-4291-9bcb-deb956b6413b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f78c711f-4604-4193-9055-0f0dd3ff4cd0" xlink:to="loc_us-gaap_InventoryNoncurrent_0f8a1e98-c539-4291-9bcb-deb956b6413b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_aff91082-698e-4ad4-b2c6-204f761ed104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f78c711f-4604-4193-9055-0f0dd3ff4cd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_aff91082-698e-4ad4-b2c6-204f761ed104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6f5558a6-ed56-4d74-b986-73424fc9e776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f78c711f-4604-4193-9055-0f0dd3ff4cd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6f5558a6-ed56-4d74-b986-73424fc9e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_32a1f600-6d7e-49aa-9c86-9ffc7990fea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f78c711f-4604-4193-9055-0f0dd3ff4cd0" xlink:to="loc_us-gaap_Goodwill_32a1f600-6d7e-49aa-9c86-9ffc7990fea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_22748051-9d82-416b-a7a7-d6ab4ddbe173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f78c711f-4604-4193-9055-0f0dd3ff4cd0" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_22748051-9d82-416b-a7a7-d6ab4ddbe173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dbbfed36-1dc6-4078-b684-eaa12ed40669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f78c711f-4604-4193-9055-0f0dd3ff4cd0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dbbfed36-1dc6-4078-b684-eaa12ed40669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a89651b7-8081-49f9-8506-0ab88ce8b68d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f78c711f-4604-4193-9055-0f0dd3ff4cd0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a89651b7-8081-49f9-8506-0ab88ce8b68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7e2b13bc-788e-4dc0-a942-e3bacf557fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f78c711f-4604-4193-9055-0f0dd3ff4cd0" xlink:to="loc_us-gaap_Assets_7e2b13bc-788e-4dc0-a942-e3bacf557fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_985ba94f-cd52-44a4-b1d1-8706c4437c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a391805-7edf-4dcf-b19a-bafb5fa831aa" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_985ba94f-cd52-44a4-b1d1-8706c4437c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5e1b90b5-c9e4-479c-bd59-1796fbac20c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_985ba94f-cd52-44a4-b1d1-8706c4437c9f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5e1b90b5-c9e4-479c-bd59-1796fbac20c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2072fa88-4c33-4b27-a7a3-e033544d7069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e1b90b5-c9e4-479c-bd59-1796fbac20c8" xlink:to="loc_us-gaap_AccountsPayableCurrent_2072fa88-4c33-4b27-a7a3-e033544d7069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_caed6587-dbae-4f1a-a9cc-c016af6de699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e1b90b5-c9e4-479c-bd59-1796fbac20c8" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_caed6587-dbae-4f1a-a9cc-c016af6de699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3001db75-4b8b-4448-93e2-0bd20c80b7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e1b90b5-c9e4-479c-bd59-1796fbac20c8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3001db75-4b8b-4448-93e2-0bd20c80b7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_17f1704e-241e-4327-95da-8086ed436e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e1b90b5-c9e4-479c-bd59-1796fbac20c8" xlink:to="loc_us-gaap_LinesOfCreditCurrent_17f1704e-241e-4327-95da-8086ed436e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_dd5c34e9-e5f1-4802-84e2-16e985e130ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e1b90b5-c9e4-479c-bd59-1796fbac20c8" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_dd5c34e9-e5f1-4802-84e2-16e985e130ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ded562b7-5552-45d1-88a0-1a23b368d7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e1b90b5-c9e4-479c-bd59-1796fbac20c8" xlink:to="loc_us-gaap_LiabilitiesCurrent_ded562b7-5552-45d1-88a0-1a23b368d7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_8e8db073-a44c-40ce-9e2c-544e03daf71a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_985ba94f-cd52-44a4-b1d1-8706c4437c9f" xlink:to="loc_us-gaap_LongTermLineOfCredit_8e8db073-a44c-40ce-9e2c-544e03daf71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_318c7259-b25a-4448-9234-44393db7cb13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_985ba94f-cd52-44a4-b1d1-8706c4437c9f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_318c7259-b25a-4448-9234-44393db7cb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_d8184653-131a-4f31-841d-10ed95be974f" xlink:href="cpix-20200930.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_985ba94f-cd52-44a4-b1d1-8706c4437c9f" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_d8184653-131a-4f31-841d-10ed95be974f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1a62305e-7e8f-444d-8910-5bb666cd65d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_985ba94f-cd52-44a4-b1d1-8706c4437c9f" xlink:to="loc_us-gaap_Liabilities_1a62305e-7e8f-444d-8910-5bb666cd65d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_17741c5a-e1cb-4fb8-8dd6-3c2b3ce7d618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_985ba94f-cd52-44a4-b1d1-8706c4437c9f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_17741c5a-e1cb-4fb8-8dd6-3c2b3ce7d618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_99c44c44-0592-496f-8c69-556a5ed808b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_985ba94f-cd52-44a4-b1d1-8706c4437c9f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_99c44c44-0592-496f-8c69-556a5ed808b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4fb0194a-dd84-4172-84b4-ba7ef003b76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_99c44c44-0592-496f-8c69-556a5ed808b3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4fb0194a-dd84-4172-84b4-ba7ef003b76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5534901b-bc6a-4897-9bb4-52ce64d8163e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4fb0194a-dd84-4172-84b4-ba7ef003b76d" xlink:to="loc_us-gaap_CommonStockValue_5534901b-bc6a-4897-9bb4-52ce64d8163e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5b652ed7-22b0-4f02-8924-4778acd60c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4fb0194a-dd84-4172-84b4-ba7ef003b76d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5b652ed7-22b0-4f02-8924-4778acd60c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_77c5ae9b-2b52-44be-b078-03fc1493603a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4fb0194a-dd84-4172-84b4-ba7ef003b76d" xlink:to="loc_us-gaap_StockholdersEquity_77c5ae9b-2b52-44be-b078-03fc1493603a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3867f132-1a0a-4e30-bdcb-342b6a2120b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_99c44c44-0592-496f-8c69-556a5ed808b3" xlink:to="loc_us-gaap_MinorityInterest_3867f132-1a0a-4e30-bdcb-342b6a2120b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a6088ae1-ba58-48a9-9749-d87da88f217e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_99c44c44-0592-496f-8c69-556a5ed808b3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a6088ae1-ba58-48a9-9749-d87da88f217e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e1774c96-be4c-4651-80ae-a3b9ebef37a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_985ba94f-cd52-44a4-b1d1-8706c4437c9f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e1774c96-be4c-4651-80ae-a3b9ebef37a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_539379ab-2698-4ce4-b556-bca841377856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_32e90ca0-e974-4c56-a323-106e88728982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_539379ab-2698-4ce4-b556-bca841377856" xlink:to="loc_us-gaap_CommonStockNoParValue_32e90ca0-e974-4c56-a323-106e88728982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_30bd9af6-3937-4cf3-b4fc-e089af5c40ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_539379ab-2698-4ce4-b556-bca841377856" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_30bd9af6-3937-4cf3-b4fc-e089af5c40ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5b55412e-ccaf-4299-852e-b803f7b0516f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_539379ab-2698-4ce4-b556-bca841377856" xlink:to="loc_us-gaap_CommonStockSharesIssued_5b55412e-ccaf-4299-852e-b803f7b0516f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_21166cb6-af2b-45a4-b699-7e9c63ab0759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_539379ab-2698-4ce4-b556-bca841377856" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_21166cb6-af2b-45a4-b699-7e9c63ab0759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ceabc84a-baaa-4def-9d3e-98b6fdc24a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ceabc84a-baaa-4def-9d3e-98b6fdc24a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_17b50199-95af-4d55-b68e-a5595132da56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_17b50199-95af-4d55-b68e-a5595132da56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9b664d6f-9a86-4dd1-9641-626e78e148a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_17b50199-95af-4d55-b68e-a5595132da56" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9b664d6f-9a86-4dd1-9641-626e78e148a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_d98cfa32-de79-48cf-babf-0475e119adde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_17b50199-95af-4d55-b68e-a5595132da56" xlink:to="loc_us-gaap_SellingAndMarketingExpense_d98cfa32-de79-48cf-babf-0475e119adde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_659de514-abfa-4180-9b7f-4a80aded5521" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_17b50199-95af-4d55-b68e-a5595132da56" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_659de514-abfa-4180-9b7f-4a80aded5521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_31348e61-1791-4933-abc6-11dbe1f7b0ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_17b50199-95af-4d55-b68e-a5595132da56" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_31348e61-1791-4933-abc6-11dbe1f7b0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0beca0d3-601d-44fe-b129-573d180669bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_17b50199-95af-4d55-b68e-a5595132da56" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0beca0d3-601d-44fe-b129-573d180669bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3f6bc395-188d-4c84-9603-e4932c28f672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_17b50199-95af-4d55-b68e-a5595132da56" xlink:to="loc_us-gaap_CostsAndExpenses_3f6bc395-188d-4c84-9603-e4932c28f672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7ff78eb9-0677-494f-9db3-915d6d6a3ced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_17b50199-95af-4d55-b68e-a5595132da56" xlink:to="loc_us-gaap_OperatingIncomeLoss_7ff78eb9-0677-494f-9db3-915d6d6a3ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_864841a6-aa7f-469a-8e51-295b796bf9e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_864841a6-aa7f-469a-8e51-295b796bf9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6279a5ce-1fd8-47df-a392-121a55b40fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_InterestExpense_6279a5ce-1fd8-47df-a392-121a55b40fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ad02a940-ea59-44c1-bfca-7a5196cd5a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ad02a940-ea59-44c1-bfca-7a5196cd5a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9f97a530-7c29-46f6-937b-7ce0c1dd9a71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9f97a530-7c29-46f6-937b-7ce0c1dd9a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_559a02ad-10d3-4981-a726-cb2e94964c17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_559a02ad-10d3-4981-a726-cb2e94964c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7e6239d2-5fa1-4c29-ab58-61d9206fc697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7e6239d2-5fa1-4c29-ab58-61d9206fc697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f17d3a3c-8cc4-4d9e-bffc-15e95355f942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_ProfitLoss_f17d3a3c-8cc4-4d9e-bffc-15e95355f942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_664037e4-a4e3-440c-88ed-1b080c4bba18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_664037e4-a4e3-440c-88ed-1b080c4bba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c2d53cf-2e03-47bd-bae6-d30800317c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_NetIncomeLoss_2c2d53cf-2e03-47bd-bae6-d30800317c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_98848ce1-17fd-4915-a1b5-33617b4639c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_EarningsPerShareAbstract_98848ce1-17fd-4915-a1b5-33617b4639c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f252b796-1c91-46f8-8b6f-ce43f969a725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98848ce1-17fd-4915-a1b5-33617b4639c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f252b796-1c91-46f8-8b6f-ce43f969a725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_75111e83-2439-4e57-bec7-0295b560b2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98848ce1-17fd-4915-a1b5-33617b4639c7" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_75111e83-2439-4e57-bec7-0295b560b2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_208bc6b7-6c95-4757-9a57-e4b5e521bb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98848ce1-17fd-4915-a1b5-33617b4639c7" xlink:to="loc_us-gaap_EarningsPerShareBasic_208bc6b7-6c95-4757-9a57-e4b5e521bb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a7f1192a-3e0d-4285-b06e-912dc5d26bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98848ce1-17fd-4915-a1b5-33617b4639c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a7f1192a-3e0d-4285-b06e-912dc5d26bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_5ffbd928-66b8-45e3-b1bc-451fe1fc66f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98848ce1-17fd-4915-a1b5-33617b4639c7" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_5ffbd928-66b8-45e3-b1bc-451fe1fc66f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cdce3af6-c532-41ee-a197-4e6c849905b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98848ce1-17fd-4915-a1b5-33617b4639c7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cdce3af6-c532-41ee-a197-4e6c849905b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c8d874e1-09c2-49e4-b02e-23b9680735fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5add9b18-5163-4482-9d2e-3035951be9c9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c8d874e1-09c2-49e4-b02e-23b9680735fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2bc3d0e0-2802-498d-9b10-c89783f96ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c8d874e1-09c2-49e4-b02e-23b9680735fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2bc3d0e0-2802-498d-9b10-c89783f96ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0192848b-019f-473f-a5bf-685a83d408e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c8d874e1-09c2-49e4-b02e-23b9680735fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0192848b-019f-473f-a5bf-685a83d408e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bc0152b9-85d8-47f1-a50b-8f18c8142ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_387aac7b-528a-45ca-93d4-88de85f44f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc0152b9-85d8-47f1-a50b-8f18c8142ff9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_387aac7b-528a-45ca-93d4-88de85f44f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_aa946daf-53e4-4216-b5bb-2fbd0c61e0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_387aac7b-528a-45ca-93d4-88de85f44f9d" xlink:to="loc_us-gaap_ProfitLoss_aa946daf-53e4-4216-b5bb-2fbd0c61e0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7ecde16e-ca0c-4142-a73f-676c61e0af67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_387aac7b-528a-45ca-93d4-88de85f44f9d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7ecde16e-ca0c-4142-a73f-676c61e0af67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_beca6240-f0cc-4865-a8e3-5f9b917d7cc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_387aac7b-528a-45ca-93d4-88de85f44f9d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_beca6240-f0cc-4865-a8e3-5f9b917d7cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83175061-9582-4080-a6b6-c6f580d43d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_387aac7b-528a-45ca-93d4-88de85f44f9d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83175061-9582-4080-a6b6-c6f580d43d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_382acbd6-d7f6-4d76-be49-e4a8283bac96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83175061-9582-4080-a6b6-c6f580d43d38" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_382acbd6-d7f6-4d76-be49-e4a8283bac96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a7ab5a68-1e2a-4a03-9e70-2fd91c866e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83175061-9582-4080-a6b6-c6f580d43d38" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a7ab5a68-1e2a-4a03-9e70-2fd91c866e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_15c59cbe-eba8-4ca2-8cd8-4f6e348fcc73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83175061-9582-4080-a6b6-c6f580d43d38" xlink:to="loc_us-gaap_ShareBasedCompensation_15c59cbe-eba8-4ca2-8cd8-4f6e348fcc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_f9bd7e48-75ae-4df7-99e1-62c66870193f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83175061-9582-4080-a6b6-c6f580d43d38" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_f9bd7e48-75ae-4df7-99e1-62c66870193f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f4bdd2cb-eb06-440a-8548-578a3b0446af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83175061-9582-4080-a6b6-c6f580d43d38" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f4bdd2cb-eb06-440a-8548-578a3b0446af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b4606584-e6ac-442d-9547-a722d22f5669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83175061-9582-4080-a6b6-c6f580d43d38" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b4606584-e6ac-442d-9547-a722d22f5669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_493b4cde-e735-4edd-ba6c-4620d7184224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83175061-9582-4080-a6b6-c6f580d43d38" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_493b4cde-e735-4edd-ba6c-4620d7184224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_34105659-962a-4d95-8d7d-44fb5cc75646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_493b4cde-e735-4edd-ba6c-4620d7184224" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_34105659-962a-4d95-8d7d-44fb5cc75646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0b18ec9a-edd3-42fb-9672-b30cecc185a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_493b4cde-e735-4edd-ba6c-4620d7184224" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0b18ec9a-edd3-42fb-9672-b30cecc185a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8bc2d01f-7069-4254-b5ce-515b4ca91d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_493b4cde-e735-4edd-ba6c-4620d7184224" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8bc2d01f-7069-4254-b5ce-515b4ca91d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_3caddd65-47cb-40e4-a125-476e396aa56c" xlink:href="cpix-20200930.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_493b4cde-e735-4edd-ba6c-4620d7184224" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_3caddd65-47cb-40e4-a125-476e396aa56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_aab4c4f7-4fe4-4e06-a5e2-f382c278894b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_493b4cde-e735-4edd-ba6c-4620d7184224" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_aab4c4f7-4fe4-4e06-a5e2-f382c278894b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b737ce10-d18a-46ad-ad1c-7d0d38dd95bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_387aac7b-528a-45ca-93d4-88de85f44f9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b737ce10-d18a-46ad-ad1c-7d0d38dd95bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bec52ee5-df57-4e7d-85ab-4dcc5276d5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_387aac7b-528a-45ca-93d4-88de85f44f9d" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_bec52ee5-df57-4e7d-85ab-4dcc5276d5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c73a6243-8a3b-4c6b-958a-c76abaf08a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_387aac7b-528a-45ca-93d4-88de85f44f9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c73a6243-8a3b-4c6b-958a-c76abaf08a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d26268c-9fd4-43d5-805a-bd54272a71c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc0152b9-85d8-47f1-a50b-8f18c8142ff9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d26268c-9fd4-43d5-805a-bd54272a71c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_33793182-61e4-4bf3-aae8-df22a1198854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d26268c-9fd4-43d5-805a-bd54272a71c1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_33793182-61e4-4bf3-aae8-df22a1198854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_475a7e29-46dc-47ce-8f92-f2d4f8f7a647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d26268c-9fd4-43d5-805a-bd54272a71c1" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_475a7e29-46dc-47ce-8f92-f2d4f8f7a647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8edb9a85-5b07-4dab-a01a-429a87349653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d26268c-9fd4-43d5-805a-bd54272a71c1" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8edb9a85-5b07-4dab-a01a-429a87349653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_c90a4934-cb84-490c-84dc-a037aa02d877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d26268c-9fd4-43d5-805a-bd54272a71c1" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_c90a4934-cb84-490c-84dc-a037aa02d877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0a7925dd-bf0b-45b4-bedc-427b0f47e482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d26268c-9fd4-43d5-805a-bd54272a71c1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0a7925dd-bf0b-45b4-bedc-427b0f47e482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0c6a0edf-4ba3-4fa4-9ec4-673130054c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d26268c-9fd4-43d5-805a-bd54272a71c1" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0c6a0edf-4ba3-4fa4-9ec4-673130054c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80393d6d-4b40-4388-bf95-ed7f5ef4ce31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d26268c-9fd4-43d5-805a-bd54272a71c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80393d6d-4b40-4388-bf95-ed7f5ef4ce31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc0152b9-85d8-47f1-a50b-8f18c8142ff9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_90e82c4d-4a20-4d53-a84f-36fbd34e88a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_90e82c4d-4a20-4d53-a84f-36fbd34e88a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_a1c68a61-e730-4c20-9319-2f2947c2c8b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_a1c68a61-e730-4c20-9319-2f2947c2c8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_11f8bc82-d80b-40f3-8a57-4da8af1d4c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_11f8bc82-d80b-40f3-8a57-4da8af1d4c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_dc579ad8-4805-4537-a69d-a619b0a814dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_dc579ad8-4805-4537-a69d-a619b0a814dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_5af2246f-606e-4bfe-bf9b-610980c5ef9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_5af2246f-606e-4bfe-bf9b-610980c5ef9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cc0a2928-70da-431a-9123-ae8f567d9d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cc0a2928-70da-431a-9123-ae8f567d9d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_09ddb79a-3f48-4fe2-a533-a7ed6d65bfc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_09ddb79a-3f48-4fe2-a533-a7ed6d65bfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8455c293-545a-4c5d-989b-d8afaf360927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8455c293-545a-4c5d-989b-d8afaf360927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db344ce1-f9aa-4b50-91ff-20c4c003e759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db344ce1-f9aa-4b50-91ff-20c4c003e759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89409c22-2f87-4b58-a99d-997286c23656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f04f0d-4500-4a4c-978e-d493364cf446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89409c22-2f87-4b58-a99d-997286c23656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_46e8d2c6-d705-4333-b878-38a1a56fd59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0e7cfb2c-20ff-4297-ac5c-37a57c3acee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_46e8d2c6-d705-4333-b878-38a1a56fd59d" xlink:to="loc_us-gaap_StatementTable_0e7cfb2c-20ff-4297-ac5c-37a57c3acee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_77889d3f-3c89-4505-86ba-09bcf65cb43c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0e7cfb2c-20ff-4297-ac5c-37a57c3acee4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_77889d3f-3c89-4505-86ba-09bcf65cb43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b9fc826-be27-4530-8d84-bf5fe235cdb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_77889d3f-3c89-4505-86ba-09bcf65cb43c" xlink:to="loc_us-gaap_EquityComponentDomain_7b9fc826-be27-4530-8d84-bf5fe235cdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a80461ca-8e89-4f65-adf8-9e9532e5a60e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b9fc826-be27-4530-8d84-bf5fe235cdb5" xlink:to="loc_us-gaap_CommonStockMember_a80461ca-8e89-4f65-adf8-9e9532e5a60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d8309226-678a-4aff-be9b-1abd56a66262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b9fc826-be27-4530-8d84-bf5fe235cdb5" xlink:to="loc_us-gaap_RetainedEarningsMember_d8309226-678a-4aff-be9b-1abd56a66262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_8997b870-21cb-4aea-ac4b-c307333d816a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b9fc826-be27-4530-8d84-bf5fe235cdb5" xlink:to="loc_us-gaap_NoncontrollingInterestMember_8997b870-21cb-4aea-ac4b-c307333d816a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4bf6f615-39e0-4d0d-9c08-609df639d153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0e7cfb2c-20ff-4297-ac5c-37a57c3acee4" xlink:to="loc_us-gaap_StatementLineItems_4bf6f615-39e0-4d0d-9c08-609df639d153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4bf6f615-39e0-4d0d-9c08-609df639d153" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_774a2cd4-39e0-4bb4-a852-fbf8bb36999f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_774a2cd4-39e0-4bb4-a852-fbf8bb36999f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f13ccd66-0107-436c-bdf0-ed0edaebb43d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f13ccd66-0107-436c-bdf0-ed0edaebb43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_170a777e-f26f-43e5-932e-4d47e7b43c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_170a777e-f26f-43e5-932e-4d47e7b43c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6a3d6d3a-d2c8-415e-ba15-521c2bcf6461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6a3d6d3a-d2c8-415e-ba15-521c2bcf6461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_1064cffc-5f81-4774-a61e-0eca038ab017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_1064cffc-5f81-4774-a61e-0eca038ab017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f4f463ac-8595-4097-8d97-ce2742a43fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f4f463ac-8595-4097-8d97-ce2742a43fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_7e0c3562-14a9-4c06-a259-369b7e5447f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_7e0c3562-14a9-4c06-a259-369b7e5447f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d2b312af-0c0d-4dfa-a4d0-3989e2f27e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_ProfitLoss_d2b312af-0c0d-4dfa-a4d0-3989e2f27e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca4a4e2a-b224-4abb-bd7b-9e3002f92a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca4a4e2a-b224-4abb-bd7b-9e3002f92a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f1c7f59d-1199-4f10-95fa-4728f6ef818f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18bd8536-0ce9-4655-a6f0-0874725d6b8d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f1c7f59d-1199-4f10-95fa-4728f6ef818f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8162888f-5114-411b-95d5-9881e4408c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_55e4b194-779c-4f05-b147-7716bc135504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8162888f-5114-411b-95d5-9881e4408c96" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_55e4b194-779c-4f05-b147-7716bc135504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34a79d5f-4a02-4218-9b0d-f262e721b278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_48d137a7-5805-493f-8107-3466eff59e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34a79d5f-4a02-4218-9b0d-f262e721b278" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_48d137a7-5805-493f-8107-3466eff59e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a04fcc59-b262-4f30-8c67-545d3d68d395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34a79d5f-4a02-4218-9b0d-f262e721b278" xlink:to="loc_us-gaap_UseOfEstimates_a04fcc59-b262-4f30-8c67-545d3d68d395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_11fbdbbe-b6b5-4e15-97d9-3fe8128b318f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34a79d5f-4a02-4218-9b0d-f262e721b278" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_11fbdbbe-b6b5-4e15-97d9-3fe8128b318f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4ece2f1-7d98-4d19-ba3b-267f57474dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_605873ac-f1a9-4660-8db7-7a2c95d1158d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4ece2f1-7d98-4d19-ba3b-267f57474dc7" xlink:to="loc_us-gaap_NumberOfOperatingSegments_605873ac-f1a9-4660-8db7-7a2c95d1158d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_64f6ac17-97bc-42bf-8d7d-50a728afea75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6a1f3e8e-5d33-47fc-a42a-384f494a6c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_64f6ac17-97bc-42bf-8d7d-50a728afea75" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6a1f3e8e-5d33-47fc-a42a-384f494a6c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_efb074a7-b26d-41d2-bbdd-56d891534941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4949d81f-a7e3-45e4-ada2-2d498e0b71be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_efb074a7-b26d-41d2-bbdd-56d891534941" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4949d81f-a7e3-45e4-ada2-2d498e0b71be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2580634d-73f4-4040-ba43-77421f2a1bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e7aa0f18-09fa-4b0c-aaea-81c9f8c8bd43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2580634d-73f4-4040-ba43-77421f2a1bea" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e7aa0f18-09fa-4b0c-aaea-81c9f8c8bd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbd91108-30e9-4048-b22e-2b24e39100d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e7aa0f18-09fa-4b0c-aaea-81c9f8c8bd43" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbd91108-30e9-4048-b22e-2b24e39100d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef119d0c-dc47-47d2-b3d6-b17de258a123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbd91108-30e9-4048-b22e-2b24e39100d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef119d0c-dc47-47d2-b3d6-b17de258a123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cf3880e8-a229-443f-a2c9-e495b52a621c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef119d0c-dc47-47d2-b3d6-b17de258a123" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cf3880e8-a229-443f-a2c9-e495b52a621c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3352df52-d2df-4ce5-ae41-5b76f5ada121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef119d0c-dc47-47d2-b3d6-b17de258a123" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3352df52-d2df-4ce5-ae41-5b76f5ada121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_83681818-721b-4ebe-bf82-af6c019fcffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e7aa0f18-09fa-4b0c-aaea-81c9f8c8bd43" xlink:to="loc_us-gaap_FinancialInstrumentAxis_83681818-721b-4ebe-bf82-af6c019fcffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_217d95a1-7fd6-4dc0-b322-c16b5a757fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_83681818-721b-4ebe-bf82-af6c019fcffe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_217d95a1-7fd6-4dc0-b322-c16b5a757fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_76431c9e-97e5-448b-b088-25891f17ece6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_217d95a1-7fd6-4dc0-b322-c16b5a757fa4" xlink:to="loc_us-gaap_CommercialPaperMember_76431c9e-97e5-448b-b088-25891f17ece6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0115ba75-99ed-493f-a216-8571215a35e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e7aa0f18-09fa-4b0c-aaea-81c9f8c8bd43" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0115ba75-99ed-493f-a216-8571215a35e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_03343937-56fb-44ea-bf5b-fce41251135f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0115ba75-99ed-493f-a216-8571215a35e5" xlink:to="loc_us-gaap_TradingSecurities_03343937-56fb-44ea-bf5b-fce41251135f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5877dbef-922f-4513-9f6a-c66804ab082c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0df77ed2-573d-46ec-84f1-b495090f19b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5877dbef-922f-4513-9f6a-c66804ab082c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0df77ed2-573d-46ec-84f1-b495090f19b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ceed8645-bdc1-4f56-948c-71c95cc5ce32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_445cf060-0c58-4eab-ad41-88ede4e3c2a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ceed8645-bdc1-4f56-948c-71c95cc5ce32" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_445cf060-0c58-4eab-ad41-88ede4e3c2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d4dc7ff7-07cc-476a-a578-aa47b394641d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_09c0a3c3-317e-43ee-a14c-247caabd4696" xlink:href="cpix-20200930.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d4dc7ff7-07cc-476a-a578-aa47b394641d" xlink:to="loc_cpix_NumeratorAbstract_09c0a3c3-317e-43ee-a14c-247caabd4696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1c3f1d80-4be5-4c2a-8dac-3bf01271bf94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_09c0a3c3-317e-43ee-a14c-247caabd4696" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1c3f1d80-4be5-4c2a-8dac-3bf01271bf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7959e1ad-0744-4bd8-ba71-18994c215a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_09c0a3c3-317e-43ee-a14c-247caabd4696" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7959e1ad-0744-4bd8-ba71-18994c215a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7c7c81cc-eee4-4ee9-814e-12bd0fdf5935" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_09c0a3c3-317e-43ee-a14c-247caabd4696" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7c7c81cc-eee4-4ee9-814e-12bd0fdf5935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15c9b3e9-6930-4a5b-ad7e-c56acb6eb2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_09c0a3c3-317e-43ee-a14c-247caabd4696" xlink:to="loc_us-gaap_NetIncomeLoss_15c9b3e9-6930-4a5b-ad7e-c56acb6eb2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_d09e26f3-ccec-42fe-b1fb-1b575f9ddbe9" xlink:href="cpix-20200930.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d4dc7ff7-07cc-476a-a578-aa47b394641d" xlink:to="loc_cpix_DenominatorAbstract_d09e26f3-ccec-42fe-b1fb-1b575f9ddbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c2511ed9-912e-48c7-a999-96ccab61a581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_d09e26f3-ccec-42fe-b1fb-1b575f9ddbe9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c2511ed9-912e-48c7-a999-96ccab61a581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_14621e88-8750-4b6c-87ef-8d11d41da534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_d09e26f3-ccec-42fe-b1fb-1b575f9ddbe9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_14621e88-8750-4b6c-87ef-8d11d41da534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bba0f309-324f-40da-ba19-54166427d03c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_d09e26f3-ccec-42fe-b1fb-1b575f9ddbe9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bba0f309-324f-40da-ba19-54166427d03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8b5b8a6a-386f-4760-ae6d-a1f4f54b94fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d2752adf-068d-448a-8f84-7f106d4df00e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8b5b8a6a-386f-4760-ae6d-a1f4f54b94fc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d2752adf-068d-448a-8f84-7f106d4df00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20200930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_51d4e4fa-37eb-4b15-9996-be5e5a6ca405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_006a0afe-f598-413d-b9db-70f6b93d4d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_51d4e4fa-37eb-4b15-9996-be5e5a6ca405" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_006a0afe-f598-413d-b9db-70f6b93d4d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a60b6880-9746-4b82-894f-bc92ed559477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_bd6ed266-dc9b-4685-b673-a0bd9ba51e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a60b6880-9746-4b82-894f-bc92ed559477" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_bd6ed266-dc9b-4685-b673-a0bd9ba51e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_031d419a-e792-4723-b26b-bb2286811afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_60db111c-097e-47dc-9c4a-01f40c49857e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_031d419a-e792-4723-b26b-bb2286811afa" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_60db111c-097e-47dc-9c4a-01f40c49857e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fc3470ac-b84d-42d9-b6ad-98dff2088371" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_60db111c-097e-47dc-9c4a-01f40c49857e" xlink:to="loc_srt_ProductOrServiceAxis_fc3470ac-b84d-42d9-b6ad-98dff2088371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fc3470ac-b84d-42d9-b6ad-98dff2088371" xlink:to="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_491b7dff-c8e1-4e18-ae0b-e906716bf486" xlink:href="cpix-20200930.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_AcetadoteMember_491b7dff-c8e1-4e18-ae0b-e906716bf486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_460c66d5-0c41-440f-9bc6-7f2fc9c4fcd4" xlink:href="cpix-20200930.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_OmeclamoxPakMember_460c66d5-0c41-440f-9bc6-7f2fc9c4fcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_44bfcf88-e123-4132-a0b8-97d97eff84b8" xlink:href="cpix-20200930.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_KristaloseMember_44bfcf88-e123-4132-a0b8-97d97eff84b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_6a0144d4-7a96-4796-9df5-14569fa45519" xlink:href="cpix-20200930.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_VaprisolMember_6a0144d4-7a96-4796-9df5-14569fa45519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_857dd5b2-f403-444f-a965-112793bab496" xlink:href="cpix-20200930.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_CaldolorMember_857dd5b2-f403-444f-a965-112793bab496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_bad0f4e7-af2f-46aa-b56f-447a2b252f08" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_VIBATIVMember_bad0f4e7-af2f-46aa-b56f-447a2b252f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_7644390e-b41d-4bed-92d7-4eaecac44804" xlink:href="cpix-20200930.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_cpix_OtherProductsMember_7644390e-b41d-4bed-92d7-4eaecac44804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_3ead9275-ad9c-4c42-af8a-e04ed86c42be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9b50c6c7-5907-434e-8d2b-229b3062aecc" xlink:to="loc_us-gaap_GrantMember_3ead9275-ad9c-4c42-af8a-e04ed86c42be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_b9a33243-8a0b-42ca-b61b-2d23011065e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_60db111c-097e-47dc-9c4a-01f40c49857e" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_b9a33243-8a0b-42ca-b61b-2d23011065e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_fb719877-a8c9-41a9-ac84-90555b2b707a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_b9a33243-8a0b-42ca-b61b-2d23011065e5" xlink:to="loc_us-gaap_RevenuesAbstract_fb719877-a8c9-41a9-ac84-90555b2b707a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_7ad909f1-5358-459d-b393-597d087e147f" xlink:href="cpix-20200930.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_fb719877-a8c9-41a9-ac84-90555b2b707a" xlink:to="loc_cpix_ProductsAbstract_7ad909f1-5358-459d-b393-597d087e147f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4633e06c-e109-45ad-9172-3b2b83852e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_7ad909f1-5358-459d-b393-597d087e147f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4633e06c-e109-45ad-9172-3b2b83852e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20200930.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_357ac0c1-955a-4ebd-88fd-783981b5729d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_2097b8dd-0097-4465-83a7-8326da744d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_357ac0c1-955a-4ebd-88fd-783981b5729d" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_2097b8dd-0097-4465-83a7-8326da744d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d66db278-efc4-4c0e-bbf9-2b0bdeac80b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4acdf638-8fee-4604-81d0-9357c94118ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d66db278-efc4-4c0e-bbf9-2b0bdeac80b0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4acdf638-8fee-4604-81d0-9357c94118ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_db85409b-b13c-49d5-9bff-f75cf652750d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_34390169-f105-4a0e-9d04-e82fe727447b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_db85409b-b13c-49d5-9bff-f75cf652750d" xlink:to="loc_us-gaap_InventoryCurrentTable_34390169-f105-4a0e-9d04-e82fe727447b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e52b459b-de55-4369-b167-18c8f7f5af05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_34390169-f105-4a0e-9d04-e82fe727447b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e52b459b-de55-4369-b167-18c8f7f5af05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8e83ac2-ef29-44c3-adee-3c73aadc0c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e52b459b-de55-4369-b167-18c8f7f5af05" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8e83ac2-ef29-44c3-adee-3c73aadc0c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_8f00de63-cacd-46cd-b2dc-7da7e85d963b" xlink:href="cpix-20200930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8e83ac2-ef29-44c3-adee-3c73aadc0c3c" xlink:to="loc_cpix_IfetrobanClinicalMember_8f00de63-cacd-46cd-b2dc-7da7e85d963b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_2ed139f1-ef22-455d-a25f-bd11122e71c3" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8e83ac2-ef29-44c3-adee-3c73aadc0c3c" xlink:to="loc_cpix_VIBATIVMember_2ed139f1-ef22-455d-a25f-bd11122e71c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_5b5fb6ff-f65b-4cc2-bd98-fd1ffd255d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_34390169-f105-4a0e-9d04-e82fe727447b" xlink:to="loc_us-gaap_InventoryLineItems_5b5fb6ff-f65b-4cc2-bd98-fd1ffd255d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c0f47c83-fe6b-46ca-9107-9d91c7ed7f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_5b5fb6ff-f65b-4cc2-bd98-fd1ffd255d69" xlink:to="loc_us-gaap_InventoryNoncurrent_c0f47c83-fe6b-46ca-9107-9d91c7ed7f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_06e625e1-6ad7-4021-be21-383c978cbfbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_5b5fb6ff-f65b-4cc2-bd98-fd1ffd255d69" xlink:to="loc_us-gaap_InventoryFinishedGoods_06e625e1-6ad7-4021-be21-383c978cbfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_945fb394-1529-495d-bb92-ef504650895a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_4389b154-1c2e-4a12-afd9-b9c307650e5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_945fb394-1529-495d-bb92-ef504650895a" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_4389b154-1c2e-4a12-afd9-b9c307650e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d74408e8-9524-48f3-ad5e-edee62b65482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_4389b154-1c2e-4a12-afd9-b9c307650e5b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d74408e8-9524-48f3-ad5e-edee62b65482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_2b3e24e9-fdef-43d7-9220-67425d1a2780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_4389b154-1c2e-4a12-afd9-b9c307650e5b" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_2b3e24e9-fdef-43d7-9220-67425d1a2780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9ddab01f-81a8-45fa-a09b-db045f564779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_4389b154-1c2e-4a12-afd9-b9c307650e5b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9ddab01f-81a8-45fa-a09b-db045f564779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d75cb46b-b9a5-4c3d-ab4b-64507ec2383c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_4389b154-1c2e-4a12-afd9-b9c307650e5b" xlink:to="loc_us-gaap_InventoryGross_d75cb46b-b9a5-4c3d-ab4b-64507ec2383c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_04d4d562-423b-4423-a2c6-2e898560c47f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_4389b154-1c2e-4a12-afd9-b9c307650e5b" xlink:to="loc_us-gaap_InventoryNoncurrent_04d4d562-423b-4423-a2c6-2e898560c47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cbcad55c-b344-4aea-8b44-4b4294a0244f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_4389b154-1c2e-4a12-afd9-b9c307650e5b" xlink:to="loc_us-gaap_InventoryNet_cbcad55c-b344-4aea-8b44-4b4294a0244f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20200930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c1e3d13c-28cb-42c4-9983-135072bbbd8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_4a4aff00-bcb1-41a0-bc68-e79fd6701a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c1e3d13c-28cb-42c4-9983-135072bbbd8c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_4a4aff00-bcb1-41a0-bc68-e79fd6701a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b096917e-0dac-44ef-9fce-591aa76a4c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_4c71e433-58af-477a-b464-07679f6e6b55" xlink:href="cpix-20200930.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b096917e-0dac-44ef-9fce-591aa76a4c74" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_4c71e433-58af-477a-b464-07679f6e6b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_81a73060-7c3f-4a47-815c-bc8483fedc58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b096917e-0dac-44ef-9fce-591aa76a4c74" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_81a73060-7c3f-4a47-815c-bc8483fedc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_eeed52be-7c6a-4cbc-9f9e-964aac49d62a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_986a6fd5-67ea-4d0c-8871-0fdfb386241f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eeed52be-7c6a-4cbc-9f9e-964aac49d62a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_986a6fd5-67ea-4d0c-8871-0fdfb386241f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_18665be6-cc67-4b86-b3f3-7178e9da48e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eeed52be-7c6a-4cbc-9f9e-964aac49d62a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_18665be6-cc67-4b86-b3f3-7178e9da48e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1261b74a-cd96-40ef-9f67-be8b3c19ae09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2076de01-bfd2-48a2-bfb7-5c9eea3a7a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1261b74a-cd96-40ef-9f67-be8b3c19ae09" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2076de01-bfd2-48a2-bfb7-5c9eea3a7a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b28c87a0-74f8-4b6c-a036-141d8b102677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1261b74a-cd96-40ef-9f67-be8b3c19ae09" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b28c87a0-74f8-4b6c-a036-141d8b102677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_72cba0cd-9601-40fc-85a7-1e0b70442e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1261b74a-cd96-40ef-9f67-be8b3c19ae09" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_72cba0cd-9601-40fc-85a7-1e0b70442e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_9cc03ca6-d3af-4458-b12b-3836d4a67010" xlink:href="cpix-20200930.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1261b74a-cd96-40ef-9f67-be8b3c19ae09" xlink:to="loc_cpix_LeaseLiability_9cc03ca6-d3af-4458-b12b-3836d4a67010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d943932e-7e57-4fc5-9488-92e43f20b1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3540d7c2-3368-41a1-8876-ac9ced717b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d943932e-7e57-4fc5-9488-92e43f20b1f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3540d7c2-3368-41a1-8876-ac9ced717b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fac9d14e-3e74-490d-9429-49dc4d058b56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3540d7c2-3368-41a1-8876-ac9ced717b8a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fac9d14e-3e74-490d-9429-49dc4d058b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_90988e8c-0882-442e-83fd-1fd93ee482a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3540d7c2-3368-41a1-8876-ac9ced717b8a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_90988e8c-0882-442e-83fd-1fd93ee482a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bc24684b-a350-4557-a094-9caaa9157e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3540d7c2-3368-41a1-8876-ac9ced717b8a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bc24684b-a350-4557-a094-9caaa9157e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8f929ad7-7cd7-416c-ab42-e04377347e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3540d7c2-3368-41a1-8876-ac9ced717b8a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8f929ad7-7cd7-416c-ab42-e04377347e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_8356e76f-47b9-4081-af62-adefeb73fd4c" xlink:href="cpix-20200930.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3540d7c2-3368-41a1-8876-ac9ced717b8a" xlink:to="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_8356e76f-47b9-4081-af62-adefeb73fd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_88fba43a-a03a-49e8-8629-a9aebe60a0d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3540d7c2-3368-41a1-8876-ac9ced717b8a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_88fba43a-a03a-49e8-8629-a9aebe60a0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3cf23456-5a07-457e-9208-f59427444a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3540d7c2-3368-41a1-8876-ac9ced717b8a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3cf23456-5a07-457e-9208-f59427444a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_223ef4ac-2ccf-46c2-b23e-af1ca2e350d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3540d7c2-3368-41a1-8876-ac9ced717b8a" xlink:to="loc_us-gaap_OperatingLeaseLiability_223ef4ac-2ccf-46c2-b23e-af1ca2e350d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_c41911c6-f5c6-4925-a02c-18ec5a2aefd6" xlink:href="cpix-20200930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6bc9f701-72a7-43ec-b636-a3d002dfa152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_c41911c6-f5c6-4925-a02c-18ec5a2aefd6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6bc9f701-72a7-43ec-b636-a3d002dfa152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_c8e4fa53-ed94-4b23-a64b-fdd1699a2a93" xlink:href="cpix-20200930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_c8e4fa53-ed94-4b23-a64b-fdd1699a2a93" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4defdb70-8e5d-4042-89d4-e5d2d3f8c8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4defdb70-8e5d-4042-89d4-e5d2d3f8c8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_872daac6-351c-477a-9ace-5953f0272d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4defdb70-8e5d-4042-89d4-e5d2d3f8c8d1" xlink:to="loc_us-gaap_EquityComponentDomain_872daac6-351c-477a-9ace-5953f0272d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_243f9f46-9de7-4bb9-bb67-1d28fd7f508f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_872daac6-351c-477a-9ace-5953f0272d4f" xlink:to="loc_us-gaap_CommonStockMember_243f9f46-9de7-4bb9-bb67-1d28fd7f508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ee7de312-5f94-44b8-94bf-e6361b6de86c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:to="loc_srt_TitleOfIndividualAxis_ee7de312-5f94-44b8-94bf-e6361b6de86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4be02463-733a-461f-8253-8ba75d81482b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_ee7de312-5f94-44b8-94bf-e6361b6de86c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4be02463-733a-461f-8253-8ba75d81482b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_22ae7b5c-2214-4dd6-9925-e991f6506ce1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4be02463-733a-461f-8253-8ba75d81482b" xlink:to="loc_srt_DirectorMember_22ae7b5c-2214-4dd6-9925-e991f6506ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1acbf69f-a617-424d-9229-23bedb3fe003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:to="loc_us-gaap_AwardTypeAxis_1acbf69f-a617-424d-9229-23bedb3fe003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7243946e-1b0e-4c82-ba86-b7ce701e7911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1acbf69f-a617-424d-9229-23bedb3fe003" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7243946e-1b0e-4c82-ba86-b7ce701e7911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ae38abaf-15cd-44b9-a3a0-aa77ff648657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7243946e-1b0e-4c82-ba86-b7ce701e7911" xlink:to="loc_us-gaap_RestrictedStockMember_ae38abaf-15cd-44b9-a3a0-aa77ff648657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_48e0901c-64f6-44b0-9911-6222b4693aa7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:to="loc_srt_CounterpartyNameAxis_48e0901c-64f6-44b0-9911-6222b4693aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0535b8a-6067-499f-8ca3-6f9df0cc8329" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_48e0901c-64f6-44b0-9911-6222b4693aa7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0535b8a-6067-499f-8ca3-6f9df0cc8329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_ba92f722-8322-4c67-a973-453a13b09901" xlink:href="cpix-20200930.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0535b8a-6067-499f-8ca3-6f9df0cc8329" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_ba92f722-8322-4c67-a973-453a13b09901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_ecc885b2-bb53-4e9c-9873-83607729bb0b" xlink:href="cpix-20200930.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0535b8a-6067-499f-8ca3-6f9df0cc8329" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_ecc885b2-bb53-4e9c-9873-83607729bb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ac92d86-764e-42ac-a65a-7c29e53ef189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b117be12-e9b2-47e5-b877-30e50c6ae422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ac92d86-764e-42ac-a65a-7c29e53ef189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:href="cpix-20200930.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ac92d86-764e-42ac-a65a-7c29e53ef189" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1ec18ef9-f44a-4d1c-87d7-fe16385e86aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1ec18ef9-f44a-4d1c-87d7-fe16385e86aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_d1045cca-215d-492f-aeb1-c9bb8fd48f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_d1045cca-215d-492f-aeb1-c9bb8fd48f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_7c64686b-3c9a-4f89-829c-210d4c82189c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_7c64686b-3c9a-4f89-829c-210d4c82189c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_cc6c334c-cc33-4844-9a46-99c778531989" xlink:href="cpix-20200930.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_cc6c334c-cc33-4844-9a46-99c778531989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b8badbda-6717-4606-8882-bbe71098c52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b8badbda-6717-4606-8882-bbe71098c52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d294c622-1542-462c-8abb-f269e4e12d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d294c622-1542-462c-8abb-f269e4e12d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_455a61f4-3454-4f63-a98c-592d24e96df2" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_455a61f4-3454-4f63-a98c-592d24e96df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution_1d2fe42e-b515-434d-95d5-060dd37222d0" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_cpix_SubsidiaryInvestmentCashContribution_1d2fe42e-b515-434d-95d5-060dd37222d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_2dcfe494-d9ad-4e00-a091-c94d16405f50" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_2dcfe494-d9ad-4e00-a091-c94d16405f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_71281ce0-ca8c-407d-981d-c547ec66f3bd" xlink:href="cpix-20200930.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_ba408b27-4572-45c7-8b55-d90d4d768584" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_71281ce0-ca8c-407d-981d-c547ec66f3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_dfb17d49-3715-4954-9cfe-a20df497fb7f" xlink:href="cpix-20200930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_dfb17d49-3715-4954-9cfe-a20df497fb7f" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_2cdddd77-0749-4311-82b7-42f042ae1241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_2cdddd77-0749-4311-82b7-42f042ae1241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed0bda6d-0c76-4fbd-9637-20e4cac9a5ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_2cdddd77-0749-4311-82b7-42f042ae1241" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed0bda6d-0c76-4fbd-9637-20e4cac9a5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_73e4678a-6d7d-40e8-8839-473bea5d7140" xlink:href="cpix-20200930.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed0bda6d-0c76-4fbd-9637-20e4cac9a5ce" xlink:to="loc_cpix_PinnacleBankMember_73e4678a-6d7d-40e8-8839-473bea5d7140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a21976ee-a101-475a-86e7-adf66de851fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_DebtInstrumentAxis_a21976ee-a101-475a-86e7-adf66de851fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_24ca0a51-77c1-421c-993e-0aa2ae26e7d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a21976ee-a101-475a-86e7-adf66de851fc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_24ca0a51-77c1-421c-993e-0aa2ae26e7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FourthAmendmentMember_7d2e815f-0289-4032-bde2-172eee6b8c2e" xlink:href="cpix-20200930.xsd#cpix_FourthAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_24ca0a51-77c1-421c-993e-0aa2ae26e7d3" xlink:to="loc_cpix_FourthAmendmentMember_7d2e815f-0289-4032-bde2-172eee6b8c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ef965c46-6aa2-4674-8f62-341839cf6da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_24ca0a51-77c1-421c-993e-0aa2ae26e7d3" xlink:to="loc_us-gaap_LineOfCreditMember_ef965c46-6aa2-4674-8f62-341839cf6da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2e387ef4-63da-47c8-878e-ff8589750891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_CreditFacilityAxis_2e387ef4-63da-47c8-878e-ff8589750891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_88647aa3-75e6-4115-b6e4-a94ef317dced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2e387ef4-63da-47c8-878e-ff8589750891" xlink:to="loc_us-gaap_CreditFacilityDomain_88647aa3-75e6-4115-b6e4-a94ef317dced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f2a74f2b-32b6-47db-a307-9a9a9f922f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_88647aa3-75e6-4115-b6e4-a94ef317dced" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f2a74f2b-32b6-47db-a307-9a9a9f922f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b0591fc1-66a1-44f7-bd47-aed7b176d791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b0591fc1-66a1-44f7-bd47-aed7b176d791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0bba7415-e56c-4b2d-879d-9a44d94ede5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b0591fc1-66a1-44f7-bd47-aed7b176d791" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0bba7415-e56c-4b2d-879d-9a44d94ede5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ab16d11b-9efd-4d73-b482-bd14aa4a0af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0bba7415-e56c-4b2d-879d-9a44d94ede5f" xlink:to="loc_us-gaap_SubsequentEventMember_ab16d11b-9efd-4d73-b482-bd14aa4a0af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8028d925-34aa-4172-8ec0-712e32ca21ed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_srt_RangeAxis_8028d925-34aa-4172-8ec0-712e32ca21ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20fdf9d5-0bb5-4f86-bd11-8d0f0cdcda34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8028d925-34aa-4172-8ec0-712e32ca21ed" xlink:to="loc_srt_RangeMember_20fdf9d5-0bb5-4f86-bd11-8d0f0cdcda34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c09052a-1ac6-4c4e-8d2d-3bacffe362bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_20fdf9d5-0bb5-4f86-bd11-8d0f0cdcda34" xlink:to="loc_srt_MinimumMember_5c09052a-1ac6-4c4e-8d2d-3bacffe362bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_20b38c68-7956-48a5-950d-66ba5678615a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_20fdf9d5-0bb5-4f86-bd11-8d0f0cdcda34" xlink:to="loc_srt_MaximumMember_20b38c68-7956-48a5-950d-66ba5678615a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d01b5d33-bc83-4d85-89cd-92177a06801c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_VariableRateAxis_d01b5d33-bc83-4d85-89cd-92177a06801c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_caee02e7-7df9-49ba-924c-e4795e4e7ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_d01b5d33-bc83-4d85-89cd-92177a06801c" xlink:to="loc_us-gaap_VariableRateDomain_caee02e7-7df9-49ba-924c-e4795e4e7ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_44c8f3df-6b1a-438e-b5e1-e57aa3771e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_caee02e7-7df9-49ba-924c-e4795e4e7ddb" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_44c8f3df-6b1a-438e-b5e1-e57aa3771e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aa156ea3-d342-43f6-86f6-9b367909f0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aa156ea3-d342-43f6-86f6-9b367909f0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a7469390-a525-4d65-979d-4ebe2ffcf124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa156ea3-d342-43f6-86f6-9b367909f0e5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a7469390-a525-4d65-979d-4ebe2ffcf124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_15d6904c-7198-46ac-9ff5-3066cbd4e085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a7469390-a525-4d65-979d-4ebe2ffcf124" xlink:to="loc_us-gaap_ConvertibleDebtMember_15d6904c-7198-46ac-9ff5-3066cbd4e085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_96caaa0f-25da-417e-be47-4cb827f2f456" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_srt_CounterpartyNameAxis_96caaa0f-25da-417e-be47-4cb827f2f456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5d246b06-073b-4374-994d-d00218bf2dc6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_96caaa0f-25da-417e-be47-4cb827f2f456" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5d246b06-073b-4374-994d-d00218bf2dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_979c72eb-c05b-45f1-a033-a6e74e170c27" xlink:href="cpix-20200930.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5d246b06-073b-4374-994d-d00218bf2dc6" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_979c72eb-c05b-45f1-a033-a6e74e170c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6b5322d2-2fd5-4d6a-a208-2a965a3cd96e" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_16535cd6-d080-4e66-8985-ac5d2d1b49f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_16535cd6-d080-4e66-8985-ac5d2d1b49f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_dad3f67f-8832-4876-916b-f8d72ca3d1c4" xlink:href="cpix-20200930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_dad3f67f-8832-4876-916b-f8d72ca3d1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_65c143fc-2b1c-4a94-ad27-fa1cb58d9c04" xlink:href="cpix-20200930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_65c143fc-2b1c-4a94-ad27-fa1cb58d9c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2981a60a-99cd-4778-9706-8e01cda2e54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2981a60a-99cd-4778-9706-8e01cda2e54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_80b4d999-1924-4a54-a0ea-23a7c8386149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_80b4d999-1924-4a54-a0ea-23a7c8386149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_8126b73f-f443-4f50-9881-7d8890af5978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_8126b73f-f443-4f50-9881-7d8890af5978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_71df5709-d29c-49fa-adcd-37a1ca3461bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_LongTermLineOfCredit_71df5709-d29c-49fa-adcd-37a1ca3461bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_f28000c3-9013-4f32-b2d4-69aa1829b883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_LinesOfCreditCurrent_f28000c3-9013-4f32-b2d4-69aa1829b883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_40e48ad7-34b0-41be-afc8-713c834f2e5f" xlink:href="cpix-20200930.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_40e48ad7-34b0-41be-afc8-713c834f2e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9bd9f03e-50ef-4d38-a333-96a97c74d0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9bd9f03e-50ef-4d38-a333-96a97c74d0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ce529215-5387-45b7-b0e9-171728b7ede7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_802e60fa-330f-45d9-9aeb-a63acf93b298" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ce529215-5387-45b7-b0e9-171728b7ede7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20200930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6f0971db-8731-4997-92e0-da87d6610f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5b11ad96-66a7-4295-a659-2b24b3b8af38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6f0971db-8731-4997-92e0-da87d6610f7c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5b11ad96-66a7-4295-a659-2b24b3b8af38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20200930.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d068bda5-8f23-4246-8e01-0805aebd009b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_51e0a218-7656-4f7d-a8c1-be1bb93a6a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d068bda5-8f23-4246-8e01-0805aebd009b" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_51e0a218-7656-4f7d-a8c1-be1bb93a6a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4ad5aa8f-9a41-4f91-a2b2-4e48bb6fc77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_51e0a218-7656-4f7d-a8c1-be1bb93a6a40" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4ad5aa8f-9a41-4f91-a2b2-4e48bb6fc77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6469c657-7d7a-47fe-a875-7fb1ab11f3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4ad5aa8f-9a41-4f91-a2b2-4e48bb6fc77a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6469c657-7d7a-47fe-a875-7fb1ab11f3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_85f282c2-b94f-4ef0-b450-2279902544ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6469c657-7d7a-47fe-a875-7fb1ab11f3de" xlink:to="loc_us-gaap_DomesticCountryMember_85f282c2-b94f-4ef0-b450-2279902544ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_c6d8d015-d345-4023-98ef-b4d100093c20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_51e0a218-7656-4f7d-a8c1-be1bb93a6a40" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_c6d8d015-d345-4023-98ef-b4d100093c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_e1f392bb-6c7c-4064-9f57-445c13783a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c6d8d015-d345-4023-98ef-b4d100093c20" xlink:to="loc_us-gaap_OperatingLossCarryforwards_e1f392bb-6c7c-4064-9f57-445c13783a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20200930.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c965b4ae-5582-4382-aa6e-161ba5dc7a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_272fb17e-9c0a-4ee6-b248-3e89b5446c49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c965b4ae-5582-4382-aa6e-161ba5dc7a62" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_272fb17e-9c0a-4ee6-b248-3e89b5446c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRights"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_02f55a9e-cf80-4517-b7cc-22d2a358450d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6f4d8946-f54a-4663-bcb4-20f410b11e26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_02f55a9e-cf80-4517-b7cc-22d2a358450d" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6f4d8946-f54a-4663-bcb4-20f410b11e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2f4f7487-2866-4c20-b723-6a5a8528c188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1db40b2f-3772-40bc-8134-6b6737658e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2f4f7487-2866-4c20-b723-6a5a8528c188" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1db40b2f-3772-40bc-8134-6b6737658e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_b460fd3b-64d2-49be-8cf6-751c71e4e92d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2f4f7487-2866-4c20-b723-6a5a8528c188" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_b460fd3b-64d2-49be-8cf6-751c71e4e92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_4d04e35a-c2ee-4661-b8b3-f4f420c61f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2f4f7487-2866-4c20-b723-6a5a8528c188" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_4d04e35a-c2ee-4661-b8b3-f4f420c61f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1c57e31f-9952-45df-a712-535e00853b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1c57e31f-9952-45df-a712-535e00853b49" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9726ab99-f71b-4438-ad18-4e5b95d91936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9726ab99-f71b-4438-ad18-4e5b95d91936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16b07753-75ed-4090-aa8d-e96011682938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9726ab99-f71b-4438-ad18-4e5b95d91936" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16b07753-75ed-4090-aa8d-e96011682938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_96424076-bca3-4f14-9e16-a3c4062b9524" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16b07753-75ed-4090-aa8d-e96011682938" xlink:to="loc_cpix_VIBATIVMember_96424076-bca3-4f14-9e16-a3c4062b9524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_82ea646e-92f0-4d23-9733-ed09c385e88f" xlink:href="cpix-20200930.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16b07753-75ed-4090-aa8d-e96011682938" xlink:to="loc_cpix_MethotrexateMember_82ea646e-92f0-4d23-9733-ed09c385e88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_20f68235-08ac-4521-b802-654167664dbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:to="loc_srt_CounterpartyNameAxis_20f68235-08ac-4521-b802-654167664dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e722a267-58e1-44b1-995f-5f22b424dc3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_20f68235-08ac-4521-b802-654167664dbc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e722a267-58e1-44b1-995f-5f22b424dc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_5a380156-fa5e-41ee-89d6-5f69940c1b29" xlink:href="cpix-20200930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e722a267-58e1-44b1-995f-5f22b424dc3c" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_5a380156-fa5e-41ee-89d6-5f69940c1b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_82bc3342-d208-4c43-b1ca-f35802565e06" xlink:href="cpix-20200930.xsd#cpix_NordicGroupBVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e722a267-58e1-44b1-995f-5f22b424dc3c" xlink:to="loc_cpix_NordicGroupBVMember_82bc3342-d208-4c43-b1ca-f35802565e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_cbfa032a-5c83-493e-b44d-209aabcb91be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:to="loc_srt_StatementScenarioAxis_cbfa032a-5c83-493e-b44d-209aabcb91be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1024b11e-00fb-45cf-a124-a2922f33963d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_cbfa032a-5c83-493e-b44d-209aabcb91be" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1024b11e-00fb-45cf-a124-a2922f33963d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_520e0751-1d13-403e-8a18-691c348f7eb0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1024b11e-00fb-45cf-a124-a2922f33963d" xlink:to="loc_srt_ScenarioForecastMember_520e0751-1d13-403e-8a18-691c348f7eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7298ea1b-4e1b-499b-af2c-478257ce5f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:to="loc_us-gaap_AwardTypeAxis_7298ea1b-4e1b-499b-af2c-478257ce5f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2ff1290-a3f5-464f-8c05-5512a8ccdf21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7298ea1b-4e1b-499b-af2c-478257ce5f23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2ff1290-a3f5-464f-8c05-5512a8ccdf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0c921b1f-3ab3-4921-a95c-a4db339385c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2ff1290-a3f5-464f-8c05-5512a8ccdf21" xlink:to="loc_us-gaap_RestrictedStockMember_0c921b1f-3ab3-4921-a95c-a4db339385c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bf7f5f5c-da8a-4c61-82d5-81ce9ddc5647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bf7f5f5c-da8a-4c61-82d5-81ce9ddc5647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cd0af246-80c3-42fa-87d0-a70044a76fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf7f5f5c-da8a-4c61-82d5-81ce9ddc5647" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cd0af246-80c3-42fa-87d0-a70044a76fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_d1bf07ac-9f0c-4148-94ce-46592e723a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cd0af246-80c3-42fa-87d0-a70044a76fbc" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_d1bf07ac-9f0c-4148-94ce-46592e723a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8c4b1752-b1cc-4486-bfa2-1f6fd04a9fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cd0af246-80c3-42fa-87d0-a70044a76fbc" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8c4b1752-b1cc-4486-bfa2-1f6fd04a9fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e26b409a-73fc-440a-bed4-facefcd10d85" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_504f5d46-74a7-457a-88ba-0d7038202084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_504f5d46-74a7-457a-88ba-0d7038202084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_a9219da7-d7c4-4230-b6eb-5307d887cead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_a9219da7-d7c4-4230-b6eb-5307d887cead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_d6903df8-8e6c-4b82-9120-840f1bfacec9" xlink:href="cpix-20200930.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_d6903df8-8e6c-4b82-9120-840f1bfacec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_88159907-ddaa-49b0-91e6-0358d1ff10ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_88159907-ddaa-49b0-91e6-0358d1ff10ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_9ea5708f-f23b-4a96-9dfe-37beb1d7cba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_9ea5708f-f23b-4a96-9dfe-37beb1d7cba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_78452908-a33b-4c59-914a-a3f18d4b8640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_78452908-a33b-4c59-914a-a3f18d4b8640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_82515526-ed80-4ab4-922b-cd8c332c4856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_82515526-ed80-4ab4-922b-cd8c332c4856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2c0e54b4-dfee-48ea-a8b3-048d9caf4be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2c0e54b4-dfee-48ea-a8b3-048d9caf4be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8744332c-e8f8-4424-a30d-b0e5ec2f817d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_Revenues_8744332c-e8f8-4424-a30d-b0e5ec2f817d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_e8dadd71-b506-411c-92ec-49600a8c201a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_e8dadd71-b506-411c-92ec-49600a8c201a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_33d42c2f-1d26-4431-abfd-498a59985918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_OperatingExpenses_33d42c2f-1d26-4431-abfd-498a59985918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1e66504c-b2bf-4fbd-9ce8-61602336cb84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1e66504c-b2bf-4fbd-9ce8-61602336cb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_33f4616c-e4b0-400c-9067-b6ca9c2d3cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8c0858a2-d8e0-4f35-9c74-3fbcf7a8bb87" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_33f4616c-e4b0-400c-9067-b6ca9c2d3cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b2ead5e2-37ee-4fd2-ba75-bc3b7493bd75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3ca8ff01-c9d1-478c-aade-a15093c842f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b2ead5e2-37ee-4fd2-ba75-bc3b7493bd75" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3ca8ff01-c9d1-478c-aade-a15093c842f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4920bdcf-ceb6-4fd0-948c-f4588161f71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3ca8ff01-c9d1-478c-aade-a15093c842f1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4920bdcf-ceb6-4fd0-948c-f4588161f71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a9bb9a2f-a3a7-4515-ab21-cf4a75e7159c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4920bdcf-ceb6-4fd0-948c-f4588161f71e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a9bb9a2f-a3a7-4515-ab21-cf4a75e7159c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_4e80d3c3-0008-4fad-8fd6-59dfb593d237" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a9bb9a2f-a3a7-4515-ab21-cf4a75e7159c" xlink:to="loc_cpix_VIBATIVMember_4e80d3c3-0008-4fad-8fd6-59dfb593d237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3ca8ff01-c9d1-478c-aade-a15093c842f1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7539c025-ba06-4bad-8e4e-72bfe77b5c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7539c025-ba06-4bad-8e4e-72bfe77b5c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_62bcae5b-8fce-47bb-a38a-ce56076d24a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_62bcae5b-8fce-47bb-a38a-ce56076d24a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_cf81d6d6-07cc-453b-8547-301f4da18719" xlink:href="cpix-20200930.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:to="loc_cpix_PaymentsForContingentConsideration_cf81d6d6-07cc-453b-8547-301f4da18719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fbcaa87a-9422-42cf-82a5-b04eadbf8760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2d777230-94ef-4d8f-a289-80253f871d9a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fbcaa87a-9422-42cf-82a5-b04eadbf8760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_801eed33-9cc7-493e-9c6a-01f7802c6bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d6c1764-e58f-4e6f-a0f7-d6207f03e9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_801eed33-9cc7-493e-9c6a-01f7802c6bdd" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d6c1764-e58f-4e6f-a0f7-d6207f03e9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e1075452-870c-4ee2-bd6f-3a6d909aac56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d6c1764-e58f-4e6f-a0f7-d6207f03e9da" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e1075452-870c-4ee2-bd6f-3a6d909aac56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96425c4f-50b2-4e6e-bd39-7a336682d7ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1075452-870c-4ee2-bd6f-3a6d909aac56" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96425c4f-50b2-4e6e-bd39-7a336682d7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_e21713b5-6003-45dd-8217-a1cf1f2b30ec" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96425c4f-50b2-4e6e-bd39-7a336682d7ec" xlink:to="loc_cpix_VIBATIVMember_e21713b5-6003-45dd-8217-a1cf1f2b30ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d6c1764-e58f-4e6f-a0f7-d6207f03e9da" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_44d8cd92-3e69-4102-8a73-40d27f7e022b" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_44d8cd92-3e69-4102-8a73-40d27f7e022b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_8d7036c2-f44a-4d4c-9472-3ed8effc4da2" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_8d7036c2-f44a-4d4c-9472-3ed8effc4da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_927e8ed1-ee8c-4144-9768-462fae8085a6" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_927e8ed1-ee8c-4144-9768-462fae8085a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_ce261449-13bd-441d-a1a0-4bc0b24af51b" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_ce261449-13bd-441d-a1a0-4bc0b24af51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2af60168-3cba-45ec-8377-9e3dad08a96c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2af60168-3cba-45ec-8377-9e3dad08a96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f0718118-ddaf-4e7e-8aa8-dd370e61865b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f0718118-ddaf-4e7e-8aa8-dd370e61865b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b3edc18d-9f55-4980-8ac9-ecf6a9391d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_us-gaap_Goodwill_b3edc18d-9f55-4980-8ac9-ecf6a9391d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_53fe428b-f0f6-4efc-98c8-48e942991796" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_53fe428b-f0f6-4efc-98c8-48e942991796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_8d8dfab0-cfed-48bb-aabd-f653a7ea3422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac007b2a-aaec-4513-9dcb-a2dddb1f6763" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_8d8dfab0-cfed-48bb-aabd-f653a7ea3422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2116bf29-aab5-4b1e-befa-f095c7ce764b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4be39c45-e52d-4094-844f-9f430c18dd32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2116bf29-aab5-4b1e-befa-f095c7ce764b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4be39c45-e52d-4094-844f-9f430c18dd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c98d7d3a-3b0c-4491-9ce0-d6e4891a8b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4be39c45-e52d-4094-844f-9f430c18dd32" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c98d7d3a-3b0c-4491-9ce0-d6e4891a8b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6f10d192-7b14-4146-906f-844013c23c27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c98d7d3a-3b0c-4491-9ce0-d6e4891a8b43" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6f10d192-7b14-4146-906f-844013c23c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_985e9396-de72-451c-8321-93f55023e710" xlink:href="cpix-20200930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6f10d192-7b14-4146-906f-844013c23c27" xlink:to="loc_cpix_VIBATIVMember_985e9396-de72-451c-8321-93f55023e710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bf7b2be6-e2d5-430c-ad5a-d119ac9c363f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4be39c45-e52d-4094-844f-9f430c18dd32" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_bf7b2be6-e2d5-430c-ad5a-d119ac9c363f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bf7b2be6-e2d5-430c-ad5a-d119ac9c363f" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d5431bce-93e3-4b14-8820-fa75090adc89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d5431bce-93e3-4b14-8820-fa75090adc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_224cd125-c4ad-405c-a01c-0978c4f644af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:to="loc_us-gaap_PaymentsForRoyalties_224cd125-c4ad-405c-a01c-0978c4f644af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fb44afe8-202b-4be2-a882-d37ad3d31c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fb44afe8-202b-4be2-a882-d37ad3d31c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ba545564-4e84-4da4-a6aa-2f38e41a5f0a" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ba545564-4e84-4da4-a6aa-2f38e41a5f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a4742cf1-4f53-40da-a932-22aed2f568cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_faa4aa25-d72a-44f0-b130-aa454caa7ef2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a4742cf1-4f53-40da-a932-22aed2f568cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>cpix-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20200930"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20200930.xsd" xlink:type="simple"/>
    <context id="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i806f0e664f9d4316a3583b5943ad619c_I20201110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-11-10</instant>
        </period>
    </context>
    <context id="i2aae3ade58f14629babea615840c16d4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib48367eed5394c5ea20e7dc76326dace_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i51d553293659413f87554dc788d4bcce_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4b79c2df727e4b81b6070f5e05dfd76a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibbfd45792901404db84b4c62a7d2ab4b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i98c007d4ad524e538f8276538642ea78_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1b9bb42baaef4c5094e0ab9146fbecb9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3d3c6c171eb84faea1a073a15ee27d73_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6b2670bfac16431b81e1d0ae43216d38_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ief40d394930e4ad8aa55d1f1875a0473_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id532a92619594716b8d454accfec3e8c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie2aa2b7754394bca86b16a6b683ae214_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1dfbc6c701c545729ec01b3e104fd1fa_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id931366f1dd048809e78a414f3cc4061_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ibe4dbdb42df24afb92bd43a4728b5831_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7330257a2be7418096532eb1e582d5d5_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i466e638f1cf944169e790ce328cd7e79_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id8f9b7046ef944bf8bc512a3664d2b5c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1766bc56f0844f99bf09b7d344eb14ed_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia8e552015b714eeb8c0eba2c8da97ef4_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i183ac2b291524d89a1a470882b24289e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i437f92c999684ffb86a16fe5adde240b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i728e3047fc24462aab7d9ddd4d5160fd_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i99444b1a69614eebaa428eeb94e3bb1d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic3e8253dce984097b996ea192173d741_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4af8aa9fc5194cd4a1b4cda6e6eed41b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4f5deb38ccd648d2b3ae820c2917f209_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3789f076fc20455ba5086e4654a7b173_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if3e79a34ef554fed993caa85ec4ed80b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ce06f07f5994164ae6cf178e40174fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if07b4fb1f80e4674a4387c2c2fb38f86_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8216f15d99a94a2a86c19d3b1bad2bf5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i89152ce5d22b489f9ea811b4bb61d18d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i62a06f5b04844061940fdd3b9480439c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i26772e0071d34883b195a26267505a52_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifbc1fd769f9740e989a4d2fd47f1ced4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icae833f7b3f44f0f9e58b7193716452c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0ca469517291478aa2e4c1fa421bd3d3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ife9646ecd78c471da7ec0b9ae8d48366_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6edc159368b349ed8d34e1d4bd240e22_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic40b1cdafe584ea8a9f3cf4307d96744_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if52f80cf1d0e45cb97aae49b8c8230f2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic21315fbf39347a28cfc557393bc9c1f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia0c42cdc6a024ef985b79c61a90bbe9e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i32fea5db2d3c47e9a21a5f1f1ab0b6e4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6d382f4a1c3c4e77bba4a6e17311df80_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i13e05db5bc634c8395dc7ba20fd01c1f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5a6b0baa09b04dc8ad7327ed08a971d4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaa532992c0504e0ba3d7d267f54270d4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibe1c68d19eec4a38a757dd2e42c81bf6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i37fd46b1fc0d4e5c9cf794637e21ef86_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie1d9d3ac014b4702a58b9bc1204a2cb5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2f9e4efabd72491282314ba3c4151d14_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id07d176dae7e493b8fd0de707a8f73b1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iab8d543293c243d483f364b765f13a5a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib0a4e269bc9b4de18ca89b7b6757b95e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if6b1300825a343c492f6cec5fac50c3f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b6aa7e3eea8489992e4ccb91292c2ba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f317e5f67db4275a57f6749f14461f1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i971765b8c0cf44faa48dc5064fcf9605_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8eb93e31604f48009bc491bfe2432446_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i595eb369427c497fac23d3e8c5820214_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd5b9e6ccc0d4886acc721fa7dbb63c7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie302cf43817549578a8f9ef152a447b1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i25de277b0b0646cb9281cd16f837c44a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i90fb467e2733434596b17207333e3bfe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ce5aa81441845e89b5271f86420011f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icc6245a0edd04497ac8b9d6d6e9f57ab_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idf4e408c7b1844ffb641ff92ed986d13_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie79fe091e6954839a3d9614623decb4f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia33026525efb4a2fba6cc177559e712b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ideedcf83bae049bdaf355ac459d10cf8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id9da2d5ab42648409a9408e0b935a37d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i52c8721688534cb184cbf86471fe0d57_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6f094a21244147fb9ce5e1bb5b80e965_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1481a754bb38453f812b6c54c7a6c98b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5fd27b429249456c90fc071b0ff8b3bd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5902cac206e44f0da81556294b8309f5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0d88d58c35bc420b81d5571b5f859389_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7b0440b8c0a141a6bd9f692f2deeb4ba_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if9483466598e4f23ae7a5abdf7100ada_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8fb1ae19da3f45d18b49aaf25f1dbd88_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie18912dcb3d24ad7a55576713413c72c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3299d8817d7541f3bdc4c7f01ae7bd80_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5447d4c0f5a349c1a9861329416d6e25_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if90916a859244a87afe32a6420d18ffa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if4c798a624494da4a9a833b2d4b416cd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i13a8c2296b3941e0a307a7590c71f19b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i95daedfded3c472b9eb62ad072b1551e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i810fe6fe3d5d4acc95a6434905ad9bbd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i11f33391c5194ed3a2eab2153394a830_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6cc85fa1f23c400f98a38cd8f0ac2143_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6e3533c9ef434f2296767af0d6fa95cd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6666cecacb694b16a57f4cfa2cedd55d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7b09030d4c8746e39c72272a8087f528_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i43031ec5d6b146e396b7ed311aeda9fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e39f507697344bf966ae5d85dc07c38_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibb00b2069e194ae3b41a6bbd3811b9ef_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="i8cea20af1c7a4bf8892167b3a57bb8b3_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i5651034dcdff44f08080de6ea37be942_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1f1cc7c6f3f64637b1ca6aea46ce29a1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0a446f495cd042eca3da6e7c97bb5b5d_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i5eed37f174f24049b2b6ad3653f05bbe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i41de7f64b76f4893a406e9afd4a76a14_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6006916e3bab4f718de88600cfdcb08d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i930ad17f078c46d582cdf90475e66e78_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="ib2affeac992f45c1807ad24d6642935c_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i02dfaa25707a4e09b76974e10fd34245_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i26301daa05cd47268f1bd0644a7e18a1_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ia98b89ba857e4a2cb67df1f1038088f9_I20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FourthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-07</instant>
        </period>
    </context>
    <context id="i19338c6b30fd4b21b231c47865291087_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="ie2620c3a3fad4da8b66e2277201834e8_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="i407f51866f02409cb9fad138500d14d1_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="iaadf65c3ea20463da1472b122fe42d41_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i19e5831ccde74dbba7c187512febfbb2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9d96acd949234acfb136a690bec1d7ce_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i04eb73a534cd4abf9da31ee653c6edde_D20200420-20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-20</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="id6ec3802e7f5429586813fbc92cd89e5_I20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-20</instant>
        </period>
    </context>
    <context id="i593c0deb73804b658d160e2556b47e42_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i0afbb1a866c34e2b917ab586687f4135_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i75f6e5e1e35347acb9908a1fc5e7a4d9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i657f7cc3031d4101af068d47a7501bd3_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i582dbdc998d44cdbab1a7981ad14c27c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5495d94083d24a5989730f4a6f7ba7da_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5a6bfe43ca624e09b88b884aa61ffce5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i89aa0df8ed9e4d689422daf8e8aeff91_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i0da1b98b323a4b7fb67fd0ac6aa17246_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i8af93abad7204f41a2937bac9ef79281_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2c32aec9cced429d9682d29a48e13689_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i1bdfcc93ab6345078a0b921b7524f21f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6eee9c230ea246608d8ad3a6a84a3a71_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc4d6bac512842b1af4d4a5a540f3881_D20191001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9cb62c40adac4ab6b3e98357baff55af_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6687a95bae3143d5b4bd7100bc41042c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i955fd3b444074d18a8861d6a9e06f6e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cpix:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180L2ZyYWc6Y2Q4ZmY1N2JlYTliNGU1MGFiZjlmOWViYmI0YTg5NjYvdGFibGU6ODViMmI4ZDY2MDk2NDZiZThhZDM2MmY5Yzk1Y2NkMGEvdGFibGVyYW5nZTo4NWIyYjhkNjYwOTY0NmJlOGFkMzYyZjljOTVjY2QwYV81LTEtMS0xLTA_63cfb404-9746-46f9-bfc9-c0b5457d836f">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180L2ZyYWc6Y2Q4ZmY1N2JlYTliNGU1MGFiZjlmOWViYmI0YTg5NjYvdGFibGU6ODViMmI4ZDY2MDk2NDZiZThhZDM2MmY5Yzk1Y2NkMGEvdGFibGVyYW5nZTo4NWIyYjhkNjYwOTY0NmJlOGFkMzYyZjljOTVjY2QwYV82LTEtMS0xLTA_8b014f49-cedc-48a0-82eb-9edbc5da1d5e">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180L2ZyYWc6Y2Q4ZmY1N2JlYTliNGU1MGFiZjlmOWViYmI0YTg5NjYvdGFibGU6ODViMmI4ZDY2MDk2NDZiZThhZDM2MmY5Yzk1Y2NkMGEvdGFibGVyYW5nZTo4NWIyYjhkNjYwOTY0NmJlOGFkMzYyZjljOTVjY2QwYV83LTEtMS0xLTA_355e9036-85fd-4971-9bf2-ef3e7fc7bcb5">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180L2ZyYWc6Y2Q4ZmY1N2JlYTliNGU1MGFiZjlmOWViYmI0YTg5NjYvdGV4dHJlZ2lvbjpjZDhmZjU3YmVhOWI0ZTUwYWJmOWY5ZWJiYjRhODk2Nl83OQ_94febea4-a4dd-48a9-aa72-510b5a26c71e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180L2ZyYWc6Y2Q4ZmY1N2JlYTliNGU1MGFiZjlmOWViYmI0YTg5NjYvdGV4dHJlZ2lvbjpjZDhmZjU3YmVhOWI0ZTUwYWJmOWY5ZWJiYjRhODk2Nl84MA_a4af4f15-d21d-4142-93b6-c19d0e87e6c8">0001087294</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDI0_26ccb216-1d53-4043-8477-6e8d3e008991">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6MjBjZWFlYmQzNGIwNGQyOGJmZDQ0NDljYzdkZGNkM2EvdGFibGVyYW5nZToyMGNlYWViZDM0YjA0ZDI4YmZkNDQ0OWNjN2RkY2QzYV8wLTAtMS0xLTA_51fca158-3c23-426d-83e2-9da4880f5e68">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8xMDk5NTExNjI5ODE5_00beaa23-8cb5-4565-a950-e839b3da2d55">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YjAzNzk3NTFkZDc0NDQxNzgzN2JlNDY2OGVkNGI1MzAvdGFibGVyYW5nZTpiMDM3OTc1MWRkNzQ0NDE3ODM3YmU0NjY4ZWQ0YjUzMF8wLTAtMS0xLTA_c5aa0bc4-47df-4ed7-92de-5e3cba934c98">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDE4_9cb07708-5efb-4a76-aa61-e439b70f1fd9">001-33637</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDI3_0a3aa515-c8c7-4c6c-ae59-4b363cb811b6">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8wLTAtMS0xLTA_dcf0d76d-8ab2-41e1-8aae-ff64cced49a4">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8wLTItMS0xLTA_b1e4abd9-acf9-4a5f-95ce-71d195f9a64c">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMTI5N2M5ZWY3YjU0MjAxODFhMTVhNzQ5MmFjYzMzMV81_9839231c-1eac-4b25-aad9-15138fc10242">2525 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMTI5N2M5ZWY3YjU0MjAxODFhMTVhNzQ5MmFjYzMzMV85_a7937d36-e0df-4e47-bb49-e11c095ce8c0">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMTI5N2M5ZWY3YjU0MjAxODFhMTVhNzQ5MmFjYzMzMV8xMw_94fea98f-0b82-44ed-8127-bb3e9f371073">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMTI5N2M5ZWY3YjU0MjAxODFhMTVhNzQ5MmFjYzMzMV8xNw_9bf4a540-f320-46c6-af7e-2fa9c3229870">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6ZDExNDMwZmRjMDI1NDgyNDk1ZDRjZTQzMzk5MDY2YzYvdGFibGVyYW5nZTpkMTE0MzBmZGMwMjU0ODI0OTVkNGNlNDMzOTkwNjZjNl8zLTItMS0xLTA_b85de85a-deda-47e3-9dca-65282a3a9439">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDIw_12a65283-7f76-4914-a5df-0108578c1ce8">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDIx_c080729c-6c06-4c23-818d-5047b13fa11a">255-0068</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDIy_eedc4313-7811-48a6-ab11-aa69c29e6c2d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDE5_4663b5ae-21ca-451d-937a-05f2f8024265">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWRmZGE4NDBiNzZlNDNiMTgzM2M0Y2Y4OTk4NWEzMTYvdGFibGVyYW5nZTphZGZkYTg0MGI3NmU0M2IxODMzYzRjZjg5OTg1YTMxNl8xLTAtMS0xLTA_35c21b91-e5fd-4ea5-88ac-951b773b5b29">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWRmZGE4NDBiNzZlNDNiMTgzM2M0Y2Y4OTk4NWEzMTYvdGFibGVyYW5nZTphZGZkYTg0MGI3NmU0M2IxODMzYzRjZjg5OTg1YTMxNl8xLTUtMS0xLTA_479ac604-c5bd-46ac-b860-4c3633262ae4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWRmZGE4NDBiNzZlNDNiMTgzM2M0Y2Y4OTk4NWEzMTYvdGFibGVyYW5nZTphZGZkYTg0MGI3NmU0M2IxODMzYzRjZjg5OTg1YTMxNl8yLTItMS0xLTA_84db1b0f-6776-4763-bf11-e0550349db3e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGV4dHJlZ2lvbjo3ZjcxN2FiYWUzMjA0MmNiYTkxM2EyZjVlMThlNzc5Nl8yMDIz_b125b40e-37aa-4878-a0c6-ed8ed997be9d">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWFlNWU4MjhiYzlmNDQ1ZGExMjAxNjU4YWRhZTZlZTgvdGFibGVyYW5nZTphYWU1ZTgyOGJjOWY0NDVkYTEyMDE2NThhZGFlNmVlOF8xLTAtMS0xLTA_c3de2ece-c0b9-439d-aa11-fbc17aa07982">Common stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWFlNWU4MjhiYzlmNDQ1ZGExMjAxNjU4YWRhZTZlZTgvdGFibGVyYW5nZTphYWU1ZTgyOGJjOWY0NDVkYTEyMDE2NThhZGFlNmVlOF8xLTItMS0xLTA_7860f767-3fb3-4056-9e38-877e73b258ab">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWFlNWU4MjhiYzlmNDQ1ZGExMjAxNjU4YWRhZTZlZTgvdGFibGVyYW5nZTphYWU1ZTgyOGJjOWY0NDVkYTEyMDE2NThhZGFlNmVlOF8xLTQtMS0xLTA_d89b56a9-ca8d-40c2-b951-bb3a690b006c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i806f0e664f9d4316a3583b5943ad619c_I20201110"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xL2ZyYWc6N2Y3MTdhYmFlMzIwNDJjYmE5MTNhMmY1ZTE4ZTc3OTYvdGFibGU6YWFlNWU4MjhiYzlmNDQ1ZGExMjAxNjU4YWRhZTZlZTgvdGFibGVyYW5nZTphYWU1ZTgyOGJjOWY0NDVkYTEyMDE2NThhZGFlNmVlOF8xLTYtMS0xLTA_f82a5bf1-126a-4fd9-a73f-a4848622be99"
      unitRef="shares">15036923</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMy0xLTEtMS0w_81710ca7-e226-4191-9abf-182aea7cbae9"
      unitRef="usd">26646530</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMy0zLTEtMS0w_884c2edd-f01e-4d0b-8354-e5d6d6b22438"
      unitRef="usd">28212635</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNS0xLTEtMS0w_bd5b2591-70c6-4fb6-8cce-3948cf839157"
      unitRef="usd">9661407</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNS0zLTEtMS0w_ae609960-c006-4e38-9f40-9e5ca113009e"
      unitRef="usd">7843917</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNi0xLTEtMS0w_a6e0b769-21ef-4003-ac51-3690ac507a95"
      unitRef="usd">10080394</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNi0zLTEtMS0w_44b4b590-b6f9-43ae-965f-40d941cbf650"
      unitRef="usd">8871254</us-gaap:InventoryNet>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNy0xLTEtMS0w_003d395e-fba8-4a9a-ba46-97d0edffa630"
      unitRef="usd">727670</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfNy0zLTEtMS0w_ecb384a5-f5d1-4cb7-bee2-b4bc2db9eb8f"
      unitRef="usd">2477813</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfOC0xLTEtMS0w_7c1899ad-442d-4162-85db-6dd9d95503b2"
      unitRef="usd">1778078</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfOC0zLTEtMS0w_367b0241-15a7-4abe-a7b6-533ed188bab5"
      unitRef="usd">2757456</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfOS0xLTEtMS0w_1d72f3eb-b62f-466e-b88d-ce5098197bd7"
      unitRef="usd">48894079</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfOS0zLTEtMS0w_838f0679-068a-4a8c-8bb8-41d27668a16f"
      unitRef="usd">50163075</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTAtMS0xLTEtMA_aff30a22-4550-4f01-80c0-3d17254c1ada"
      unitRef="usd">12649184</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTAtMy0xLTEtMA_4c697fa0-cbf4-4065-9a24-ea8245b58db9"
      unitRef="usd">15554992</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTEtMS0xLTEtMA_e23ec190-280c-4b77-9175-83f428e2a25e"
      unitRef="usd">602911</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTEtMy0xLTEtMA_92f85e39-0ad9-4d0a-8075-268d93119399"
      unitRef="usd">747796</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTItMS0xLTEtMA_1304b6ba-07a4-4e6f-bfec-52194028b890"
      unitRef="usd">28180090</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTItMy0xLTEtMA_10738e56-7641-4f8d-ab04-aa01b3391afc"
      unitRef="usd">30920324</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTMtMS0xLTEtMA_13ccd029-c7e7-4c4a-ab50-81e03ed3fb96"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTMtMy0xLTEtMA_48366bea-1217-4271-ae1b-10c494a708f2"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTQtMS0xLTEtMA_bb66e516-81d1-4892-9fcb-6bd4f8511f0c"
      unitRef="usd">21802</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTQtMy0xLTEtMA_97c5ebf7-0ed7-4431-9e08-9c861ae669e2"
      unitRef="usd">21802</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTUtMS0xLTEtMA_da2f3247-a2fa-48bc-9733-06fb4cfc3cc7"
      unitRef="usd">2267669</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTUtMy0xLTEtMA_73853f4e-b175-415c-b69c-ed56e7a68bb4"
      unitRef="usd">2960569</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTYtMS0xLTEtMA_44bf0e20-f920-4435-b6a4-c241605d3644"
      unitRef="usd">2511894</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTYtMy0xLTEtMA_9014b2d6-1727-4d44-8236-112e943b2fb5"
      unitRef="usd">3298725</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTctMS0xLTEtMA_7a49e0aa-310e-49a1-a28c-e74bdfb2caf8"
      unitRef="usd">96009629</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMTctMy0xLTEtMA_f042da5d-d7b4-42e8-b539-cde043edb25d"
      unitRef="usd">104549283</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjAtMS0xLTEtMA_8f14246a-f2b9-4a8d-94dc-fd22e2a5fb63"
      unitRef="usd">10833972</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjAtMy0xLTEtMA_607f9965-8723-4669-b09a-57e61a43dff7"
      unitRef="usd">9993578</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjEtMS0xLTEtMA_48398525-3e2b-4c6a-85e3-d5e26a16048c"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjEtMy0xLTEtMA_69d7698d-d5c5-4921-8226-3feb5a9ae0dd"
      unitRef="usd">1918868</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjItMS0xLTEtMA_5810fa0f-9be6-43be-b43f-8f832ef5d5ed"
      unitRef="usd">991969</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjItMy0xLTEtMA_6c0c18cb-5849-4209-923c-fa2ce43439af"
      unitRef="usd">920431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjMtMS0xLTEtMTk_62b0d0f6-cf70-49af-bed6-9c5edd3c58cb"
      unitRef="usd">2000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjMtMy0xLTEtMTk_9f81cbec-c9de-497b-b9a2-218bf8eba8b4"
      unitRef="usd">0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjMtMS0xLTEtMA_d4f8ac6b-4850-4bdb-8748-ffa0e902e3eb"
      unitRef="usd">10112100</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjMtMy0xLTEtMA_e109bc9d-5bbf-4351-bcc3-1090cafc244d"
      unitRef="usd">11317358</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjQtMS0xLTEtMA_3234b9fa-59a7-4e37-8908-1848b9281437"
      unitRef="usd">23938041</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjQtMy0xLTEtMA_8af1849c-9a12-451a-9935-8837d20957fa"
      unitRef="usd">24150235</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjUtMS0xLTEtMA_7c28da46-5dba-477c-8c8c-c03ceea7879b"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjUtMy0xLTEtMA_b052841f-c504-44c7-80e0-1b495a88ff41"
      unitRef="usd">18500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjYtMS0xLTEtMA_bfeb40bd-82a3-474f-8ccf-179474b50435"
      unitRef="usd">1323792</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjYtMy0xLTEtMA_8af13e3f-82dd-4edb-a075-ad62fbdbcfcb"
      unitRef="usd">2076472</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjctMS0xLTEtMA_9741ebdd-1b5e-41ec-8738-5162c2383f9d"
      unitRef="usd">7904419</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjctMy0xLTEtMA_45c992c8-9a2a-4073-8226-ac3f613444bd"
      unitRef="usd">8737323</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <us-gaap:Liabilities
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjgtMS0xLTEtMA_9335dd40-5040-4086-bbbe-aa2ddc846aa1"
      unitRef="usd">48166252</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjgtMy0xLTEtMA_cbaa3750-62dc-4c32-ab29-24c752efac94"
      unitRef="usd">53464030</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjktMS0xLTEtMA_51ad0cab-fefc-45b9-8e87-215eae9f9d4f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMjktMy0xLTEtMA_c1168de5-ea51-4ead-9ebf-5ce3209658d7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzE3_92a3a022-9af4-4127-aa0f-34d83b2b7b98"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzE3_faa0ebb9-fc82-4631-8d67-a9ed403f90b0"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzMx_608602a1-7401-4be3-97ea-78df5e0c3055"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzMx_de708b29-cb7e-4783-bb3b-59cdcaa9d44a"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzUz_32aa97f5-16f4-4eed-a7fd-6e9cf53ca502"
      unitRef="shares">15084372</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzUz_89c66577-61e4-4f0c-8219-9be7693109d4"
      unitRef="shares">15084372</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzYw_c789e6b3-1366-4a7d-915d-90b13fabf118"
      unitRef="shares">15263355</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjU5YjljM2IwNjdkMjQ2NjM4M2RiY2Y5OWI1MjdmOGRjXzYw_ce51757b-0cab-4572-8625-dcde6c270773"
      unitRef="shares">15263355</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMS0xLTEtMA_29ccc6db-e49a-42c8-936a-2224965018a1"
      unitRef="usd">49176040</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzItMy0xLTEtMA_b4abf02d-d137-42f2-8456-b73861df82f3"
      unitRef="usd">49914478</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzMtMS0xLTEtMA_b3cdd169-71da-4a41-98df-44d30f723372"
      unitRef="usd">-1247237</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzMtMy0xLTEtMA_63c20bf1-250e-413a-9f2d-ed9796527970"
      unitRef="usd">1208395</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzQtMS0xLTEtMA_f3b1468d-0645-45a1-bd17-cd97bd586366"
      unitRef="usd">47928803</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzQtMy0xLTEtMA_3d9312ab-2f7b-472f-a6f6-5e347fbb140b"
      unitRef="usd">51122873</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzUtMS0xLTEtMA_7a0015a3-e4f7-4394-9759-89faaa6cf2f8"
      unitRef="usd">-85426</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzUtMy0xLTEtMA_7c3d01c6-9746-4349-bd08-f315c59fcd82"
      unitRef="usd">-37620</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzYtMS0xLTEtMA_0bc63762-9134-4dee-945e-ef140d20aca0"
      unitRef="usd">47843377</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzYtMy0xLTEtMA_361b03d5-e705-47fc-b5d3-7f36a7243606"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzctMS0xLTEtMA_7ba572cf-94f3-42eb-af2d-a32dc821f185"
      unitRef="usd">96009629</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xNi9mcmFnOmIxZGI4Yzc5NWJjOTRkMDliYjEyOGZiM2NlOWVjZTAzL3RhYmxlOjhiYjM0NWM3NWMwNzQzYzNhMDY4ZjIzZWFjOTBlYzgyL3RhYmxlcmFuZ2U6OGJiMzQ1Yzc1YzA3NDNjM2EwNjhmMjNlYWM5MGVjODJfMzctMy0xLTEtMA_1abe1294-d5a6-4d98-b766-1d295bce5690"
      unitRef="usd">104549283</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMi0xLTEtMS0w_3c845a34-6641-4042-93f1-3db372f2c06a"
      unitRef="usd">9250689</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMi0zLTEtMS0w_af363671-b2e5-47c8-bf2d-122b961c9aee"
      unitRef="usd">6935439</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMi01LTEtMS0w_8c4993ce-380f-4ffe-a1d9-47902e66cce8"
      unitRef="usd">27179600</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMi03LTEtMS0w_03fd59ab-280f-4e15-b1a9-42a831c72b05"
      unitRef="usd">25082742</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNC0xLTEtMS0w_8c206724-66b7-44c3-9e88-667cf9315776"
      unitRef="usd">2142839</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNC0zLTEtMS0w_28e1d379-5216-466c-bb68-febbea7c7e43"
      unitRef="usd">1580650</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNC01LTEtMS0w_fc85daea-7be9-46a5-8d9c-d2346ba2b075"
      unitRef="usd">6387002</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNC03LTEtMS0w_18ae2c75-65ab-4876-b3ba-25c8c365f58e"
      unitRef="usd">5031732</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNS0xLTEtMS0w_7e0742ad-d8f8-4554-9b1a-8959d05f1b7d"
      unitRef="usd">3587842</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNS0zLTEtMS0w_a2158190-70f0-407a-a57b-a9e237a670bb"
      unitRef="usd">3812467</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNS01LTEtMS0w_8aa205b3-4654-45e6-8cd6-76bf0965939e"
      unitRef="usd">11160924</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNS03LTEtMS0w_4e53fae5-1894-45c3-bc16-848052021115"
      unitRef="usd">11231778</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNi0xLTEtMS0w_1de61b97-869d-4165-854d-07eb135c7bd7"
      unitRef="usd">1230335</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNi0zLTEtMS0w_3b99813d-82d8-466d-b9ce-d9984acc3524"
      unitRef="usd">1672843</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNi01LTEtMS0w_c870718f-a770-4b69-8de9-e44b9a74d1c4"
      unitRef="usd">4374392</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNi03LTEtMS0w_91d96dd0-c296-443e-ae6e-bfe5b8e12aaa"
      unitRef="usd">4788698</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNy0xLTEtMS0w_8226ad5e-ae9b-45ac-880c-b43b4cd0a57d"
      unitRef="usd">2381273</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNy0zLTEtMS0w_efb8e402-c1e5-4fc5-af9a-09bcecdb7ace"
      unitRef="usd">2032129</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNy01LTEtMS0w_9d32f83b-935d-4c32-89e4-6bf9648608cc"
      unitRef="usd">6608322</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfNy03LTEtMS0w_5426541c-ce3f-44a8-97ca-b3563532dd13"
      unitRef="usd">6839187</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOC0xLTEtMS0w_38de8255-52ab-44bb-b2c6-d30f5c21a719"
      unitRef="usd">1117086</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOC0zLTEtMS0w_8b55a071-a067-4bf9-9467-a72e1aba90f2"
      unitRef="usd">1033786</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOC01LTEtMS0w_2101e84d-152c-4777-b307-2facc1389715"
      unitRef="usd">3284610</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOC03LTEtMS0w_99911cb3-1aee-4993-afdb-1ab72d68fae7"
      unitRef="usd">3085139</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOS0xLTEtMS0w_b6f8301b-c810-413c-adfe-ff1e0d579487"
      unitRef="usd">10459375</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOS0zLTEtMS0w_d72c17b3-c076-4637-af3c-5ac096026385"
      unitRef="usd">10131875</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOS01LTEtMS0w_57031076-2068-4a22-98ef-14b46c887aea"
      unitRef="usd">31815250</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfOS03LTEtMS0w_ccd6e876-8db4-4e2a-9b03-10e9a0198031"
      unitRef="usd">30976534</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTAtMS0xLTEtMA_9ef15477-480d-4872-a47e-1e1cd9bc1b67"
      unitRef="usd">-1208686</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTAtMy0xLTEtMA_db6d0d04-37f2-4a0e-9305-c0172c60f831"
      unitRef="usd">-3196436</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTAtNS0xLTEtMA_e31d8a65-a507-4fe9-a254-c6d5b2654b14"
      unitRef="usd">-4635650</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTAtNy0xLTEtMA_de3b2c81-a1de-46e7-aad7-2dc02f01b80c"
      unitRef="usd">-5893792</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTEtMS0xLTEtMA_427ca1bd-13b9-468a-a2b2-645828539245"
      unitRef="usd">12004</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTEtMy0xLTEtMA_9f5a231e-a834-455a-94b8-4ba28e343d1e"
      unitRef="usd">-50511</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTEtNS0xLTEtMA_46e17015-b128-431e-880f-50229018cbfa"
      unitRef="usd">70553</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTEtNy0xLTEtMA_5a06ddde-c632-474c-8a9c-0816988f8304"
      unitRef="usd">195915</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTItMS0xLTEtMA_0cec5268-97e3-4fe2-b129-e0fa2d95df43"
      unitRef="usd">75210</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTItMy0xLTEtMA_40d40758-4304-4bfd-9f80-349886e6b792"
      unitRef="usd">64877</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTItNS0xLTEtMA_777361f6-354a-4252-940a-2f360bedacea"
      unitRef="usd">227730</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTItNy0xLTEtMA_28fc7fa4-900b-4c64-b04a-9b835d08ac58"
      unitRef="usd">216988</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTMtMS0xLTEtMA_19a5ff8f-d961-4dec-956e-196e33fa174a"
      unitRef="usd">-1271892</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTMtMy0xLTEtMA_4c74256b-4c7f-4020-b8ec-a6a024bee5b0"
      unitRef="usd">-3311824</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTMtNS0xLTEtMA_c92a2a5f-01a4-41b4-9176-9f13c2b85c72"
      unitRef="usd">-4792827</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTMtNy0xLTEtMA_6edc627d-6ee1-48a0-ae13-d895e89decec"
      unitRef="usd">-5914865</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTQtMS0xLTEtMA_96492f75-3df0-4698-b09b-00cf4e3b97b0"
      unitRef="usd">3728</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTQtMy0xLTEtMA_e4b9f0db-9295-4aa8-86c9-e815a4d3a1f3"
      unitRef="usd">4462</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTQtNS0xLTEtMA_fe789b9a-c2b7-404d-bfcb-6c64a7dc10ce"
      unitRef="usd">45423</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTQtNy0xLTEtMA_3d488bf9-0a90-4702-8826-1d416a3303cd"
      unitRef="usd">-72504</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTUtMS0xLTEtMA_dc933537-d6c3-48ff-a0cd-f6960200066e"
      unitRef="usd">-1275620</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTUtMy0xLTEtMA_381be7ac-a55e-4cbb-8b4e-b27c2ab55f63"
      unitRef="usd">-3316286</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTUtNS0xLTEtMA_ba6c153c-d20c-4201-9194-d99af8da848f"
      unitRef="usd">-4838250</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTUtNy0xLTEtMA_279857ff-511d-4ae7-99f6-6e2ae17c9f5f"
      unitRef="usd">-5842361</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTYtMS0xLTEtMA_810e6874-b3f8-4a92-ab84-d9901715c353"
      unitRef="usd">777916</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTYtMy0xLTEtMA_9bd44394-86b7-4da6-9f91-dd9bcfe0d2bd"
      unitRef="usd">1349351</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTYtNS0xLTEtMA_31a5f830-9e36-446a-bdb9-0b6b6c6c847b"
      unitRef="usd">2334811</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTYtNy0xLTEtMA_bf1f3af9-faff-4042-b46b-2684d5e47fd2"
      unitRef="usd">3268196</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTctMS0xLTEtMA_7c120e3b-7a84-4df6-b4b4-ef3fee1a3dd7"
      unitRef="usd">-497704</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTctMy0xLTEtMA_6eac5a43-e67b-435f-aa7d-89e6f7749169"
      unitRef="usd">-1966935</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTctNS0xLTEtMA_f7a3f5c7-7346-4b3c-a706-5377b195e2b9"
      unitRef="usd">-2503439</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTctNy0xLTEtMA_854a8d3f-5411-4706-9a32-a439a2787e25"
      unitRef="usd">-2574165</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTgtMS0xLTEtMA_df562953-c9f0-4226-91a7-24dc38981cd8"
      unitRef="usd">-15967</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTgtMy0xLTEtMA_bab9f3ca-afdc-4cc1-8633-81bba402b9bb"
      unitRef="usd">-13267</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTgtNS0xLTEtMA_058de113-d6f7-46c0-8dfd-d000d9e95ebf"
      unitRef="usd">-47806</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTgtNy0xLTEtMA_53700455-ad83-4e97-aee6-ffb515c89a96"
      unitRef="usd">2888</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTktMS0xLTEtMA_180a2986-e02b-4467-bf4c-ca6cb1d6a282"
      unitRef="usd">-481737</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTktMy0xLTEtMA_51079ceb-063b-4736-a081-28fb404a8fb9"
      unitRef="usd">-1953668</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTktNS0xLTEtMA_ccc4dc60-fb64-412b-be54-1d316c350883"
      unitRef="usd">-2455633</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMTktNy0xLTEtMA_b6bf7a28-b262-4a5b-bbcf-7220da734f82"
      unitRef="usd">-2577053</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjEtMS0xLTEtMA_c63a89a7-6447-44f6-a43c-f9cde23e26ff"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjEtMy0xLTEtMA_6a5323b0-3367-4c6f-8de5-addead3f9ad8"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjEtNS0xLTEtMA_ce4d0a9f-2997-4907-8137-613a952671a2"
      unitRef="usdPerShare">-0.31</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjEtNy0xLTEtMA_f3647442-6292-4754-8268-82f45a74db63"
      unitRef="usdPerShare">-0.38</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjItMS0xLTEtMA_34775022-dac9-4c8b-9f27-397ecbda50b3"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjItMy0xLTEtMA_21d57ce8-704b-4372-ad50-36da31e9b6f7"
      unitRef="usdPerShare">0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjItNS0xLTEtMA_8c1b6d37-3748-48c0-9063-818dfccbb05d"
      unitRef="usdPerShare">0.15</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjItNy0xLTEtMA_b46f96d1-5d2f-473c-80eb-12e626b6dc51"
      unitRef="usdPerShare">0.21</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjMtMS0xLTEtMA_98d083fb-0298-4932-ab2b-4134fd1daac0"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjMtMy0xLTEtMA_007189ea-6c3d-4637-8fef-c6fcdde9c883"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjMtNS0xLTEtMA_ab7c0717-a335-40fc-8d60-7dac4c3bca9d"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjMtNy0xLTEtMA_e1b15612-93f7-45b7-bedf-2901cbcc04fe"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjUtMS0xLTEtMA_836a4f7d-d33c-41cd-b050-21433715d822"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjUtMy0xLTEtMA_59710a8e-6743-4459-a6d6-597a179486b5"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjUtNS0xLTEtMA_c202a72e-e404-4587-95c9-370455bc9b2f"
      unitRef="usdPerShare">-0.31</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjUtNy0xLTEtMA_a1cb6b89-d699-4732-8780-08cbd7b64384"
      unitRef="usdPerShare">-0.38</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjYtMS0xLTEtMA_8592f224-8283-4775-9a9a-39e861ed2d4d"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjYtMy0xLTEtMA_d0eb876a-56df-44e0-823d-7ec9f1d0a432"
      unitRef="usdPerShare">0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjYtNS0xLTEtMA_80b7f76d-4206-4d3f-8fc2-6f25af60da83"
      unitRef="usdPerShare">0.15</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjYtNy0xLTEtMA_f1a1b805-fec1-4901-82c6-bf4a2435cd00"
      unitRef="usdPerShare">0.21</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjctMS0xLTEtMA_79b9d96f-c0bb-4169-800e-992e0f0b4062"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjctMy0xLTEtMA_0938a04d-9f8f-4680-8452-bd70a64fdc61"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjctNS0xLTEtMA_d8c7e2c1-ff03-4708-9b11-dfdda828b859"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjctNy0xLTEtMA_539562b7-7921-442f-96ed-0ed6bb8b0935"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjktMS0xLTEtMA_8dfcac58-c245-479b-90ea-d8198b82823c"
      unitRef="shares">15134583</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjktMy0xLTEtMA_3b6e15d2-7246-4765-9742-c48e22fe21b2"
      unitRef="shares">15368027</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjktNS0xLTEtMA_0e159637-02d4-496a-b203-4931667f0908"
      unitRef="shares">15206179</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMjktNy0xLTEtMA_41976643-df91-4c1d-abea-2c78c614ea27"
      unitRef="shares">15454159</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMzAtMS0xLTEtMA_680661da-9c2e-4bc7-bb8a-ef68aff517cb"
      unitRef="shares">15134583</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMzAtMy0xLTEtMA_bef24f96-7f94-4b28-aa5e-e7f87d8c4a77"
      unitRef="shares">15368027</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMzAtNS0xLTEtMA_b68d2d90-e060-4487-afbb-a6507fa3130a"
      unitRef="shares">15206179</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18xOS9mcmFnOmI3MmU3NTE1MjM2NTQ2ZjE4MWViMTVjNmVjYzdjMWQxL3RhYmxlOjNmMzA3MjU5NDIwZTQ0YjRiMmNjMjdjNjE3MzkyZGE0L3RhYmxlcmFuZ2U6M2YzMDcyNTk0MjBlNDRiNGIyY2MyN2M2MTczOTJkYTRfMzAtNy0xLTEtMA_7dad67b7-bb9e-40b1-9a84-98a6333c5d90"
      unitRef="shares">15454159</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMy0zLTEtMS0w_1d774375-c870-4c25-af54-d9bb5f23477e"
      unitRef="usd">-2574165</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNC0xLTEtMS0w_f9c0b223-3110-468b-9fa2-48b87d31ed7d"
      unitRef="usd">2334811</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNC0zLTEtMS0w_b3684d21-b220-42c1-82a1-bf505d73369c"
      unitRef="usd">3268196</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNS0zLTEtMS0w_34102501-45d9-4a28-a8a7-8c1e145015c6"
      unitRef="usd">-5842361</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNy0xLTEtMS0w_613c388c-e8c0-428e-a699-620fa69919db"
      unitRef="usd">3524684</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNy0zLTEtMS0w_9000a2fd-c601-455a-85d1-110c27427975"
      unitRef="usd">3278958</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfOC0xLTEtMS0w_a2eaff2d-e420-4c88-b5f2-cb6ca258aa75"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfOC0zLTEtMS0w_2e688db1-b0f2-46fc-a84a-d3d1361a5419"
      unitRef="usd">43605</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfOS0xLTEtMS0w_895ee644-0818-4133-8a9d-d14aebd45f07"
      unitRef="usd">805338</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfOS0zLTEtMS0w_8a84ac57-19c4-4834-b767-d7fcbb3c97dc"
      unitRef="usd">1107817</us-gaap:ShareBasedCompensation>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTAtMS0xLTEtMA_1705c9e6-8a5b-4bc1-bd04-501d044d26f2"
      unitRef="usd">806390</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTAtMy0xLTEtMA_6ce8c804-fe0f-4c01-8af7-15570631bd57"
      unitRef="usd">681577</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTEtMS0xLTEtMA_3af19422-44ae-45ef-b3d4-1949e4096923"
      unitRef="usd">36197</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTEtMy0xLTEtMA_327db869-f067-40e4-b668-9ff7a915c021"
      unitRef="usd">36292</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTItMS0xLTEtMA_213aad4a-0706-4044-9467-481065c56eb6"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTItMy0xLTEtMA_6d817466-e60f-4f16-8bf0-5bd7a52b7038"
      unitRef="usd">34303</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTQtMS0xLTEtMA_c0d19c97-3cb0-4757-b316-92e67e5a4762"
      unitRef="usd">1817490</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTQtMy0xLTEtMA_2de24f82-2242-42b1-a6c6-6edac16a6475"
      unitRef="usd">-1026633</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTUtMS0xLTEtMA_0d1adcad-1e05-4b65-9be0-85a5bfc2ef45"
      unitRef="usd">-1696668</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTUtMy0xLTEtMA_d7d88852-abca-4151-86f2-0a60f6c8231b"
      unitRef="usd">-1332140</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTYtMS0xLTEtMA_908d3ed6-f93b-4ad6-aa7e-3f362e62d703"
      unitRef="usd">-1962024</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTYtMy0xLTEtMA_97f40e3f-ab14-4818-b790-9c837a6b0c5b"
      unitRef="usd">-195529</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTctMS0xLTEtMA_269d6b7c-c9e1-4e48-b0ca-00ed476e190d"
      unitRef="usd">3417856</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTctMy0xLTEtMA_3bdeb0a1-499d-4c3b-b740-087dae7afca4"
      unitRef="usd">-539525</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTgtMS0xLTEtMA_e1b3b9cb-d4af-408e-b8ad-b16af58e9c1c"
      unitRef="usd">-1585584</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTgtMy0xLTEtMA_6888685c-aaad-4b0b-a8c7-d2e51d20ee75"
      unitRef="usd">-207648</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTktMS0xLTEtMA_678782f8-ddc0-44ca-b16b-2fda57cabefb"
      unitRef="usd">2395054</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMTktMy0xLTEtMA_4a003989-4e4d-4613-80c2-3563686908df"
      unitRef="usd">-284440</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjAtMS0xLTEtMA_505b36f7-35a0-42aa-99df-7db9ec811eb2"
      unitRef="usd">2166086</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjAtMy0xLTEtMA_a508e50a-4761-4bc4-aba7-3ad4e28d5745"
      unitRef="usd">2483796</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjEtMS0xLTEtMA_1e750025-bf9a-4ecf-a758-6618e7a411c0"
      unitRef="usd">4561140</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjEtMy0xLTEtMA_da8a51a3-dde9-4822-8b96-303f73679e3b"
      unitRef="usd">2199356</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjMtMS0xLTEtMA_d1a811c2-4480-41d3-84e2-50074228abef"
      unitRef="usd">95189</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjMtMy0xLTEtMA_89a9cec0-c99f-4cc3-b39b-a4e4bb2fc859"
      unitRef="usd">166407</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjQtMS0xLTEtMA_c28ed2a9-b181-4953-8d67-bd508dc04df3"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjQtMy0xLTEtMA_7ce78207-9200-45b1-b548-20ecd2e5967d"
      unitRef="usd">9627191</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjUtMS0xLTEtMA_5f22bb2a-4f69-4aa7-8910-7d2dbbd28a85"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjUtMy0xLTEtMA_93480273-b087-4c84-bf49-7994f1d44214"
      unitRef="usd">15686334</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromLifeInsurancePolicies
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjYtMS0xLTEtMTExOQ_bf1684e9-894e-4956-a43b-2b83522c00ae"
      unitRef="usd">460888</us-gaap:ProceedsFromLifeInsurancePolicies>
    <us-gaap:ProceedsFromLifeInsurancePolicies
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjYtMy0xLTEtMTExOQ_6c5b0f67-3e0b-40ce-8126-8d9a58ab09d7"
      unitRef="usd">0</us-gaap:ProceedsFromLifeInsurancePolicies>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjYtMS0xLTEtMA_ec88a97e-c215-4ecc-a7be-481462e963b2"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjYtMy0xLTEtMA_ec180742-d1cc-43a9-ba80-d8c951783bd9"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjctMS0xLTEtMA_ab18ec10-d2d0-445b-b8a0-65e2b366eb70"
      unitRef="usd">1807467</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjctMy0xLTEtMA_cbd83afd-a941-4def-9832-d91f69f6eeb1"
      unitRef="usd">498003</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjgtMS0xLTEtMA_d1d92e7e-381e-4902-8d25-d56a8ed0ca27"
      unitRef="usd">-1441768</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMjgtMy0xLTEtMA_1a759470-0609-4b03-8107-9949c4821f78"
      unitRef="usd">394733</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzEtMS0xLTEtMA_e2a303ce-d078-4f46-aaf8-0b0f36458531"
      unitRef="usd">44000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzEtMy0xLTEtMA_6d0075c0-1a40-48f0-b6cf-7b7c5c5dc65d"
      unitRef="usd">56000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzItMS0xLTEtMA_7670dc12-6126-4262-bfb1-feba334fa9f9"
      unitRef="usd">45500000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzItMy0xLTEtMA_a40ca680-119f-41db-8995-94ec2354c745"
      unitRef="usd">56000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzQtMS0xLTEtMA_0af70ba8-9a5a-429f-a0f3-88553a4dbadb"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzQtMy0xLTEtMA_d9fb5d61-c91f-4ba5-9752-fba6ca12d9c2"
      unitRef="usd">52500</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzUtMS0xLTEtMA_b14b2dd3-2b07-430c-95fb-462f4e41f4c9"
      unitRef="usd">834014</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzUtMy0xLTEtMA_a947abd3-1d3d-4ab5-b158-6c100effddd8"
      unitRef="usd">908347</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzgtMS0xLTEtMA_dda69f64-6e09-441e-97e6-6d0f8599c7a0"
      unitRef="usd">800000</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzgtMy0xLTEtMA_945cd36a-e3c2-4fae-b631-5fd6989d632b"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzktMS0xLTEtMA_2c0aeef9-be8b-404b-b995-2f9b23ce9d40"
      unitRef="usd">1551463</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfMzktMy0xLTEtMA_b486326f-2aa2-4534-80dd-185231950ae1"
      unitRef="usd">2593778</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDAtMS0xLTEtMA_643e74ba-a671-4d28-92f5-007aa3ce7661"
      unitRef="usd">-4685477</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDAtMy0xLTEtMA_17c21507-cd35-4617-a6aa-5ee5e2e89687"
      unitRef="usd">-3554625</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDEtMS0xLTEtMA_923ad82a-3dfb-4c9a-93fe-dc15a9d7a4af"
      unitRef="usd">-1566105</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDEtMy0xLTEtMA_2a2bdc4c-a863-45bb-a828-93668c8a6e70"
      unitRef="usd">-960536</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDItMS0xLTEtMA_c288ab12-5793-46d1-b35f-256ac30934bf"
      unitRef="usd">28212635</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4b79c2df727e4b81b6070f5e05dfd76a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDItMy0xLTEtMA_c928998c-4107-4c5a-86e0-355dd1b1767a"
      unitRef="usd">27938960</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDMtMS0xLTEtMA_c93d919c-cc77-43bb-99cd-854a86ace542"
      unitRef="usd">26646530</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibbfd45792901404db84b4c62a7d2ab4b_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yMi9mcmFnOmI5ZGU5ODU4OTkwMDRiODg4Mjk2NWNlNzA4YWIwZDg5L3RhYmxlOjZhMWEyZjhiMmEwYzQ5NzY4NTJiZTM5OTg5ZGNkZDg5L3RhYmxlcmFuZ2U6NmExYTJmOGIyYTBjNDk3Njg1MmJlMzk5ODlkY2RkODlfNDMtMy0xLTEtMA_8362a4da-0df0-447b-993b-970b79fb89b0"
      unitRef="usd">26978424</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i98c007d4ad524e538f8276538642ea78_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMi0xLTEtMS0w_fc66179c-a415-4418-b870-5dc9c4238e75"
      unitRef="shares">15481497</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98c007d4ad524e538f8276538642ea78_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMi0zLTEtMS0w_582154fd-edc5-43a5-9068-816f52b031db"
      unitRef="usd">51098613</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b9bb42baaef4c5094e0ab9146fbecb9_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMi01LTEtMS0w_99e11dd6-866e-409a-85f0-034abb14d3d3"
      unitRef="usd">4746154</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d3c6c171eb84faea1a073a15ee27d73_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMi03LTEtMS0w_5d14919e-b02b-4b94-8d53-266f97d81ab3"
      unitRef="usd">-274266</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b79c2df727e4b81b6070f5e05dfd76a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMi05LTEtMS0w_6f4bc998-937e-4d2d-a844-d3f3700d3838"
      unitRef="usd">55570501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6b2670bfac16431b81e1d0ae43216d38_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMy0xLTEtMS0w_d2f0e1f1-042a-4282-af29-522d03ab172e"
      unitRef="shares">187486</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6b2670bfac16431b81e1d0ae43216d38_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMy0zLTEtMS0w_92aedca2-19f4-4aad-a874-a6e504e7c9b2"
      unitRef="usd">364434</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ief40d394930e4ad8aa55d1f1875a0473_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfMy05LTEtMS0w_63514e18-15bb-4f01-8a81-fed482762b35"
      unitRef="usd">364434</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6b2670bfac16431b81e1d0ae43216d38_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNC0xLTEtMS0w_c7989a56-8c8f-49f4-99ce-820bd47bfc25"
      unitRef="shares">121466</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6b2670bfac16431b81e1d0ae43216d38_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNC0zLTEtMS0w_e5998124-ce28-41fa-a8bf-04e7f6dd4e58"
      unitRef="usd">703790</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ief40d394930e4ad8aa55d1f1875a0473_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNC05LTEtMS0w_65b79c10-6606-481a-8cb7-623207a9f128"
      unitRef="usd">703790</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="id532a92619594716b8d454accfec3e8c_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNS01LTEtMS0w_c875d3f2-a9be-4c1d-8490-905245bfee35"
      unitRef="usd">-73878</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie2aa2b7754394bca86b16a6b683ae214_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNS03LTEtMS0w_02fb60c6-425c-4f68-a4ae-6d8da497e596"
      unitRef="usd">33460</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ief40d394930e4ad8aa55d1f1875a0473_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNS05LTEtMS0w_4c1de8b2-11f5-498e-8040-e85761682c61"
      unitRef="usd">-40418</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1dfbc6c701c545729ec01b3e104fd1fa_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNi0xLTEtMS0w_4e50f862-b28c-4cb8-be86-d1830c0cfbff"
      unitRef="shares">15547517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1dfbc6c701c545729ec01b3e104fd1fa_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNi0zLTEtMS0w_01d47994-0d51-4f45-950d-156019d6d654"
      unitRef="usd">50759257</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id931366f1dd048809e78a414f3cc4061_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNi01LTEtMS0w_26cb8182-bb98-4c57-86ac-4b56044cfb70"
      unitRef="usd">4672276</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe4dbdb42df24afb92bd43a4728b5831_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNi03LTEtMS0w_68fd22c3-1265-47dd-be52-624bb33e78cb"
      unitRef="usd">-240806</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7330257a2be7418096532eb1e582d5d5_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjJiMzgzZmM5NDRkNjQ3NjQ5ZmZhM2UyMmE0YTkyZTk5L3RhYmxlcmFuZ2U6MmIzODNmYzk0NGQ2NDc2NDlmZmEzZTIyYTRhOTJlOTlfNi05LTEtMS0w_3d769cb0-b52f-4705-b893-161a1894be4a"
      unitRef="usd">55190727</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1dfbc6c701c545729ec01b3e104fd1fa_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMC0xLTEtMS0w_775d67c9-bf35-45f9-becb-289aa6baae6e"
      unitRef="shares">15547517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1dfbc6c701c545729ec01b3e104fd1fa_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMC0zLTEtMS0w_5b8c40a7-2fbf-4b79-8ddb-39e0ac9f0910"
      unitRef="usd">50759257</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id931366f1dd048809e78a414f3cc4061_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMC01LTEtMS0w_7ce042d7-a40b-4db6-bbab-631187477617"
      unitRef="usd">4672276</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe4dbdb42df24afb92bd43a4728b5831_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMC03LTEtMS0w_d90a3f91-1482-4c65-b464-6caf24303d3a"
      unitRef="usd">-240806</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7330257a2be7418096532eb1e582d5d5_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMC05LTEtMS0w_ad0838d1-5274-499c-9906-c0953e52ba6c"
      unitRef="usd">55190727</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMS0xLTEtMS0w_156098d8-eebd-4c22-8d27-3b898bb27479"
      unitRef="shares">8000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMS0zLTEtMS0w_6162a88b-fcec-4cef-b97c-7118ed42cb81"
      unitRef="usd">396548</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i466e638f1cf944169e790ce328cd7e79_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMS05LTEtMS0w_a1c23935-79e3-47b5-a17e-f0b3dda535ac"
      unitRef="usd">396548</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMi0zLTEtMS0w_654293bb-6180-42af-a49f-fa281a80551c"
      unitRef="usd">685805</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="id8f9b7046ef944bf8bc512a3664d2b5c_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMi03LTEtMS0w_e21f18ac-0c8b-4849-a30d-93914032c4e6"
      unitRef="usd">114195</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i466e638f1cf944169e790ce328cd7e79_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMi05LTEtMS0w_9841635e-ef60-4ac5-a3cd-550293c1e880"
      unitRef="usd">800000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMy0xLTEtMS0w_15e2d7f0-79d5-41ed-aff8-23b322b0b994"
      unitRef="shares">84447</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia5bcd73df0924e0fa53a2a03cbce33a1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMy0zLTEtMS0w_791ed917-afd3-4bc8-954d-a544ee3f45d4"
      unitRef="usd">531746</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i466e638f1cf944169e790ce328cd7e79_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfMy05LTEtMS0w_26383195-4c29-49be-8f11-69d0a68afd66"
      unitRef="usd">531746</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i1766bc56f0844f99bf09b7d344eb14ed_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNC01LTEtMS0w_50525926-d062-4518-99a9-a1b57d205eea"
      unitRef="usd">-549507</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id8f9b7046ef944bf8bc512a3664d2b5c_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNC03LTEtMS0w_a049e9fc-0f90-4bd2-8c41-4d4acc04aef5"
      unitRef="usd">-17305</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i466e638f1cf944169e790ce328cd7e79_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNC05LTEtMS0w_1dc6d3b6-b37d-4aee-8c72-b28a83749290"
      unitRef="usd">-566812</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia8e552015b714eeb8c0eba2c8da97ef4_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNS0xLTEtMS0w_7bbbad36-4cad-464a-8b59-9106d7e9032a"
      unitRef="shares">15471070</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8e552015b714eeb8c0eba2c8da97ef4_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNS0zLTEtMS0w_9280b23a-4bee-41d9-9d2e-a8892d6e7d99"
      unitRef="usd">49938254</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i183ac2b291524d89a1a470882b24289e_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNS01LTEtMS0w_18c3791a-511b-48a6-8509-5779fed7e337"
      unitRef="usd">4122769</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i437f92c999684ffb86a16fe5adde240b_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNS03LTEtMS0w_480dc414-be88-4a0b-bab9-8e29ca26b850"
      unitRef="usd">-372306</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i728e3047fc24462aab7d9ddd4d5160fd_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOmJiY2ZkMjc5NTZjNTQyOGU5NTI3N2NmYmVkZWY3ODVmL3RhYmxlcmFuZ2U6YmJjZmQyNzk1NmM1NDI4ZTk1Mjc3Y2ZiZWRlZjc4NWZfNS05LTEtMS0w_c18c09d5-3c52-424c-8c75-91c547b38554"
      unitRef="usd">53688717</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia8e552015b714eeb8c0eba2c8da97ef4_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMC0xLTEtMS0xMTQ_46ca856b-639f-4fb3-8f84-1a6c1b7391c6"
      unitRef="shares">15471070</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8e552015b714eeb8c0eba2c8da97ef4_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMC0zLTEtMS0xMTQ_135bfcbc-ee90-4307-90ce-08b2a3be4ca6"
      unitRef="usd">49938254</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i183ac2b291524d89a1a470882b24289e_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMC01LTEtMS0xMTQ_b6df9602-b4f5-4a85-bb22-b5fcc3c57c34"
      unitRef="usd">4122769</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i437f92c999684ffb86a16fe5adde240b_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMC03LTEtMS0xMTQ_00cd3ce7-63f7-4a23-a872-d3d525dc7e7f"
      unitRef="usd">-372306</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i728e3047fc24462aab7d9ddd4d5160fd_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMC05LTEtMS0xMTQ_492ca9fb-0c12-473a-8805-69337c0f8f85"
      unitRef="usd">53688717</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMS0xLTEtMS0xMTQ_b324e321-f799-4fda-8841-82d9ec79ec14"
      unitRef="shares">6450</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMS0zLTEtMS0xMTQ_ae260e33-41d6-45d6-8d99-7d2b7b9b8195"
      unitRef="usd">346835</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMS05LTEtMS0xMTQ_5cda4ba2-eab8-44c6-988b-bf31f8c41ac3"
      unitRef="usd">346835</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMi0zLTEtMS0xMTQ_2c29c5de-ae8b-4242-89f8-02de85ab205d"
      unitRef="usd">-640407</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i99444b1a69614eebaa428eeb94e3bb1d_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMi03LTEtMS0xMTQ_99e7334f-7721-4a90-a951-ef3d963bd2a7"
      unitRef="usd">-359593</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMi05LTEtMS0xMTQ_4c158356-58e9-423c-8077-a7a0f9c5b369"
      unitRef="usd">-1000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMy0xLTEtMS0xMTQ_51c1f55a-3fdf-486d-b988-d8e9a8f3b589"
      unitRef="shares">246242</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i66608d2ae6a24959bb4882733589f09f_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMy0zLTEtMS0xMTQ_e99730f1-f617-482a-b05e-c815f928f7c2"
      unitRef="usd">1361689</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfMy05LTEtMS0xMTQ_0ec98fbd-bfd7-490b-87fe-61d2e4e303d3"
      unitRef="usd">1361689</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ic3e8253dce984097b996ea192173d741_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNC01LTEtMS0xMTQ_534c7638-1332-4b27-b21f-57919b2e6fc4"
      unitRef="usd">-1953668</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i99444b1a69614eebaa428eeb94e3bb1d_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNC03LTEtMS0xMTQ_5fe36477-5408-46d3-84b5-7ff11ec2483f"
      unitRef="usd">-13267</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNC05LTEtMS0xMTQ_fc0da82c-9539-4c54-b1d7-755701b33d70"
      unitRef="usd">-1966935</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4af8aa9fc5194cd4a1b4cda6e6eed41b_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNS0xLTEtMS0xMjY4_5344213a-13a2-4c28-8bf7-abb9bbae41e2"
      unitRef="shares">15231278</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4af8aa9fc5194cd4a1b4cda6e6eed41b_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNS0zLTEtMS0xMjY1_21a574b7-57ba-43ea-b6ff-d36ca7ce1905"
      unitRef="usd">49563807</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f5deb38ccd648d2b3ae820c2917f209_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNS01LTEtMS0xMjcy_610c65fb-64a2-428b-a2b8-12483c8db612"
      unitRef="usd">2169101</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3789f076fc20455ba5086e4654a7b173_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNS03LTEtMS0xMjc0_c60414d3-8755-4c24-a725-e1acd8742d8f"
      unitRef="usd">-25980</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibbfd45792901404db84b4c62a7d2ab4b_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjYwYzdmMGFjYWRkNDQ2NGNhMmU5MTBjOGRmNGNkMjU3L3RhYmxlcmFuZ2U6NjBjN2YwYWNhZGQ0NDY0Y2EyZTkxMGM4ZGY0Y2QyNTdfNS05LTEtMS0xMjYz_d7fb8f99-8329-4822-91b6-c65a89e634e8"
      unitRef="usd">51706928</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if3e79a34ef554fed993caa85ec4ed80b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMi0xLTEtMS0w_a5182f35-5ef3-4455-ac6b-e942e408ef89"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3e79a34ef554fed993caa85ec4ed80b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMi0zLTEtMS0w_de15750b-8dfd-4cd3-8bb1-78965264933a"
      unitRef="usd">49914478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ce06f07f5994164ae6cf178e40174fe_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMi01LTEtMS0w_1ca1c6f9-c12a-47b8-b52f-9243eace4c1d"
      unitRef="usd">1208395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if07b4fb1f80e4674a4387c2c2fb38f86_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMi03LTEtMS0w_635f5c77-b16e-4245-9865-a26bc753ae64"
      unitRef="usd">-37620</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMi05LTEtMS0w_c97ea4ec-3810-4081-9ac0-0313fc33f2c3"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8216f15d99a94a2a86c19d3b1bad2bf5_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMy0xLTEtMS0w_19e9b389-7c55-4888-bd75-fa1d7ed0bfe8"
      unitRef="shares">219850</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8216f15d99a94a2a86c19d3b1bad2bf5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMy0zLTEtMS0w_c6f13dd1-ecfe-4ba2-9291-2139b5fa661d"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i89152ce5d22b489f9ea811b4bb61d18d_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfMy05LTEtMS0w_aa9b806b-10b3-4e95-a98a-26fe96965ced"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8216f15d99a94a2a86c19d3b1bad2bf5_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNC0xLTEtMS0w_b0cb0d93-e12b-4d99-9b42-2cc9da8ff25f"
      unitRef="shares">164866</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8216f15d99a94a2a86c19d3b1bad2bf5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNC0zLTEtMS0w_47ea7093-a363-4053-9686-fd21c5e414d0"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i89152ce5d22b489f9ea811b4bb61d18d_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNC05LTEtMS0w_d57a2523-d34c-4e65-9a52-5c1615c3cc32"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i62a06f5b04844061940fdd3b9480439c_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNS01LTEtMS0w_db246fe9-b9a5-41a8-b313-ec3ed2320cef"
      unitRef="usd">-1055620</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i26772e0071d34883b195a26267505a52_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNS03LTEtMS0w_a6b1b920-b945-4abc-918f-8c3090274738"
      unitRef="usd">-9525</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i89152ce5d22b489f9ea811b4bb61d18d_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNS05LTEtMS0w_759e5c4f-91df-4fbe-98b9-1ab862f81f6c"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifbc1fd769f9740e989a4d2fd47f1ced4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNi0xLTEtMS0w_2c2f4054-f9b1-4492-b45c-c1c815058206"
      unitRef="shares">15318539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbc1fd769f9740e989a4d2fd47f1ced4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNi0zLTEtMS0w_f637fe5b-0052-4a1f-80d6-8c0adda30924"
      unitRef="usd">49737428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icae833f7b3f44f0f9e58b7193716452c_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNi01LTEtMS0w_49285752-3f23-47f0-a304-483178d03354"
      unitRef="usd">152775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ca469517291478aa2e4c1fa421bd3d3_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNi03LTEtMS0w_d5f4bd11-714a-43ca-8120-b12a75e19b0c"
      unitRef="usd">-47145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife9646ecd78c471da7ec0b9ae8d48366_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjBiZTFhODkzNDQ2NTRkOTg5MWNmNGRmM2M3NTU5NWU0L3RhYmxlcmFuZ2U6MGJlMWE4OTM0NDY1NGQ5ODkxY2Y0ZGYzYzc1NTk1ZTRfNi05LTEtMS0w_2f75a559-f0f3-4413-995f-815dedb08ed8"
      unitRef="usd">49843058</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifbc1fd769f9740e989a4d2fd47f1ced4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMC0xLTEtMS0w_76866803-3690-4fb6-8a45-768ec2e21efc"
      unitRef="shares">15318539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbc1fd769f9740e989a4d2fd47f1ced4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMC0zLTEtMS0w_2d0331d1-7742-4ea8-9881-198d6606932d"
      unitRef="usd">49737428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icae833f7b3f44f0f9e58b7193716452c_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMC01LTEtMS0w_7efa1561-9f39-4f10-adf4-abcbc314f485"
      unitRef="usd">152775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ca469517291478aa2e4c1fa421bd3d3_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMC03LTEtMS0w_95306963-d090-4072-ad06-9b67697134db"
      unitRef="usd">-47145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife9646ecd78c471da7ec0b9ae8d48366_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMC05LTEtMS0w_59f4426a-e91e-4e1f-84f0-95b327d4f442"
      unitRef="usd">49843058</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6edc159368b349ed8d34e1d4bd240e22_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMS0xLTEtMS0w_2aa7fb39-dbb3-4847-a24d-30d1eeed9307"
      unitRef="shares">4200</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6edc159368b349ed8d34e1d4bd240e22_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMS0zLTEtMS0w_2754b3f7-2822-4ca0-82a5-3e7277535282"
      unitRef="usd">278349</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic40b1cdafe584ea8a9f3cf4307d96744_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMS05LTEtMS0w_d2455288-20d4-4807-b1a1-8ee333c2f712"
      unitRef="usd">278349</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6edc159368b349ed8d34e1d4bd240e22_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMi0xLTEtMS0w_2c5c05d7-268f-4f4e-b12f-b39bb5b7fdb8"
      unitRef="shares">141463</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6edc159368b349ed8d34e1d4bd240e22_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMi0zLTEtMS0w_4b77dcb4-6e50-4cfa-a1dc-904db546f58e"
      unitRef="usd">769648</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic40b1cdafe584ea8a9f3cf4307d96744_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMi05LTEtMS0w_b4634a3c-c6a7-4c74-ad6d-5a011dfd5362"
      unitRef="usd">769648</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="if52f80cf1d0e45cb97aae49b8c8230f2_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMy01LTEtMS0w_54cf1945-c06f-42c9-9eb6-cc5b6faf86a4"
      unitRef="usd">-918275</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic21315fbf39347a28cfc557393bc9c1f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMy03LTEtMS0w_4ce8fa1f-3785-493f-b147-0a67c7be2026"
      unitRef="usd">-22314</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic40b1cdafe584ea8a9f3cf4307d96744_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfMy05LTEtMS0w_eb732db7-9517-4f06-97fe-bd635e0c2b89"
      unitRef="usd">-940589</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia0c42cdc6a024ef985b79c61a90bbe9e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfNC0xLTEtMS0w_fdd0f1a3-dee1-4f62-aaa9-1392b62a58e7"
      unitRef="shares">15181276</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia0c42cdc6a024ef985b79c61a90bbe9e_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfNC0zLTEtMS0w_2e99f8e7-1f24-4bdb-8292-7acb6d373c36"
      unitRef="usd">49246129</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32fea5db2d3c47e9a21a5f1f1ab0b6e4_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfNC01LTEtMS0w_9df56f40-e6b8-4388-9a9d-887e536cd74c"
      unitRef="usd">-765500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d382f4a1c3c4e77bba4a6e17311df80_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfNC03LTEtMS0w_7b6409c1-24b8-4275-b949-5228e5dc7e02"
      unitRef="usd">-69459</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13e05db5bc634c8395dc7ba20fd01c1f_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjFjMGVjYTlhZjRlMTQyNTViOGUxYzBlN2ExMTA0ZTM1L3RhYmxlcmFuZ2U6MWMwZWNhOWFmNGUxNDI1NWI4ZTFjMGU3YTExMDRlMzVfNC05LTEtMS0w_99de2034-1ecf-438a-84b5-de659935ed3a"
      unitRef="usd">48411170</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia0c42cdc6a024ef985b79c61a90bbe9e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMC0xLTEtMS03Mzk_2892bdcc-c572-4e5e-af43-1f79a0c2baf8"
      unitRef="shares">15181276</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia0c42cdc6a024ef985b79c61a90bbe9e_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMC0zLTEtMS03Mzk_33f7a98c-44ae-4757-821e-d3507b934581"
      unitRef="usd">49246129</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32fea5db2d3c47e9a21a5f1f1ab0b6e4_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMC01LTEtMS03Mzk_56a68f51-01c9-4522-a272-e6945538e6aa"
      unitRef="usd">-765500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d382f4a1c3c4e77bba4a6e17311df80_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMC03LTEtMS03Mzk_6d1ca28c-98d0-48a7-b193-4de99d207e49"
      unitRef="usd">-69459</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13e05db5bc634c8395dc7ba20fd01c1f_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMC05LTEtMS03Mzk_f4b7ee11-30cb-414d-af06-a04ac91d3591"
      unitRef="usd">48411170</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5a6b0baa09b04dc8ad7327ed08a971d4_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMS0xLTEtMS03Mzk_6d1764fc-a0a0-44af-89fa-0f311f1d0763"
      unitRef="shares">4450</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5a6b0baa09b04dc8ad7327ed08a971d4_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMS0zLTEtMS03Mzk_02d9425d-0d8f-44a1-85fd-d5e6a1f6d237"
      unitRef="usd">262415</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMS05LTEtMS03Mzk_145b0588-f5a0-4ed9-839e-a567225db742"
      unitRef="usd">262415</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i5a6b0baa09b04dc8ad7327ed08a971d4_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMi0xLTEtMS03Mzk_9c85f5c5-c742-4eb1-bd0c-164a039cfce1"
      unitRef="shares">101354</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i5a6b0baa09b04dc8ad7327ed08a971d4_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMi0zLTEtMS03Mzk_8679c202-8f15-4b2c-a5be-b5c84311e82a"
      unitRef="usd">332504</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMi05LTEtMS03Mzk_d6416b7e-b18b-488f-bd48-73587bace1b4"
      unitRef="usd">332504</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="iaa532992c0504e0ba3d7d267f54270d4_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMy01LTEtMS03Mzk_d43a429a-c3eb-4844-8c07-bff555be369e"
      unitRef="usd">-481737</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibe1c68d19eec4a38a757dd2e42c81bf6_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMy03LTEtMS03Mzk_1adccc1d-d111-4e5a-97fd-25edaf7b6f71"
      unitRef="usd">-15967</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfMy05LTEtMS03Mzk_6146402c-5848-4427-8dfa-9df7875cf413"
      unitRef="usd">-497704</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i37fd46b1fc0d4e5c9cf794637e21ef86_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfNC0xLTEtMS0xMjc2_5b622dc5-ab72-4538-9f92-76f9df995d8c"
      unitRef="shares">15084372</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i37fd46b1fc0d4e5c9cf794637e21ef86_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfNC0zLTEtMS0xMjgw_227eb86c-d0f0-4898-81bd-e99f76ac77d7"
      unitRef="usd">49176040</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1d9d3ac014b4702a58b9bc1204a2cb5_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfNC01LTEtMS0xMjgy_490e3cbc-6ce0-4d80-9220-7e47f62bd910"
      unitRef="usd">-1247237</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f9e4efabd72491282314ba3c4151d14_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfNC03LTEtMS0xMjg0_ce2fab72-eb7b-418b-b179-3379af0e3019"
      unitRef="usd">-85426</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18yNS9mcmFnOjllY2NjYTM0ZDdiODQxNmJiNWU5MDZlYjYxMzgzYWEzL3RhYmxlOjUzMzQxZTU3NWI5NTQ0Njc5YWU4ZTIyNmU2MjgyOGVkL3RhYmxlcmFuZ2U6NTMzNDFlNTc1Yjk1NDQ2NzlhZThlMjI2ZTYyODI4ZWRfNC05LTEtMS0xMjc4_f8c8a085-8e6a-4ff7-9a34-2566c20e98ca"
      unitRef="usd">47843377</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zMS9mcmFnOmNiNjgwNjYzOTdjMjQ4MjJiZDYwOGM0OTAzYzA4MWU1L3RleHRyZWdpb246Y2I2ODA2NjM5N2MyNDgyMmJkNjA4YzQ5MDNjMDgxZTVfMTExMTk_63245673-46b4-4de3-8853-c5bc0c43b538">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2019 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the &#x201c;2019 Annual Report on Form 10-K&#x201d;). The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Totect&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 10, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification of prior period amounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has made certain reclassifications to prior period amounts to conform to the current-year presentation of the reporting of research and development expense and general and administrative expense on the condensed consolidated statements of operations. Certain costs and expenses related to research and development were previously reported as general and administrative expenses on the condensed consolidated statements of operations. These reclassifications have no effect on the reported operating loss or equity for the 2019 periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect the employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland's sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, much of their contact has shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.  Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  During this &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pandemic, less patients sought care, some patients postponed elective surgeries and Cumberland's access to medical facilities was substantially limited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain the employees&#x2019; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zMS9mcmFnOmNiNjgwNjYzOTdjMjQ4MjJiZDYwOGM0OTAzYzA4MWU1L3RleHRyZWdpb246Y2I2ODA2NjM5N2MyNDgyMmJkNjA4YzQ5MDNjMDgxZTVfMTExMjI_d9f8f627-4802-45e2-8c78-73ae2c8c5156">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zMS9mcmFnOmNiNjgwNjYzOTdjMjQ4MjJiZDYwOGM0OTAzYzA4MWU1L3RleHRyZWdpb246Y2I2ODA2NjM5N2MyNDgyMmJkNjA4YzQ5MDNjMDgxZTVfMTExMjM_2bf63bcc-0d1f-43a9-8a0d-6c71bd2f2ee8">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zMS9mcmFnOmNiNjgwNjYzOTdjMjQ4MjJiZDYwOGM0OTAzYzA4MWU1L3RleHRyZWdpb246Y2I2ODA2NjM5N2MyNDgyMmJkNjA4YzQ5MDNjMDgxZTVfMTExMjU_be9575a1-96d9-40a5-9737-43c3552c6351">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zMS9mcmFnOmNiNjgwNjYzOTdjMjQ4MjJiZDYwOGM0OTAzYzA4MWU1L3RleHRyZWdpb246Y2I2ODA2NjM5N2MyNDgyMmJkNjA4YzQ5MDNjMDgxZTVfMTAzMTU_8ac70437-3212-43d2-bf80-651e51e24bc3"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RleHRyZWdpb246ZjQ1MzBiZjFkNWE0NGYyNmE3MzIxZDE1NGUzN2JiZThfMzQzNA_ce47c01a-0880-4e96-a936-fe72c6338f81">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests in marketable securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of September 30, 2020 and December 31, 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of September 30, 2020 and December 31, 2019, all trading securities were investments with original maturities of less than ninety days and as a result, were classified as cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:81pt;text-indent:-45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -   Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of marketable  securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RleHRyZWdpb246ZjQ1MzBiZjFkNWE0NGYyNmE3MzIxZDE1NGUzN2JiZThfMzQzMg_2a571bbd-d916-4ef9-849f-0596e45ab8b3">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of marketable  securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:TradingSecurities
      contextRef="id07d176dae7e493b8fd0de707a8f73b1_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC0xLTEtMS0w_150bbc96-ead1-42e2-a418-71527160e604"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="iab8d543293c243d483f364b765f13a5a_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC0zLTEtMS0w_dc3f60c0-6888-45cf-bf1c-e781f086c267"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ib0a4e269bc9b4de18ca89b7b6757b95e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC01LTEtMS0w_223a8653-4d6e-4da2-a196-ce0d1164b2a1"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="if6b1300825a343c492f6cec5fac50c3f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC03LTEtMS0w_78df5f80-0a78-4a8a-87bb-dbbc5102a7b9"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i8b6aa7e3eea8489992e4ccb91292c2ba_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC05LTEtMS0w_b46125fa-fa4b-4fcc-aa1e-7537ef1f0a97"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i7f317e5f67db4275a57f6749f14461f1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNC0xMS0xLTEtMA_bf8191ed-8bf5-435c-b20c-a7af9fb76489"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i971765b8c0cf44faa48dc5064fcf9605_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi0xLTEtMS0w_bbf0b269-6984-4f0c-913a-b1a685bc4ace"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i8eb93e31604f48009bc491bfe2432446_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi0zLTEtMS0w_62b62e4d-581f-4422-bafd-e63e8beccfae"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi01LTEtMS0w_5de2a2cf-4f55-4cb0-bf96-08c69a547120"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i595eb369427c497fac23d3e8c5820214_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi03LTEtMS0w_544b26d4-84e8-445b-b4a5-bdfc284ad746"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="idd5b9e6ccc0d4886acc721fa7dbb63c7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi05LTEtMS0w_3af029a0-5dbb-4f1d-abdd-0309b4c51010"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNC9mcmFnOmY0NTMwYmYxZDVhNDRmMjZhNzMyMWQxNTRlMzdiYmU4L3RhYmxlOmJkNjdiMDE3MTAwYzQ5MWM5MDFkNDU4NjY2OGFkYzNkL3RhYmxlcmFuZ2U6YmQ2N2IwMTcxMDBjNDkxYzkwMWQ0NTg2NjY4YWRjM2RfNi0xMS0xLTEtMA_5f1848dc-ba56-45be-95a2-6b4e64a2fd08"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RleHRyZWdpb246M2VlOGNhNzhiNzkwNDA2OWI2OTM3OWIzZTRjY2Q2MjZfNDMy_fdc2f7e5-4bd6-4676-87e2-54d1ffa9bfd2">EARNINGS (LOSS) PER SHARE&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,316,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (income) loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,953,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,134,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,368,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,134,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,368,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,838,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,842,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,268,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,455,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,577,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,206,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,454,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,206,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,454,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2020 and 2019, restricted stock awards and options to purchase 197,210 and 3,600 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RleHRyZWdpb246M2VlOGNhNzhiNzkwNDA2OWI2OTM3OWIzZTRjY2Q2MjZfNDMz_bd5ef630-2a14-45bf-870b-ca0301207356">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,316,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (income) loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,953,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,134,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,368,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,134,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,368,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,838,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,842,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,268,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,455,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,577,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,206,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,454,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,206,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,454,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfMy0xLTEtMS0w_dc933537-d6c3-48ff-a0cd-f6960200066e"
      unitRef="usd">-1275620</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfMy0zLTEtMS0w_381be7ac-a55e-4cbb-8b4e-b27c2ab55f63"
      unitRef="usd">-3316286</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNC0xLTEtMS0w_810e6874-b3f8-4a92-ab84-d9901715c353"
      unitRef="usd">777916</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNC0zLTEtMS0w_9bd44394-86b7-4da6-9f91-dd9bcfe0d2bd"
      unitRef="usd">1349351</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNS0xLTEtMS0w_df562953-c9f0-4226-91a7-24dc38981cd8"
      unitRef="usd">-15967</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNS0zLTEtMS0w_bab9f3ca-afdc-4cc1-8633-81bba402b9bb"
      unitRef="usd">-13267</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNi0xLTEtMS0w_180a2986-e02b-4467-bf4c-ca6cb1d6a282"
      unitRef="usd">-481737</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfNi0zLTEtMS0w_51079ceb-063b-4736-a081-28fb404a8fb9"
      unitRef="usd">-1953668</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfOC0xLTEtMS0w_8dfcac58-c245-479b-90ea-d8198b82823c"
      unitRef="shares">15134583</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfOC0zLTEtMS0w_3b6e15d2-7246-4765-9742-c48e22fe21b2"
      unitRef="shares">15368027</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfMTAtMS0xLTEtMA_680661da-9c2e-4bc7-bb8a-ef68aff517cb"
      unitRef="shares">15134583</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOmE4MWRjY2JiYTY0NjRlMjNhNTE5MGQ4MjVkMWU4OTM0L3RhYmxlcmFuZ2U6YTgxZGNjYmJhNjQ2NGUyM2E1MTkwZDgyNWQxZTg5MzRfMTAtMy0xLTEtMA_bef24f96-7f94-4b28-aa5e-e7f87d8c4a77"
      unitRef="shares">15368027</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfMy0xLTEtMS0w_ba6c153c-d20c-4201-9194-d99af8da848f"
      unitRef="usd">-4838250</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfMy0zLTEtMS0w_279857ff-511d-4ae7-99f6-6e2ae17c9f5f"
      unitRef="usd">-5842361</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNC0xLTEtMS0w_31a5f830-9e36-446a-bdb9-0b6b6c6c847b"
      unitRef="usd">2334811</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNC0zLTEtMS0w_bf1f3af9-faff-4042-b46b-2684d5e47fd2"
      unitRef="usd">3268196</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNS0xLTEtMS0w_058de113-d6f7-46c0-8dfd-d000d9e95ebf"
      unitRef="usd">-47806</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNS0zLTEtMS0w_53700455-ad83-4e97-aee6-ffb515c89a96"
      unitRef="usd">2888</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNi0xLTEtMS0w_ccc4dc60-fb64-412b-be54-1d316c350883"
      unitRef="usd">-2455633</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfNi0zLTEtMS0w_b6bf7a28-b262-4a5b-bbcf-7220da734f82"
      unitRef="usd">-2577053</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfOC0xLTEtMS0w_0e159637-02d4-496a-b203-4931667f0908"
      unitRef="shares">15206179</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfOC0zLTEtMS0w_41976643-df91-4c1d-abea-2c78c614ea27"
      unitRef="shares">15454159</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfOS0xLTEtMS0w_dd6c223f-195b-4901-996a-00ab599e630a"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfOS0zLTEtMS0w_92e0f461-7307-44a3-8c35-43ce9526c42e"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfMTAtMS0xLTEtMA_b68d2d90-e060-4487-afbb-a6507fa3130a"
      unitRef="shares">15206179</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RhYmxlOjJjYTYzYTY0ZjBhYTRiZjU4MjllNzc4MmI5MWJhZjJmL3RhYmxlcmFuZ2U6MmNhNjNhNjRmMGFhNGJmNTgyOWU3NzgyYjkxYmFmMmZfMTAtMy0xLTEtMA_7dad67b7-bb9e-40b1-9a84-98a6333c5d90"
      unitRef="shares">15454159</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RleHRyZWdpb246M2VlOGNhNzhiNzkwNDA2OWI2OTM3OWIzZTRjY2Q2MjZfMjUz_ad96c4ab-32e1-4e5e-89f9-8674cced46f7"
      unitRef="shares">197210</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M18zNy9mcmFnOjNlZThjYTc4Yjc5MDQwNjliNjkzNzliM2U0Y2NkNjI2L3RleHRyZWdpb246M2VlOGNhNzhiNzkwNDA2OWI2OTM3OWIzZTRjY2Q2MjZfMjYw_203fc88b-6c91-4433-93e1-c61d46344b5f"
      unitRef="shares">3600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjMzMw_26069a21-d2f9-4817-a2bf-8420f6952bc0">REVENUES&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three and nine months ended September 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,720,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,677,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,813,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,551,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,156,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,250,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,179,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,082,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#x2019;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual payments associated with the partner&#x2019;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#x2019;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.1&#160;million and $0.2 million for the three months ended September 30, 2020 and 2019, and $0.4 million and $0.9 million for the nine months ended September 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjMyOQ_9dee81b1-6076-4bc5-96f2-56c0097ee7fe">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three and nine months ended September 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,720,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,677,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,813,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,551,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,156,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,250,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,179,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,082,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie302cf43817549578a8f9ef152a447b1_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMy0xLTEtMS0w_6296417f-b8f4-4b44-81ea-20daf71e9b07"
      unitRef="usd">218462</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25de277b0b0646cb9281cd16f837c44a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMy0zLTEtMS0w_0336afbc-5e5e-4c30-bb9d-cc79bc1621e4"
      unitRef="usd">777185</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90fb467e2733434596b17207333e3bfe_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMy01LTEtMS0w_81806951-8afb-40c9-bd47-cfb8097589ac"
      unitRef="usd">1527173</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ce5aa81441845e89b5271f86420011f_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMy03LTEtMS0w_1feb4b46-5505-40c0-87e1-8e3164c41b48"
      unitRef="usd">2608160</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc6245a0edd04497ac8b9d6d6e9f57ab_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNC0xLTEtMS0w_be859111-a609-4c66-abb3-ea10e53cae65"
      unitRef="usd">516066</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf4e408c7b1844ffb641ff92ed986d13_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNC0zLTEtMS0w_063defb0-aa0c-46f6-b630-42ae4cf38d95"
      unitRef="usd">116063</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie79fe091e6954839a3d9614623decb4f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNC01LTEtMS0w_eec74c39-a860-4a57-883c-3d71c7976c1f"
      unitRef="usd">640435</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia33026525efb4a2fba6cc177559e712b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNC03LTEtMS0w_d7cb62d3-2571-4d50-b4c0-e921246d02d8"
      unitRef="usd">794205</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ideedcf83bae049bdaf355ac459d10cf8_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNS0xLTEtMS0w_0e6a3f10-e4d7-4e84-8c8f-d6cac7a3ca5f"
      unitRef="usd">3615557</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9da2d5ab42648409a9408e0b935a37d_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNS0zLTEtMS0w_7f2400c6-267d-4c66-bbfd-6a11e683d22d"
      unitRef="usd">2924237</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52c8721688534cb184cbf86471fe0d57_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNS01LTEtMS0w_cbceb907-4795-48ad-ab14-e80a82580a40"
      unitRef="usd">10387046</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f094a21244147fb9ce5e1bb5b80e965_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNS03LTEtMS0w_13dd0c5f-fa24-4c4d-86ff-de02b39881b4"
      unitRef="usd">9720434</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1481a754bb38453f812b6c54c7a6c98b_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNi0xLTEtMS0w_92af7254-df90-48ec-a173-21c4e3d2f387"
      unitRef="usd">406162</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fd27b429249456c90fc071b0ff8b3bd_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNi0zLTEtMS0w_5e71d9a6-2863-4b19-9231-cd69f50613bd"
      unitRef="usd">224940</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5902cac206e44f0da81556294b8309f5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNi01LTEtMS0w_53f5def0-08c4-42df-ac2a-6508918ab64b"
      unitRef="usd">790817</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d88d58c35bc420b81d5571b5f859389_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNi03LTEtMS0w_5f1649ff-cc8d-4c3d-a8c2-66a401f18c30"
      unitRef="usd">724143</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b0440b8c0a141a6bd9f692f2deeb4ba_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNy0xLTEtMS0w_0504c5ec-a9d9-4217-b271-62e0c900f0c3"
      unitRef="usd">1416146</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9483466598e4f23ae7a5abdf7100ada_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNy0zLTEtMS0w_a486a786-bd97-4414-8e77-950543f8a1a1"
      unitRef="usd">1170567</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fb1ae19da3f45d18b49aaf25f1dbd88_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNy01LTEtMS0w_14a44f5d-f060-4cd0-8f13-96cc9e0312e9"
      unitRef="usd">3677434</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie18912dcb3d24ad7a55576713413c72c_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfNy03LTEtMS0w_368e51b9-bed2-4c8c-976c-bea7670e5ef9"
      unitRef="usd">3543166</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3299d8817d7541f3bdc4c7f01ae7bd80_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOC0xLTEtMS0w_899fe3a0-b7b9-45b1-a552-ee8d0f1c22fb"
      unitRef="usd">2813249</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5447d4c0f5a349c1a9861329416d6e25_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOC0zLTEtMS0w_1a7bd2d2-c5ff-4ac5-aa0b-61da4d21ec8c"
      unitRef="usd">1451595</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if90916a859244a87afe32a6420d18ffa_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOC01LTEtMS0w_b0c66910-5bd4-4222-9757-4d4eecbdb9f5"
      unitRef="usd">8551125</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4c798a624494da4a9a833b2d4b416cd_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOC03LTEtMS0w_b4bebd2a-0825-42d8-b5da-cf8417abfbc2"
      unitRef="usd">6156653</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13a8c2296b3941e0a307a7590c71f19b_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOS0xLTEtMS0w_53921d87-993f-4e02-b811-f20b818e0209"
      unitRef="usd">265047</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95daedfded3c472b9eb62ad072b1551e_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOS0zLTEtMS0w_9c7b6414-c52a-42ce-a789-7c5ab42cb354"
      unitRef="usd">270852</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i810fe6fe3d5d4acc95a6434905ad9bbd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOS01LTEtMS0w_3801a808-0142-4889-95a3-01516b806561"
      unitRef="usd">1605570</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11f33391c5194ed3a2eab2153394a830_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfOS03LTEtMS0w_a34d696f-f02c-4558-9a99-7590d172e637"
      unitRef="usd">1535981</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51d553293659413f87554dc788d4bcce_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMTAtMS0xLTEtMA_5d7a0aae-3a2a-45a3-acd3-0ec4ed885fbd"
      unitRef="usd">9250689</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc18baafb97a4c71abb2c356d426bc04_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMTAtMy0xLTEtMA_5f9b71e3-6322-47af-8588-79837b499e52"
      unitRef="usd">6935439</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMTAtNS0xLTEtMA_1aaf4ae4-8220-45d7-872f-362ba8033d08"
      unitRef="usd">27179600</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14d9d3c140d74c3c8549280f3566324b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RhYmxlOmRkMjIyZDg5MTQwMjRiNjQ4MjUxMTJhMzMxYWYzNDY0L3RhYmxlcmFuZ2U6ZGQyMjJkODkxNDAyNGI2NDgyNTExMmEzMzFhZjM0NjRfMTAtNy0xLTEtMA_9fc75bae-dffb-4ed8-99d7-7b83ae60461f"
      unitRef="usd">25082742</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cc85fa1f23c400f98a38cd8f0ac2143_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjIxNw_b3b48ba1-de99-4b50-b50a-4bf3459275e3"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e3533c9ef434f2296767af0d6fa95cd_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjIyNA_7478b020-6ee0-4ad0-8fcf-546838c56356"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6666cecacb694b16a57f4cfa2cedd55d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjI3MQ_011e3e04-ad9e-4501-8a39-07bee5fa650e"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b09030d4c8746e39c72272a8087f528_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180MC9mcmFnOjNmM2YwNDZhZTEzMjQyMTc4MzA4NGFiYTViYTRkMGMyL3RleHRyZWdpb246M2YzZjA0NmFlMTMyNDIxNzgzMDg0YWJhNWJhNGQwYzJfMjI3OA_515ff6ad-44fd-4a79-9ca5-c518b63fbec6"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMTk4Ng_1a4510ba-e2c7-4226-a0bb-3f621c392cb4">INVENTORIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#x2019;s warehouses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At September 30, 2020 and December 31, 2019, there were no cumulative obsolescence and discontinuance losses necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for the purchase of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory at multiple locations. As that API is consumed in production, the value of the API is transferred from raw materials to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;finished goods inventory. Cumberland also maintains API for its Vaprisol brand which is classified as raw materials inventory.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consigned inventory represents Authorized Generic product which is shipped to the Company&#x2019;s distribution partner and stored until sale.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories that are classified as non-current inventories.  The Company also has obtained $0.4&#160;million in non-current inventory for API related to its ifetroban clinical initiatives. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2020 and December 31, 2019, total non-current inventory, including Vibativ and ifetroban, was $12.6&#160;million and $15.6&#160;million, respectively. The Company had $2.7 million of Vibativ finished goods included in non-current inventory at September 30, 2020 and did not have any finished goods included in the non-current inventories at December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,064,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,345,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,664,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,729,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,426,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,649,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,554,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,080,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,871,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryNoncurrent
      contextRef="i43031ec5d6b146e396b7ed311aeda9fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMTY0NQ_0e0619fc-b38e-4638-b00c-1ce60add6342"
      unitRef="usd">400000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMTA5OTUxMTYzMDEwMQ_64b2b7cd-5036-4948-a4e1-7eb14726a36f"
      unitRef="usd">12600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMTgwOQ_05002ff1-3bcd-419e-bb77-1e01a175852f"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryFinishedGoods
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMjE5OTAyMzI1NzU4MQ_461a51fe-15ca-4a70-a81d-bead90aab7c2"
      unitRef="usd">2700000</us-gaap:InventoryFinishedGoods>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RleHRyZWdpb246ZTMzMjYwNjIxMWJiNDMxNDgxZmQ0Y2U5NzViODc4MjVfMTk4NQ_d67fb9c1-cedf-44db-96d1-b52e3fdce570">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,064,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,345,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,664,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,729,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,426,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,649,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,554,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,080,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,871,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMi0yLTEtMS0w_b3a4dabf-3645-4603-9ebc-caac20721ff2"
      unitRef="usd">17064269</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMi00LTEtMS0w_08e30314-1177-47bf-be5a-9c9ec9df601c"
      unitRef="usd">19345723</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMi00LTEtMS0w_9af82daa-eb8d-4137-b904-ed7a5a6acac5"
      unitRef="usd">19345723</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMy0yLTEtMS0w_c5da7325-fb74-49e5-838d-908e842e6f66"
      unitRef="usd">250615</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMy00LTEtMS0w_6279b88e-7c12-4636-99c3-10bcfe7d35d4"
      unitRef="usd">416468</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfMy00LTEtMS0w_dfa92176-2af6-4f10-ae58-ec5ee3c4519c"
      unitRef="usd">416468</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNC0yLTEtMS0w_c5d1f9ed-da6c-4244-be0d-6da6e862dcdb"
      unitRef="usd">5414694</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNC00LTEtMS0w_21a7572e-7145-46e4-8fe9-53c057ecbb82"
      unitRef="usd">4664055</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNC00LTEtMS0w_ba585f71-43ae-4f47-86ba-62422cb3e054"
      unitRef="usd">4664055</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNS0yLTEtMS0w_356eca39-3d56-45f0-ba61-2c1f2fe48fd0"
      unitRef="usd">22729578</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNS00LTEtMS0w_0c31476f-665a-46cc-82ef-f6355c6689f6"
      unitRef="usd">24426246</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNi0yLTEtMS0w_11f5bf7e-3110-420c-9494-9ae7751bc07d"
      unitRef="usd">12649184</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNi00LTEtMS0w_678dbe7c-ac42-427e-9278-a9e043c632a6"
      unitRef="usd">15554992</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNy0yLTEtMS0w_b2eece9d-5e68-42ad-a8f9-b971d217d3e8"
      unitRef="usd">10080394</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180My9mcmFnOmUzMzI2MDYyMTFiYjQzMTQ4MWZkNGNlOTc1Yjg3ODI1L3RhYmxlOjU2OTU3NTFmYzU2MzRjYmY5ODBiNDkyMGQ5YTYzYzI1L3RhYmxlcmFuZ2U6NTY5NTc1MWZjNTYzNGNiZjk4MGI0OTIwZDlhNjNjMjVfNy00LTEtMS0w_a484a681-e37d-478b-94f3-f73b53588d14"
      unitRef="usd">8871254</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RleHRyZWdpb246YWIwYWM3ODZkZjE4NGVkNWEyYjA4ZDQ3OTc0MGQ3MGRfMTc5NA_933c34a8-ca4e-4e55-8dfe-2fab149edcf6">LEASES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#x2019;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases classified as operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at September 30, 2020 is 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,267,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,315,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Leases Liabilities at September 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,545,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,315,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RleHRyZWdpb246YWIwYWM3ODZkZjE4NGVkNWEyYjA4ZDQ3OTc0MGQ3MGRfMTYzNw_f2123260-174e-4e4d-acfe-9e4399c14d7f"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RleHRyZWdpb246YWIwYWM3ODZkZjE4NGVkNWEyYjA4ZDQ3OTc0MGQ3MGRfMTY5Mg_a6ac60c9-90c9-4ea7-ae14-5ad12a192099">P2Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RleHRyZWdpb246YWIwYWM3ODZkZjE4NGVkNWEyYjA4ZDQ3OTc0MGQ3MGRfMTc5NQ_485e9c6c-8cfb-44f3-b2c2-cae1b6ce3a11">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,267,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,315,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOmEwZjUyNGRkZjYxNzRhNGFiZTU4MzlkZDhiZDRmNzFkL3RhYmxlcmFuZ2U6YTBmNTI0ZGRmNjE3NGE0YWJlNTgzOWRkOGJkNGY3MWRfMS0yLTEtMS0w_da2f3247-a2fa-48bc-9733-06fb4cfc3cc7"
      unitRef="usd">2267669</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOmEwZjUyNGRkZjYxNzRhNGFiZTU4MzlkZDhiZDRmNzFkL3RhYmxlcmFuZ2U6YTBmNTI0ZGRmNjE3NGE0YWJlNTgzOWRkOGJkNGY3MWRfMS00LTEtMS0w_adaaae97-ca49-4eff-81cb-e5fee7146e03"
      unitRef="usd">2960569</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfMS0yLTEtMS0w_5810fa0f-9be6-43be-b43f-8f832ef5d5ed"
      unitRef="usd">991969</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfMS00LTEtMS0w_0b833995-fb48-4fd2-8ab3-45c97ffe67a3"
      unitRef="usd">920431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfMy0yLTEtMS0w_bfeb40bd-82a3-474f-8ccf-179474b50435"
      unitRef="usd">1323792</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfMy00LTEtMS0w_b1ad6ff1-500c-49fd-ab91-6d9bbd8fe9ab"
      unitRef="usd">2076472</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfNC0yLTEtMS0w_dd2989c6-971a-43f2-a484-8bcb1b38410f"
      unitRef="usd">2315761</cpix:LeaseLiability>
    <cpix:LeaseLiability
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjM1NTI1NzA3MjZiNjQ2ZjA5NGE3MTJmZGZjMzllNjA0L3RhYmxlcmFuZ2U6MzU1MjU3MDcyNmI2NDZmMDk0YTcxMmZkZmMzOWU2MDRfNC00LTEtMS0w_e431d227-3a35-48e9-9786-ba5fe7a9fe87"
      unitRef="usd">2996903</cpix:LeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RleHRyZWdpb246YWIwYWM3ODZkZjE4NGVkNWEyYjA4ZDQ3OTc0MGQ3MGRfMTc5Ng_4466b21a-6095-4685-8d63-be1d0081d2d9">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Leases Liabilities at September 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,545,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,315,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfMS0yLTEtMS0w_e4a47a4d-c047-4aaf-a124-1955ccae9ceb"
      unitRef="usd">288781</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfMi0yLTEtMS0w_e5dd9595-3265-44ed-84bd-25ed8c596502"
      unitRef="usd">1144889</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfMy0yLTEtMS0w_b1793d1f-dc20-4efb-a54e-e127fce513be"
      unitRef="usd">1019313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfNC0yLTEtMS0w_8bc30cff-66af-4cd0-a08a-d185c84122e7"
      unitRef="usd">92478</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfNS0yLTEtMS0w_8a824dff-815a-4e53-b7dd-997e10f3d1bf"
      unitRef="usd">0</cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfNi0yLTEtMS0w_df7b55d9-367c-4bc8-b5a5-e6425459c9a7"
      unitRef="usd">2545461</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfNy0yLTEtMS0w_365cec16-f7c4-4309-8a3b-6b8ff8efe151"
      unitRef="usd">229700</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180Ni9mcmFnOmFiMGFjNzg2ZGYxODRlZDVhMmIwOGQ0Nzk3NDBkNzBkL3RhYmxlOjE4ZDExZjJmODhkODRmNmI4YzE3ZjJhNzY1MzU2NDcyL3RhYmxlcmFuZ2U6MThkMTFmMmY4OGQ4NGY2YjhjMTdmMmE3NjUzNTY0NzJfOC0yLTEtMS0w_e15ad447-69d9-4f38-a56a-c9d977e88882"
      unitRef="usd">2315761</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNzMxNA_7a4bd390-4d0a-42e6-ba9f-aecd047e6b69">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the nine months ended September 30, 2020 and September 30, 2019, the Company repurchased 407,683 shares and 452,155, respectively, of common stock for approximately $1.5 million and $2.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share purchases and sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the Company's March 2020 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  During the nine months ended September 30, 2020, a total of 10,080 shares have been purchased.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018 including an At-The-Market ("ATM") feature enabling the Company to sell shares at market prices.  The Company did not issue any shares under the ATM during the nine months ended September 30, 2020 or September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Share Grants &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2020, and September 30, 2019, the Company issued 230,491 shares and 225,869 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cumberland Emerging Technologies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an agreement whereby Hongkong WinHealth Pharma Group Ltd. ("WinHealth") made a $1&#160;million investment in CET through the purchase of shares of its common stock. As part of the agreement, WinHealth obtained the rights to name an individual for appointment to the CET Board of Directors  as well as the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, during 2019, Cumberland also made an additional $1&#160;million investment in CET.  Cumberland purchased additional CET common shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for $0.8&#160;million that was funded during 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#x201c;Fourth Amendment&#x201d;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#x201c;Pinnacle Agreement&#x201d;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $15&#160;million and Cumberland has the ability to request an increase of up to an additional $5&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20&#160;million, which was also the maximum aggregate principal available for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;borrowing under the previously amended Pinnacle Agreement. The Fourth Amendment extends the maturity date of the Pinnacle Agreement through October 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement. The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 2.90% at September 30, 2020, prior to entering into the Fourth Amendment.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. As of September 30, 2020 and December 31, 2019, the Company had $17.0 million and $18.5 million in borrowings outstanding under our revolving credit facility, respectively.  Of the $17.0 million in borrowings outstanding at September 30, 2020, $2.0 million is classified as current based on the terms of the Fourth Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The PPP is administered by the U.S. Small Business Administration ("SBA").&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly commencing during November 2020. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From the date of funding the Company has used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As result, the Company has recorded the $2,187,140 as a deferred income liability, which is included as a component of other current liabilities on the condensed consolidated balance sheet. The Company intends to apply IAS 20 to the PPP loan forgiveness and has presented the amounts expected to be forgiven as deferred income. The Company will account for the anticipated forgiveness of the PPP loan under IAS 20 when the Company believes that the forgiveness is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. In October 2020, the Company submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to SBA for the SBA's review and approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;WHC Biopharmaceuticals, Pte. Ltd&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of $0.2&#160;million convertible note. The joint venture will seek additional future &lt;/span&gt;&lt;/div&gt;capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ibb00b2069e194ae3b41a6bbd3811b9ef_I20100513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTI5_098ae41a-550e-4b1e-ae0c-8963972e3622"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i8cea20af1c7a4bf8892167b3a57bb8b3_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjkw_73671c84-3c72-4508-b974-d352b9eeab34"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i5651034dcdff44f08080de6ea37be942_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMzk2_3b52f490-e43b-4385-93b7-87f0b7f3bb22"
      unitRef="shares">407683</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i1f1cc7c6f3f64637b1ca6aea46ce29a1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNDEw_b4f8f426-91a5-4f81-99a9-c5d9302b5748"
      unitRef="shares">452155</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i5651034dcdff44f08080de6ea37be942_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNDYy_3fadca04-77b5-45b4-ab37-ef8b9b80212d"
      unitRef="usd">1500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i1f1cc7c6f3f64637b1ca6aea46ce29a1_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjE5OTAyMzI2MjkwNA_5ba39d6d-87bf-4d56-b91a-a6019d674399"
      unitRef="usd">2600000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjE2NQ_9f46ea93-7399-4645-bc5e-301550321cdf"
      unitRef="shares">10080</us-gaap:StockRepurchasedDuringPeriodShares>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i0a446f495cd042eca3da6e7c97bb5b5d_D20171101-20171130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfOTc2_3cf8c2aa-329b-4ec3-9664-0226616cf1ce"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5eed37f174f24049b2b6ad3653f05bbe_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTMwMw_ff5bb096-2f54-4ab7-84b1-7805934458a5"
      unitRef="shares">230491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i41de7f64b76f4893a406e9afd4a76a14_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTMxNw_ea7cd7a9-ce54-4966-bfcd-0dec331a9c4e"
      unitRef="shares">225869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6006916e3bab4f718de88600cfdcb08d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNzMxOA_27df579d-b552-45c1-b485-50837ba7104e">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="i930ad17f078c46d582cdf90475e66e78_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTkyNQ_1e622c72-9f89-440e-a1bc-28ec8521c8a3"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="i930ad17f078c46d582cdf90475e66e78_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjMwMg_d1445918-55da-4c73-8ec6-d4e0382aa911"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentCashContribution
      contextRef="ib2affeac992f45c1807ad24d6642935c_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjM5OQ_d573f6ac-ac8b-4b3b-976a-d0ccb9860679"
      unitRef="usd">300000</cpix:SubsidiaryInvestmentCashContribution>
    <cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable
      contextRef="i02dfaa25707a4e09b76974e10fd34245_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjQzMA_8ec0960a-80f9-4a32-9f08-c1ac8efc1730"
      unitRef="usd">700000</cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable>
    <cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital
      contextRef="i26301daa05cd47268f1bd0644a7e18a1_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjYwNQ_46ed80d1-4539-4a85-9b9f-5788fb8db769"
      unitRef="usd">800000</cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia98b89ba857e4a2cb67df1f1038088f9_I20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjE3Mw_2d6f83e0-8db3-46c0-9aa4-e8e1c3e9c812"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount
      contextRef="ia98b89ba857e4a2cb67df1f1038088f9_I20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjE0MA_2872198a-1368-4ae7-ab75-002fb4a5a685"
      unitRef="usd">5000000</cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity
      contextRef="ia98b89ba857e4a2cb67df1f1038088f9_I20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjE1Mg_ec434b0e-2f7c-47f4-b0fa-29e77b07f8ff"
      unitRef="usd">20000000</cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i19338c6b30fd4b21b231c47865291087_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjExMg_3d475739-554e-46b7-b40a-d5ea0487dbb5"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie2620c3a3fad4da8b66e2277201834e8_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjExOQ_d65274ab-a3a5-4e50-9645-3449c724220f"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i407f51866f02409cb9fad138500d14d1_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjEyNg_1137001a-b271-48a5-b940-8f4782c491b6"
      unitRef="number">0.0090</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaadf65c3ea20463da1472b122fe42d41_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNDQ0Mw_aba27eac-1617-4366-bced-f8dd6818ffe8"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i19e5831ccde74dbba7c187512febfbb2_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjEzMw_661d18a5-3673-4be7-9a98-ab4761d4d4ef"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LongTermLineOfCredit
      contextRef="i9d96acd949234acfb136a690bec1d7ce_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjE5OTAyMzI2MzI4Mg_32696a96-4f09-4293-b89f-7f67f59db63a"
      unitRef="usd">17000000.0</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="ib48367eed5394c5ea20e7dc76326dace_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNDcyMg_b052841f-c504-44c7-80e0-1b495a88ff41"
      unitRef="usd">18500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i9d96acd949234acfb136a690bec1d7ce_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjE5OTAyMzI2OTA0Ng_32696a96-4f09-4293-b89f-7f67f59db63a"
      unitRef="usd">17000000.0</us-gaap:LongTermLineOfCredit>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMjE5OTAyMzI2OTA4OQ_ae1b133d-90bc-4977-a982-fbd1db6cba7f"
      unitRef="usd">2000000.0</us-gaap:LinesOfCreditCurrent>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i04eb73a534cd4abf9da31ee653c6edde_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNDk0Mw_8fe63e02-31d6-43c6-8091-1c7fce450603"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id6ec3802e7f5429586813fbc92cd89e5_I20200420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNTI1NA_b9fe871c-f42e-4adb-b089-589ddbdb37d5"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i04eb73a534cd4abf9da31ee653c6edde_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfNjIyOA_8fe63e02-31d6-43c6-8091-1c7fce450603"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i593c0deb73804b658d160e2556b47e42_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjE4Ng_4f6dcdae-50ab-4b0b-9a71-994b55044016"
      unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0afbb1a866c34e2b917ab586687f4135_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M180OS9mcmFnOjkyYjYxOWNjMWVkZjRhNjA5NWQ4NzMzMDFkNGUxYWE5L3RleHRyZWdpb246OTJiNjE5Y2MxZWRmNGE2MDk1ZDg3MzMwMWQ0ZTFhYTlfMTA5OTUxMTY0MjIwMA_abc5af37-02bf-4707-8d07-5cb663b8942e"
      unitRef="usd">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181Mi9mcmFnOmZkZGVkNjllMDg1MDQzNmY5ODA4MjVlYzM1MjJiZmQ1L3RleHRyZWdpb246ZmRkZWQ2OWUwODUwNDM2Zjk4MDgyNWVjMzUyMmJmZDVfNjM2_071f9184-afb6-418c-9b36-ab3576305608">INCOME TAXESAs of September 30, 2020, the Company has approximately $56.3 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i75f6e5e1e35347acb9908a1fc5e7a4d9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181Mi9mcmFnOmZkZGVkNjllMDg1MDQzNmY5ODA4MjVlYzM1MjJiZmQ1L3RleHRyZWdpb246ZmRkZWQ2OWUwODUwNDM2Zjk4MDgyNWVjMzUyMmJmZDVfNjM_79796c30-8646-4082-8a2e-7ce5ac7d2360"
      unitRef="usd">56300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2aae3ade58f14629babea615840c16d4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181Mi9mcmFnOmZkZGVkNjllMDg1MDQzNmY5ODA4MjVlYzM1MjJiZmQ1L3RleHRyZWdpb246ZmRkZWQ2OWUwODUwNDM2Zjk4MDgyNWVjMzUyMmJmZDVfMTM0_2c65ea3f-151d-4fc8-b775-7c6ec1dd3c37"
      unitRef="usd">44100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181NS9mcmFnOmZkNmZhMzU1YzJjNDQ3YmU5NzI4MTgzOWRhY2I0ODBmL3RleHRyZWdpb246ZmQ2ZmEzNTVjMmM0NDdiZTk3MjgxODM5ZGFjYjQ4MGZfMTAyMg_5f01a0f2-0b81-4dd3-afeb-fd97eac5d57c">COLLABORATIVE AGREEMENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 10 do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNjUxOA_ab53e377-af01-4870-a90d-ec5c377538bf">ADDITIONS AND RETURN OF PRODUCT RIGHTS&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  The Company expects to deduct the goodwill acquired in the acquisition for tax purposes.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment during 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,633,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(834,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(806,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,105,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability of $8.1&#160;million was classified as other current liabilities of $2.8&#160;million and other long-term liabilities of $5.3&#160;million on the condensed consolidated balance sheet as of September 30, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company announced an agreement with the Nordic Group B.V.&#x2019; ("Nordic") to acquire the exclusive U.S. rights to Nordic&#x2019;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received FDA approval for the first Nordic injectible product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020 and was recorded as an other current liability at December 31, 2019.  Cumberland has approximately $1.9&#160;million in net intangible assets related to RediTrex at September 30, 2020.  During the three months ended June 30, 2020, Cumberland recognized $0.5&#160;million of other revenue in its condensed consolidated statement of operations for a collaborative payment due from Nordic. The payment was received during July 2020.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ethyol and Totect &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#x201c;the Products&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the return of these product license rights and the non-compete provisions of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first three quarterly installments totaling $2.3 million during the nine months ended September 30, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as discontinued operations and will record each future quarterly installment over the two year period.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As there are no expenses associated with these payments, approximately $2.3 million in discontinued operations income was recorded during the period ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Products provided $8.8&#160;million in revenue, with $5.5&#160;million in direct expenses resulting in $3.3&#160;million in discontinued operations income during the nine months ended September 30, 2019. These direct expenses do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Those sales and marketing individuals who supported the Products have subsequently shifted their efforts to support other Cumberland brands.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2019 current assets of discontinued operations included $0.5&#160;million in remaining &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inventory for the Products sold and returned to Clinigen as part of the transaction. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2019, &lt;/span&gt;the remaining balance of the current assets of discontinued operations were accounts receivable and the current liabilities of discontinued operations were accounts payable associated with Ethyol and Totect.  As of September 30, 2020, the remaining balance of the current assets of discontinued operations was accounts receivable.   The accounts receivable and accounts payable balances were not sold or disposed of as part of the Dissolution Agreement.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i657f7cc3031d4101af068d47a7501bd3_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDcwOA_b5b151c0-426e-440a-b651-2a0649be8c7a"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i657f7cc3031d4101af068d47a7501bd3_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDY4OQ_011733d9-4bfa-41f2-9662-ac11e79d5bae"
      unitRef="usd">5000000.0</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="i657f7cc3031d4101af068d47a7501bd3_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDcwMw_6dccc6f0-6b52-4921-b750-2c308d3d4cf2"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNjUxOQ_9fdae32c-10cc-4629-a858-94ae9f5b2388">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment during 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE3ODA5ZWY3YWMxMzQzOTJhYTJjZDhkZDcwNTFhNzM4L3RhYmxlcmFuZ2U6MTc4MDllZjdhYzEzNDM5MmFhMmNkOGRkNzA1MWE3MzhfMi0xLTEtMS0w_c35d8e79-d613-47a3-8e57-b40ac86b792b"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE3ODA5ZWY3YWMxMzQzOTJhYTJjZDhkZDcwNTFhNzM4L3RhYmxlcmFuZ2U6MTc4MDllZjdhYzEzNDM5MmFhMmNkOGRkNzA1MWE3MzhfMy0xLTEtMS0w_b8789c93-2ac2-4543-a7b9-09b95de158bf"
      unitRef="usd">5000000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:PaymentsForContingentConsideration
      contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE3ODA5ZWY3YWMxMzQzOTJhYTJjZDhkZDcwNTFhNzM4L3RhYmxlcmFuZ2U6MTc4MDllZjdhYzEzNDM5MmFhMmNkOGRkNzA1MWE3MzhfNC0xLTEtMS0w_e36f2bd1-9932-4d17-a273-03b85a482c1d"
      unitRef="usd">9182000</cpix:PaymentsForContingentConsideration>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE3ODA5ZWY3YWMxMzQzOTJhYTJjZDhkZDcwNTFhNzM4L3RhYmxlcmFuZ2U6MTc4MDllZjdhYzEzNDM5MmFhMmNkOGRkNzA1MWE3MzhfNS0xLTEtMS0w_a167fc2e-4f3a-481f-9e1a-ff723a0fbb0a"
      unitRef="usd">34182000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNjUyMA_a3da4942-3d7b-4382-b8b1-2b6b7767cf69">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfMC0xLTEtMS0w_33fd5b9b-c9a8-4d77-9c53-c15ed99e2ec0"
      unitRef="usd">6624000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfMS0xLTEtMS0w_a7b7cbc8-fad0-4b97-8b8c-b473e6643d7d"
      unitRef="usd">3970000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfMi0xLTEtMS0w_fe00f875-0df6-4259-9a50-5e4af774cce2"
      unitRef="usd">1827000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfMy0xLTEtMS0w_be8abfd4-1912-4a67-afc9-e8e7650f0aa9"
      unitRef="usd">9129000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfNC0xLTEtMS0w_1c2f497e-4fcc-4239-91fe-c27fa176e168"
      unitRef="usd">21550000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfNi0xLTEtMS0w_ffe75796-d949-490b-8086-ab74bab9e206"
      unitRef="usd">11750000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfNy0xLTEtMS0w_989d5753-e5cb-49d2-9296-1c2e91dd5946"
      unitRef="usd">882000</us-gaap:Goodwill>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfOC0xLTEtMS0w_9f686fd1-414a-465f-ae0e-cbf2355a3e82"
      unitRef="usd">12632000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjAzZjJmOWIwNTE0MzRkZjU5YzM2ZGJjMTkyNjFjMjNiL3RhYmxlcmFuZ2U6MDNmMmY5YjA1MTQzNGRmNTljMzZkYmMxOTI2MWMyM2JfOS0xLTEtMS0w_f2d57291-6d47-4de3-81c2-8484a8aef180"
      unitRef="usd">34182000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNjUyMQ_b352dd2b-f5a1-4f1c-9a01-b1051f189088">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,633,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(834,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(806,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,105,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i582dbdc998d44cdbab1a7981ad14c27c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE0ZDA4NGRhNTEwYTQxMjk4MTg5MmQwYTc0YmVlZjZjL3RhYmxlcmFuZ2U6MTRkMDg0ZGE1MTBhNDEyOTgxODkyZDBhNzRiZWVmNmNfOS0xLTEtMS0w_41f5d1b6-a8e3-4da2-8ce5-47a1c791693a"
      unitRef="usd">8633589</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE0ZDA4NGRhNTEwYTQxMjk4MTg5MmQwYTc0YmVlZjZjL3RhYmxlcmFuZ2U6MTRkMDg0ZGE1MTBhNDEyOTgxODkyZDBhNzRiZWVmNmNfMTAtMS0xLTEtMA_dff4ff65-8926-4cc3-9419-526ecda2482d"
      unitRef="usd">834014</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE0ZDA4NGRhNTEwYTQxMjk4MTg5MmQwYTc0YmVlZjZjL3RhYmxlcmFuZ2U6MTRkMDg0ZGE1MTBhNDEyOTgxODkyZDBhNzRiZWVmNmNfMTEtMS0xLTEtMA_784bfdec-f121-4723-8970-109230201288"
      unitRef="usd">-806390</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE0ZDA4NGRhNTEwYTQxMjk4MTg5MmQwYTc0YmVlZjZjL3RhYmxlcmFuZ2U6MTRkMDg0ZGE1MTBhNDEyOTgxODkyZDBhNzRiZWVmNmNfMTItMS0xLTEtMA_4aa7f1ca-9290-415c-8035-5dd71b5f9d13"
      unitRef="usd">1112393</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RhYmxlOjE0ZDA4NGRhNTEwYTQxMjk4MTg5MmQwYTc0YmVlZjZjL3RhYmxlcmFuZ2U6MTRkMDg0ZGE1MTBhNDEyOTgxODkyZDBhNzRiZWVmNmNfMTMtMS0xLTEtMA_30285658-2720-458a-94f2-2688c759aa94"
      unitRef="usd">8105578</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5e39f507697344bf966ae5d85dc07c38_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMjQ2NA_a754508e-050c-437f-a666-ab7ebea4bd24"
      unitRef="usd">8100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5495d94083d24a5989730f4a6f7ba7da_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMjUxNA_ef696233-eada-4f13-b457-4b235fe80ab9"
      unitRef="usd">2800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5a6bfe43ca624e09b88b884aa61ffce5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMjU1Mg_0950b3b5-bf17-46b4-8c82-b35f0a3a5adf"
      unitRef="usd">5300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i89aa0df8ed9e4d689422daf8e8aeff91_D20161101-20161130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDcyMw_b891d0c1-7edd-4e00-b15c-8accb029f5ed"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i89aa0df8ed9e4d689422daf8e8aeff91_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDc5NQ_e0178915-fc1e-48b9-b901-07cba57c6679"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i0da1b98b323a4b7fb67fd0ac6aa17246_D20161101-20161130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDczMw_3714fc34-98c6-4ab5-a179-12c8982e8016"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i0da1b98b323a4b7fb67fd0ac6aa17246_D20161101-20161130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDc0Mg_9cc46208-3770-42d3-b314-40082670956a"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i8af93abad7204f41a2937bac9ef79281_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDc1MQ_f725da2f-2e71-49ef-bddf-a7315938e71c"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2c32aec9cced429d9682d29a48e13689_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDc2NQ_468671b2-2729-475f-acf5-7456b34ebd04"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i1bdfcc93ab6345078a0b921b7524f21f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfMTA5OTUxMTYzNDc3OQ_96d03c30-0979-41c0-a7cb-08807e283d12"
      unitRef="usd">1900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Revenues
      contextRef="i6eee9c230ea246608d8ad3a6a84a3a71_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNDE2MA_d10c8348-531f-40a3-8a9f-bb73a225eda3"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="ibc4d6bac512842b1af4d4a5a540f3881_D20191001-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTEyMQ_067c56a7-d152-4334-9f80-0cbe2bfc234d"
      unitRef="usd">5000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i9cb62c40adac4ab6b3e98357baff55af_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTI5OA_e49bd2f4-f5ff-43d0-9bf7-c5ad2bcf50c3"
      unitRef="usd">2300000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i9cb62c40adac4ab6b3e98357baff55af_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTQ5MA_e49bd2f4-f5ff-43d0-9bf7-c5ad2bcf50c3"
      unitRef="usd">2300000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:Revenues
      contextRef="i6687a95bae3143d5b4bd7100bc41042c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTU5MQ_d26f7272-d379-42b3-aacd-27b3d720ba27"
      unitRef="usd">8800000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i6687a95bae3143d5b4bd7100bc41042c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTYxMQ_0eda52a7-c43e-4100-a975-b3fa40eeff76"
      unitRef="usd">5500000</us-gaap:OperatingExpenses>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i6687a95bae3143d5b4bd7100bc41042c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNTY0Ng_583f5069-d88a-4c76-9de7-fbb007609051"
      unitRef="usd">3300000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="i955fd3b444074d18a8861d6a9e06f6e9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YmRiZDNiNGZjNTRjZTBiMWY3ZTc3NjIzOGRmNTczL3NlYzo3OWJkYmQzYjRmYzU0Y2UwYjFmN2U3NzYyMzhkZjU3M181OC9mcmFnOmUxODQ5NjkzODc2OTQ3ZDU4MzhmMGZiMWZiZTQyOGRmL3RleHRyZWdpb246ZTE4NDk2OTM4NzY5NDdkNTgzOGYwZmIxZmJlNDI4ZGZfNjA2Mw_2cf4184c-d09c-4180-bd88-c2b94e6d23c3"
      unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953844773960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,036,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953769640632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,646,530<span></span>
</td>
<td class="nump">$ 28,212,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">9,661,407<span></span>
</td>
<td class="nump">7,843,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">10,080,394<span></span>
</td>
<td class="nump">8,871,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="nump">727,670<span></span>
</td>
<td class="nump">2,477,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,778,078<span></span>
</td>
<td class="nump">2,757,456<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">48,894,079<span></span>
</td>
<td class="nump">50,163,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">12,649,184<span></span>
</td>
<td class="nump">15,554,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">602,911<span></span>
</td>
<td class="nump">747,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">28,180,090<span></span>
</td>
<td class="nump">30,920,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">21,802<span></span>
</td>
<td class="nump">21,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,267,669<span></span>
</td>
<td class="nump">2,960,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,511,894<span></span>
</td>
<td class="nump">3,298,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">96,009,629<span></span>
</td>
<td class="nump">104,549,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,833,972<span></span>
</td>
<td class="nump">9,993,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,918,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">991,969<span></span>
</td>
<td class="nump">920,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Current portion of revolving line of credit</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">10,112,100<span></span>
</td>
<td class="nump">11,317,358<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">23,938,041<span></span>
</td>
<td class="nump">24,150,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">18,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">1,323,792<span></span>
</td>
<td class="nump">2,076,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
<td class="nump">7,904,419<span></span>
</td>
<td class="nump">8,737,323<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">48,166,252<span></span>
</td>
<td class="nump">53,464,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">49,176,040<span></span>
</td>
<td class="nump">49,914,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (deficit)</a></td>
<td class="num">(1,247,237)<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">47,928,803<span></span>
</td>
<td class="nump">51,122,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(85,426)<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">47,843,377<span></span>
</td>
<td class="nump">51,085,253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 96,009,629<span></span>
</td>
<td class="nump">$ 104,549,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Long Term Obligations, Excluding Current Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherLongTermObligationsExcludingCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953854449800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,084,372<span></span>
</td>
<td class="nump">15,263,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,084,372<span></span>
</td>
<td class="nump">15,263,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953769910824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 9,250,689<span></span>
</td>
<td class="nump">$ 6,935,439<span></span>
</td>
<td class="nump">$ 27,179,600<span></span>
</td>
<td class="nump">$ 25,082,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">2,142,839<span></span>
</td>
<td class="nump">1,580,650<span></span>
</td>
<td class="nump">6,387,002<span></span>
</td>
<td class="nump">5,031,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">3,587,842<span></span>
</td>
<td class="nump">3,812,467<span></span>
</td>
<td class="nump">11,160,924<span></span>
</td>
<td class="nump">11,231,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,230,335<span></span>
</td>
<td class="nump">1,672,843<span></span>
</td>
<td class="nump">4,374,392<span></span>
</td>
<td class="nump">4,788,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,381,273<span></span>
</td>
<td class="nump">2,032,129<span></span>
</td>
<td class="nump">6,608,322<span></span>
</td>
<td class="nump">6,839,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,117,086<span></span>
</td>
<td class="nump">1,033,786<span></span>
</td>
<td class="nump">3,284,610<span></span>
</td>
<td class="nump">3,085,139<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">10,459,375<span></span>
</td>
<td class="nump">10,131,875<span></span>
</td>
<td class="nump">31,815,250<span></span>
</td>
<td class="nump">30,976,534<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(1,208,686)<span></span>
</td>
<td class="num">(3,196,436)<span></span>
</td>
<td class="num">(4,635,650)<span></span>
</td>
<td class="num">(5,893,792)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">12,004<span></span>
</td>
<td class="num">(50,511)<span></span>
</td>
<td class="nump">70,553<span></span>
</td>
<td class="nump">195,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(75,210)<span></span>
</td>
<td class="num">(64,877)<span></span>
</td>
<td class="num">(227,730)<span></span>
</td>
<td class="num">(216,988)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) from continuing operations before income taxes</a></td>
<td class="num">(1,271,892)<span></span>
</td>
<td class="num">(3,311,824)<span></span>
</td>
<td class="num">(4,792,827)<span></span>
</td>
<td class="num">(5,914,865)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(3,728)<span></span>
</td>
<td class="num">(4,462)<span></span>
</td>
<td class="num">(45,423)<span></span>
</td>
<td class="nump">72,504<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</a></td>
<td class="num">(1,275,620)<span></span>
</td>
<td class="num">(3,316,286)<span></span>
</td>
<td class="num">(4,838,250)<span></span>
</td>
<td class="num">(5,842,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">777,916<span></span>
</td>
<td class="nump">1,349,351<span></span>
</td>
<td class="nump">2,334,811<span></span>
</td>
<td class="nump">3,268,196<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(497,704)<span></span>
</td>
<td class="num">(1,966,935)<span></span>
</td>
<td class="num">(2,503,439)<span></span>
</td>
<td class="num">(2,574,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">15,967<span></span>
</td>
<td class="nump">13,267<span></span>
</td>
<td class="nump">47,806<span></span>
</td>
<td class="num">(2,888)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (481,737)<span></span>
</td>
<td class="num">$ (1,953,668)<span></span>
</td>
<td class="num">$ (2,455,633)<span></span>
</td>
<td class="num">$ (2,577,053)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">0.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</a></td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
<td class="num">(0.16)<span></span>
</td>
<td class="num">(0.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</a></td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
<td class="num">(0.31)<span></span>
</td>
<td class="num">(0.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">15,134,583<span></span>
</td>
<td class="nump">15,368,027<span></span>
</td>
<td class="nump">15,206,179<span></span>
</td>
<td class="nump">15,454,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">15,134,583<span></span>
</td>
<td class="nump">15,368,027<span></span>
</td>
<td class="nump">15,206,179<span></span>
</td>
<td class="nump">15,454,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953769903560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (2,503,439)<span></span>
</td>
<td class="num">$ (2,574,165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">2,334,811<span></span>
</td>
<td class="nump">3,268,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(4,838,250)<span></span>
</td>
<td class="num">(5,842,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">3,524,684<span></span>
</td>
<td class="nump">3,278,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">805,338<span></span>
</td>
<td class="nump">1,107,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Decrease in non-cash contingent consideration</a></td>
<td class="num">(806,390)<span></span>
</td>
<td class="num">(681,577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">36,197<span></span>
</td>
<td class="nump">36,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Noncash investment gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(34,303)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,817,490)<span></span>
</td>
<td class="nump">1,026,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,696,668<span></span>
</td>
<td class="nump">1,332,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">1,962,024<span></span>
</td>
<td class="nump">195,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">3,417,856<span></span>
</td>
<td class="num">(539,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(1,585,584)<span></span>
</td>
<td class="num">(207,648)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities from continuing operations</a></td>
<td class="nump">2,395,054<span></span>
</td>
<td class="num">(284,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Discontinued operations</a></td>
<td class="nump">2,166,086<span></span>
</td>
<td class="nump">2,483,796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">4,561,140<span></span>
</td>
<td class="nump">2,199,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(95,189)<span></span>
</td>
<td class="num">(166,407)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,627,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,686,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLifeInsurancePolicies', window );">Proceeds from surrender of life insurance policies</a></td>
<td class="nump">460,888<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(1,807,467)<span></span>
</td>
<td class="num">(498,003)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(1,441,768)<span></span>
</td>
<td class="nump">394,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">44,000,000<span></span>
</td>
<td class="nump">56,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(45,500,000)<span></span>
</td>
<td class="num">(56,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred loan costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(52,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payment of contingent consideration</a></td>
<td class="num">(834,014)<span></span>
</td>
<td class="num">(908,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest', window );">Repurchase of subsidiary shares from noncontrolling interest</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(1,551,463)<span></span>
</td>
<td class="num">(2,593,778)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,685,477)<span></span>
</td>
<td class="num">(3,554,625)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(1,566,105)<span></span>
</td>
<td class="num">(960,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">28,212,635<span></span>
</td>
<td class="nump">27,938,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 26,646,530<span></span>
</td>
<td class="nump">$ 26,978,424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period for redemption of redeemable noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLifeInsurancePolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21C<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080552-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLifeInsurancePolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953769297128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2018</a></td>
<td class="nump">$ 55,570,501<span></span>
</td>
<td class="nump">$ 51,098,613<span></span>
</td>
<td class="nump">$ 4,746,154<span></span>
</td>
<td class="num">$ (274,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">364,434<span></span>
</td>
<td class="nump">$ 364,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(703,790)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(40,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,878)<span></span>
</td>
<td class="nump">33,460<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2019</a></td>
<td class="nump">55,190,727<span></span>
</td>
<td class="nump">$ 50,759,257<span></span>
</td>
<td class="nump">4,672,276<span></span>
</td>
<td class="num">(240,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,547,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2018</a></td>
<td class="nump">55,570,501<span></span>
</td>
<td class="nump">$ 51,098,613<span></span>
</td>
<td class="nump">4,746,154<span></span>
</td>
<td class="num">(274,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(452,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(2,574,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2019</a></td>
<td class="nump">51,706,928<span></span>
</td>
<td class="nump">$ 49,563,807<span></span>
</td>
<td class="nump">2,169,101<span></span>
</td>
<td class="num">(25,980)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,231,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2019</a></td>
<td class="nump">55,190,727<span></span>
</td>
<td class="nump">$ 50,759,257<span></span>
</td>
<td class="nump">4,672,276<span></span>
</td>
<td class="num">(240,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,547,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">396,548<span></span>
</td>
<td class="nump">$ 396,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares from noncontrolling interests</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="num">$ (685,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(531,746)<span></span>
</td>
<td class="num">$ (531,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(566,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(549,507)<span></span>
</td>
<td class="num">(17,305)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2019</a></td>
<td class="nump">53,688,717<span></span>
</td>
<td class="nump">$ 49,938,254<span></span>
</td>
<td class="nump">4,122,769<span></span>
</td>
<td class="num">(372,306)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,471,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">346,835<span></span>
</td>
<td class="nump">$ 346,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares from noncontrolling interests</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 640,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(1,361,689)<span></span>
</td>
<td class="num">$ (1,361,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(246,242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,966,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,953,668)<span></span>
</td>
<td class="num">(13,267)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2019</a></td>
<td class="nump">51,706,928<span></span>
</td>
<td class="nump">$ 49,563,807<span></span>
</td>
<td class="nump">2,169,101<span></span>
</td>
<td class="num">(25,980)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,231,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2019</a></td>
<td class="nump">$ 51,085,253<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2019</a></td>
<td class="nump">15,263,355<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 264,574<span></span>
</td>
<td class="nump">$ 264,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(441,624)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,065,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,055,620)<span></span>
</td>
<td class="num">(9,525)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2020</a></td>
<td class="nump">49,843,058<span></span>
</td>
<td class="nump">$ 49,737,428<span></span>
</td>
<td class="nump">152,775<span></span>
</td>
<td class="num">(47,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,318,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2019</a></td>
<td class="nump">$ 51,085,253<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2019</a></td>
<td class="nump">15,263,355<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="num">(10,080)<span></span>
</td>
<td class="num">(407,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (2,503,439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2020</a></td>
<td class="nump">$ 47,843,377<span></span>
</td>
<td class="nump">$ 49,176,040<span></span>
</td>
<td class="num">(1,247,237)<span></span>
</td>
<td class="num">(85,426)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2020</a></td>
<td class="nump">15,084,372<span></span>
</td>
<td class="nump">15,084,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2020</a></td>
<td class="nump">$ 49,843,058<span></span>
</td>
<td class="nump">$ 49,737,428<span></span>
</td>
<td class="nump">152,775<span></span>
</td>
<td class="num">(47,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,318,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">278,349<span></span>
</td>
<td class="nump">$ 278,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(769,648)<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(940,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(918,275)<span></span>
</td>
<td class="num">(22,314)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2020</a></td>
<td class="nump">48,411,170<span></span>
</td>
<td class="nump">$ 49,246,129<span></span>
</td>
<td class="num">(765,500)<span></span>
</td>
<td class="num">(69,459)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,181,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">262,415<span></span>
</td>
<td class="nump">$ 262,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(332,504)<span></span>
</td>
<td class="num">$ (332,504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(497,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(481,737)<span></span>
</td>
<td class="num">(15,967)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2020</a></td>
<td class="nump">$ 47,843,377<span></span>
</td>
<td class="nump">$ 49,176,040<span></span>
</td>
<td class="num">$ (1,247,237)<span></span>
</td>
<td class="num">$ (85,426)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2020</a></td>
<td class="nump">15,084,372<span></span>
</td>
<td class="nump">15,084,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953766899512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2019 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the &#8220;2019 Annual Report on Form 10-K&#8221;). The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 10, for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification of prior period amounts</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made certain reclassifications to prior period amounts to conform to the current-year presentation of the reporting of research and development expense and general and administrative expense on the condensed consolidated statements of operations. Certain costs and expenses related to research and development were previously reported as general and administrative expenses on the condensed consolidated statements of operations. These reclassifications have no effect on the reported operating loss or equity for the 2019 periods presented. </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect the employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland's sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, much of their contact has shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.  Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  During this </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pandemic, less patients sought care, some patients postponed elective surgeries and Cumberland's access to medical facilities was substantially limited.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain the employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Adopted Accounting Pronouncement</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div>Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953768830552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES</a></td>
<td class="text">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in marketable securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of September 30, 2020 and December 31, 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of September 30, 2020 and December 31, 2019, all trading securities were investments with original maturities of less than ninety days and as a result, were classified as cash equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:81pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -   Significant inputs to the valuation model are unobservable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of marketable  securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953766901080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2020 and 2019:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275,620)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,316,286)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481,737)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,953,668)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,134,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,368,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,134,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,368,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,838,250)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,842,361)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,268,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,888)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,455,633)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,577,053)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,206,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,454,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,206,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,454,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and 2019, restricted stock awards and options to purchase 197,210 and 3,600 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953767069240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:39.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,720,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,677,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543,166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,813,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,156,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,047&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,852&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605,570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535,981&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,179,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,082,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.1&#160;million and $0.2 million for the three months ended September 30, 2020 and 2019, and $0.4 million and $0.9 million for the nine months ended September 30, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953768841880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At September 30, 2020 and December 31, 2019, there were no cumulative obsolescence and discontinuance losses necessary.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at multiple locations. As that API is consumed in production, the value of the API is transferred from raw materials to </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">finished goods inventory. Cumberland also maintains API for its Vaprisol brand which is classified as raw materials inventory.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consigned inventory represents Authorized Generic product which is shipped to the Company&#8217;s distribution partner and stored until sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories that are classified as non-current inventories.  The Company also has obtained $0.4&#160;million in non-current inventory for API related to its ifetroban clinical initiatives. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020 and December 31, 2019, total non-current inventory, including Vibativ and ifetroban, was $12.6&#160;million and $15.6&#160;million, respectively. The Company had $2.7 million of Vibativ finished goods included in non-current inventory at September 30, 2020 and did not have any finished goods included in the non-current inventories at December 31, 2019. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following:</span></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,064,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,345,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,664,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,729,578&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,649,184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,554,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,080,394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,871,254&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953768426024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases classified as operating leases. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at September 30, 2020 is 2.2 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,267,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,960,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,761&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996,903&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:76.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at September 30, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,781&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,700)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953768645144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the nine months ended September 30, 2020 and September 30, 2019, the Company repurchased 407,683 shares and 452,155, respectively, of common stock for approximately $1.5 million and $2.6 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2020 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  During the nine months ended September 30, 2020, a total of 10,080 shares have been purchased.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sale</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018 including an At-The-Market ("ATM") feature enabling the Company to sell shares at market prices.  The Company did not issue any shares under the ATM during the nine months ended September 30, 2020 or September 30, 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, and September 30, 2019, the Company issued 230,491 shares and 225,869 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumberland Emerging Technologies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an agreement whereby Hongkong WinHealth Pharma Group Ltd. ("WinHealth") made a $1&#160;million investment in CET through the purchase of shares of its common stock. As part of the agreement, WinHealth obtained the rights to name an individual for appointment to the CET Board of Directors  as well as the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, during 2019, Cumberland also made an additional $1&#160;million investment in CET.  Cumberland purchased additional CET common shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for $0.8&#160;million that was funded during 2020.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $15&#160;million and Cumberland has the ability to request an increase of up to an additional $5&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20&#160;million, which was also the maximum aggregate principal available for </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrowing under the previously amended Pinnacle Agreement. The Fourth Amendment extends the maturity date of the Pinnacle Agreement through October 1, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement. The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of September 30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 2.90% at September 30, 2020, prior to entering into the Fourth Amendment.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. As of September 30, 2020 and December 31, 2019, the Company had $17.0 million and $18.5 million in borrowings outstanding under our revolving credit facility, respectively.  Of the $17.0 million in borrowings outstanding at September 30, 2020, $2.0 million is classified as current based on the terms of the Fourth Amendment.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP is administered by the U.S. Small Business Administration ("SBA").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly commencing during November 2020. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the date of funding the Company has used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As result, the Company has recorded the $2,187,140 as a deferred income liability, which is included as a component of other current liabilities on the condensed consolidated balance sheet. The Company intends to apply IAS 20 to the PPP loan forgiveness and has presented the amounts expected to be forgiven as deferred income. The Company will account for the anticipated forgiveness of the PPP loan under IAS 20 when the Company believes that the forgiveness is reasonably assured.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. In October 2020, the Company submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to SBA for the SBA's review and approval. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of $0.2&#160;million convertible note. The joint venture will seek additional future </span></div>capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953767000712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESAs of September 30, 2020, the Company has approximately $56.3 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953766899512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text">COLLABORATIVE AGREEMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 10 do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953767076008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ADDITIONS AND RETURN OF PRODUCT RIGHTS</a></td>
<td class="text">ADDITIONS AND RETURN OF PRODUCT RIGHTS<div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  The Company expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the initial payments and consideration for the business combination:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.269%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment during 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,182,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,624,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - unlabeled vials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,970,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - validation vials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,129,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,550,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property amortizable intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles and goodwill</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,632,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,633,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(834,014)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(806,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,105,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $8.1&#160;million was classified as other current liabilities of $2.8&#160;million and other long-term liabilities of $5.3&#160;million on the condensed consolidated balance sheet as of September 30, 2020.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V.&#8217; ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectible product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020 and was recorded as an other current liability at December 31, 2019.  Cumberland has approximately $1.9&#160;million in net intangible assets related to RediTrex at September 30, 2020.  During the three months ended June 30, 2020, Cumberland recognized $0.5&#160;million of other revenue in its condensed consolidated statement of operations for a collaborative payment due from Nordic. The payment was received during July 2020.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#8220;the Products&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first three quarterly installments totaling $2.3 million during the nine months ended September 30, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations and will record each future quarterly installment over the two year period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As there are no expenses associated with these payments, approximately $2.3 million in discontinued operations income was recorded during the period ended September 30, 2020. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Products provided $8.8&#160;million in revenue, with $5.5&#160;million in direct expenses resulting in $3.3&#160;million in discontinued operations income during the nine months ended September 30, 2019. These direct expenses do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those sales and marketing individuals who supported the Products have subsequently shifted their efforts to support other Cumberland brands.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019 current assets of discontinued operations included $0.5&#160;million in remaining </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventory for the Products sold and returned to Clinigen as part of the transaction. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, </span>the remaining balance of the current assets of discontinued operations were accounts receivable and the current liabilities of discontinued operations were accounts payable associated with Ethyol and Totect.  As of September 30, 2020, the remaining balance of the current assets of discontinued operations was accounts receivable.   The accounts receivable and accounts payable balances were not sold or disposed of as part of the Dissolution Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953855198744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Adopted Accounting Pronouncement</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953767098632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair value of marketable securities, by type</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of marketable  securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953768476392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2020 and 2019:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275,620)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,316,286)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481,737)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,953,668)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,134,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,368,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,134,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,368,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,838,250)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,842,361)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,268,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,888)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,455,633)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,577,053)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,206,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,454,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,206,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,454,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953767103912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:39.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,720,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,677,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543,166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,813,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,156,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,047&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,852&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605,570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535,981&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,179,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,082,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953768541352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following:</span></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,064,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,345,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,664,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,729,578&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,649,184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,554,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,080,394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,871,254&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953768693224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Position</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,267,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,960,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,761&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996,903&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:76.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at September 30, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,781&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,700)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953768376552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the initial payments and consideration for the business combination:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.269%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment during 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,182,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,624,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - unlabeled vials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,970,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - validation vials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,129,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,550,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property amortizable intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles and goodwill</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,632,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,633,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(834,014)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(806,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,105,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953768531592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953769978552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Cash Equivalents and Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,119,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953847521528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">$ (1,275,620)<span></span>
</td>
<td class="num">$ (3,316,286)<span></span>
</td>
<td class="num">$ (4,838,250)<span></span>
</td>
<td class="num">$ (5,842,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">777,916<span></span>
</td>
<td class="nump">1,349,351<span></span>
</td>
<td class="nump">2,334,811<span></span>
</td>
<td class="nump">3,268,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">15,967<span></span>
</td>
<td class="nump">13,267<span></span>
</td>
<td class="nump">47,806<span></span>
</td>
<td class="num">(2,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (481,737)<span></span>
</td>
<td class="num">$ (1,953,668)<span></span>
</td>
<td class="num">$ (2,455,633)<span></span>
</td>
<td class="num">$ (2,577,053)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">15,134,583<span></span>
</td>
<td class="nump">15,368,027<span></span>
</td>
<td class="nump">15,206,179<span></span>
</td>
<td class="nump">15,454,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">15,134,583<span></span>
</td>
<td class="nump">15,368,027<span></span>
</td>
<td class="nump">15,206,179<span></span>
</td>
<td class="nump">15,454,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953767038776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">197,210<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953770213512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 9,250,689<span></span>
</td>
<td class="nump">$ 6,935,439<span></span>
</td>
<td class="nump">$ 27,179,600<span></span>
</td>
<td class="nump">$ 25,082,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">218,462<span></span>
</td>
<td class="nump">777,185<span></span>
</td>
<td class="nump">1,527,173<span></span>
</td>
<td class="nump">2,608,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">516,066<span></span>
</td>
<td class="nump">116,063<span></span>
</td>
<td class="nump">640,435<span></span>
</td>
<td class="nump">794,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">3,615,557<span></span>
</td>
<td class="nump">2,924,237<span></span>
</td>
<td class="nump">10,387,046<span></span>
</td>
<td class="nump">9,720,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">406,162<span></span>
</td>
<td class="nump">224,940<span></span>
</td>
<td class="nump">790,817<span></span>
</td>
<td class="nump">724,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1,416,146<span></span>
</td>
<td class="nump">1,170,567<span></span>
</td>
<td class="nump">3,677,434<span></span>
</td>
<td class="nump">3,543,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">2,813,249<span></span>
</td>
<td class="nump">1,451,595<span></span>
</td>
<td class="nump">8,551,125<span></span>
</td>
<td class="nump">6,156,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">265,047<span></span>
</td>
<td class="nump">270,852<span></span>
</td>
<td class="nump">1,605,570<span></span>
</td>
<td class="nump">1,535,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953867295784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">$ 12,649,184<span></span>
</td>
<td class="nump">$ 15,554,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953769490744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 17,064,269<span></span>
</td>
<td class="nump">$ 19,345,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">250,615<span></span>
</td>
<td class="nump">416,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,414,694<span></span>
</td>
<td class="nump">4,664,055<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross, Total</a></td>
<td class="nump">22,729,578<span></span>
</td>
<td class="nump">24,426,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="num">(12,649,184)<span></span>
</td>
<td class="num">(15,554,992)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories classified as current</a></td>
<td class="nump">$ 10,080,394<span></span>
</td>
<td class="nump">$ 8,871,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953843991416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">7.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953772521576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Lease Position) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,267,669<span></span>
</td>
<td class="nump">$ 2,960,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">991,969<span></span>
</td>
<td class="nump">920,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">1,323,792<span></span>
</td>
<td class="nump">2,076,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 2,315,761<span></span>
</td>
<td class="nump">$ 2,996,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953855097112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Leases Liabilities at September 30, 2020</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 288,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">1,144,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,019,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">92,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree', window );">After 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,545,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(229,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,315,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953844267016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Shareholders' Equity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (332,504)<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="num">$ (1,361,689)<span></span>
</td>
<td class="num">$ (531,746)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentCashContribution', window );">Contribution of cash</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable', window );">Conversion of intercompany loans payable</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember', window );">WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPurchaseOfShares', window );">Investment through purchase of shares of CET Stock</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember', window );">Gloria Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital', window );">Cash payments for return of shares</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,491<span></span>
</td>
<td class="nump">225,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,354<span></span>
</td>
<td class="nump">141,463<span></span>
</td>
<td class="nump">164,866<span></span>
</td>
<td class="nump">246,242<span></span>
</td>
<td class="nump">84,447<span></span>
</td>
<td class="nump">121,466<span></span>
</td>
<td class="nump">407,683<span></span>
</td>
<td class="nump">452,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (332,504)<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="num">$ (1,361,689)<span></span>
</td>
<td class="num">$ (531,746)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="num">$ (1,500,000)<span></span>
</td>
<td class="num">$ (2,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentCashContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Cash Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentCashContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Conversion Of Intercompany Loans Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Payments For Return Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953847864984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Debt) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2020</div></th>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 07, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Current portion of revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain', window );">WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Initial investment in joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,187,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Fourth Amendment | Revolving Credit Facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount', window );">Increase amount (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity', window );">Total capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_FourthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_FourthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953768510040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 44,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 56,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953769563320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Direct expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Discontinued operations income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Financial consideration received in exchange for product license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during 2019</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Percentage of tiered royalty payments (up to)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,105,578<span></span>
</td>
<td class="nump">8,105,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,633,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Net intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,750,000<span></span>
</td>
<td class="nump">11,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ | Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Vested common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Net intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Unvested restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NordicGroupBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953847846520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during 2019</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PaymentsForContingentConsideration', window );">Fair value of contingent consideration - net sales royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsForContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsForContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953769141000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="nump">$ 882,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory', window );">Finished goods inventory</a></td>
<td class="nump">6,624,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials', window );">Work in process - unlabeled vials</a></td>
<td class="nump">3,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials', window );">Work in process - validation vials</a></td>
<td class="nump">1,827,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory', window );">Raw materials</a></td>
<td class="nump">9,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Total inventory</a></td>
<td class="nump">21,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intellectual property amortizable intangible assets</a></td>
<td class="nump">11,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill', window );">Total intangibles and goodwill</a></td>
<td class="nump">12,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">$ 34,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953764186056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Change in Consideration (Details) - Vibativ<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 8,633,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(834,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">(806,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="nump">1,112,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 8,105,578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M&WYR@]<B-)\N;Z?8(89_=#R#V_3!68LQ6!9CL+2'6>1KKJ$Z9B9Z30=)I?+
M*ILSS]W$&[C^<$RA'NZ.J9RC0S:36_;L49' K)R+\[;J:76^.;6G>D[]>7$X
M^H69U%0DX6MHZIZ/X.=E<=Y8W&BQM4=V*Z&U2.UEQ%G(I?D WJ^%T(<;\P/5
MJ>_D/U!+ P04    "  #BFU1_\?[8[$&  "&&@  &    'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;*U9;6_;-A#^*X(W#!V0U'R11#%-#+0)MG7 VB!9M\^,
M1-M"9=$3:;O9K]]1<BQ;I.@46( D>GEX>NYTO.=(7>]4\U4OI331MU55ZYO)
MTICUU72J\Z5<"?U6K64-=^:J60D#I\UBJM>-%$4[:%5-"4+I="7*>C*[;J_=
M-[-KM3%56<O[)M*;U4HTSQ]DI78W$SQYN?!0+I;&7IC.KM=B(1^E^;*^;^!L
M>K!2E"M9ZU+542/G-Y/W^.J6)G9 B_BKE#M]=!Q95YZ4^FI//A8W$V09R4KF
MQIH0\&\K;V5564O XY^]T<GAF7;@\?&+]5]:Y\&9)Z'EK:K^+@NSO)EDDZB0
M<[&IS(/:_2;W#K4$<U7I]F^TVV/1),HWVJC5?C P6)5U]U]\VP?B: ".1P:0
M_0#RV@%T/X"VCG;,6K?NA!&SZT;MHL:BP9H]:&/3C@9ORMJ^QD?3P-T2QIG9
MK:H+>"FRB.!(JZHLA(&3#Z(2=2ZC1VM81Y?1E\>[Z,V//U]/#3S4#IWF^P=\
MZ!Y 1A[P*-=O(XHN(H((\@R_#0^_DSD,QW8XYJ?#I^#JP5]R\)>T]NB8OYNF
MD;6)A-;@V%7 (CU8I*W%>,RBT,M(U$64VP/YSZ;<B@H>H7VQZDREK2D[P[8S
MDJ9QFE (S?8X*AY@1C!):7( GK"-#VSC(-OW>:XV0 ZF8"Z!Z5,E+Z):&A_9
MSE)RQ(&G*8X1&W!U<2R+*<?,3S4Y4$V"5#_66PBC:DKI#67B/!4CE"'*XP$]
M%YAE#),D]M-+#_32\'L_R:1(S:.BU+FJ35EO8 9!H6V$K51>\JD;,L)2-LP"
M%T9BQC),_=39@3H+4K]OY%J419NURBQE Y7FV!D?8^:&&Y@@E@THNSC"$A8G
MJ9]R=J"<!2G_J8RH7D$S<QX?9QF'G.4#GBXP03BEB(U,,'X@RH-$/ZGZ\H5F
M&<Y@[H:4I#''V3"#/< D26+.B9\K1GWU1V<RP>:I>6Y3P=:N-4BT&:T(>VO'
M3%)$.,8#PAX<@\3E(TF C]0*GZD)1M2+$JK6/@?&J6(W$3.<(<2'D\R#I(@3
M1,E(A<"]V& 2I/NK4L6NK"HO0>*I2]!].?3.XD[)];J%P\)U)^<2\K2(C/AV
M-IK4C28$DPRYGH.=4NU%"X=5ZW-73.M%5$GHV:+&-F>7:GZYT3)0#+"K3(2D
M+$V'Q< 'Y"E*CH"GS'L-PV$1^]R6UP!%5YU(@G'FJ)@'2 G/&!FI5[C7,1P6
MLJZT!BBZ*@2Q03PE3AA=)$8Q%"J2C2@6[B4+LU<U;E4IGLJJ-%!30]T;[H4%
MAY7ET!&MQ;-MA[PA<-4"HXQ2SIP9X"(YYS0YTLE3GKVNX+"P> +PG4T'=G7$
M*38>J0%!RM(1^J17&A)6FN$4SEUW?)R)JR2<8^[,8!^.H)CB$=Z]XI"PXKR$
M?:V:=MT)(6_D5E7;UA4 VRLYE-'26SB)1X90^S-TP 6.5'ARM-8)R\_GD][N
M7*1=G<$(8X)=JAXDIIC19"Q+>DTB84TZ;?/.,?:H#>4T0_&P'_$A8YP@,K:<
M(KTTD; T/7Q/,K@R R2\V>!!9LDI\I1PKTCDC"(-)F*MZM?&V[/DHH0R/BR"
M'B!!+(W92"- >JTB8:WJ,KI2]>+2R&9UEK%GG<51'&.G?+C C%$&WHTP[G6+
MA-=:74:?X^FNFN(,IRE)G-"ZR(3&:8SH6&+T0DC"0GBK5JO2V/Y?=_L9K:PL
M9)V/L0[:LQN05WHM<GDS63=2RV8K)[/(MP7T/Q@Z];D75<*#7<7C4C1RJ:I"
M-OJG'S*"V;MV&62>@UM#O>K1L.K9F()H:*/RKZU]\JY6T&DTT594&_DN@NIZ
M@;K?2%LR$/N-6<*:\5]9P.WD E9Z%UF:M*\$3AFA%[!(?0&76EOA;U?R&Z-A
M=538J2W:WN#W#52D;N\-9RWF3N9R]013:+^EQBY S?1:MINIU;-WR\I55EBC
MLA3%SIZ5#\EQ'(\U/[1781I6X0=I!%R"-:IH:G!01V\*.2_STGBW)*DKII>8
M0/VAP[TK#Q(3:.WXB##07GQI6'R[B:]'$\S+VU76&,IKEB$ZY.TB8=E "%2M
M$>)'^YEA#?X$@@!3OU%595.IK*'22CVRG^D*ZV66Q"0=TO7@*$O)2-&BO?S2
ML/QV40Y$U!72V.Y.4N9D@HM,H,E/2#(6T5YR:5AR'0TX;+>,D$Z<W=^1%9<'
M.;;BFAY])+!?:/X0S:*L-70!<QB+WC(PU70?/;H3H];M=X,G98Q:M8=+*2"1
M+0#NSY4R+R?V4\3AT]/L/U!+ P04    "  #BFU1/J_1Q8,"  #0!@  &
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M=#XA#MWVSW9B5>-;T$I9:FA^6-$G![4+H/VU4O9QXKI:_Q'+_P%02P,$%
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M0A1G/GD$!VE&E<3)4S(T9C))_W9G:EO\K^V[:+,E6&Q*HA*/,0:$J) ^<(D
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MY@L#P7DF5M%<)3CUT1B>WI'Q,_#G*G^D?LYHBAY9J$ZW)3>NH!!/9TC ;)]
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MN#,GM-Q55X*L;[SAH6\97]]3-';SJA"/RE-\TD-D&D*#/M;8B^G@)AYOP[B
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MG-%]%(UD<>F<@C!<6TKE! BD)I!9*$1MD!"-A.=BA3&18-?6>^+T9W9EXAD
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MLR"PC.,;<+ZTX+/F#QOH7I==_ 502P,$%     @  XIM4=5R_#DK!   < H
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M1.T$Z'ZKE#UNG(%QR%S^"5!+ P04    "  #BFU1P3RW[.(&  "Q#P  &0
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MX6-(0M)OXGG"[-/C.,6#='KP_/3UO8>N: 3*OD3>?(7\?YWFHI,IIH_SESX
M%B>?4=BU]^%CD4<MCN']%]7T=/H>O>P_PYZ6]Q^S/PF[YVU%RQU,X_DJG_4S
M=;SQI@T?95OC<78/EP=\4TO+"_!^9W N'&[8P?25?O$_4$L#!!0    (  .*
M;5%(+-11( 8  "T.   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;)57
M:V_;-A3]*X07;"V@^J'(CITF 9(^MF!H%R1=^F'8!UJZCKA0I$I2<=-?OW,I
MV;$3)\. UA&I^SKG/B@>+:V[]251$-\K;?QQKPRA/AP,?%Y2)7W?UF3P9F%=
M)0.6[F;@:T>RB$J5'J3#X610265Z)T=Q[\*='-DF:&7HP@G?5)5T]V>D[?*X
M-^JM-B[531EX8W!R5,L;NJ+P9WWAL!JLK12J(N.5-<+1XKAW.CH\RU@^"EPK
M6OJ-9\%(YM;>\N*\..X-.2#2E >V(/'GCMZ1UFP(87SK;/;6+EEQ\WEE_6/$
M#BQSZ>F=U5]5$<KCWK0G"EK(1H=+N_R-.CQCMI=;[>.O6+:R^VE/Y(T/MNJ4
M$4&E3/M7?N]XV%"8#I]12#N%-,;=.HI1OI=!GAPYNQ2.I6&-'R+4J(W@E.&D
M7 6'MPIZX>3<W)$)UBGR1X, @[P]R#OELU8Y?49Y)CY9$THO/IB"BFW] 0)9
M1Y.NHCE+7S1X175?[ \3D0[3X0OV]M?H]J.]_?] =R_>*Y]KZQM'XJ_3N0\.
MY?#W"QZRM8<L>LB>\_#Y^L/G+W]<GG^XVL7?B\K<<(>^ECD=]]!1GMP=]38M
MBB\EB7>VJJ6YC]7M!8,@C94*I0BE<H6HI0M(GP@6A6&:!9 Q3&GX57Z+UA(+
M911JI! WUA9>H)>%EYKZX@P%70AT1X GZ9PT-X26"W[E@#9M.@'%SJ9+XMMU
M=$IK0="!4)"W)((*FC@FEGKD7X:X&]#=PBZ$+U7-3MGZHU<(2=U)O=KNO/W\
MTS0=';Q%D-)1:1M/OK_%%62-**V&+]_D9>=6&?Q;%41C@M*B4"@%-6_:"0'&
M6EI@RS^)6CVT"N(BX8,,>-F%ANG&_"Q$;GU$8C!1,2:U^B'G8 (H&FI9C1(%
M!7)H:%AHO#(W'4_.AS?*)-T3IJBH*)2VV,9'; W>_08@3FIM U8*A*%,P(HH
MFI@#^IZ3]XFP<V\U''-\'A&_J>P=^VX!SN\1&APXWF(BO"C!#QN/Q>3L/^TL
M]:N\/G@'?26$^N(K4T]WJB"3LT"A\AAH*#NB<N3TGCVTC%3R7A@;Q)S 5F[O
MR#%=B9 B+Z5#[2H?"\JP3T=% ZO;KK&O4+!YXQP7T2[>^^(T" R70-4<65I-
MF CK/>7=[HAW1[-8V,CODG^,A>&JT9(/CXX_GT=LK(SZR3$"E6DD;W6L&V*Z
M<<9M9PU(T.4U^%,<&2>,D=2- U0?ZSVV83RH1 WX%68#:C-'0L$8T"M&^(KK
M/QV^/;TXCT^CMZ^CL=\=LB5Y0,38^$@.^.\?\84\ %!0M>: D1W.*!CJ<@2K
M'"E@X:!&=:)KD'GPSG)MT[>9Z\+MY#%1C5\0<E"(A;.5<'*)$%#D*,=8,,^T
M$TAZUW "- <-6;L1.1MG:)S@:UD#($[(N6/)9:G0V1RIEMZKA>)>](_<;CCA
M3# H=6,BJA4=CN+LY9EWVJ#5G/J!][^2@8E\!?W!&P^K&@)=!SR>2%L#A2<S
MS+2#!<ZXU^/8::<,&&>)%9'7:LY5AOQ_:Y17+=V;U/ ^VV!2(@,X$;KT<+UM
M#:B82IY2V^P8:]ZL&F5#?+M.8PY0D2AWS@(T]X;]#%\?6C,J>-QEIIU ')LC
M'2=CUYAJ0<'9N32(!270%C/@Q9;R_[<U+2I\M_\$C[EN"IXM:RYA9>T_P7GA
MQ=XH[4_68%A@;S1^V$EBCU+L0?VH@4L)X;1_L-9&YE:>GE0WA]*VSVZVY+.P
M"U7$D5C*.^[D^Y=L<^$\DU3V\(3!+4"_^#@M-W5BAWC.7E>5"ZMQ4(#3PUWA
M/K$O+K?Z;U>9[HG103*<9$DZF?%BENQGX^0@W4=83]LS'0^3R6@LLM$DR293
M\7&;BW&2C;)D,LL$?F%S.!Z++[%&-E&E*>S/DO'!5*19DJ63),TF0G,TSY'W
M:I0FDVR6C*;9:RS&R7B<);-9^GJ'^>T>6UD#M&$RG Z3?42W)Z;)]&"4I.-,
M[/KL'&Q\PE>$<X\O*IP.#(SV:WZ]N[X+G;97@ ?Q]B+U"<<FSTY-"Z@.^P?C
MGG#MY:1=!%O'"\'<!EPOXF.)^QPY%L#[A<5G1+=@!^L;XLF_4$L#!!0    (
M  .*;5&!.+!RL@4  *4-   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;)U7VW+;-A#]E1TUO<W0$D7='=LSLN-,TW$:3^2T#YT^0"0D(0$)%@ M*U_?
MLR"ER+&L9/HB$2!V]YR]@F=K8S^YE92>'G)=N//6ROORM--QZ4KFPK5-*0N\
M61B;"X^E779<::7(@E"N.TD<#SNY4$7KXBSLW=J+,U-YK0IY:\E5>2[LYE)J
MLSYO=5O;C?=JN?*\T;DX*\52SJ3_4-Y:K#H[+9G*9>&4*<C*Q7EKVCV][//Y
M<.!/)==N[YF8R=R83[QXDYVW8@8DM4P]:Q#XNY=74FM6!!C_-CI;.Y,LN/^\
MU?XZ< >7N7#RRNB_5.97YZUQBS*Y$)7V[\WZ-]GP&;"^U&@7?FE=G^WB<%HY
M;_)&& AR5=3_XJ'QPY[ .'Y&(&D$DH"[-A10OA)>7)Q9LR;+IZ&-'P+5( UP
MJN"@S+S%6P4Y?W$C0<F==3QT\4XG;>0N:[GD&;D)O36%7SFZ+C*9/9;O ,,.
M2+(%<ID<53B399MZ<41)G,1']/5VQ'I!7^\H,?I[.G?>(O;_'-'9W^GL!YW]
MYW1>3V?7LT/..BK'A77J2I'*\Q8JQTE[+UN-,GI3T%MATQ5X=X<1^96DU]/9
M)2GG*IG1=/8AO#F)D_;^XJ<?QDEW]-)1:JRDTJHB5:66$"-O""O+_ G4"UBV
MLD@W)(H,QW,LQ5QIY;&3FV))*&E1J,^"R\31?(-B2\T2.PHO== CG)/>!0U:
MU=(*WD59,>"YT*)()=5MA ]ERJ7:.%;P26Z IVX?,-"FNU4 S#V Y&*!\B2S
M()&9TO/Y/9),A?5?,>AB0VL1V#$\FY'E@CLQBY/J,4 SUVK9D('9H$'7V9!J
MG%,+!<="%3J;%7Y'TK7IJLKGTH),MO.O4_#$0J6B\$\$V,^ZRN07$X%)65KS
M 'Y>Z@TE@V@0Q^@V%:) "W80SI@%5,)AG!300G\(M[I76LN([F112+"1 ;SR
M(<2E@6%)*[1=5N2E=>Q(1+LVFU86,?:P)Q]*90,T>I=Z SI<44GM]B<$A';F
M>UAT^U'RE,4:?UK,&9NQ=7Y]%S&DV-7U742FLNAE'XU%+IZ8=8&PN&KN5*:0
M&Q&M5Q+&U-;O@!N2X?J.;M1"TBQ52&OL7H&YM-_VQQ19I]D;O3:]>^R)1UG-
M%.L<J_/$AX1%W2(%[H6N@G^LY)'W14$I-IA5B%9A/&W@F%*H[''^$5#FH31,
M!<095:% ^'TH6)87FN!/]"5^$V*.C#6I$GQ^K?R*I$"S"/J>LCA4$E9NL9MC
MG+./&#:R1ER_!B9(86;6906R7@%>!G>B9%/C<!N@J3M4-$UV929X(\6D@*](
MY:56*>+YF*&+ON$"AT1#2%*ATTH'1_ <SKC[[#46$O="(1O1!(6GWT51<8/I
M\D#I3MKHL\^KQT6 ;PG[O69'13H?BH =@/AAV0BQHS!]&9 56GUF6%N]Z"WW
M*#RG<B"R>]%W=1VNPV5!9B<"QW#W.1;_BJFBZVWSYG Z\N:S*8FR&+7[R8_/
M&/]:+J0I?(B1["7'=C>765/23I#?@AM0F+%TBSX? C ]*,*Y\TJFS6X3#XKV
MG?VS.SYF0O@%NUSC$NE.Z?TVSS] :%H+'3#]U.SW%,P+2J)D.(J&PTEXG@SC
M:(#GFNW-'J[_9;)I38\(OJ#)I M#;'"2Q%&_UWTB5YCBD&@WZB6]:#1)@#0>
M#:/^**$[PWG$V'O=030:=FL>DV$TB7NX;OB*.RZG37-+VB=U./!?T#0B81=J
MQ^-H-.[RL@LLW7X_&H\G8>1@"?Z T L]%\0 ;DS3A:]G4H]"D24O&[Q?)6T2
M#?J#J _P-Y@:IRC@IOQ^29))-(KC7^GVZRIXVM?VG7#H!MC9NSKGTB[#!P*/
M7%1:?8O>[>Z^0:;UU?O+\?H#!M>XI2HXE1<0C=NC0:O.K^W"FS)<Q.?&XUH?
M'GF@2\L'\'YAC-\NV,#NR^SB/U!+ P04    "  #BFU1VSCFXP@/  #&)P
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M^\C*1<,VO X[O)FY0QL2"H&*ZG%+CEC*@H(;IZ=ZK=,:9@SYTT!T9@RK.'C
MW)Z,!7>X)TS!7_9875DP@NV5JTLJ)[$]![J0%Q )Y.6T3G X'<-TEV +#ST4
M<9D#YRA#9\)HVTB!3+>CL6&$H!T/D+DU0><P8)IJH@@!']-_S^7::J2SFX2(
MZO<VB28#VXCW>>U"!?AD/#KNI01IESY(:"E%8[OPK+M0D_,E :QR(TNR[P:
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M[9I.T&D;M!V7H]]&__C;8CHY>X6QP[_:':C4 Q#@J"/_/+H="<N#.BWR&X(
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M .]7!D4^?*$#FG\#\?9_4$L#!!0    (  .*;5$KCB:N9@H  .8:   9
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M=W"BDGZV'/F,NRD4--+T=4.8K##:FC@EPFWMT,70Y)9(7KP7I\;<MQJ!8&5
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M >CQIA\%JW;^=ETK2W>U7[;T<X3:*=#Y1BE[%)R#T^_6ZG=02P,$%     @
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M!0-+4=4@="4%45 NO%5T?C&QY]V![Q7L]=&:V$@V4OZVPJ=BX876(>"0&\O
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M7%D<POQRA5,OTTX [Q=*V7;C''1S]/1_4$L#!!0    (  .*;5$QH#V/)@(
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M>T+V.^\WAB@SP6H1*YI)Q&"ID4&KKQ^>*(;"8J-X;N>J.5=Z2K/+1 _2($R
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MU7?E_<#(?==VKJ6!)K9[K.!+ABD+@/=;*<WSP#H8OXWF?P-02P,$%     @
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MP".;/-T*#OZ,_/[\D#UR\UGBVU8.UH?@9#G0X'P(39*C"S^9\C&,S*RWY'
M(2:0)/9"[@#&A$"([,7# 30N22DY\WJ@P:"1WZ"_ZZU0[VG[RCB8'\+311G<
M#_EW?#\5A3@V.01@>_UPX1B(";(E&>/,JF_6(WN+ZP*2B"0Q/"/)8-'(;]&_
M*UYJ7_$&[T-LNA2#^2'_ON^G4L2C73\$]9\MQ1B''+B5 X<=N+4#EYSBVH3#
MHP_T0JCGYF2D"C9R7^KV^ZWO[4]?KILS!ZO_!EXNH:-_!2_7[=G*0-\>]7SC
MZCDKJR 73V8H<,',M%'MZ4G;T'+7' \\2JUET5QN!4^%J@'F_I,T'SU=HQZ@
M/\-:_ =02P,$%     @  XIM4>K"]OI= @  J 8  !D   !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&ULK55=;]HP%/TK5K0'D%;R0?A(%2*MH&I(6X6*VCU,
M>S#)!:PZ=F8;:/_];"=X5(5L#^0A\?6]Y^2>D^0F/7#Q(K< "KV6E,F)MU6J
MNO5]F6^AQ++'*V ZL^:BQ$J'8N/+2@ N+*BD?A0$0[_$A'E9:O<6(DOY3E'"
M8"&0W)4E%F]W0/EAXH7><>.1;+;*;/A96N$-+$$]50NA(]^Q%*0$)@EG2,!Z
MXGT);Z>)J;<%SP0.\F2-C)(5YR\FF!<3+S - 85<&0:L+WN8 J6&2+?QN^'T
MW"T-\'1]9+^WVK66%98PY?0'*=1VXHT]5, :[ZAZY(>OT.@9&+Z<4VG/Z%#7
MQK&'\IU4O&S NH.2L/J*7QL?3@#A)4#4 *+_!?0;0-\*K3NSLF98X2P5_("$
MJ=9L9F&]L6BMAC#S%)=*Z"S1.)7-V1Z8XH* 1)T'+ 0VMG919P8*$RJ[Z 8]
M+6>H\ZF;^DK?T,#\O"&_J\FC"^1+J'JH'WQ&41 %9^#3=O@,<@T/#3Q,WL-]
M+=-IC9S6R/+U_Z'U#?W\IE-HKJ"4OUJ(^XZX;XGC"\0/G-WD.R$T.R)_#3UG
M6$TTM$3F"]MG832,DW <I_[^U)HSA8/!($Z2R!6^ZS5VO<:MO<[7H 1?88:F
M.D5R3%L,&#C2P76='3KBX96<G0X_&!8'YCAOU\@U,&IMX)FLS!?1(F7LF,;7
M]2AQQ$EKB_?Z,>H!4* -Y\79ER[Y8$TT.N>-?S)'S S_CL6&,(DHK#4RZ(WT
M6R#JN5@'BE=VM*RXTH/*+K?Z5P+"%.C\FG-U#,RT<C^G[ ]02P,$%     @
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MR57N\M?M?=%.K&K"D?NDK#O PW#MKEBF?8!;7RIEWR?^%.\N[>D_4$L#!!0
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MYLR^5C,-O;"+LN*2E8:K$FFVG@0WT?5MA)W K_C)V=X<M9&SLE#JS74>5Y,
MNXR88$OK0E!X[=@=$\)%@CQ^MT&#CNF$Q^U#] =O'LPLJ&%W2OSB*[N=!'F
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M&Z?)I=J%9PWN[HHO5&^9-(3#!J'1X#U60+?SUQI6U;[GU\KB!/EEA5<6:.>
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @  XIM49W'A0R" P  Z!H
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M<',O87!P+GAM;%!+ 0(4 Q0    (  .*;5'[O-E.[P   "L"   1
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M965T,BYX;6Q02P$"% ,4    "  #BFU1/J_1Q8,"  #0!@  &
M    @(%T%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M XIM4:W2KVR1!P  12(  !@              ("!+1<  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    (  .*;5%#RS>AA <   X?   8
M          " @?0>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    "  #BFU15BO]ST\)  #^.0  &               @(&N)@  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @  XIM4=#@IUNJ$0  ="X
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    (  .*;5&!.+!RL@4  *4-   9
M      " @8Q;  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @  XIM4=LXYN,(#P  QB<  !D              ("!=6$  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  #BFU1!C0BNAT#  #2!@
M&0              @(&T<   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    (  .*;5%"[0(S[0,  '<(   9              " @0AT  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @  XIM42^N[G9C
M#   #R$  !D              ("!+'@  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    "  #BFU1*XXFKF8*  #F&@  &0
M@('&A   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  .*
M;5&<8WHPKP(  #\&   9              " @6./  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @  XIM4:FK&,/! P  >@D  !D
M         ("!29(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    "  #BFU1,\)415P#  #.!@  &0              @(%!E@  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (  .*;5&^KW&UTP(  -0%
M   9              " @=29  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @  XIM49GUU>DO P  EP<  !D              ("!WIP
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  #BFU1199.
MJ7\$  !3"P  &0              @(%$H   >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    (  .*;5$QH#V/)@(  * $   9
M  " @?JD  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M XIM4=P!DP_4 @  I@L  !D              ("!5Z<  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    "  #BFU1IN)LK>H#   G#0  &0
M            @(%BJ@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    (  .*;5$%%G&36P(  $\%   9              " @8.N  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @  XIM4;V5^4E.!
MSQ(  !D              ("!%;$  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    "  #BFU1ZL+V^ET"  "H!@  &0              @(&:
MM0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (  .*;5$4
M8:?,R@(  , '   9              " @2ZX  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @  XIM44GZO)0' @  BP0  !D
M     ("!+[L  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  .*;5$S?.)\$P(  ! %   9              "
M@5O-  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @  XIM
M4<4%_/?!!0  +QH  !D              ("!I<\  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    "  #BFU1NERN)!(#  !$"0  &0
M        @(&=U0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   (  .*;5'8+=Y30 ,  /P)   9              " @>;8  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @  XIM41LB?+_6 @  _@8
M !D              ("!7=P  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    "  #BFU1FNHL?2L"  !]"0  #0              @ %JWP
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  .*;5&7BKL<P    !,"   +
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4!08     ,  P  <-  #PZ0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>142</ContextCount>
  <ElementCount>274</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Investments in Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities</Role>
      <ShortName>Investments in Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129110 - Disclosure - Additions and Returns of Product Rights</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</Role>
      <ShortName>Additions and Returns of Product Rights</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Investments in Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Additions and Returns of Product Rights (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables</Role>
      <ShortName>Additions and Returns of Product Rights (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Investments in Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Leases (Lease Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases (Lease Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Shareholders' Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cpix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Change in Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20200930.htm">cpix-20200930.htm</File>
    <File>a2020q3-exhibit101.htm</File>
    <File>a2020q3-exhibit311.htm</File>
    <File>a2020q3-exhibit312.htm</File>
    <File>a2020q3-exhibit321.htm</File>
    <File>cpix-20200930.xsd</File>
    <File>cpix-20200930_cal.xml</File>
    <File>cpix-20200930_def.xml</File>
    <File>cpix-20200930_lab.xml</File>
    <File>cpix-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 142,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 334,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 21,
   "keyStandard": 253,
   "memberCustom": 16,
   "memberStandard": 20,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Shareholders' Equity and Debt",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Collaborative Agreements",
     "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129110 - Disclosure - Additions and Returns of Product Rights",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights",
     "shortName": "Additions and Returns of Product Rights",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables",
     "shortName": "Investments in Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Additions and Returns of Product Rights (Tables)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables",
     "shortName": "Additions and Returns of Product Rights (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Investments in Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i51d553293659413f87554dc788d4bcce_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual",
     "shortName": "Earnings (Loss) Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i51d553293659413f87554dc788d4bcce_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Revenues (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "ie302cf43817549578a8f9ef152a447b1_D20200701-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i43031ec5d6b146e396b7ed311aeda9fd_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Leases (Lease Position) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases (Lease Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i8cea20af1c7a4bf8892167b3a57bb8b3_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i8cea20af1c7a4bf8892167b3a57bb8b3_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
     "shortName": "Shareholders' Equity and Debt (Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i593c0deb73804b658d160e2556b47e42_I20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
     "shortName": "Additions and Returns of Product Rights - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i6687a95bae3143d5b4bd7100bc41042c_D20190101-20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
     "shortName": "Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:PaymentsForContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i2aae3ade58f14629babea615840c16d4_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
     "shortName": "Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5e39f507697344bf966ae5d85dc07c38_I20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i51d553293659413f87554dc788d4bcce_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i51d553293659413f87554dc788d4bcce_D20200701-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i582dbdc998d44cdbab1a7981ad14c27c_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
     "shortName": "Additions and Returns of Product Rights - Change in Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i6029a53d251a4c738d4ca429b6ceb191_D20200101-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i4b79c2df727e4b81b6070f5e05dfd76a_I20181231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statement of Equity",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
     "shortName": "Condensed Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "ief40d394930e4ad8aa55d1f1875a0473_D20190101-20190331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Investments in Cash Equivalents and Marketable Securities",
     "role": "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities",
     "shortName": "Investments in Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200930.htm",
      "contextRef": "i5bb4993704074c9daa76df17c89ca35b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acetadote",
        "label": "Acetadote [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Position"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "terseLabel": "Finished goods inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "totalLabel": "Total intangibles and goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "terseLabel": "Work in process - unlabeled vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "terseLabel": "Work in process - validation vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Caldolor",
        "label": "Caldolor [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ClinigenHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinigen Healthcare Limited",
        "label": "Clinigen Healthcare Limited [Member]",
        "terseLabel": "Clinigen"
       }
      }
     },
     "localname": "ClinigenHealthcareLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "cpix_FourthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fourth Amendment",
        "label": "Fourth Amendment [Member]",
        "terseLabel": "Fourth Amendment"
       }
      }
     },
     "localname": "FourthAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_GloriaPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gloria Pharmaceuticals",
        "label": "Gloria Pharmaceuticals [Member]",
        "terseLabel": "Gloria Pharmaceuticals"
       }
      }
     },
     "localname": "GloriaPharmaceuticalsMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HongKongWinHealthPharmaGroupCoLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "HongKong WinHealth Pharma Group Co. Limited",
        "label": "HongKong WinHealth Pharma Group Co. Limited [Member]",
        "terseLabel": "WinHealth"
       }
      }
     },
     "localname": "HongKongWinHealthPharmaGroupCoLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "IncreaseDecreaseInCurrentOperatingLiabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCurrentOperatingLiabilities",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Kristalose",
        "label": "Kristalose [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Three",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Three",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount",
        "terseLabel": "Increase amount (up to)"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity",
        "terseLabel": "Total capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NordicGroupBVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nordic Group B.V.",
        "label": "Nordic Group B.V. [Member]",
        "terseLabel": "Nordic"
       }
      }
     },
     "localname": "NordicGroupBVMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Omeclamox-Pak",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherLongTermObligationsExcludingCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long Term Obligations, Excluding Current Portion",
        "label": "Other Long Term Obligations, Excluding Current Portion",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermObligationsExcludingCurrentPortion",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Products",
        "label": "Other Products [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PaymentsForContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Contingent Consideration",
        "label": "Payments for Contingent Consideration",
        "terseLabel": "Fair value of contingent consideration - net sales royalty"
       }
      }
     },
     "localname": "PaymentsForContingentConsideration",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ShareholdersEquityTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shareholders Equity.",
        "label": "Shareholders Equity (Textual) [Abstract]",
        "verboseLabel": "Shareholders' Equity (Textual) [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityTextualAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentCashContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Cash Contribution",
        "label": "Subsidiary Investment, Cash Contribution",
        "terseLabel": "Contribution of cash"
       }
      }
     },
     "localname": "SubsidiaryInvestmentCashContribution",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Conversion Of Intercompany Loans Payable",
        "label": "Subsidiary Investment, Conversion Of Intercompany Loans Payable",
        "terseLabel": "Conversion of intercompany loans payable"
       }
      }
     },
     "localname": "SubsidiaryInvestmentConversionOfIntercompanyLoansPayable",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Payments For Return Of Capital",
        "label": "Subsidiary Investment, Payments For Return Of Capital",
        "terseLabel": "Cash payments for return of shares"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPaymentsForReturnOfCapital",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPurchaseOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Purchase Of Shares",
        "label": "Subsidiary Investment, Purchase Of Shares",
        "terseLabel": "Investment through purchase of shares of CET Stock"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPurchaseOfShares",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "label": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Percentage of tiered royalty payments (up to)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vaprisol",
        "label": "Vaprisol [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WinHealthInvestmentSingaporeLtdDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "WinHealth Investment (Singapore) Ltd",
        "label": "WinHealth Investment (Singapore) Ltd [Domain]",
        "terseLabel": "WinHealth"
       }
      }
     },
     "localname": "WinHealthInvestmentSingaporeLtdDomain",
     "nsuri": "http://www.cumberlandpharma.com/20200930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r57",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r225",
      "r228",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r362",
      "r397",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r225",
      "r228",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r362",
      "r397",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r162",
      "r213",
      "r214",
      "r363",
      "r396",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r162",
      "r213",
      "r214",
      "r363",
      "r396",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r215",
      "r225",
      "r228",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r362",
      "r397",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r215",
      "r225",
      "r228",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r362",
      "r397",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r203",
      "r226",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r167",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r16",
      "r29",
      "r168",
      "r169"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r66",
      "r85",
      "r320"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r85",
      "r196",
      "r198"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r142",
      "r152",
      "r158",
      "r181",
      "r293",
      "r298",
      "r309",
      "r367",
      "r384"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r56",
      "r91",
      "r181",
      "r293",
      "r298",
      "r309"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r9",
      "r10",
      "r12",
      "r199",
      "r201"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets of discontinued operations"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r231",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r224",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r224",
      "r227",
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r276",
      "r277",
      "r279"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r274",
      "r276",
      "r277",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liability recorded"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r84",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r275",
      "r278",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Additional liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ADDITIONS AND RETURN OF PRODUCT RIGHTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r271",
      "r272"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 1.0,
       "parentTag": "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intellectual property amortizable intangible assets",
        "verboseLabel": "Net intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r271",
      "r272"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r14",
      "r39",
      "r87"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r81",
      "r87",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r81",
      "r310"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r8",
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r202",
      "r372",
      "r389"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r68",
      "r363"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r368",
      "r369",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r319",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Convertible note"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r92",
      "r254",
      "r260",
      "r261",
      "r262"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r85",
      "r140"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r63",
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Discontinued operations income"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r0",
      "r1",
      "r9",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r65",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r110",
      "r112",
      "r115",
      "r116",
      "r117",
      "r121",
      "r122",
      "r377",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r65",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r112",
      "r115",
      "r116",
      "r117",
      "r121",
      "r122",
      "r377",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r124",
      "r182",
      "r209",
      "r210",
      "r237",
      "r238",
      "r239",
      "r256",
      "r257",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "Decrease in non-cash contingent consideration"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r307",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Fair value of marketable securities, by type"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r308",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r216",
      "r217",
      "r222",
      "r223",
      "r308",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r216",
      "r217",
      "r222",
      "r223",
      "r308",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r197",
      "r364"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r194",
      "r195",
      "r366"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 2.0,
       "parentTag": "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r95",
      "r142",
      "r151",
      "r154",
      "r157",
      "r160"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r91",
      "r100",
      "r142",
      "r151",
      "r154",
      "r157",
      "r160",
      "r181",
      "r290",
      "r309"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from continuing operations",
        "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r60",
      "r65",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r112",
      "r115",
      "r116",
      "r374",
      "r375",
      "r377",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r60",
      "r65",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r112",
      "r115",
      "r116",
      "r117",
      "r377",
      "r390",
      "r393",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r11",
      "r12",
      "r265",
      "r391"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r63",
      "r65",
      "r113",
      "r115",
      "r116",
      "r377",
      "r391",
      "r393",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r113",
      "r115",
      "r116",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r248",
      "r249",
      "r251",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r246",
      "r250",
      "r252",
      "r258",
      "r263",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r108",
      "r109",
      "r141",
      "r245",
      "r259",
      "r264",
      "r395"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r61",
      "r139",
      "r318",
      "r320",
      "r378"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r34",
      "r192"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Inventory, Gross, Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r15",
      "r53"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories classified as current",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "Inventory, Noncurrent",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r35",
      "r192"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r70",
      "r138"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Initial investment in joint ventures"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r180",
      "r365",
      "r382",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r44",
      "r91",
      "r153",
      "r181",
      "r294",
      "r298",
      "r299",
      "r309"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r91",
      "r181",
      "r309",
      "r371",
      "r387"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r91",
      "r181",
      "r294",
      "r298",
      "r299",
      "r309"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r9",
      "r10",
      "r12",
      "r199",
      "r201"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities of discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r43",
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r43",
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r24",
      "r368"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current",
        "terseLabel": "Current portion of revolving line of credit"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r48",
      "r205",
      "r206"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r48",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r51",
      "r91",
      "r181",
      "r309",
      "r370",
      "r386"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r210",
      "r291",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Repurchase of subsidiary shares from noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r81",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by (used in) operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r12",
      "r58",
      "r59",
      "r64",
      "r86",
      "r91",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r114",
      "r142",
      "r151",
      "r154",
      "r157",
      "r160",
      "r181",
      "r309",
      "r376",
      "r392"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r58",
      "r59",
      "r108",
      "r109",
      "r296",
      "r301"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r210",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Direct expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r142",
      "r151",
      "r154",
      "r157",
      "r160"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Maturity of Leases Liabilities at September 30, 2020"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r325",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Present value of remaining lease payments, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r324",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r13",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r45"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Cash payment during 2019"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period for redemption of redeemable noncontrolling interests.",
        "label": "Payments for Repurchase of Redeemable Noncontrolling Interest",
        "negatedLabel": "Repurchase of subsidiary shares from noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments of deferred loan costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r73",
      "r280"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for acquisition",
        "terseLabel": "Payment to acquire business upon closing",
        "verboseLabel": "Payment to acquire business upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLifeInsurancePolicies": {
     "auth_ref": [
      "r72",
      "r80"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy.",
        "label": "Proceeds from Life Insurance Policy",
        "terseLabel": "Proceeds from surrender of life insurance policies"
       }
      }
     },
     "localname": "ProceedsFromLifeInsurancePolicies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Financial consideration received in exchange for product license rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r12",
      "r58",
      "r59",
      "r79",
      "r91",
      "r100",
      "r108",
      "r109",
      "r142",
      "r151",
      "r154",
      "r157",
      "r160",
      "r181",
      "r290",
      "r295",
      "r297",
      "r301",
      "r302",
      "r309",
      "r379"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r22",
      "r23",
      "r200",
      "r388"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r242",
      "r406"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r210",
      "r240",
      "r385",
      "r403",
      "r404"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings (deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r182",
      "r237",
      "r238",
      "r239",
      "r256",
      "r257",
      "r400",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r136",
      "r137",
      "r150",
      "r155",
      "r156",
      "r162",
      "r163",
      "r165",
      "r212",
      "r213",
      "r363"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net revenues",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r62",
      "r91",
      "r136",
      "r137",
      "r150",
      "r155",
      "r156",
      "r162",
      "r163",
      "r165",
      "r181",
      "r309",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r172",
      "r173",
      "r176",
      "r177",
      "r178",
      "r179",
      "r380",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r21",
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r231",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r134",
      "r135",
      "r142",
      "r143",
      "r154",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r50",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r124",
      "r182",
      "r209",
      "r210",
      "r237",
      "r238",
      "r239",
      "r256",
      "r257",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r124",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r27",
      "r28",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Unvested restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r27",
      "r28",
      "r209",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r50",
      "r209",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Vested common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r27",
      "r28",
      "r210",
      "r230",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Repurchase outstanding common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r27",
      "r28",
      "r209",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r27",
      "r28",
      "r209",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "negatedTerseLabel": "Repurchase of shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r31",
      "r32",
      "r91",
      "r170",
      "r181",
      "r309"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r91",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r181",
      "r182",
      "r210",
      "r237",
      "r238",
      "r239",
      "r256",
      "r257",
      "r288",
      "r289",
      "r300",
      "r309",
      "r311",
      "r312",
      "r316",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r317",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r317",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r317",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Noncash investment gains"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r111",
      "r117"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r110",
      "r117"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11374-113907"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r407": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r408": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r409": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r411": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r412": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080552-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001628280-20-016446-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-016446-xbrl.zip
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MJ$\=$TQ7GIC/9B5N/@4O!=P0!]@-?):K2J'3O+BNH>[ANMLQ#SR,K93@GH9
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M/\YBO;._VK01XPQZ@[*LU<BL*<":-X,46"F@6/_2ZU42'>2A[4J/F_)UY@.
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M5BPS[>!9SC+3K69+R1)J\%9*UR5FZF4FQ4(.60]\42+AH3FO5H6O>,BIY#@
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M&7=9A?H X4*O5[GCY?_RT_X.P?PBXO!_4$L#!!0    (  .*;5%D:ZRX?@@
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M4C+L0*[N<KLNM_B$AD",VJG_0.;F=@MVH7^ZK,TPM8F_?81 @C)ILB['W$J
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MK[_ GTGW\X6N>^(S8QNO]*\ ;"6-MVI" T!Q;C:;?.-7 ,6G^T&"_6G$\?\
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M"< **IW'/(\;,<-Q@Q>S-VY@.O<=MWSHF,:-\& "\X3C /R!>2VXH1HG&#J
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M=**3,4D)8L7(,%?)4\XEM19\E@DA\""(Q"E,3DK3&@$I)=:!VB@MY4;DZ4@
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M"B?O"Z7W6B1+$@4@Q3@!J6':!YVP]91P-M>^<+0HY6W7MA>RRY2,#(S-FY@
M.5.F-$I"((&#3-8(/]_S?1.4WG0\H(3_?/36.VFX@UA0*(@KDJ4^AB#$?'O
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M!(39F-B$I0X\KY#'Q(7!/@)Z5/^G)U'_]U@!3:D4_\9<J;Y_+:(>6RVBQ-0
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MG:2>Y]T5/ =@=BP:S010GI2$L/.R6>GLB7-*^[9)K:P1SD9&. O"<1?RYAD
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MPUC,'N12O>Y5^<-OY/=!K="A[17%9:%BFTTX(M?-]N#?_YPVNO!AOU-Q<7@
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MN(P9BF[&/=?QXFWV^;E!:;./M]DK+L"YXTX8C)Q,>3-F&Y&1(EMO,)QXEZ3
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MM$G66ND337II58LJI[),@RRFZ3Z:5I2F.WG3/;_6$YP%3+P$@^5YNW9N(*;
M&B5&A!<F^:#ITBI354F_GQZ=BNF^M+1'F>*8LQ3'9GO8)VS8(&RMW^\VW&G?
MNF;<[=QDA26$/0K";G0?QLY+IB1%AC".>(@1&2XBBB!R'"BVWN(B+:(YJS+U
M_43,C 9(95IDT=,B)5), BFNI5(D<9@%@:+" G&5/'(B,*02DU91SB2612H%
M0ZQ"Q4M+I<P-);K6C+ H:KV;(MVSD\I@*%<8/'_HG(+E78KF:6AXU\!-%0S_
MUQ0':&'<Q$2[.*ZU0YE+?Z(#N-%$6CDK%/4)"&)BB-/HD,V3_9;1X#4EB6BQ
MM&ID%20($>^XNDB/SY"FG.\J(;6$U#EDWB6DCAM2KS@U 0=(J.$H""LA^C8:
M.24E(H$:X7P4TN3Z*<RK@ILJU>-JXCU]3"U8]ZLB6!LMF+K6;ZEENP>-=G%Y
M,XUF2[1HL!5CQ7K?:<&US_,D9+W3A[/W.Y6/;0N19S^&RNM..\1V;_"J&*5<
M65AYTVC;MF\ V][IPP=%0[_ERLWU8=<>=WA9+N"^3CJ]1I;L2C<V;5Y7]L>W
M1N@?CI#AVJ^&TL-7/[$.;N&T_^.?Y#8[".24M6>E=]J"<3Z_+C@?<Z \I?$F
MM];/7?L[/T*!+<JXX )S/'G!?<2.)!65DI3E[A^*?2%F:?2CP^Y5^ZZ#B%PW
MVF-@+/" *[;YS9[WEE[=5#K0N.N2^-$@#I5S./P2CKRFKH1>ZNOJGZX+5[CC
MH69/(NI.B;S^6/M[8_O=6GV]\OY?:]NUM=<;'W<W7Z^]VZELUE\O5_(7.Q__
MWME<WUS;WMS8^:&"S\P#W6VN5T::%W\.]\B" V;^>7Z[1*+?'WRO=ZGGS[0<
M?E; ]17\%"X"'K5I3WIQ9?3BC]#HG33M^4JC7=QP\:,[DB!7]K6,!S8V3,(,
MSS_\>KGXZI9C&WS'Y;(QYH=?XV7RP^]^=EI"EH$\/>JT/_].L!]?M+S96;Q9
MQNYUVE^D$'\YN6"^._2.^&U@O%.*4[Z#GT%"\; +'*D%QQWV*A&@-=Q<.7^/
M/J0+.S9U^.2^0_-4_;F6E'@ ;Y_6 .I[C5_.!-ZGC^U#.GJ_D('+&[@]W? 6
M<VQ*I1J/4BU^ 7+L5[KQ:VR??K\?QCW3*R\]4?N2\K""!"$8-4P*PPE+6@G!
M@U=:!^Y@6+ZL%U-;"A/TU#FN[8%6ONEV6GF'B'QSGQO]P]>G/1BIV+W<:7&M
MUXOP?]BU9S.3H]W:N<S1LEH+OM_=(+6C&JWO?J#[1QN\]OE3H[;[Z:C>^G2T
M=Q&.:I\_G%WE:.NMVL4:JQU]%/7US6_[NQ\P7+-1:]6/:D?AJ'ZTP6H7Q^?[
M;S?P[1QMC>Y=U-;]>7WW&->._F[6U[?A^3;/]VCMO$YKM ;/L[4+S[&[G6J-
M87YV!W_[PKSFPC*.I.0$<<PI,BP1Q()CBB;JL;1+JZ9*!:Y*/>8YKT69TBJ!
M\.4 H?=$.VN3,\IRKXAUCGHF9.!4.H]Y!D)BAD (+TH@G&4@O+@$0IN89%(1
MY&C,Y5]>(Y=G_PFESDCBC8UQ:556#1-5SDH@+('PA0.A<(X;PQ3F6'%O@K5*
MAD3 <(RW3+@A(R0E(YP'("270*A]%JN/B&F<$$\I(DN" 4@TF$8I0>,U!,RJ
M2I2IRCLZQI=(6"+ABT)"PH,)S.<%)8"$$%$);B@8#[!"R2AW0TI(2DHX#TC(
M+I$0LQ2$R<T5"B2,1"!'+" AM9H1KZC# I P-YFG5<6?O-?WI)#PGM,Q,Y_"
M?-WI#7?WC6<GN>RA=Y^= 1^0WWY)A[Z<SJ19;7(=S$FW$TX]:!!86'AA?3=F
M,_.;);.5WG8ZH2C%C=VO#1][.R">THD]P(G57U]+\&I/L50T)WB=0ASX"3)1
M:WBK?#*,"*4D.+$JX;2JQY;7F"'"7EKR%%*7I26/RY*O,I141Q*8,DA0(A&'
M2!PY)S5*T;EHE5>1Y[U"JD+CJA3CBLM+2YY!2YY@[JVTY'%9\E6*+7DM@LU[
M>KH(X:2T NE@/ J4<>DLQ)5*Y+D&IE45XW'%E:4ESZ E3S!W5%KRN"SY*D5$
MM(W4*X&DR/MW:2618\XB*KSV$#$EH>/2JJAB1JJ*S9(E/RP)- =A_4X<M-+,
M^:"6[1['/KR[1UB_V/@RP>A]* # EMIH^#<&>;D27QZ"+SO7HG<5@>!1&U#0
M22,.LD/&$8NT$29@D8A386F5 >?/':P>B"_/1P@>X/<7V_PF&'*7YC<N\[M6
M%$2)T" 6I'#""((MBVS>K=.:2)FR4F'GLOEI0JM</K!Y7&E^BQ0GE^8W+O.[
M5HIB+<7",0B1P?%Q$272/DBDI$O8 *-A!M@U(56PLJJAO+2_&;._"4:WI?V-
MR_ZNHEL>!4LV"D2TR?;G&7*>@!%RC04 )B%$%/9'<WC[T(TV9ZVYX6R'M]NQ
M%VW7'Q;Q;8A?8[-SDELZE!/7,Q#ZCH0#Z+-^)9H2?QZ!/]<7)Y$0)8'0"6EI
M N)$"@0>)""LHB-,>.6"*K;?8[C*V"QMOU?FR><WD"Z->8S&?!5+,V>,)BP@
M38/.T]<!.>,C"O QMQZ$27DV9JEH;L9>&O/B&O-$EXZ4QCPV8[Z*S+U66!&=
MD%4*(^ZD03I$@R+GSEC% _%@S+S*%/PQLS3O51KS_,;XI3&/T9BOPGQ#@I$A
M8.2ID8AS%I&-,B*7HG Z$FJMS<8,D5-5F@=&^>4D]D/L[FULQZYM%D&^#:U&
MN]'K=XLVJ>5,]N3"^:$4 &;6;LB@1)I'(,WY]6)T2J4-(N.+<7F3:H^TQAXY
MSASW 5N1I[-IE6D(ZA^Z6VV9SU^D*+RTP;':X%4<'A/X=(XI\B0WNDA>()N,
M1=@X'WUPROJ8;1 S6B4/W>6BM,%%"IY+&QRK#5Z%SQ PT:290X:)@"!JHDB;
MR)%TR4BN)=;>YP)P>%%EM"SKFC4;G&#,6]K@6&WP*NH5P%D$)Q[YR!)$O58C
MH[Q%#H3((- (@;!L@YJ9*M%3J.UZ.7/;:ZV\Q>5%L2E!.9\] P'P=8%LI<UV
MW[8/&JX9<UN1?J_$G =@SM;UQ=A,AZBI$$C0O%R$.X<@@)(H,)R$I\2JO+\+
MJ1*BJEC+&<JTE6GS^0VE2VL>IS5?1=+:"6&Q(LABJ1 '[HX,AU=6T0CRM 8G
MFJT9,U95I34OLC5/,"@OK7F<UGP5DU,03M0\("*H1US]/_;>O;>-(WD7_BJ"
MWH.#+#"5[4MU=W7V]PIP;"?'BY6<V/(&]C]!7VW:NOA0<A+YTY]N2C(I2W)$
MD2*'9 >(1?&FF:EYGKI7&5-< 69 9%>X6I(UM=A5=H*PT[R-5UAC-"_0O6]H
MGB>:)W+:UG(>O 3N4H+*S>!R].57;T34E%TR%<V,5,=[-?9H7:;S[1^?NH-R
M!E_/Z+N+@S_3#-65IIX%3UNKDR N(HF-;*8BF\DN;:\S2<8]!.(,BM@"N)@3
MY,P3B\I8I%JGSCI4MI-FVD+UY4Q&GL9,V%R\+GBF6L/K_?$Z=MRC$8&;8AP$
M9NHD-5E\]EQ JUQ@5C.A):D17KGD'36\KA%>%SPYK>'U_G@=N^;*,,DK5 73
M!.B$ $LI T>/.A 9EUPQY@M6N:J;JAI>UP:O"YZ/UO!Z?[R.G>\0HDYU%AI%
MCX!).+">%5^<)>N*E*C N>"5==;H3LDIYS8L>S[^ZN_^?/XQU2*2H[=;@Z-P
M?)BVOCLX/CGYQRRI]W6CJ.\6ZK.?E//]_[=A"K+Z(L)G(PG^I\BO\=4TBS[V
M'U6N.O?A'_UN4^8*C0$D%NL<1P$.30*>>(C6!^[U>:<YHT[?D,J[AIVE+_E8
M0E)@DSE@]CA XX"E<,#9%PZ(7D<6&8(T610O@R4H4E(0&#<B:)9I9+5TW.H.
M9>. Q@%SCRTT#E@&!^R-[8 D>22G%3C%BC&0DP4G%$+04?E:+^SYJ*]=2W7C
MCH7& 1O. ;/'*QH'+(4#)NR )(OM1KRN/4V .AEP+AH0,3"1&??$0IWI3E9V
MYH;9%OWC@'4I*7A6@#9,)Z<788O6$K^X8H%G1W^4"U_';9R3S*4H&M%,131/
M)X,.*$QPW$?@TM<U,.2*L>$%:%0D2$DKL*8A1<=8&VW;.TV_#(^_H7!>*!RK
M>YN5$Y(G<"3KD%OEP*(G0.\$)8DR\KK"A76*\SOK^@; =<KD-]C-"783GG:Q
MJWGAQKI26Q2P50!27;.MF!#%/Z+@L]O>,05VJLV!Z1OV%IB5;]B;%_;&*D\Y
MIF,LSFTHT@(L(@1R-@ CKBU1+6:MHUBMZBR?LOBMY=^G\6,O:N(WK.=]L;GU
M*9CF7"IMLL9]".;9I&?+0@I*Z#I1(\D:1A=5S5M(+#L1K8JYKBHVJA,W--)-
M'3];T3#YFB-W@97Q#;DS(G=L&A2+KOA3JEKD#&M/>P2;B8'$8ACHI+VQ8GM'
M8T?F^DB<AMRU0.Y"/>N&W%F0.^%0&V.DYEF#5.@ A1)@D3D066KF4W2A%LD+
M83HCF])=4^@NU#%OT)T)NF.E*R@'DQV"9<P#!HW@&=:B>9(J,G)!48$NUUU1
MPOV [MI-7G\V60F_E8?'AR-D#8X^U3KYX_,2B^.CDRV?"D329>7\J?MK(UO:
M^UX?/RZ%^:F(\O$723[_(L@?1W(\?]]^E>+NX.AX.#@]NR2V1T?QZK<\_;^?
MRLN[Z?3=<1R')5NMS73,MSL9*.#6J9PI0[2: Q9A@E4Z ;<Z29D=-^A&=?>&
M=S1-K4WKZ>LQ(2PG==X(H;>$,!%_"*:X+KI:028#%G4 G@HK..U8L5]34I[5
M(GS)"R'<L/&Y$<(J$L(R*N<;(?27$";"&L$*)XJ1 (P7!PFY+UX2-QILYC((
M3RH8,5I.944AA"EBDHT0>DP(RRBC;X308T(86P@ZQ:"%B:!3*BX#.08N<0F1
MK$IDBW#3J#S?<NQ(7R]?6!HA;$!9PV5(9.N[B\J&?VSY=)3R8-/6U/>VQ.&"
MNBZ"MC^>"Z?1T51T].N5R0&Z:*9L%,B8&:"V!)Y9#XR%C$D6%_?<83&B)Y';
MEG3I7SBC 7C1 ![;$PF]S2QZL,(J0.<(2 <+B;AR&*7C658' _4<6OT:@/L(
MX(46/#0 SP/ $Q&"G Q9;QT$X0T@PP@^!P\Z:'0F!L[J0DM4'8KKG00-P;U%
M\$J$"QJ29T;R6!7+B$1UC0YSMMC2A@D@$AIX1*Z=E$R&N+UC1*>F;8AMM1#3
M(&\OG5Z=#/B->HA6^[""M0_E'0>?ZF7_I6X?.3YZ='HZ'/A/I\X?I/WCO>.C
M>@[#XX.#T5"1UG!U#V)[-1DDB,%*J:2!J(,$I)S!L1 AZSINO-RM6J?S,@?5
M:3%%=69+8O08^_TL<VC87P3V)XP:XCX9%\ IE0"#]T >$WAA@G!>J:SE>46#
M[L0THT4;]GN,_7Y6-#3L+P#[$Z$)[W3@2@:(@@7 PO)@N46(UKI,T5$Q!6IL
MD23=N+>@87\5L=_/XH6&_45@?Z*IPUA2IECZBO,(Z)(!:[,&G81+11'8K/)H
MC""*3NJ[CQ9J=0JS8OG)X.0BE)'BE)&,S0RO+KQ"X9+')B4U9K*]=/H\[[N_
M&CM-Q4ZO)R,2Q%G29!!\$6=A)RO >1I9)HP;KHJ?6B<T&--9WC:7KS&V%UZ\
MT+#],-B>F&CH(Z(L;@;IFA"-KE9+6PZQ;C+)B47A8XTV2K2=5-<MCX;NM4'W
MPBL;&KH?!-T3,07)G:H3VL FJ0%1._#16V!>>QUT(#1^>Z?X%!([NF%D:4/W
MVJ![H=,>&KH?#MUCW>TSS])E6^ZM7/L?48!'[4%HPJ@2FAQ%S1:4W^LBHAZA
M>_VK(&8I=5A%)NI[G<,OP^,\.&WK3J9FG# 9"3"!"Y:D!^.*_X\QZ\(X'B%E
MF5/B3L9HMG?0FL[<4'4U=92RY^F)=<?I,FH2&D[OC]/)OD<7E$,)21L/*%6&
MXLU%()MT-@8MU[9Z]5;KSLHY]#TVI&Y<!4%#ZKV1.MF08)S,*A@P$HN'[F4
M9Y@&)8WQW*HDO*T>NF*R0VD;4E<<J<O(]S>DWA^I8YU:).4HR@P*.:\-!QJL
MDW7WM[1.&#))J!%2#79\'K,$6H+^KI[W=^>N]S^VJNN]Y<I%_.1/!G'@AF?E
MMW'IRM;I\=;1E>*5XK2?5Z^TC'ZOW/4BU7$4L54?S9W9WE[I.,A*"ZLD!%O'
M$@A1F(T[ Z)(69(E'B(5;T$5=^'ZS*26(E@;H"_#WV] ?W"@3R0,G+=9!@<N
MQP!8Y VDI03BWCMDQ=7PO@"]9@P:T-<8Z,L(%S2@/S30)Z(*3%%,O XZT]D
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MK&NE<(!L0TQ")J%SWMYAW[.[AVR6Y@\UXE@1XI@QTMN(8VG$,=&[YPKU2\]
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M(#U[F*%!>CF0GH@S4.!>1UG4LD$"I,# ,EV[B"GF$+QG*E9(\Z:E-P#2LP<
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M'$3BMECN@H0,VSM<=5QBI^AZQ.";R9'%6^N;B,L98W,-E[W!Y=C*E5XGKJ(
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M]-G1I:A>?)%44TY3*:=?)XW-P"*WP1J0P3- HPQX6324%4F;I!P:7?<7UY*
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MFTAN<)ML,;8MF% KQ8F*TQJ-*C<=CR9%YG.MEA3<=M0V&O?.9)@1EVT#99]
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M>4HI6LE,H:JN"'56EEJ)GOB-P/@-PVAF W@;Y]XG=$]$KXU"+[,!04( !L>
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M/G+LHKZS82;U% M7/L? 1 &Z88?/8%CZ-*I5RMXI+BP*K5$0>]6(\7@9=M
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M@$8" -B"#2@A6R%R :3@XV"'D![#]N&=6\Y49V<IGIVE>;0PC"M>'I J)-#
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M_"+5.7AP*R;:@$O651(%I/A,L;B005LK%NA@&/6&H&X@/GP;]KXY5!Q >9N
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MAJVOS3DU+E7A:6^F@2WK8\/!P1#Q=6:,U"0'T+LT[)J]2F(!N32I++1S=T8
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M\5THS[M>YD,=U%FNEZME9IG-8^)B&0.P92E17FNBI(A3KQ(:M)8[=Z/<I$+
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M%1)1,9@&_:]4G\/VI+FVVH*<]-B QL6:^M2EJ61)9KU(DZ\\>7&!S@T:L"%
MDSCX5^-I'S3NT]^O4L3O7>M.+]2Z7XK?HO]9<BK>011SF5%V!L H:(EM%6/3
M&XY!*]^#Y__1&YJCQ^:#TXH/^I_.VF<[K+T%U_> [@_?G[7WWO/VYR]'G7>=
MWNZ>H?N'!\GNU@Y=Y8,O>VW@&^ A4*O:G_\L.EOM[YVM@^]?^N_QW:)S]D^Q
MNP4\=?B/;^\=\<[!5ZJXH+%6Q#&3XO%_252L-4F\9-0D.3.:E\@&1.GL)L*1
M<X8#*<9" K3ETFB5 +Y2*EV<YXH"<CD EV-TZ(ZF@*L[G7^V.WN['W:V/Y[S
M&B_1_PKYEQMR]=N61R= ?:.&>>$$YT*#VJ %*)(6_IM:,-A>/)K+^=H>VI/A
MZ&@<(8&BH5/Y&8J1#9Z&HK2IX(53C]Z)46EV@?UUI [ @$+[L0L@=# <VM+Q
MB1Z$7]B7\X=";\6P] .J$9B;!XNN;_QV83%'Z#^I%G/46O*;!'>P*X)].U%'
MZ.2<@/E;N2-7%G[1#SKTT;A;')<.H='J)1A2$5Q_2UZ:F4E_HD:N.YR.?WE_
M7+T-L$B#J#OLP2(')U>YW@7 18WNH)=-BM[%KOG:S;NR7?6]1>5K&T^">Z7:
MD][P! D#O63CL(7EJ800$D$/"&P?NLF0G,(OK)NX43\X>=&S<U 1R&@\(<6@
M5?TUG$ZBOIMTGX?/;'&''*X'K-]X84M"$&,X05\2T#I &Q!T9*>!?=QW]"FU
MHJ$>#WNP=+C"8UASTA]^P]4KMTB?8BP*(!"_*KVB7=CAX%=% !P-#UU0T681
M@OG;@0"Z\*.-Z#,2C_M6>3J+ 7JC<* SGZ<!=CS%-Y1[BM[VF>/3#+^Y41GW
M4)'IPDZX$#,!+!B4+G@[#?[3Q5?#]P5@3>F?G5Q(.1M1M#FY3&O<<J;ZEK8J
M%1(1",@-_QD,X<E]]"^C[[]<P+$)D\.;@05JB8I?5<L^<+C>H I>27AK36;%
M^,+(W/%T!'LS=G6\0Y5AGV/8K[XR;AJBW+!!![!=Z-N,7B+6LOCWS;]WPE_T
M]]_"P_YW!.2E>B$ZN11I6]Y@(!S8@$EQC*[0H0FJRW@CVJR("IZ*(\5H%R@]
MP6U>.3_A=Z6 *4FM&F[U^SHL@W[CX!0=J9,(79^C @.:0%77L1VJW:F6D M8
MX^/A.$2N7HU<236_GQ1VTJW37!;NJE GGM^BD+ZFD\MON=#>6"">TL7\2+23
MKZS8PK_=T?QHWH$C&CCTB"@/8WVE>B?J=/SBW\OL ;Q1/5MP>/EEZ_%#_$;)
M^X/$B!_HQ#?3<=>5ER\1P<LQZ1!\F;,><@?R)D)JW<$VTB/\Y4FW &T 6:VG
MQN/"%U6<;(EOYB_YM96I$'P_& 0\JH%LY(XQ%H2:\>84]))1"#6^PU@3V.)U
M8'ZVS*C2'I>QYXOTUB7MJ\ZH"%H8O P5HZ"CK9%M\H25+Y UN,*U"*E*4H/D
M^^^T**&[M<13^#WN 7)38!TP."O!%*)[B]IP$&*H$B^S%2:"U#K-PL]!E5D4
MT8%[,=X\U,B_[F8^5)[$"75&6*EI\*%*G3H+YK]R5N7>?MU!?8BRA-[:=3KS
M"'6&@VHZZ^,:?7"7T'[<>?\U=K&DN3=$)YDC7"89T7%L"#5.QLI:F7!VL;-\
M.1H']'01D92F %)>4$!* $$X+[R;C(8:N,< A5=*&A!O4%* L)X#G]Y(RR_/
MOU^TA*V%%(,9LV,"5[V$K>@$F.XFO,:4<HFR3F0>>(WE6FFG)!49CPV5EB.O
M_63@JN&U15[;%+M[F*R\?];>VCYIO_\JN68Z-9:(.)&$YSPCBCM*4@?HES*I
M$NE?O*9LX[(N#K<-56F>)3)USHHDQZ9HBL4NM2:5"9,6+*8&9N]XZP].=M]C
M![J8>4])HF'/.<W![-!I2JB+J:*IR 3#[197;?=*1&E)_';5S2A!@(SU(DYE
MGB8<#(I<2N6$S80U<6J2["Y!X&VE_;]#Y?_7)8;#;<"!31C##NV<?>*  UQ2
M):AWA JC,#09$Y51BRU=;!XK!1@!\I=MG*^<. M-@AY8BX5S1M8\$?MBZ:PN
ME5&V*), NPI3@8&\?O#L$!B]6$7$-YP3=ZOB_7[C@!\-C'K:<[M^1HYORH'N
MH5?NEXX)OO]J9>IU;B@QSGK"N=4DEY82+9A+O#5.I/%JC.]_PJX]LD?P7^/@
M7EVDM6#GCE'+K&RC6=+_J^OX/M-E[7'FO@HG8>9^LG#Z!B;<4\=C]ZK^XW<P
M@8][ZO15,0C##C==4%^I\A[E^8:0%!U(556GZO&5;VDC^)96C@R5UT2Z(9/T
MTLOQ!KW5-;I!V6WOO'RP--L N^[.!QMOR.R>!GN]QUZS5O6E!?-^ZJ<7G"TM
M:?5ASE#F5R5X!,?H>;%R:07LI[P85Z>[A-4X)P*7%J.BIA4'?AZ6X"$)[%HG
M"Q_[E<^^%-Z')1_V!1Z[:S#2G9^-_P5.MS_/\^FW<_7<Y%CZ3*L&PFW7=-MQ
MDUW_P<'\OKGQ^IQ"OYV.79Y"/_S$=O?@F7MO\3VL??;A<+^_+W:W_@ ]^^BT
M_>Z]V-_;/]L_F]]3GT+O[.T+&#.%Y\.<]L_@'<67PR/>?K<3[^[MG'S9ZG4[
MAYW#H)<7\>F\FT>BN%4::WQP0;B,$Y([;8A1RK X9=1[, ]IVHHE;S'Y#/ON
M-<#T3('I=H[(!I@>$YCB&3#%F<-X'2>4IBGA*4"4=D*1W.3.Y-;+F)J&''X9
M<LB5SYA5BCB=H7\[28G.8TX<-A]74AEE!,BIO)5PT4K9^;93:R2X;FQ@^/"?
MIV-@O#F?#G(KDV)EWK?JM7?!VCV_M@'WKX.'0^PS@)NAV\>JN,/FP+8=)DH.
M;#%VGP9@<E=$T%\,SC6P=PW8.UU0SXVP*DV8(%ZGG/#<"9(E ( YB,>,,R>]
ME%@B*F[!;O\LQ%T,,_>JFS<<OC;:2\/A#\CA<\5&LC376>9(:BC#_"A)\MPD
MA,;:>-CB1%C>4$I#*2=?K5<YHZDD3'E)N*<Q42#QB8--=HGA@N9@$7$J6UQF
M=Z[_WJ%P>/8.]K=+F0SWX4UOVDP_@OMY*<>HL>MO"VJ=-\L*+O6YL\0J:0AG
MG!/M8DM 5$F726:-U2]>BQ:GO"7SRY*$G[#[N>'D1W#0-9Q\5YP\5T\85:E(
M&2BR-$22L(R\=SD1B8E%ZHS6&6OHX=>A!ZU$)GQ*"4^4 W65IR236A').,/V
MP"[&!L& ZI*W8G'>>;%&4']'#ML2L9-UUES++HD+*8^/[;?]N8X(3UH>/J!F
M^VXT'#=0=R.H^[B@Q"9".H,5X!(KP#(7/B8:=HHP0SWSCF?>QB]>,]9*6=X2
MZ7GC_':V^-JT16GX_8GIOPV_WX+?%W(33$)Y*CV14BA0=8TA&7.>>)D(8:3,
M<H]1&=[B3+88O^S(U=KQ^QTYYIZ GM/#<^F7G"AJ_'4W7LZ7ZZG67' \M,&Z
M:V#=8H(HI5YHGSJ24!H3SF)#<IYSDBN7IH)J$Z<6SQ&W),];-#OOH?NM<<X]
M![9]0.VD8=O;LNU"6#G-K':I(<IP!FP+#)RS-",J=S%/#.R:DG@>O"4$;^7Y
M^:+GC\*VSSXS[IQ_9:4.3D7W]^%UN:9V>7%;N&LVEW]N^?%WN33K+0K65(%S
MC0BXD0A8S!W4S#GC<DN$DQF( &6)RGQ.=)Y2RVAJ$Y>!"(A;<1:WDI^/K=XA
MLSRRPZJ!R@8JGYI+KX'*&T/E7%M6/.-*9I2X)+4$&P6!D>L3XM-$BT1DF:7\
MQ>NLE:6TQ<1S0,IKM.#]80W@&S?EO6;?$7E1WY&%$BK9XS44D??>4.0O[*?C
M=H]#%]/!P5_8I&^\+N6#.D7-U&^+]KNWAYVS _;EW?[WW:T/O2];_W3;_9V3
MW7?OX\[94=+9^N.H<_;'T6KYH/W/.R?[G]O \%_@N=N\\^Z?H\[G[=/]PTW^
M9>M] H 0 X,G[7?8+-N(SN;7/$E,PE5&C.*.<"<$ 5IQA'FE*<^=-5ZN-NTP
M&OA8IC:US/'4F2QUVEB1RSR1VB1VM=S07]N;'V_53>3J%RT/S"N6IU998Q+#
M,Z,RECO''6>@DV7<JJ=1:7EG$+5#BT<07K*L.?YV\^,?43$>3[$,[,=/X0J)
MV<;BAUDM7S,<83_&8F!"E?,BU!^'3Z/0E#*4*C]6V'ZT+,5?ENE752-BU1\.
M#J+AZ$ -J@[2H99_W<T4:UB6S2W!K'956]I>4=Y=M4+% 6O5"S7LQUWG)K/B
M]KUAZ*]PY$YA/*4,AA>45?!@P%A_/'+>.U/VWK7#8^33Q4FNU"\.A3/+=KH
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MA;UW^L>]P@!-+L]PW+IB"<9E&Q-0>LVTK :MZW9-"W@>J6^JZ(6:>VH2_:E
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M06F^_W9X]LD !6H=O?L2I@X E]#6?=".NN,YKA[%+M=M W"585LF@!QT 7N
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M=B1$W3R?("1Q?!N]CCZ&]I\I*^$O<$<1JS*D_(* ]J?G<$8TTR$9#;HRJA3
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MQ$2NLOYFU*#XZA(TN2*FM_01.T*.WYX7Q-D@';X8ZDLPP)=%=)&>C"^IV!Q
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M\]^LR46R4\F:*@U7$U9NK<:(=,[B&!MLJJP.81N5(5W1X.)VUQNS&9-4NTY
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M^1-ZS?,QT9NF(_U:Q6.Q0UC5,QG""Y)\? (:0WLE[D:2CVDUY,NG(-AHYHX
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M.1L-6X^LH"#LB5;%</C!/R?_(ZW1'1S>:B!(1^B$R+,O\P%P"PG[#RQ:$5^
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M//+B9!.%@LG%P%9B6?YU6LK.+VG)9$U'J^)')+LHG(0A\ZRL)F#MRKC 3XL
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M:4>\G46&>]D7Y178+U"LI]8GS7TJEQF3M 7(857'";I6<,GCM5CL5&Z2MHQ
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MRID&> &-9#!")9_+$(H(<^F-FO[3!DY[EFEU<$S778.B8:2!10S%\<1P\1G
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M(=IU?"6'A85QG9RDP'5,SXMAF<^?>DH,5*L,&$D<97E@YR"YGMQ.DQ.6:8\
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MK(BC*GTDWC'L_(<S@JVX$ZS]:>23\QMIZ=9T<OY1$NJ59_DC;.SQ(W6X]Y/
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M)415( E;'/.>QN1C?HZ):4B1WJ'-3H)!=&76FAEJ%2B;1R9G;SX[ ?QF2C:
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M@+8WORB[F;2V(FH_R\$6TGF4,@3,$'+B8FGM$D:%K$"\A3&P70'R5B+O4AF
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M-(^Z@O,R=,89A0'V\G?S$2D9$_(3U8!UE"$6*\Q3#+CW# .2X65B:2%:!'&
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MVZ^+:=:ZG<TJ6!9]I]>TSO8'WC1JK=9J4UG6JK9IU/3Z]BN.&K5Z>[4:GA(
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M?I]?X?6\+F+<+ZG)3#EVG$J5$[ML9S+[Q,*E(7%#D=Y#TI?Y]=L@=1<E43P
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MC#/>ST#T$WAOQ9>"B-.<P:FI>A,FXZ.5".8_?3EUT4ZAG1ZE'4GK<DXV$\.
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M/,.X=^A#6,6&,R^NA#C#IE&=,+K]&'^?KMX):3U$89RWE@NBM:?ENF%!K%:
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M@KHXZV4R:(PS0?H@%-Y/U$;I6O#4E9_^>3Y>?!F>HZN1C\;/9EG6)SVGBC7
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M_MP@= P8NEWQ?$UE>/I^AG@1DG(3XFISLP/(H8^3=D9W_(.D_D1VQV)AX,.
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M:MU1V5Y+5;US*VYDX"GS5BI3P\QT6?/I+\!'OLD$^!(W9KIL2R1PSH_$C^<
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M3I<P\HE>V2H*()-A"$D4<Q8)EF#&W#R0_>&GYWM4TJ6N6:8'J,4>%8AB E5
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M4P#EZ113,\*V$G;I<'<*I)WIU0V>H5G3#1GWCG2URO?:=NYTEG%[R]5J>=)
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M.444(Q'0  ;43R!"@D&"8PE#ABF/?2^).6H=3_9_0"A97F\^^)?%<A=2]B_
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M";2<P]=5MH&DY^#6^OG&#FJ]J/F98-;+][3-[+H6(C-^E?[KI^QQ^>=BILG
MQ\Q3,%:>,*9'#*DF!Z@P1KYD(N9)Y);;=3+'U/BAS&$JY;P"1E*-(S"RNF9X
MG0+:3!,]P30P.[1"J$6F5RT&G7.]3D<>.=NK5K73?*_Z2]L9!A]HFN5U]]Z]
M;O_Z]U1F>J"OK_?RF];\>[J:)3006&E7(S'UBI 72>UT* 9C[C,L960R.UU,
M!+MIIT8&1M2BNB38"IO;T1^O?P._&XD=@\PMT;>S)OK'=&#FZ *GLV'AADZ?
M)H;ES*,:&VYH')L=CG=W.X-^7)85>^X6:_WVI-M"/C,1A9X?B03&'I40)2J!
M!'L>I)0B'DLI(A&[Y?%=G+/%0?3 G*0_"&D>MF-BC=.MN(#F\K8[@JZ'W.T<
MNAN,(Q]&:_A*:<%.W+)B6?\GTA>A&>)8NG[2-SF;OHA!W0'UY1O;4<[/<J%)
M;'Z]$-?B.5VD)B79-*&Y_?XB%RLY0RA"/E(!Y)Y)',8AARP4 2011E%(94PB
MX5;+_,*,+NMDG"KFI<#Y9YH>B.Q&-9>@MB.:'N$;F&;V<3N4%93"]L<QEJCT
MR3"7IAR57RSU/V87V]M:.EJGV6JY;6^.<I@GM>D2<LTIRE.:3O1_/(8BA:A*
M0N'4'*]FGLFY4F>20MNY4#6X6OI,W=$:VDEJ 92[<]0,0Z_>4,U4X[H_S?J>
M^#L7+F_'"->+=2K2^<9P3-GM.96KV^\FO%<*4^KZ9OG\LBFR:#ZI6YHMTL63
M2;K(F[A</YNJ!3,3;N(SBB%C&FPD!(<8L00JWX]IR (O3AP;,O4BU_0LE_WV
M38!^H^D\S]!4RPR\Z#F^FFH>ZZ_9<O/T%>AYUUG*M?=67?\GS41Q9KI\*=RM
MUBV?^GGN=OPV^K,<F WW]0$[A4"E4=&B8$\G$V-<:67RPHH65%>@T*P_!NT5
MZ#[YMA_!1F7G7K$\YO)^!V\;X[.0G]1-)D6Z_D!Y7EC6_.QN+9^U1<A(P"0/
M((V1;_;:$21$<6T12B8$8C'S/;=DMH;9IF87&L',FBW$!96\X/?\%[G(C@9B
M,]AV--H;A /38R?T6D3[6*#2;ZA/TX0CQ_E8Z'X:Y&-S4XNJ!9_3Q8+RN7Q'
M%W^4 ;(BB42$? 6#@'"($(HA#02#OF)4\)#@) ZL"Q6<CC\UWJ@D!$9$AP3Z
M,\@U4T(/> R]H[T/Q>708;NWR;Z.0#=L1BH=8/>ZN!4)J%>\L2[ F=O&*P50
M+_-!]G_#96U++-%UWM1=TR%=??U@6H>[%IMM&&)"JW$K9OY=-H76<TF'*3MK
M 4F_18(:YANY7-!ES4\+!UG<T^[U_H=,G[ZNI;C^)C/Z)#]NS))Y;[P.*8H.
MO)\VZ]6:+DP>][7X_S:KM1%DED2^('&LK7X2"(A$B"!COH!>&"/!9.PC[%3L
ML:4<4_NXOZ\\?JF4Y/E*6N;I,JO=#D#K[9BVS\J.I49X @,36*4!*%4 A0Z@
M5*+LZ0WVU  [/?KCMHY ]DE[;449E1$[XG5,EEV':\>C1>Z#V9!9+O1H9375
M((JU.^-Y4(9>!)'9]V8H8A!%<9#(F"A)G;(LS\XR-0XLJPMNI6Q9UO8\HG9<
MUAFG@9G*'2)G%FJ$H$^..3_1J S2J.LQ/S1?/)%>WMOT'"(BGH1^ CD-8H@\
M$D#*$@$%C@//5RKRD-.A^V"23HV%'C;/SS1[-1;80JY!5BCVQIVZ';.N)O&P
M!J;"CAV[P2"Y78,#/^D&WF^3538XYH,W\NZ8S[;S]LN21E*\US[CXNFSS-*E
MR&/7\VC251%&/6,!282OK4O3CQLB1#Q(:(0A\2/D82(XY4ZI+K833XWJ?Y,K
MX][QO;")JZ*!:XO2WS; VV[[]0_GX%N 58TSC6<A-"BDOBK27Z[ ON0]EPIW
MP*KW N(V<X]?5MP!D;/%QEWN;]U6,5]V^70G[O7,IYQCQK6]&G-L*C!RB(.$
M019QWPN#Q*,".?98;)AN:L14)IR6\5P/!3&=[D(Y]U]L0KR9F_K'<6A/N2.$
M;1HU6B#3O6MCTR1CMW"T4/A,/T>;NUI$".15B^Z7BZ='F3U_8O/TJ2CV7 0^
MZ<'+PK&?33L^<\0;)IZ/ J4]Y"B!*(PUQ<1>!*7T@SC&GN=CSRZLM,WT+DME
MG.C1SI7-6CT%BU"$ 9$=F(0*2(WHP,@.]H2_ EOQJXK7H%1@0+0=@AP&1'VD
M"(B>T7<+E6@)7V,<A>N8XP59M-3V( *C[1@M U3E:B7EMEWXO6F46%6HVG9_
M>+^1_R%I]OCG<A91_9)AS"$+F$F,-,&KR(NA#$.:\$#H[X55T^^6\T_-0M4O
M9^ 8I.H(N)VO/"", W\;"LFOP%9VD N_:X;P>F42MID$GVFJW6BC = J]!C<
MV@Z[7L-='448-P"V'3XG(;$MA^EZHG1=)0!]6&8/=+Z7"I!O@,^DH''L"Z5Y
M3$80(27UWX(\)A_%,E+4HU;AL\XS3XW+*L'-D<]6=*B6&5QIX?=S<(JC \?S
M:/LGXGJXTR/.0^\/]@9QAR,92[B&.6*Y-/D;'9E88E)_!&([0 N'_M^S=+6F
M<^WYEB':(1:FOK@/?9F81M$DAI3X A),.48>\X6T2ALZ._K46&DGGX,_> *9
MA7O=!8B!:6,G6IL@_Q,P'+S?+J",Y-Y:O"!N+FN=SHT^Z<E-XSF==?(>>)6U
M%[4SKS[*M8FD_IPMOZ5"BG>OOZZDN%N4Z?.+IVN^3K\5-8ZK6'^*54(ICF'
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MBJXR]\O5:B:%B&+I!5#)),]*3R!6<0PYQ4QBA4,JB$NSN8/1G6R)$3K+F<V
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M&YF+*/2XFCG?]FAW-!?5JU_67'ZXJPNN9Y1V56[^>I;+C9Q'D$E$20PBA3*
M8E-H$Z8<"$R3-,(9B[&:+^4WNI7"SFDXZL'J"R;%%USO9]"3O%S 0!82NO+Z
M'@)HNU%Q!V6LW4B)QLT%-#KL-1IU]KNA..QBY%U#HWZG6X/FQ]Z8>/<K_7.7
MY+%+^YA#'"(BA 22TA @'&> &4^ (D$(I!@RN]36<<2=FB.AA0R>*BG?B!^U
M>5S;K=3T1FM@HS<0[ZD9_YW>^YR[27T);\2.V_N+^.=FQ'7],MZ. [=UH$;C
MO6V6XI^3Z[85T<'X;=M[[1CR)9_7DB]RP?3/C]+\H'N_>C(,:?\H3$H&,8XC
M#@%""08HC5*0D30$7&4D9)BB)'0\AK3I=GH'DG6I<\- :^)VVWM8X6^W(?&-
MZ="'#S5QS:5)*7".:UUDCU%4#@!Y#9&RZ7?<^"<')$Z"FUS>=2?9NENOQ O?
MWJ[OY?K'@A<7X6F*,!0D!"H."4"QC$ 690JH5%$2A3 5R(J>]5P'4]MUE#+F
M<Z$4TYEMJQ'(=DOB YZ!K48'9)QHM]K4[\NZU=CV:*1;;9K5.;=:G^M(N;5W
M9>92(261C$&6)=JA((8I#U,%L$JP8HS*)'+BIZRU[32+1R.">-P+Z$BK54/-
MS@/HB,7 4_:S!0#NI%FGJGKERJHU/RY%UJE>)\Q8#8]TO3DH(XVO\U#D;W+)
M7S_K[<JGK7S2BZY")(50@)BR!""*])R-! 4IXZ$2"L<J=JI,VMK;U%;@?11_
M4!,W^-T('.02.\;XM6-M>^7@"<'!+R"Z@]?A3L("%+\W%&T=CGQ?8:'[Z>V%
MS4O=+$IUW)&?8Q3%7\HC#?EA9<JJS\,0A3B,%>!I(LV!0@*H$!C@3'OU4$ES
M>^EB52[V.#7+LCN.K$D\J\X;M3-;2.UH72[C;F=AO*(YUHE_1R"=+8TU.#ZM
MS>5.1[4XUA@<6QW[%[L67C"%8_8,&(9:O_*47G\U%'=\];+<2G'S%S=B/)E_
MS56H(I%&#'"9<.WC8 &(T(,@,\E1PFC"1>(6*]%)CNE%5!@U_B.H+KH=-RZ=
MAL)RBS,8O&-5U##RSX(:<8Y18;:[8WJ=!74U@D*/H%#$9_F-'CCZK=+119"1
MBWGTP.JTYD>?QMP#0V^TC[=]_;AXE.MK;3>^F0OC3!&8LI@9$DX*$*<04*D2
M$&:1@C%/LTQ9[>S.M#\UCZL0,<AE#"HA[:- FQ!L-U8><!G8#+E!XA3RV:)X
MCV#/IE9'"_-L4:D>X-GV6#>GYCHGCLH#QG^13TRNYS#BH90"@C0U3+J(YBSD
M^I^"A%D6";V)<KR*/>EC>O>NUR5_EI'1S14Y!=#.S>@%RL!SMT0C%R[XO1#/
MXR[GK.H^5_W33D9=T<_J>+Q:GW^P\\VFX=TNKU8VY=X\BO2*C"4!H2'%1L+$
M5["$@ 3*R-QNRD2X7F^>]C*U5;GQ)L_I\*,=5.NKSGY0O<5]I[>3#2L4/%U[
M-G0P]MWG>1T;+D!;'NZVF-_1USR;].-J_54^OQCF_8V\55^ED/+)A(!]T8JL
MEENME&[E6[7WGDN2ABHRJ[U(%4 RP8 0F &59-2PM""HB-L914=)IG=*L9?>
M4,IM7MAF(19T_5I0;6X*OJ;E@3+!HM.91M?!LW,WAAR0D>Q4J4&@5NO@<%CV
M6@2':EP^7G)V7GH"Z=/%Z2K*J(Y03[R.W:6^S74DNJ*+]6_T\45^6CZ_;#>?
MY0_Y&)7NOB0RB](T 2P6B>&FR0!-J#:>-$Y0I'=,*K6JSFC1U]0<K%RV('+D
MLVK!TLZ6>4)H8'MEI QR,0W'GQ%T%I2 #;"GLL#$*X]52W?CDEA=UON$P<KB
ME0YY=O<[WV#/ZW%@K;8OZ^6MNJ;/BRU]G*=)*#DC!/"(:,<KSCB@QHJ$:2HY
M317A&;9.FG/K>VIFY)INO@?/]>5]G0N<>URYF^60#.4X#.T69V!P![9 >\&#
MO>2S8.=(?<P=J1SI6Q64\@\'M4,2V7"0CY01YA=ZM\2N;N"U9FDY-CE>RE4W
M70_RISHVT?6X7?>QWAK.1$/Y5+H]-$,$,8&!3!("D-)K 4$J!EBF@E,LPS02
M+BYD8R^3L_I[(7-",]=C]R8@;8_>>\(S^/'[(3*#',&W0.#W&+ZIHY&/XEMT
M/3V.;WNX<Q#TVES"?Y#%?S\MJ]Q*$WB/$5&QS!B )$H!2O3DSY@AM5<RC508
M)H)'KF0J+?U-[XBM)IQSP',+KG:VH#]6HP4\Y_(%[RI)?PH6R\ &NR[QSI<Q
M\1SOW-+AV/'.EW5OB'>V>*EC8:P\2.>!_O5>+J5:; VU>TY;^%YW)*Y73R8E
M./=F=Q$_5WR[^%%D]20P3KG)IA:20)/6&)J\:OU/D44)I@E4"KL9EU[R3,_X
M5$-F)M-RM03<[$5Y%;:^-3]J[[!DSW<LJ=5KY.S,U_"C,5*T4!&#:/(Y2DV*
MFY5<%\",,D%=FWIXXUXACU6\?.#JM=17+X'&K0?F [N3HF%>&NW.0)TS8=3I
M,;[(K;EVV,BUWC3.,YDJCF,!(BST#HXF^J.-$ $9TG^)(TD3(=R"IBYW.KTH
MJ@,JJSR@X,_5^@]C6I_7*S-^KO[=1=QMG3R?6 [NZ97"'A$ Y;4OBMO.0F:_
M!-]V^/@F]K[0Z^B$WG8H-!%Y6[[9E4.';3\M-]MU?G:9\RS0,-+.&TD C;#)
M<HL$R&**@7;W5"0B3K!=1-?Y+J9V8)0?A>Q%[%0'HP%(.Q/2#YZ!388C,AUH
M;<XI[Y?$YJ27D2EKSFEY2E!S]LF.!/W\NQ0OC_)6-22Q;=Z_UO[U(/_:OM=B
M_S&'<4B3.(D!CG "$!,,4)90H'B"42H9E,@I>[Z+$%.S$94.9IULRM[4JRA[
MK?_"D>:_RSC9&9BAT1_ZKM$5^.#WASQ@RR@3Y-KX+!30 TRO)02ZR#%N<8$>
M2)V4'>C3E@_'J(KV^JI]L/NM.3VZD_K[7F[I-SE/<!0SDNDM&H]#;2XS"$@8
M<D"BB"4B4PI2WMUA:NMZ:D9RQ]ZM]\DRV#RO)15]W*A6V+NX5[[ '-?MFNVB
M30,C^"PH1 _VL@_ED=G@-9RGUMK[&WIP-JBT>W96+?0\4_IYO=ILYC#C2!&4
M 9J9 H=1(@"E, 5$,,PBR'EB\F7M.<L.FW<R0"/0EM6..'+Y9D%.9-;Q=*A
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MHO9D45_V-/:9/[X(+?'-7_R[_H:E.3R]44IJOPXG(<V(R9*7,@2("@(R'A'
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MQ3&72H4@36.FW?.4@HQ&&8A03"&DA))H1P/X8&^M++NWFE>'N8$/8Y1G[T$
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MHJWZG=[FK:37--R&A0*N.656<-OMXKQ#.+19+.0-=@+/@D+8X/?RO\.P"[G
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M[S66?W&^_DS.\']BGD@6LP_%0!43,5,D1%42('/T;9UJS_K&<+I+T]@AR^E
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M /;CM;L84M2C]N=;+=>3C]/U=IYAGGZ=YO,PV\X#0IM1DB'6I3H.*CKP*A9
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M4/LGV(26<;2>M\DS-&!F7)?_"&S=33&,K>@.P/X>5^OE-*TQWPQY DH78BC
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M I-U=C-:A=RR).YTO'F@.G>OUSV';O!/TO&BJ< [\'UVV>PW5SU\'86FAI4
M4M*R4SI[\(%X"T:&5+R,PKLFSO-C5(W3 N+T-QX/4T.GF+K(I[]<+)>+WVN!
M6/A"/UE_FW"CI4[9T/ISC%Q'0^&'=QI"J@.6>52^-&G)]10B.[P =Q@V]D#=
M((H:>V]\"F.OYVF)==_8]'B>Y) I!+:EWONC<-A9BH2YB5!<MB(%F7G:K\/[
MX33T=W'N.+B=4B7/"7D?%^LPNUI?1B>N9$D@8AT<'KR"D(6%$GB*VF6?V/#
MNT5"?_<@3HR[PQ72P:Y[^^;1R[":KCX0+2&_G=\\=^ 3DA0/AH7:*S?7"?4.
MO*U=0)'QE(- K9K4GNY+8'\%S</LMDT4U!WP-L=1%!Y55CZL:^?O=[A,58.?
MD,075?;> _="T9+2M*08!A RV.2D,UPU*5K=G\3^JA9;@&\P)74 OUTR^\O\
MO+:1O;#DKQ9G9]--O/X+XDU&N3#1RE*G>4A013/PSG&PV3G/0M'>GBRZW8OB
M_LIGVL4APZNP!ZPNYI\^XO+L)L,3RW/1EGG(=?8"A5&!_ PR_-*2HQ&D,CPV
M*<[:14Q_A]L#(>Q8P7<QS:=2O[HD_]7YLLIT4H1CC"4)GO&Z!&KO )$5&!\"
M=\)'BII:6;&[Q/1W_C2<@3I*\&.'I1\_XZO%<C$/7Z?+\]6+:7Z/LRF6%_/\
M<UK,%V?3=#%;X]N+M*X=9B^G<+S'A-.OF">*H7(A6Y!U(J_B$2&4Y,!R24Z!
M*N+>C;4'PM.C2>DO_SM F'I:!76P%5X?HJQ>SU^40H(D/W1UU:=VBJL7J]4B
M;;Y+8OCOB^E\_5?Z]?/:I=W'[ N3")HAR3E+!T%*6HHF>)NLR@Q%"Z-W%-4C
MM19N;QY/I\L.@'L[DB)!7J8I$VKA!=>@I:L-FJ.%R)#"*,NM<-%BQB8G&0\1
MM!_<GN&QQ2 :Z+UK]>LY?8H?PQ]X4'/JFW\^: _J!^DZLM7TM2VY>/Y/TU6:
M+59D(JXZ$YO"/#GM$9R5O,[DMN %,LC!V6P,9\4VB90>H>GX;?#>HVO/]Y?T
M.W^?Z,AYR-[4Z^^URZG7=82N!Q&%BC*Z4&23!,5C1(U[%CH4.N[O8 .IX1F9
ME8N&\1<C!HXT,G<>ULKD/$;S"0Q09L;%'#2X(BCD$VJ;E ?FF*;=*Y-HFER,
M.H4!JL-LIO-/.$\7]2R:(PN"4P1AZJ7'8C,$ESA$Y#%Z&4RXVU%X8&;O4M2O
MZ7D*+AXT/4<IH /'^(J1B[G9%UW)5,@Z!%=JTPTRR\5S"&0Y05&X&J,IR=HF
M,\UWD],)AH[3]4,(.ESP7<+GHJ+2*..3T?6*G*UM[>HH"F<UV!)YH*VYR-RD
M2?Y#!'4"H2.4_5W\'"#Y#A!$5-<AD&E3^+N\[#KG=!%.) '1*XHTL3"(2C,0
MPGK/A%8*VS1$WT5-;]@Y1-%WH_&CI=X!='89YNMD13+99<9UO2*G03':X[W#
M0AQESJH[G,3)/*$KJL:M$FR\DQVMA@XP]?8+UHGF\T]O%JO5J[!<?BN+91U5
MNYH@K2@O8@23;!VO9A3X0LM/*9VXM(ZDU"1]_3!)G1BFX_6^:**$WL/Z5XL9
M(7!16?UZ?0/FH,SA0X\:-*3?B]Z! OJWRT]A/OW/#;6$K]5B-LU;9,_SNQN<
MO"V_3.=AGJ9AMJF)VE!T%>(E;W14 4%K5Z])TX<0# (W/ :=DVVU9(>@_O@;
MTC?5=3V1>U>V3%A1!\@A^,3(ET T$(5R(-'Y2/N^26UJ_)Y X[C&[O1XO'_Y
MNHTZ>[>2+W*>UF>MZ&?;B:>K17FW7.3SM'X__?3Y,(.YQU,'M9U/Y6(@,_KR
M?%6K8%:O%F>1<+FAX J-3!2M@T=(I5X.TMQ"M"E!O0\7I';D^C?IR_\84<<:
MO1W/WK5 3%'9>66@:$4+Q)C:'2HJHK@HSBAX0M&DW]%^Y(UKZ@;#S%T+UD W
MS]]X;>*O1B;LXMDG-F2[.#J%.1.%XE;E+ AG:K=/6H#14MAA@@Y."PIG79.#
MUY;F[$/ZC/E\AF_+Y5M>I/\XGZZV*GCY[<97UPN(YZA8% 6DK?/&64S@N%1@
MHK&2 GR'ODGR_A!B.S9U3\'3O3[DK?760:KDFL?WF!:?R#O&_#J3U*=EBOG%
M:H7K+==$&GG);Z8AUGJB;5W9^1GFC:&X9C\JPTJ6%-JK+&I7/027B@&K>;(<
M%7K1Q!T9F(]Q4WPG0/3IM=T5V+^[H*_28>L:*$[S)I=U<YVKS!1*'2 )Q.K@
M<(@N2B#M*,&2X46VF2,R' _CWCKNP6P/JN7G[\;^%I;;S,1%L4\;A_;>6T[L
MVC[.Y2F<7)ZT1<D+>*]%+<$M$"P7H*5&QIR6L4VBKA<G=W-:10$@>4H^@*TW
M_95B 2)F!24D+"ESEMMT>7PJH1T[MT_!T3'.[9/UU<%>OX.K;2L[*TR(WD.Q
M/!(;]<Y#Y@X4ZNAU]MS+IDFC._2,/+^I*0@>R!P=HY%.@;5UF2_[W'$3F;5Z
M,\<Q4PA8^[0&EP&]89P;)WR;XO'O4M:'*3M*_WM@ZG!EC'U7]*^O7[[X^/JO
M%X4\WBBAF#404ZBW7+D"C]Q D$DQ(T@V=_MG/W#O\]9C^\/ $?I:#"*\L=7^
M9UQ_7JR7^$=87P[/<0*#40;!B\* @FL)WDH)F)E/TFET;K\[O_>?W4=JHP$
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MJ#\B;/)?__(_4$L! A0#%     @  XIM48R-R!\3$@  BHX  !8
M     ( !     &$R,#(P<3,M97AH:6)I=#$P,2YH=&U02P$"% ,4    "  #
MBFU1ZK^R((((  !L,0  %@              @ %'$@  83(P,C!Q,RUE>&AI
M8FET,S$Q+FAT;5!+ 0(4 Q0    (  .*;5%D:ZRX?@@  '4Q   6
M      "  ?T:  !A,C R,'$S+65X:&EB:70S,3(N:'1M4$L! A0#%     @
M XIM45I (?X_!0  (QL  !8              ( !KR,  &$R,#(P<3,M97AH
M:6)I=#,R,2YH=&U02P$"% ,4    "  #BFU10L%AEM:& 0#ZKA  $0
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64$L%!@     *  H F@(  #;] @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
